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Abstract
The routine application of Csp3-hybridized nucleophiles in cross-coupling has been an
ongoing pursuit in the agrochemical, pharmaceutical, and materials science industries for over 40
years. Unfortunately, despite numerous attempts to circumvent the problems associated with alkyl
nucleophiles, application of these reagents in transition metal-catalyzed C-C bond-forming
reactions has remained largely restricted. In recent years, many chemists have noted the lack of
reliable, turnkey reactions that exist for the installation of Csp3-hybridized centers - reactions that
would be useful for delivering molecules with enhanced three-dimensional topology and altered
chemical properties. As such, a general method for alkyl nucleophile activation in cross-coupling
would offer access to a host of compounds inaccessible by other means.
From a mechanistic standpoint, the continued failure of alkylmetallics is inherent to the high energy
intermediates associated with a traditional transmetalation. To overcome this problem, we
have pioneered an alternate, single-electron pathway involving 1) initial oxidation of an
alkylmetallic reagent, 2) oxidative alkyl radical capture at a metal center, and 3) subsequent
reduction of the metal center to return its initial oxidation state. This series of steps constitutes a
formal transmetalation that avoids the energy-demanding steps that plague a traditional anionic
approach. Under this enabling paradigm, a host of alkyl precursors (alkyl-trifluoroborates and -
silicates) have been generally used in cross-coupling for the first time.
In summary, the synergistic use of an Ir photoredox catalyst and a Ni cross-coupling catalyst
to mediate the cross-coupling of (hetero)aryl bromides with diverse alkyl radical precursors will be
discussed. Methods for coupling various trifluoroborate classes (α-alkoxy, α-trifluoromethyl,
secondary and tertiary alkyl) will be covered, focusing on their complementarity to traditional
protocols. Finally, a discussion of novel silicate radical precursors and their advantages in a single-electron
transmetalation regime will be included.
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ABSTRACT 
PHOTOREDOX GENERATED RADICALS IN Csp2-Csp3 BOND CONSTRUCTION 
David N Primer 
Gary A. Molander 
 
The routine application of Csp3-hybridized nucleophiles in cross-coupling has been an 
ongoing pursuit in the agrochemical, pharmaceutical, and materials science industries for over 40 
years. Unfortunately, despite numerous attempts to circumvent the problems associated with alkyl 
nucleophiles, application of these reagents in transition metal-catalyzed C-C bond-forming 
reactions has remained largely restricted. In recent years, many chemists have noted the lack of 
reliable, turnkey reactions that exist for the installation of Csp3-hybridized centers - reactions that 
would be useful for delivering molecules with enhanced three-dimensional topology and altered 
chemical properties. As such, a general method for alkyl nucleophile activation in cross-coupling 
would offer access to a host of compounds inaccessible by other means. 
From a mechanistic standpoint, the continued failure of alkylmetallics is inherent to the high-
energy intermediates associated with a traditional transmetalation. To overcome this problem, we 
have pioneered an alternate, single-electron pathway involving 1) initial oxidation of an 
alkylmetallic reagent, 2) oxidative alkyl radical capture at a metal center, and 3) subsequent 
reduction of the metal center to return its initial oxidation state. This series of steps constitutes a 
formal transmetalation that avoids the energy-demanding steps that plague a traditional anionic 
approach. Under this enabling paradigm, a host of alkyl precursors (alkyl-trifluoroborates and -
silicates) have been generally used in cross-coupling for the first time. 
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In summary, the synergistic use of an Ir photoredox catalyst and a Ni cross-coupling catalyst 
to mediate the cross-coupling of (hetero)aryl bromides with diverse alkyl radical precursors will be 
discussed. Methods for coupling various trifluoroborate classes (α-alkoxy, α-trifluoromethyl, 
secondary and tertiary alkyl) will be covered, focusing on their complementarity to traditional 
protocols. Finally, a discussion of novel silicate radical precursors and their advantages in a single-
electron transmetalation regime will be included. 
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1 
PART I 
Chapter 1. Background on Cross-Coupling of Csp3 Nucleophiles: Design 
of a New Radical-Based Approach to Alkyl Transfer 
1.1 Introduction to Alkyl Cross-Coupling and Its Limitations  
 
Palladium and nickel have transformed the landscape of catalytic chemistry over the past 
century.1 Although hardly the first metals to be used in carbon-carbon bond-forming reactions, they 
have quickly become the catalysts of choice over early copper- and cobalt-based methods. In 
particular, nickel has recently grown in popularity relative to palladium because of its low cost, 
greater abundance, and lower toxicity.2 Especially for achieving alkyl-aryl couplings, nickel 
possesses a number of notable advantages, including its higher barriers for β-hydride elimination,3 
stable odd-electron oxidation states,4 and enhanced inner sphere reduction potential toward alkyl 
halides.5 
As indicated by the 2010 Nobel Prize in Chemistry, the importance of transition metal 
catalyzed cross-coupling to organic synthesis cannot be overstated.6 To date, these methods 
continue to be among the most broad, reliable, and powerful tools for constructing C–C bonds in 
the chemical literature. A typical cross-coupling proceeds through the following catalytic cycle: (1) 
oxidative addition of an aryl electrophile to a low-valent metal center, (2) transmetalation of an 
organometallic nucleophile to displace a weakly coordinating ligand, and (3) reductive elimination 
to forge a desired C-C bond and regenerate the catalyst (Figure 1.1).7,8  
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Figure 1.1: Standard cross-coupling catalytic cycle 
These reactions work exceptionally well for Csp2-Csp2 and Csp2-Csp bond formation. 
Unfortunately, because of the nature of the transmetalation step (vide infra), these reactions are 
much less amenable to Csp2-Csp3 cross-coupling. To illustrate this point, as of 2014, over 32,000 
articles had been published on cross-coupling methods, but a mere 600 (less than 2%) have been 
related to the use of alkylmetallic reagents in these reactions.9 
Driven by this clear methodological gap, the use of Csp3-hybridized nucleophiles in cross-
coupling has been a continued goal of the synthetic organometallic community since the 
development of Pd-catalyzed cross-coupling over 40 years ago.10 However, unlike the development 
of the related Csp2 couplings, the unique challenges associated with alkylmetallics has limited their 
development and widespread adoption. Among the issues associated with these reagents include 
the following: (1) the greater propensity to undergo protodemetalation,11,12 (2) the often pyrophoric 
nature of these reagents, requiring fresh preparation and superstoichiometric loadings, (3) the high 
barrier for efficient transmetalation13 in the catalytic cycle, typically requiring additives,14 and 
finally (4) in the case of successful alkyl transfer, the ready possibility for β-hydride 
elimination/reinsertion sequences,8,15 which afford a mixture of both olefinic byproducts and 
regioisomeric coupling products (Figure 1.2). 
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Figure 1.2: Possible side reactivity with secondary organometallics 
Despite these challenges, successful use of alkyllithium,16 -zinc,17–19 -magnesium,20–23 -
indium,24 -boron,25–27 -silicon,28,29 and -tin15 reagents in the cross-coupling with aryl electrophiles 
has been realized with a variety of catalysts systems (Pd, Ni, and Fe). Typically, these cross-
coupling methods work best for primary alkyl systems where potential isomerization favors the 
less sterically hindered position. Moving to secondary alkyl nucleophiles, only Kumada23 and 
Negishi17,19 reagents have been widely employed, but these methods suffer from limited functional 
group tolerance as both protic and electrophilic handles are sensitive to these highly reactive 
reagents.18,30 Isolated examples of success exist for secondary alkyl -boron26,27 and -stannane15 
reagents. For the former, these methods are completely intolerant of steric bulk and give complex 
product mixtures when bulky organoboron reagents are engaged (Figure 1.3). For the latter, these 
reagents remain untested for isomerization, but the perceived toxicity of alkylstannanes limits their 
broader use in academic and industrial settings. A qualitative comparison of these reagents and 
their properties can be found in Figure 1.4. 
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Figure 1.3: Isomerization of bulky organoboron reagents 
 
A closer look at Figure 1.4 highlights the overall advantages of organoboron reagents when 
stacked up against their competitors in alkyl cross-coupling. Organoboron reagents, in particular 
alkyltrifluoroborates, exist as indefinitely bench-stable, fluffy powders that do not require fresh 
preparation before use and release innocuous waste after the reaction is complete (borate and 
potassium halide salts). These properties are particularly advantageous in medicinal chemistry 
where libraries of compounds are made in a parallel manner. Unfortunately, the low nucleophilicity 
of these organoborons has always limited their general use in cross-coupling. Therefore, to improve  
 
Figure 1.4: Qualitative comparison of alkylmetallic reagents  
these organoboron reagents as potential partners in cross-coupling, it seemed prudent to consider 
the key steps in the classical cross-coupling which were responsible for their failure. Here, it was 
recognized that for nearly all organoboron cross-couplings, the transmetalation step is rate-
determining (Figure 1.5) 
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Figure 1.5: Rate-determining step in organoboron cross-couplings 
Examination of this step shows that significant anionic charge builds up on the transferring 
carbon in the transition state. Therefore, reagents best able to stabilize this negative charge such as 
the Csp and Csp2 hybridized organometallics typically perform best in cross-coupling. Furthermore, 
the most successful alkyl cross-couplings have generally defaulted to the more anionic reagents 
(zinc-, magnesium-, lithium-based organometallics) to overcome this high barrier for 
transmetalation. 
Instead of attempting to override the inherent mechanistic hierarchy of classical cross-
coupling, it was hypothesized that an odd-electron manifold for achieving a formal transmetalation 
might be possible through the intermediacy of an alkyl radical precursor. Notably, this single-
electron approach to transmetalation should exhibit complementary reactivity to traditional cross-
coupling as the trends in radical stability are inverted relative to their anionic counterparts (Figure 
1.6). 
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Figure 1.6: Relative stability trends for alkyl-centered anions and radicals 
 This concept of using radicals as transmetalating agents in cross-coupling was not 
unprecedented. Key mechanistic investigation of Ni-catalyzed reductive coupling chemistry from 
the Weix group31,32 (Figure 1.7) as well as radical rebound oxidative addition of alkyl halides 
pioneered by the Fu group33,34 suggested that this strategy would indeed be possible. These 
experiments delineated the clear presence of radical intermediates in Ni-catalyzed cross-coupling, 
observing cyclization products when using alkyl halides containing pendant olefins. Furthermore, 
nickel loading in these experiments drastically affected the amount of cyclization observed 
indicating that the radicals generated by inner sphere reduction at the nickel center escape the 
solvent cage and participate in radical chain events. Beyond these reports, radical addition 
processes at metal centers were believed to be virtually barrierless based on computational and 
experimental evaluation.35 However, unlike all hitherto reported methods, the proposed radical 
intermediates from organometallics needed to be generated via oxidation instead of reduction.  
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Figure 1.7. Weix’s mechanism for selectivity in nickel catalyzed reductive coupling 
Here, examination of the alkyltrifluoroborate literature gave numerous examples of 
stoichiometric radical generation under oxidizing conditions employing [Dess-Martin 
periodinane/CuII,36 Mn(OAc)2,37 Ag salts,38 etc]. Furthermore, there were even reports of radical 
generation of alkyltrifluoroborates under photoredox catalysis.39 Based on these reports, we were 
confident that facile radical generation from alkyltrifluoroborates would indeed be possible. 
However, generation of an alkyl radical and its addition to a metal center is an incomplete 
transmetalation; instead, addition of a radical to a metal center results in a metal center that is 
formally oxidized by one electron.40 Therefore, in order to achieve the overall redox-neutral profile 
of a traditional transmetalation, a subsequent single-electron reduction event would be required. 
(Figure 1.8) 
  
Figure 1.8. Comparison between radical capture at metal and traditional transmetalation 
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 The solution to this challenge is certainly non-obvious, given that the proposed oxidation 
and reduction events need to occur simultaneously within the confines of the same flask. A proposal 
based on stoichiometric reagents in this context was likely to be ineffectual as the reagents would 
self-quench unproductively instead of performing the desired oxidation and reduction events at the 
appropriate times within the catalytic cycle.41,42 Here, an ideal solution would be the ability to 
transiently generate both a single electron oxidant and reductant in a reaction mixture without 
significant side reactivity or reagent quenching. Fortunately, it was anticipated that photoredox 
catalysis would serve as an enabling technology for this exact purpose.43 
 
1.2 Photoredox Catalysis for the Generation of Organic Radicals  
 
Photoredox catalysis has been a rapidly growing field in organic synthesis over the last 20 
years, accelerated by publications from a number of high-profile groups.44–46 However, the origins 
of this field extend back over 80 years. For example, the most well-recognized photoredox catalyst 
Ru(bpy)32+ was first synthesized in 1936 by Burstall and co-workers, and is noted for its 
phosphorescent properties and remarkable configurational stability.47 Since its discovery, this 
complex has found uses in understanding electron transfer chemistry, observing photophysical 
phenomenon, assisting molecular labeling, etc.48 However, it was not until the late 1970s that 
Ru(bpy)32+ saw its first use as a catalytic photosensitizer in organic synthesis.49  
The photochemistry of these complexes has been studied extensively since these initial forays 
into catalytic electron transfer; therefore, a full picture of their excitation and relaxation pathways 
is now well-understood (Figure 1.9).50,51 First, visible light excitation of Ru(bpy)32+ complex I (λmax 
= 452 nm) leads to efficient excitation to the lowest singlet excited state II. This initially generated 
9 
singlet state (1MLCT state, MLCT = metal-to-ligand charge transfer) then undergoes an intersystem 
crossing to afford the long-lived, luminescent triplet excited state 3Ru(bpy)32+* (III). This triplet 
state has a number of possible relaxation pathways to afford the ground state complex I.41 In the 
absence of quencher, phosphorescent decay pathways can occur from the triplet state, emitting in 
the orange spectrum (dashed green line).  In the presence of an organic acceptor, outer sphere 
electron transfer from the ligand affords the oxidized Ru(bpy)33+ complex IV and the reduced 
acceptor. This oxidized catalyst can then accept an electron from a donor to return the catalyst to 
its ground state, Ru(bpy)32+ (I). Alternatively, in the presence of an organic donor, a reductive 
quenching manifold can occur where the photocatalyst accepts an electron at the metal center to 
afford complex (V). Followed by subsequent single-electron transfer from the ligand to an 
appropriate acceptor, the catalyst can then return to the ground state. In addition to these single-
electron transfer relaxation events, energy transfer events can occur to give triplet excitation in the 
presence of appropriate acceptor molecules (e.g., diarylketones).52 Each of these quenching events 
must be carefully considered when designing any photocatalytic transformation to avoid undesired 
off-cycle intermediates. 
 
Figure 1.9: Possible quenching pathways for Ru(bpy)32+ 
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As referenced above, the earliest reports of photosensitizers in organic synthesis began in the 
late 1970s, but these transformations largely explored the use of photoredox catalysts in purely 
overall reductive or overall oxidative transformations. In these methods, a readily reducible or 
oxidizable functional group is converted into a higher or lower oxidation state via successive single-
electron transfer events (Schemes 1.1 and 1.2). Typically, a stoichiometric terminal reductant (e.g., 
1,4-dihydropyridine)49 or terminal oxidant (e.g., aryldiazonium salt)53 is used to turn over the 
photocatalytic cycle with the sensitizer serving only as an electron shuttle between the two reagents.  
Most notably, under this paradigm an entire equivalent of material is sacrificed to achieve a desired 
transformation.  
Scheme 1.1. Net reduction of acylsulfonium salts
 
Scheme 1.2. Net oxidation of benzylic alcohols
 
Although these transformations were the first to establish the feasibility of performing 
photoredox catalysis in batch format on organic molecules, the resultant products often could be 
accessed in identical yields using stoichiometric quantities of an appropriate reductant or oxidant. 
11 
Therefore, the use of these photosensitizers languished in the materials and photophysics arenas for 
another fifteen years before being rediscovered by modern synthetic laboratories.  
The modern renaissance for photoredox chemistry was likely triggered by Barton and co-
workers in 1994.54 In a modified atom transfer radical addition reaction (ATRA), Barton was able 
to use both individual single-electron steps in a productive manner for the first time. In his work, 
initial oxidation of a Se-phenyl p-tolueneselenosulfonate generates a sulfonyl radical which is 
captured by a vinyl ether. The generated α-alkoxy radical is then oxidized to afford an 
oxocarbenium ion which readily intercepts the phenylselenoate byproduct of the first step. The 
Stephenson group55 was able to extend this chemistry further to alkyl halides as shown in Figure 
1.10. 
 
Figure 1.10. Redox neutral 1,2-halofunctionalization of alkenes 
Following these two pioneering contributions, the most powerful photoredox transformations 
to date have sought to use each of the catalytic single-electron steps in a productive manner. 
Successful integration of this concept has led to some remarkable bond disconnections, particularly 
in cases where long-lived radicals are selectively coupled with concomitantly generated transient 
radicals. Selected recent highlights of redox-neutral photoredox transformations include the 
following: (1) enantioselective α-alkylation of in situ generated iminium ions,44 (2) decarboxylative 
12 
alkylation of electron-poor arenes,56,57 (3) trifluoromethylation of arenes,58 (4) enamine coupling 
with silyl enols,59 and (5) anti-Markovnikov hydrofunctionalization of olefins.60 In addition to these 
fully organic redox-neutral transformations, the use of photoredox catalysts to modulate transition-
metal catalyzed reactions has rapidly evolved into its own unique field as discussed in Chapter 1.3. 
1.3 Fusion of Transition Metal Catalysis and Photoredox Catalysis 
  
Beginning in the early 2000s, many chemists began to question the possible effect that single-
electron photosensitizers might have on transition metal-catalyzed reactions. Given that oxidation 
state has been shown to perturb the overall reaction pathway significantly by improving catalyst 
stability,61 accelerating reductive elimination,62,63 altering oxidative addition rates,64 and enabling 
C–H  activation,65 the use of photoredox catalysts to modulate transition-metal oxidation states was 
an inevitable outcome. An interesting review by the Toste group discussing this realization has 
recently been published outlining the use of single-electron transfer for all elementary steps in 
transition metal catalysis.66 
The first report on this concept focused purely on rate acceleration observed in previously 
reported Pd-catalyzed Sonogashiri couplings. Here, addition of Ru(bpy)32+ led to improved reaction 
times and electrophile scope relative to methods using more traditional stoichiometric additives 
(Cu, Ag).67 Unfortunately, in this report, no attempt was made to understand the underlying 
mechanism. Instead, the authors suggest broadly that an energy transfer or single-electron oxidation 
event may be responsible for the Pd catalyst’s greater propensity for both oxidative addition and 
alkyne coordination.  
A second application of dual photoredox/palladium catalysis in cross-coupling chemistry was 
introduced in a seminal contribution by Sanford and co-workers.68 This transformation involves the 
13 
direct arylation of arenes by C–H bond activation. Previous studies on this transformation had 
identified diaryliodonium salts as a suitable aryl coupling partner, but high reaction temperatures 
(>95 ⁰C) were always required to overcome oxidative addition to a crowded palladium center.69 
Anticipating that aryl radicals might offer an alternative, highly oxidizing aryl group source, a dual 
catalytic system was proposed based on the well-established photoredox-mediated reduction of 
aryldiazonium salts.70 In contrast to other synthetic routes to aryl radicals, this process occurs at 
room temperature, showcasing how photoredox catalysis can generate reactive species under 
remarkably mild conditions. A summary of the reaction manifold can be found in Figure 1.11. 
 
Figure 1.11. Merger of Pd C-H activation with photoredox generated radicals 
 After the introduction of this concept to the literature, numerous reports have highlighted 
the fusion of photoredox catalysis with a variety of transition metal catalysts to achieve useful and 
unprecedented reactivity. For example, trifluoromethylation of boronic acids using copper has been 
achieved using a photoredox catalysts for the reduction of trifluoromethyl iodide.71 Here, the 
photocatalyst is integral in the oxidation of the Cu to its high valent CuIII state to facilitate reductive 
elimination. Gold catalysis has also been combined with photoredox catalysis to access highly 
reactive AuIII to facilitate the alkoxyarylations of alkenes.72,73 Given the infancy of this field, further 
14 
reports on the merger of photocatalysis with various transition metal catalysts will likely continue 
to occur with greater and greater frequency.74,75  
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PART II 
Chapter 2. Proof of Concept: Photoredox/Ni Dual Catalysis for the 
Cross-Coupling of Benzylic Trifluoroborates with Aryl Halides 
2.1 Introduction 
 
As highlighted in Chapter 1, the use of alkyl nucleophiles has been an ongoing challenge 
for cross-coupling chemistry.i However, it was speculated that radical intermediates could 
potentially be funneled into a base metal cross-coupling cycle to overcome a number of the key 
issues associated with traditional catalysis. To test this hypothesis experimentally, benzylic 
trifluoroborates were selected as an optimal radical nucleophile for three main reasons. First, the 
generation of these radicals under photoredox conditions was well-established.1 Second, their 
superb stability under the reaction conditions would avoid potential H-atom abstraction2 byproducts 
and other radical chain processes.3 And, finally, their use as coupling partners removed β-hydride 
elimination as a possible challenge in reaction development.  
With the radical nucleophile selected, screening of a broad array of potential 
photocatalysts, electrophiles, and transition metal complexes to achieve the desired coupling was 
initiated (Figure 2.1). This broad examination quickly narrowed focus to nickel-based systems 
given the formation of dehalogenation products (an indicator of oxidative addition) in the presence 
                                                     
i Reproduced in part from Science, 2014, 354, 433  
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of a variety of photocatalysts and electrophiles. By contrast, the use of a variety of alternative cross-
coupling metals (Pd, Cu, and Fe) typically returned starting materials under the reaction conditions.  
 
Figure 2.1. Screening of electrophile, metal, and photocatalyst scope 
 
Based on these initial screens and a careful examination of the literature, we were able to 
key in on the combination of heteroleptic iridium catalyst 1 and Ni(bpy)X2 complexes as having 
ideally matched properties for productive coupling (Figure 2.2). For the nickel catalyst, bipyridyl 
ligated nickel systems had been shown to be productive scaffolds for radical-mediated reductive 
couplings.4 Additionally, the redox potentials of these nickel catalysts had been previously reported 
in the literature, giving us confidence that single electron reduction of the most likely Ni states (NiI 
or NiII) would indeed be possible with our selected photocatalyst. For the photocatalyst, 1 had been 
successfully used in alkyltrifluoroborate oxidation to carbon-centered radicals, engaging those 
radicals in trapping with α,β-unsaturated carbonyl compounds and long-lived radicals such as 
TEMPO.1 Furthermore, the Ir catalysts return reduction potential was cathodic enough to achieve 
reduction of any of the possible nickel intermediates of interest. For reference, the photochemical 
half-cell potential that results from reduction of Ni(bpy)X to Ni0 in the presence of IrII to the ground 
state IrIII is exothermic by greater than 0.27 V. 
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Figure 2.2. Catalyst combination for photoredox cross-coupling 
 
Figure 2.3. Proposed catalytic cycle for photoredox coupling of benzylic trifluoroborates 
 
Based on the high reactivity of nickel, it was anticipated that the combination of a 
monomeric Ni(0) catalyst 2 and an aryl halide 3 would result in rapid oxidative addition, generating 
Ni(II) species 4. Concomitantly, visible light irradiation of Ir[dFCF3ppy]2(bpy)PF6 1 would 
generate excited state complex 5, the reduction potential of which is sufficiently high (Ered = +1.21 
V vs SCE)5 to induce single-electron oxidation of an activated alkyltrifluoroborate 6 (Eox = -1.10 
V vs SCE),1 affording the desired alkyl radical 7 upon fragmentation. Subsequent capture of the 
alkyl radical at Ni(II) would then yield high-valent Ni(III) intermediate 9, which was expected to 
undergo reductive elimination to generate the desired cross-coupled product 10 and Ni(I) complex 
11. From here, reduction of 11 (E1/2 > -1.10 V vs SCE)6 by the reduced form of the photocatalyst 8 
(E1/2 = +1.37 V vs SCE)5 would regenerate both the Ni(0) catalyst 2 and the Ir catalyst 1, closing 
the dual catalytic cycle (Figure 2.3). 
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Applying this dual catalytic, single-electron transmetalation approach to the cross-coupling 
of benzylic trifluoroborates and aryl bromides (Figure 2.4), efforts were quickly gratified, as a 
catalytic system consisting of photocatalyst 4, Ni(COD)2 (COD = 1,5-cyclooctadiene), and 2,2’-
bipyridine (bpy) as a ligand in acetone effected the cross-coupling of potassium 
benzyltrifluoroborate and bromobenzonitrile in 54% yield upon exposure to visible light from a 
26W compact fluorescent light bulb (CFL) at room temperature for 24 hours. Further optimization 
of these reaction conditions significantly improved both yield and conversion. Use of more 
electron-rich ligand systems such as 4,4’-di-tert-butyl-2,2’bipyridine (dtbbpy) improved overall 
conversions, presumably by accelerating oxidative addition. The use of MeOH as a cosolvent and 
lutidine as additive also significantly accelerated the reactions. In this cases, it is surmised that the 
alcohol serves to esterify the boron trifluoride generated under the reaction conditions, and lutidine 
then sequesters the generated hydrogen fluoride. Most importantly, control reactions performed in 
the absence of photocatalyst, Ni catalyst, or light resulted in no detectable product formation, 
confirming the essential role of each of these components in the dual catalytic process. 
 
2.2 Results and Discussion 
 
With reaction concept and optimized conditions established, a full analysis of reaction 
scope was initiated on both the benzylic trifluoroborate and aryl halide (Figure 2.4). Expectedly, 
electronic modification of the trifluoroborate component had a moderate effect on reaction yield, 
with more electron rich, and thus more highly stabilized, radical precursors (12 and 18) performing 
better than those substituted with electron withdrawing groups (15 and 17). Substrates possessing 
an ortho-substituent were well tolerated, evidenced by isolation of product 13 in 82% yield. The 
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reaction also exhibited increased efficiency on scale, as diarylmethane 12 was isolated in 97% yield 
on gram scale with reduced catalyst loading [1 mol % 4 and 1.5 mol % of Ni(COD)2 and ligand]. 
 
Figure 2.4. Photoredox cross-coupling of benzylic trifluoroborates and aryl bromides. 
 
High levels of versatility and functional group tolerance were observed with regard to the 
aryl halide partner. Substrates bearing electrophilic functional groups that would be incompatible 
with more highly reactive organometallic nucleophiles were well tolerated. Protic functional 
groups, including amide 24, sulfonamide 30, phenol 23, pyrazole 28, and NHBoc 36, could also be 
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employed. Substrates possessing substituents ortho to the halide (19, 27) were tolerated, albeit in 
diminished yield.  
A variety of nitrogen-containing heteroaryl bromides, classically challenging yet highly 
valued substrates as a result of their prevalence in biologically active compounds,7 performed well 
under the optimized reaction conditions. Pyridine substrates were coupled in all possible 
regioisomeric configurations (25, 32, 33, 34). Other important N-heterocycles, including 
pyrimidine 35, indole 29, and quinoline 27 proved to be competent partners. Although five-
membered heterocyclic bromides generally exhibited poor reactivity, electron deficient thienyl 
bromides were coupled in moderate yields, leading to 30 and 31.  
Several practical and more sustainable features derive from this approach to cross-
coupling.  Previous approaches to the cross-coupling of benzylboron compounds with aryl halides 
have required excess (3 equiv) aqueous base and temperatures no lower than 60 °C.8–10 
Furthermore, the present reaction makes use of air stable and inexpensive bipyridine ligands with 
low loading of the Ni catalyst. A derivative of photocatalyst 1 has recently been made commercially 
available and is similarly effective in promoting the desired reactivity.  
The reported cross-coupling reactions generally exhibited levels of efficiency and 
functional group tolerance equal to or surpassing those of traditional cross-coupling reactions on 
similar substrates. Most reactions cleanly afforded the desired product, with the remaining mass 
balance consisting of only unreacted aryl halide. Competing homocoupling of the trifluoroborate 
to afford bibenzyl derivatives was undetectable by crude HPLC analysis, allowing use of only a 
slight excess (1.2 equiv) of this reaction partner, which is typical in traditional Suzuki-Miyaura 
cross-couplings. Also of note is the compatibility of this reaction manifold with functional groups 
susceptible to single-electron oxidation or potentially reactive toward the radical intermediates, 
including phenol, anilide, and thienyl substructures, as well as 5-membered nitrogen heterocycles. 
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Remarkably, even 4-bromostyrene could be employed as an electrophile without competitive 
radical capture or polymerization, affording diarylmethane 22 in 61% yield.  
As a demonstration of the broader potential of the application of single-electron 
transmetalation in this dual catalytic cross-coupling, the conditions optimized for use with primary 
benzylic trifluoroborates were directly applied to the cross-coupling of a secondary (α-
alkoxy)alkyltrifluoroborate (Eq. 2.2). Comparable single-electron oxidation potentials serve as the 
singular commonality between these structurally dissimilar reagents. Thus, C-C bond formation 
via single-electron transmetalation proceeded smoothly under these extremely mild and 
unoptimized conditions. The differential reactivity between the two-electron and single-electron 
transmetalation processes is underscored by the stark differences in conditions previously reported 
for (α-alkoxy)alkyltrifluoroborate cross-coupling (5 equiv CsOH, 105 °C, 24 h) compared to those 
described herein.11 The observed reactivity also serves to demonstrate tolerance of substrates 
possessing β-hydrogens, a characteristic that is requisite of any general method for the cross-
coupling of alkyl substructures. 
 
 
Eq. 2.2. Photoredox cross-coupling of a secondary (α-alkoxy)alkyltrifluoroborate  
 
To highlight further the differences between this activation mode and that of traditional 
cross-coupling, a competition experiment was performed between potassium benzyltrifluoroborate 
and potassium phenyltrifluoroborate. Exposure of these two nucleophiles to the photoredox cross-
coupling conditions resulted in isolation of diarylmethane product 38 in 91% isolated yield, with 
no observable biaryl formation (Eq. 2.3). The ability to engage a Csp3-hybridized organometallic 
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reagent selectively in a transition metal-catalyzed C-C bond-forming reaction in the presence of an 
equivalent Csp2-hybridized organometallic represents a dramatic reversal of the reactivity hierarchy 
of all previously reported cross-coupling reactions. This effectively demonstrates the 
complementary reactivity patterns observed between the single-electron and two-electron 
transmetalation modes. 
 
 
Eq. 2.3: Competition experiment between potassium benzyltrifluoroborate and potassium 
phenyltrifluoroborate under photoredox cross-coupling conditions.  
 
Another important implication of the single-electron transmetalation manifold is related to 
the stereochemical outcome of the alkyl transfer. Nearly all cross-coupling reactions of stereo-
defined nucleophiles reported heretofore have demonstrated the transmetalation event to be 
stereospecific.12 Thus, enantioenriched products may only be accessed from nonracemic and 
configurationally stable organometallic reagents, which are often difficult to access. Isolated 
examples of stereoconvergence in transmetalation exist, specifically in the context of secondary 
benzylmagnesium reagents, a pyrrolidine-based organozinc, and a diastereoconvergent cross-
coupling of substituted cyclohexylzinc reagents.13–15 Stereoconvergence in the former is thought to 
be enabled by dynamic kinetic resolution of the configurationally unstable Grignard reagent, while 
the origin of selectivity in the latter is not fully understood. None of these approaches constitute a 
general strategy for stereoconvergent transmetalation beyond the scope of the directly explored 
reagents. 
In contrast, the stereochemical outcome of the single-electron transmetalation is dictated 
by facial selectivity of the addition of a prochiral alkyl radical to a ligated Ni center. Thus, 
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application of a chiral ligand framework renders this process asymmetric and provides a general 
reaction manifold in which stereoconvergent transmetalation can be achieved. Well-known 
stereoconvergent cross-couplings of alkyl halides, which putatively employ a similar mechanistic 
step, provide guidance for selection of appropriate ligand scaffolds to maximize the 
stereoselectivity of the radical capture.16  
 
 
 
Eq. 2.4. Stereoconvergent cross-coupling of a racemic trifluoroborate 39  
and aryl bromide to afford an enantioenriched product 
 
Indeed, employing commercially available ligand L1 under slightly modified conditions, 
racemic trifluoroborate 40 was engaged in stereoconvergent cross-coupling with methyl 3-
bromobenzoate, affording 1,1-diarylethane product 41 in 52% yield and a promising 75:25 er (Eq. 
2.4). The observed stereoconvergence serves as an effective mechanistic probe, supporting the role 
of the organotrifluoroborate as a carbon radical precursor, providing evidence that the radical is 
intercepted by the ligated Ni complex, and suggesting that C-C bond formation occurs via reductive 
elimination from Ni. This preliminary result strongly implies that high levels of stereoselectivity 
are possible in the photoredox cross-coupling of secondary alkyl nucleophiles with appropriate 
modification of reaction conditions and ligand structure. Refinement of this approach to 
asymmetric cross-coupling will provide a powerful advancement to the field by alleviating the need 
for synthesis of enantioenriched organometallic reagents. Taken together, these findings effectively 
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validate the single-electron transmetalation manifold and dual photoredox/cross-coupling cycle as 
a viable alternative to conventional cross-coupling of Csp3-hybridized nucleophiles.  
2.3 Conclusions 
 
In summary, the first successful integration of photoredox catalysis with Ni cross-coupling 
catalysis has been realized. The developed protocol allows the facile synthesis of diarylmethanes 
from commercially available aryl halides and benzylic trifluoroborates. The functional group 
tolerance of this coupling is unmatched by any previously reported protocol - allowing the coupling 
of sensitive electrophilic sites, protic functional handles, and a wide array of heterocyclic halides.  
Beyond the advancements in reaction scope, the use of benzylic and secondary alkoxy 
radicals in this single-electron transmetalation manifold indicate that this concept is a general 
strategy for overcoming the classical challenges of secondary alkyl cross-coupling with alkyl 
nucleophiles. Continued development of this concept should yield protocols extending to 
unactivated secondary and hopefully tertiary alkyl systems 
2.4 Experimental 
 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless otherwise 
noted. Acetone (99.9%, extra dry), MeOH (99.8% extra dry), and DMF (99.8%, anhydrous) were 
used as received. 2,6-Lutidine (>99%, purified by redistillation) was used without further 
purification (high purity lutidine was found to be important for reproducibly obtaining high yields. 
Commercially redistilled lutidine or lutidine distilled from AlCl3 and stored under N2 gave similar 
results). CuI, IrCl3·xH2O, and Ni(COD)2 were from commercial sources. Potassium 
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benzyltrifluoroborate was purchased or prepared using a published procedure.10 Potassium (1-
(benzyloxy)-3-phenylpropyl)trifluoroborate and potassium trifluoro(1-phenylethyl)borate were 
prepared according to published procedures.11,17 All other reagents were purchased commercially 
and used as received. Photoredox reactions were irradiated with a standard 26W compact 
fluorescent light bulb. Stereoconvergent cross-couplings were irradiated with blue LED light strips 
(~425 nm). Melting points (°C) are uncorrected. NMR spectra were recorded on a 500 or 400 MHz 
spectrometer. 19F NMR chemical shifts were referenced to external CFCl3 (0.0 ppm). 11B NMR 
spectra were obtained on a spectrometer equipped with the appropriate decoupling accessories. All 
11B NMR chemical shifts were referenced to an external BF3·OEt2 (0.0 ppm) with a negative sign 
indicating an upfield shift. Data are presented as follows: chemical shift (ppm), multiplicity (s = 
singlet, d = doublet, t = triplet, dd = doublet of doublets, m = multiplet, br = broad), coupling 
constant J (Hz) and integration. The 13C signal of the carbon bonded to boron was not observed in 
some cases due to quadrupolar relaxation. 
 
 
General procedure A for synthesis of benzylic trifluoroborates 
 
 
 
 
According to an unoptimized procedure derived from that reported by Liu and coworkers,18 to a 
flame-dried 20 mL vial was added benzylic bromide (5 mmol) and PPh3 (173 mg, 0.66 mmol). The 
vial was taken into a glovebox, and CuI (95 mg, 0.5 mmol), LiOMe (380 mg, 10 mmol, 2 equiv), 
and bis(pinacolato)diboron (1.93 g, 7.6 mmol, 1.52 equiv) were added. The vial was sealed with a 
Teflon-lined silicone septum, DMF was added, and the mixture was stirred vigorously under an 
inert atmosphere at rt for 20 h. The resultant brown, viscous mixture was filtered through a pad of 
silica gel, washing with EtOAc (60–100 mL). The filtrate was diluted with MeOH (HPLC grade, 
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~50 mL) and cooled to 0 °C.  Then sat. aq. KHF2 (9 mL, 40.5 mmol, 8.1 equiv) was added dropwise 
over 15 to 30 min, and the soln was allowed to warm to rt. The resultant suspension was 
concentrated under reduced pressure. Pinacol and H2O were azeotropically removed by suspension 
in toluene (100–150 mL) followed by rotary evaporation. The remaining solid was dried under high 
vacuum and then suspended in hot acetone (3 x 100 mL) and filtered. The filtrate was concentrated 
to a minimal volume (5–20 mL) and hexane (~200 mL) was added to yield a white precipitate. The 
precipitate was isolated by filtration, washing with hexane (~30 mL), and CH2Cl2 (~30 mL) to 
afford the desired benzylic trifluoroborate. 
 
General procedure B for synthesis of benzylic trifluoroborates 
 
 
 
According to an unoptimized procedure derived from that reported by Miyaura and coworkers,19 to 
a flame dried 100 mL round bottom flask equipped with a stir bar was added benzylic bromide (5 
mmol), KOAc (736 mg, 7.5 mmol), and (4-MeC6H4)3P (91 mg, 0.30 mmol). The flask was taken 
into the glovebox, and Pd(dba)2 (86 mg, 0.15 mmol) and bis(pinacolato)diboron (1.40 g, 5.5 mmol) 
were added. The flask was sealed with a rubber septum, toluene was added (30 mL), and the mixture 
was stirred vigorously under inert atmosphere for 20 h. The resultant yellow-brown mixture was 
concentrated to near dryness and then diluted with MeOH (HPLC grade, 20 mL), cooled to 0 oC, 
and sat. KHF2 (9 mL, 40.5 mmol, 8.1 equiv) was added dropwise by an addition funnel under inert 
atmosphere for 30 min. The resulting suspension was concentrated under reduced pressure. Pinacol 
and H2O were azeotropically removed by suspension in toluene (100-150 mL) followed by rotary 
evaporation. The remaining solid was dried under high vacuum and then suspended in hot acetone 
(3 x 100 mL) and filtered. The filtrate was concentrated to a minimal volume (5 – 20 mL) and 
hexane (~200 mL) was added to yield a white precipitate. The precipitate was isolated by filtration, 
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washing with hexanes (~30 mL) and CH2Cl2 (~30 mL), to afford the desired benzylic 
trifluoroborate. 
 
Synthesis of photocatalyst 1 
 
 
The synthesis of photocatalyst 1 has been documented in literature reports, though never compiled 
in one location. In an effort to aid the practicing chemist, the procedures found to be most effective 
in our hands are compiled below. Alternatively, the 4,4’-di-tert-butyl bipyridine derivative of 1 is 
commercially available. 
 
 
To a large vial equipped with a magnetic stir bar was added S1 (3.3 g, 15 mmol), S2 (2.26 g, 10 
mmol), anhyd K2CO3 (6.9 g, 50 mmol), and Pd(PPh3)4 (1.16 g, 1 mmol). The vial was sealed tightly 
with a Teflon-coated septum cap and evacuated and purged with N2 three times. The contents were 
dissolved in THF (32 mL) and degassed H2O (16 mL), then stirred at 80 °C for 24 h. After cooling 
to rt, the reaction mixture was diluted with H2O and extracted with CH2Cl2 (3 x 60 mL). The 
combined organic layers were dried (MgSO4), filtered, concentrated under reduced pressure, and 
purified by silica gel column chromatography, eluting with 5% EtOAc in hexanes to afford ligand 
S3 as white solid (2.54 g, 98%). mp = 55-58 °C. A small amount of PPh3 was usually observed 
after column chromatography (<5 mol %) which did not interfere with subsequent reactions. 1H 
NMR (500 MHz, CDCl3): δ = 8.96 (s, 1H), 8.12-8.07 (m, 1H), 7.98 (dd, J = 8.5, 2.0 Hz, 1H), 7.90 
(d, J = 8.5 Hz, 1H), 7.06-7.02 (m, 1H), 6.97-6.92 (m, 1H). 13C NMR (125.8 MHz, CDCl3): δ = 
163.8 (dd, J = 253.1, 12.5 Hz), 161.1 (dd, J = 253.5, 12.0 Hz), 155.8, 133.8 (d, J = 3.1 Hz), 132.6 
(dd, J = 9.7, 4.0 Hz), 128.6 (d, J = 6.9 Hz), 125.2 (q, J = 33.1 Hz), 123.70 (q, J = 272.2 Hz), 123.68 
(d, J = 10.9 Hz), 122.5 (dd, J = 11.2, 3.8 Hz), 112.3 (dd, J = 21.1, 3.5 Hz), 104.7 (dd, J = 26.0, 26.0 
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Hz). 19F NMR (CDCl3, 470.8 MHz):  = -62.3, -107.1 (d, J = 8.5 Hz), 112.0 (d, J = 8.5 Hz). IR:  
= 2925, 2337, 1601, 1321, 1119, 1058 cm-1. HRMS: (ESI) m/z calc. for C12H7NF5 (M+H) 259.0499, 
found 259.0421  
 
To a 20 mL round-bottom flask equipped with a magnetic stir bar was added ligand S4 (428 mg, 
1.65 mmol) and IrCl3 hydrate (224 mg, 0.75 mmol). The flask was equipped with a cold water 
condenser and evacuated and purged with N2 five times. The contents were suspended in rigorously 
degassed ethoxyethanol (9 mL) and H2O (3 mL) and then heated with stirring to 120 °C for 20 h, 
during which time a yellow precipitate was observed to form. After cooling to rt, the precipitate 
was collected by vacuum filtration. The filter cake was washed copiously with H2O (~75 mL) and 
hexanes (~30 mL) to afford iridium μ-Cl-dimer S5 as a fine yellow powder (84%). mp = >250 °C.  
Characterization data for this compound matched that reported in the literature.5 
 
 
To a 15 mL round-bottom flask equipped with a magnetic stir bar was added iridium dimer S4 (130 
mg, 0.087 mmol) and 2,2’-bipyridine (32 mg, 0.21 mmol). The flask was attached to a reflux 
condenser and the contents were placed under an inert atmosphere by three evacuation/purge 
cycles. The reaction components were dissolved in degassed ethylene glycol (6 mL) and heated 
with stirring at 150 °C for 24 h. Upon cooling to rt, the reaction mixture was diluted with an equal 
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volume of deionized H2O and transferred to a separatory funnel. The aqueous phase was washed 
three times with hexanes (10 mL), then drained into an Erlenmeyer flask and heated to ~85 °C for 
5-15 min. to remove residual hexanes. Upon cooling to rt, an aq soln of NH4PF6 (10 mL, 0.1 g/mL) 
was added, resulting in the formation of a fine yellow precipitate that was isolated by vacuum 
filtration, washing with H2O (20 mL) and hexanes (15 mL). The solid was dried under high vacuum 
to remove residual H2O and then dissolved in acetone and recrystallized by vapor diffusion with 
pentane to yield 1 as large yellow crystals (172 mg, 88%). mp = 199-202 °C.  Characterization data 
for this compound matched that reported in the literature.20 
 
Selected reaction optimization studies 
 
 
Procedure for reaction screening at 0.01 or 0.05 mmol scale: To a reaction vial equipped with a 
Teflon coated magnetic stir bar in a glovebox was added a soln of Ni(COD)2 and ligand [1:1 
Ni(COD)2:ligand] dissolved in THF (0.1 M). The solvent was removed in vacuo under an inert 
atmosphere, then a soln of potassium benzyltrifluoroborate (1 equiv), 4-bromobenzonitrile (1 
equiv), and 4,4’-di-tert-butylbiphenyl (0.1 equiv) in 1 mL of solvent (0.1 M) was added, followed 
by a soln of photocatalyst 1. If desired, an alcoholic cosolvent or amine base was added before the 
vial was sealed and stirred over blue LED lights. After 24 h the reactions were opened to air, diluted 
with acetonitrile, and analyzed by reversed phase analytical HPLC using product:internal standard 
(4,4’-di-tert-butylbiphenyl) ratios as a qualitative assessment of reaction yield. 
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Figure 2.5. Conditions: 2 mol % 1, 10 mol % Ni(COD)2, 10 mol % 2,2’-bipyridine, 0.1 M, 24 h, 
0.01 mmol 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Conditions: 2 mol % 1, 10 mol % Ni(COD)2, 10 mol % ligand, 10:1 acetone/MeOH, 
2 equiv 2,6-lutidine, 0.1 M, 24 h, 0.01 mmol 
 
Solvent Cosolvent Additive 
MeCN MeOH 2,6-lutidine 
MeCN MeOH None 
MeCN None None 
acetone MeOH 2,6-lutidine 
acetone MeOH None 
Acetone None None 
Ligand 
prolinol 
terpyridine 
4,4’-di-tert-butyl bipyridine 
2,2’-bipyridine 
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Figure 2.7. Conditions: 1:1 Ni(COD)2/dtbbpy, 10:1 acetone/MeOH, 2 equiv 2,6-lutidine, 0.1 M, 
24 h, 0.05 mmol 
 
Figure 2.8. Conditions: 1 mol % 1, 5 mol % Ni(COD)2, 5 mol % dtbbpy, 10:1 acetone/alcohol, 2 
equiv 2,6-lutidine, 0.1 M, 24 h, 0.05 mmol 
 
Figure 2.9. Conditions: 2 mol % 1, 3 mol % Ni(COD)2, 3 mol % dtbbpy, 95:5 acetone/methanol, 
3.5 equiv 2,6-lutidine, 0.1 M, 24 h, 0.05 mmol 
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General procedure for photoredox cross-coupling reactions 
 
 
 
To a two dram (8 mL) borosilicate glass vial equipped with a Teflon-coated magnetic stir bar was 
added aryl bromide (0.5 mmol, 1 equiv) (liquid aryl bromides were added with solvent), benzylic 
trifluoroborate (0.6 mmol, 1.2 equiv), Ir[dFCF3ppy]2(bpy)PF6 1 (10 mg, 0.01 mmol), and 4,4’-di-
tert-butyl-2,2’-bipyridine (4.0 mg, 0.015 mmol). The vial was taken into a glovebox and Ni(COD)2 
(4.1 mg, 0.015 mmol) was added. The vial was sealed with a plastic screw cap containing a Teflon-
lined silicone septum, removed from the glovebox, and evacuated and purged with inert gas three 
times. Under inert atmosphere was introduced successively acetone (4.75 mL), methanol (0.25 
mL), and 2,6-lutidine (202 μL, 1.75 mmol, 3.5 equiv). The vial was sealed with Teflon ribbon, 
electrical tape, and parafilm and stirred for 24 hours approximately 3 cm from a 26 W fluorescent 
light bulb. The crude reaction mixture was filtered through an approximately 2 cm x 2 cm 
cylindrical plug of Celite, washing with EtOAc (30–50 mL). The residue was purified by column 
chromatography on silica gel, eluting with EtOAc and hexanes, to obtain products in pure form. 
 
 
Figure 2.10: Photoredox cross-coupling reaction set-up (0.5 mmol scale) 
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Gram scale reaction: To a ~75 mL Schlenk flask equipped with a Teflon-coated magnetic stir bar 
was added 4-bromobenzonitrile (1.000 g, 5.49 mmol, 1 equiv), benzyl trifluoroborate (1.306 g, 6.59 
mmol, 1.2 equiv), Ir[dFCF3ppy]2(bpy)PF6 1 (55.0 mg, 0.055 mmol, 0.01 equiv), and 4,4’-di-tert-
butyl-2,2’-bipyridine (22.0 mg, 0.082 mmol, 0.015 equiv). The flask was taken into the glovebox, 
and Ni(COD)2 (22.5 mg, 0.082 mmol, 0.015 equiv) was added. The flask was sealed, and under an 
inert atmosphere, acetone (47.5 mL), MeOH (2.5 mL), and 2,6-lutidine (2.24 mL, 19.2 mmol, 3.5 
equiv) were added successively. The reaction was stirred ~5 cm from two 26 watt compact 
fluorescent light bulbs for 24 h. After filtration though Celite, the residue was purified by column 
chromatography on silica gel, eluting with EtOAc and hexanes, to obtain the product in pure form. 
 
 
 
Figure 2.11: Gram scale photoredox cross-coupling reaction set-up (5.5 mmol) 
 
Benzyl-aryl competition experimental details 
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The reaction was performed according to the general procedure for photoredox cross-coupling at 
0.5 mmol scale using 1.2 equiv BnBF3K and 1.2 equiv PhBF3K. The crude reaction was analyzed 
by reversed phase analytical HPLC. A product standard for biaryl was synthesized according to a 
literature procedure.21 After workup and purification according to the general procedure, 
diarylmethane product 38 was isolated in 91% yield (88 mg). 
 
 
 
Figure 2.12: Crude HPLC chromatogram for benzyl-aryl competition experiment under 
photoredox cross-coupling conditions. 
 
A traditional Suzuki-Miyaura cross-coupling was performed for comparison of the product 
distribution in the photoredox cross-coupling to that of a cross-coupling employing a traditional 
transmetalation. The reaction was performed on 0.2 mmol scale using 1.2 equiv BnBF3K, 1.2 equiv 
PhBF3K, and 1 mol % Pd(OAc)2. The crude reaction mixture was analyzed by reversed phase 
analytical HPLC. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Crude HPLC chromatogram for benzyl-aryl competition experiment under 
conventional Suzuki-Miyaura cross-coupling conditions 
 
4.78 min 
4.70 min 
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Procedure for stereoconvergent cross-coupling 
 
 
 
To a two dram (8 mL) borosilicate glass vial equipped with a Teflon-coated magnetic stir bar was 
added methyl 3-bromobenzoate (108 mg, 0.5 mmol, 1 equiv), potassium trifluoro(1-
phenylethyl)borate (127 mg, 0.6 mmol, 1.2 equiv), Ir[dFCF3ppy]2(bpy)PF6 1 (10 mg, 0.01 mmol), 
and L1 (4.8 mg, 0.015 mmol). The vial was taken into a glovebox, and Ni(COD)2 (4.1 mg, 0.015 
mmol) was added. The vial was sealed with a plastic screw cap containing a Teflon-lined silicone 
septum, removed from the glovebox, and evacuated and purged with inert gas three times. Under 
inert an atmosphere, THF (4.75 mL), MeOH (0.25 mL), and 2,6-lutidine (202 μL, 1.75 mmol, 3.5 
equiv) were introduced successively. The vial was sealed with Teflon ribbon, electrical tape, and 
Parafilm and stirred for 24 h in a crystallization dish surrounded by blue LED lights. The crude 
reaction mixture was filtered through an approximately 2 cm x 2 cm cylindrical plug of Celite, 
washing with EtOAc (30–50 mL). The residue was purified by column chromatography on silica 
gel, eluting with EtOAc and hexanes, to obtain product in pure form. 
 
Compound Characterization Data 
 
 
4-(4-Methoxybenzyl)benzonitrile (12): obtained as a white solid (105 mg, 94%), mp = 48-50 °C. 
1H NMR (CDCl3, 500 MHz): δ = 7.56 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 7.5 Hz, 2H), 7.07 (d, J = 8.5 
Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 3.97 (s, 2H), 3.79 (s, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 
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158.5, 147.4, 132.4, 131.6, 130.1, 129.7, 119.2, 114.3, 110.0, 55.4, 41.2. Characterization data 
matched that reported in the literature.22  
 
4-(2,4-Difluorobenzyl)benzonitrile (13): obtained as a white crystalline solid (80 mg, 70%), Mp 
= 63-65 °C. 1H NMR (CDCl3, 500 MHz): δ = 7.59 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 
7.13-7.11 (m, 1H), 6.86-6.82 (m, 2H), 4.02 (s, 2H) 13C NMR (CDCl3, 125.8 MHz): δ = 162.3 (dd, 
J = 148.6, 11.8 Hz), 160.3 (dd, J = 148.9, 11.8 Hz), 145.1, 132.3, 131.5 (dd, J = 9.7, 6.2 Hz), 129.3, 
122.2 (dd, J = 12.5, 3.6 Hz), 118.7, 111.4 (dd, J = 21.1, 3.8 Hz), 110.3, 104.0 (dd, J = 25.5, 25.5 
Hz). 19F NMR (CDCl3, 470.8 MHz):  = -111.7, -113.0. IR:  = 2225, 1604, 1500, 1269, 1136, 968, 
852 cm-1. HRMS: (ESI) m/z calc. for C14H10NF2 (M+H) 230.0781, found 230.0772. 
 
4-(2-Methylbenzyl)benzonitrile (14): obtained as a white solid (85 mg, 82%),  mp = 50-52 °C. 1H 
NMR (CDCl3, 500 MHz): δ = 7.57 (d, J = 8.5 Hz, 2H), 7.26-7.21 (m, 5H), 7.13-7.12 (m, 1H), 4.07 
(s, 2H), 2.24 (s, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 146.2, 137.2, 136.5, 132.2, 130.5, 130.0 
129.3, 127.0, 126.2, 118.9, 109.9, 39.5, 19.6. Characterization data matched that reported in the 
literature.23 
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Methyl 4-(4-Cyanobenzyl)benzoate (15): obtained as a colorless oil (94 mg, 75%). 1H NMR 
(CDCl3, 500 MHz): δ = 7.97 (d, J = 8.0 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 
7.22 (d, J = 8.0 Hz, 2H), 4.08 (s, 2H), 3.89 (s, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 167.0, 
145.8, 144.7, 132.6, 130.2, 129.8, 129.1, 128.8, 119.0, 110.5, 52.3, 42.0. Characterization data 
matched that reported in the literature.23 
 
4-(4-(Trifluoromethoxy)benzyl)benzonitrile (16): obtained as a colorless oil (106 mg, 76%). 1H 
NMR (CDCl3, 500 MHz): δ = 7.58 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 7.19-7.15 (m, 4H), 
4.04 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 147.9, 145.9, 138.0, 132.3, 130.1, 129.5, 121.2, 
120.4 (q, J = 257.3 Hz), 118.7, 110.3, 41.1. 19F NMR (CDCl3, 470.8 MHz): δ = -57.9. IR:  = 2920, 
2228, 1608, 1508, 1257, 1222, 1161, 1020, 921, 811 cm-1. HRMS (ESI) m/z calc. for C15H11NOF3 
(M+H) 178.0793, found 178.0795. 
 
4-(Benzo[d][1,3]dioxol-5-ylmethyl)benzonitrile (17): obtained as a white crystalline solid (115 
mg, 97%) , mp = 106-108 °C. 1H NMR (CDCl3, 500 MHz): δ = 7.56 (d, J = 8.0 Hz, 2H), 7.27 (d, 
J = 8.0 Hz, 2H), 6.75 (d, J = 8.0 Hz, 1H), 6.64-6.61 (m, 2H), 5.92 (s, 2H), 3.93 (s, 2H). 13C NMR 
(CDCl3, 125.8 MHz): δ = 148.1, 147.0, 146.5, 133.2, 132.4, 129.6, 122.1, 119.1, 110.2, 109.5, 
108.6, 101.2, 41.8. IR:  = 2920, 2362, 2226, 1604, 1491, 1254, 1038, 927, 816 cm-1. HRMS: (ESI) 
m/z calc. for C15H12NO2 (M+H) 238.0868, found 238.0860. 
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1-Benzyl-4-methoxybenzene (18): obtained as a colorless oil (74 mg, 75%). 1H NMR (CDCl3, 500 
MHz): δ = 7.31-7.28 (m, 2H), 7.22-7.19 (m, 3H), 7.12 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 
3.95 (s, 2H), 3.80 (s, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 158.1, 141.7, 133.4, 130.0, 129.0. 
128.5, 126.1, 114.0, 55.4, 41.2. Characterization data matched that reported in the literature.24 
 
1-Benzyl-2-methylbenzene (19): obtained as a colorless oil (51 mg, 56%). 1H NMR (CDCl3, 500 
MHz): δ = 7.30-7.27 (m, 2H), 7.21-7.11 (m, 7H), 4.01 (s, 2H) 2.26 (s, 3H). 13C NMR (CDCl3, 125.8 
MHz): δ = 140.6, 139.1, 136.8, 130.5, 130.2, 129.0, 128.6, 126.7, 126.2, 126.1, 39.7, 19.9. 
Characterization data matched that reported in the literature.25 
 
Methyl 3-Benzylbenzoate (20): obtained as a pale yellow oil (102 mg, 90%). 1H NMR (CDCl3, 
500 MHz): δ = 7.93-7.89 (m, 2H), 7.40-7.35 (m, 2H), 7.32-7.30 (m, 2H), 7.24-7.20 (m, 3H), 4.04 
(s, 2H), 3.91 (s, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 167.3, 141.6, 140.7, 133.7, 130.5, 130.2, 
129.0, 128.8, 128.7, 127.6, 126.5, 52.3, 41.9. Characterization data matched that reported in the 
literature.26 
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1-Benzyl-4-(trifluoromethyl)benzene (21): obtained as a colorless oil (93 mg, 79%). 1H NMR 
(CDCl3, 500 MHz): δ = 7.52 (d, J = 8.0 Hz, 2H), 7.30-7.26 (m, 4H), 7.22-7.19 (m, 1H), 7.16 (d, J 
= 7.5 Hz, 2H), 4.01 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 145.4, 140.2, 129.4, 129.1, 128.9, 
128.7 (q, J = 32.2 Hz), 126.7, 125.6 (q, J = 3.9 Hz), 123.4, 41.9. 19F NMR (CDCl3, 470.8 MHz): δ 
= -62.3. Characterization data matched that reported in the literature.27 
 
1-Benzyl-4-vinylbenzene (22): obtained as a colorless oil (59 mg, 61%). 1H NMR (CDCl3, 500 
MHz): δ = 7.38-7.27 (m, 4H), 7.23–7.18 (m, 5H), 6.73 (dd, J = 17.5, 11.0 Hz, 1H), 5.74 (d, J = 
17.5, 1H), 5.23 (d, J = 11.0, 1H), 4.01 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 140.9, 140.7, 
136.5, 135.5, 129.0, 128.8, 128.4, 126.3, 126.0, 113.1, 41.6. Characterization data matched that 
reported in the literature.25 
 
4-Benzylphenol (23): obtained as a white solid (58 mg, 63%), mp = 80-82 °C. 1H NMR (CDCl3, 
500 MHz): δ = 7.32-7.29 (m, 2H), 7.23-7.18 (m, 3H), 7.07 (d, J = 8.0 Hz, 2H), 6.76 (d, J = 8.0 Hz, 
2H) 4.84 (s, 1H), 3.93 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 153.9, 141.7, 133.6, 130.3, 
129.0, 128.6, 126.2, 115.5, 41.2. Characterization data matched that reported in the literature.28 
 
N-(4-Benzylphenyl)acetamide (24): obtained as a white solid (107 mg, 96%), mp = 117-119 °C. 
1H NMR (CDCl3, 500 MHz): δ = 7.40 (d, J = 8.5 Hz, 2H), 7.28 (t, J = 7.5 Hz, 1H), 7.21-7.13 (m, 
5H), 3.94 (s, 2H), 2.16 (s, 3H).13C NMR (CDCl3, 125.8 MHz): (* denotes minor rotamer) δ = 168.8, 
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141.0, 137.1, 136.0, 131.7*, 129.3, 129.0, 128.4, 126.0, 121.5*, 120.3, 41.3, 24.3. IR:  = 3249, 
3186, 3120, 2898, 2362, 1659, 1604, 1552, 1511, 1410, 1322, 1271, 850, 731 cm-1. HRMS (ESI) 
m/z calc. for C15H16NO (M+H) 226.1232, found 226.1235. 
 
3-Benzyl-5-methoxypyridine (25): obtained as a dark yellow oil (74 mg, 75%). 1H NMR (CDCl3, 
500 MHz): δ = 8.17 (s, 1H), 8.13 (s, 1H), 7.31-7.28 (m, 2H), 7.23-7.17 (m, 3H), 6.97 (s, 1H), 3.96 
(s, 2H), 3.80 (s, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 147.9, 145.9, 138.0, 132.3, 130.1, 129.5, 
121.2, 120.4 (q, J = 257.3 Hz), 118.7, 110.3, 41.1. IR:  = 3027, 2940, 2838, 1586, 1426, 1281, 
1184, 1156, 1051, 843, 718, 669 cm-1. HRMS (ESI) m/z calc. for C13H14NO (M+H) 200.1075, found 
200.1066. 
 
2-(4-Benzylphenyl)-1,3,4-oxadiazole (26): obtained as a yellow solid (85 mg, 72%), mp = 71-73 
°C. 1H NMR (CDCl3, 500 MHz): δ = 8.43 (s, 1H), 8.00 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 
2H), 7.32 (d, J = 7.5 Hz, 2H), 7.25-7.19 (m, 3H), 4.06 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 
164.9, 152.6, 145.8, 140.1, 129.8, 129.1, 128.8, 127.4, 126.6, 121.5, 42.0. IR:  = 2924, 2854, 1614, 
1493, 1094, 1065, 865, 712 cm-1. HRMS (ESI) m/z calc. for C15H13N2O (M+H) 237.1028, found 
237.1034. 
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5-Benzylquinoline (27): obtained as a white solid (64 mg, 58%), mp = 80-81 °C. 1H NMR (CDCl3, 
500 MHz): δ = 8.90 (dd, J = 4, 1.5 Hz, 1H), 8.30 (d, J = 8.5 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.67 
(dd, J = 8.4, 7.2 Hz, 1H), 7.61-7.24 (m, 4H), 7.13 (m, 3H), 4.45 (s, 2H). 13C NMR (CDCl3, 125.8 
MHz): δ = 149.9, 148.8, 140.0, 137.0, 132.5, 129.1, 128.5, 127.7, 127.1, 126.2, 120.8, 38.4. 
Characterization data matched that reported in the literature.29 
 
5-(3-Benzylphenyl)-1H-pyrazole (28): obtained as a white solid (76 mg, 65%), mp = 78-79 °C. 
1H NMR (CDCl3, 500 MHz): δ = 11.46 (br s, 1H), 7.63 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.54 (d, J 
= 2 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.31-7.27 (m, 2H), 7.22-7.19 (m, 3H), 7.16 (d, J = 7.5 Hz, 
2H), 6.58 (d, J = 1.5 Hz, 1H), 4.01 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 141.8, 141.0, 133.3, 
132.4, 129.10, 129.09, 128.9, 128.7, 126.5, 126.3, 125.9, 123.8, 102.9, 42.1. IR:  = 3166, 3068, 
2919, 2850, 1559, 1494, 1472, 1452, 1357, 1052, 822, 771, 706 cm-1. HRMS (ESI) m/z calc. for 
C16H15N2 (M+H) 235.1235, found 235.1235. 
 
5-Benzyl-1H-indole (29): obtained in pure form as a white solid (57 mg, 55%), mp = 40-42 °C, 
and as a mixture with aryl bromide starting material [30 mg (mass of mixture), 18% (based on 1H 
NMR purity analysis)]. 1H NMR (CDCl3, 500 MHz): δ = 7.99 (br s, 1H), 7.50 (s, 1H), 7.33-7.21 
(m, 6H), 7.16 (d, J = 2.5 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.52 (s, 1H), 4.13 (s, 2H). 13C NMR 
(CDCl3, 125.8 MHz): δ = 142.3, 134.4, 132.5, 128.9, 128.3, 128.1, 125.8, 124.3, 123.5, 120.6, 
110.9, 102.4, 42.0. IR:  = 3401, 2923, 2853, 2358, 1453, 1338, 1090, 1028, 762, 730, 699 cm-1 
HRMS (ESI) m/z calc. for C15H14N (M+H) 208.1126, found 208.1135. 
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5-Benzylthiophene-2-sulfonamide (30): obtained as a white solid (71 mg, 56%), mp =89-90 °C 
1H NMR (CDCl3, 500 MHz): δ = 7.78 (d, J = 3.5 Hz, 1H), 7.34 (m, 2H), 7.29-7.23 (m, 3 H), 6.76 
(d, J = 3.5 Hz, 1H), 4.93 (s, 2H), 4.15 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 152.1, 140.8, 
138.9, 132.1, 129.0, 128.8, 127.3, 125.5, 36.5. IR:  = 3382, 3276, 3109, 2918, 1566, 1443, 1330, 
1163, 1142, 1020, 908, 704 cm-1. HRMS (ESI) m/z calc. for C11H10NO2S2 (M-H) 252.0153, found 
252.0164. 
 
5-Benzylthiophene-2-carbaldehyde (31): obtained as a colorless oil (55 mg, 54%). 1H NMR 
(CDCl3, 500 MHz): δ = 9.81 (s, 1H), 7.60 (d, J = 3.5 Hz, 1H), 7.35-7.32 (m, 2H), 7.28-7.24 (m, 
3H), 6.90 (d, J = 3.5 Hz, 1H), 4.19 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 182.8, 155.9, 142.6, 
138.9, 137.0, 129.0, 128.8, 127.2, 126.8, 37.0. Characterization data matched that reported in the 
literature.28 
 
5-Benzylpicolinonitrile (32): obtained as a colorless oil (87 mg, 90%). 1H NMR: (CDCl3, 500 
MHz): δ = 8.60 (s, 1H), 7.60 (m, 2H), 7.33 (dd, J = 7.0, 7.0 Hz, 2H), 7.27 (m, 1H), 7.16 (d, J = 7.0 
Hz, 2H), 4.06 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 151.7, 141.1, 138.3, 137.2, 131.8, 129.2, 
129.1, 128.4, 127.2, 117.5, 39.2. IR:  = 3027, 2920, 2851, 2362, 2234, 1586, 1566, 1496, 1470, 
47 
1454, 1392, 1027, 741, 706 cm-1. HRMS (ESI) m/z calc. for C13H11N2 (M+H) 195.0922, found 
195.0924. 
 
2-Benzyl-5-(trifluoromethyl)pyridine (33): obtained as a colorless oil (77 mg, 65%). 1H NMR 
(CDCl3, 500 MHz): δ = 8.84 (s, 1H), 7.82 (d, J = 7.0 Hz, 1H), 7.34-7.32 (m, 2H), 7.28-7.24 (m, 
4H), 4.25 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 165.2, 146.5 (d, J = 3.5 Hz), 138.6, 133.8, 
129.3, 129.0, 127.0, 124.6 (q, J = 33.2), 123.9 (q, J = 271.9), 122.9, 44.8. 19F NMR (CDCl3, 470.8 
MHz): δ = -62.3. IR:  = 3030, 2360, 1605, 1495, 1322, 1327, 1124, 1017, 735 cm-1. HRMS (ESI) 
m/z calc. for C13H11F3N (M+H) 208.0844, found 208.0842. 
 
4-Benzyl-2-methylpyridine (34): obtained as a light yellow oil (52 mg, 57%). 1H NMR (CDCl3, 
500 MHz): δ = 8.38 (d, J = 5.0 Hz, 1H), 7.32 (m, 2H), 7.25 (m, 1 H), 7.17 (d, J = 7.0 Hz, 2H), 6.97 
(s, 1H), 6.91 (d, J = 5.0 Hz, 1H), 3.92 (s, 2H), 2.51 (s, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 
158.6, 150.4, 149.3, 139.3, 129.2, 128.8, 126.7, 123.8, 121.5, 41.4, 24.5. IR:  = 3027, 2923, 2358, 
1600, 1558, 1495, 1453, 734, 699 cm-1. HRMS (ESI) m/z calc. for C13H14N (M+H) 184.1126, found 
184.1117. 
 
5-Benzylpyrimidine (35): obtained as yellow crystals (82 mg, 96%), mp = 45-47 °C. 1H NMR 
(CDCl3, 500 MHz): δ = 9.07 (s, 1H), 8.57 (s, 2H), 7.33-7.30 (m, 2H) 7.25-7.22 (m, 2H) 7.17-7.15 
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(m, 2H), 3.95 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 157.15, 157.08, 138.4, 134.4, 129.1, 
128.9, 127.1, 36.7. IR:  = 3032, 2916, 2850, 1560, 1408, 1230, 1100, 987, 924, 749, 729 cm-1. 
HRMS (ESI) m/z calc. for C11H11N2 (M+H) 171.0922, found 171.0919. 
 
 
 
Methyl (S)-3-(4-Benzylphenyl)-2-((tert-butoxycarbonyl)amino)propanoate (36) obtained as a 
yellow oil after purification by preparatory reverse phase high pressure liquid chromatography (19 
x 100 mm Waters XBridge Prep BHE130 C18 column, 10%  90% MeCN/H2O, 20 mL/min flow 
rate)  (116 mg, 63%). 1H NMR (CDCl3, 500 MHz): δ = 7.30-7.27 (m, 2H), 7.22-7.17 (m, 3H), 7.11 
(d, J = 8.0 Hz, 2H), 7.04 (d, J = 8.0 Hz, 2H), 4.96 (d, J = 7.5 Hz, 1H), 4.57 (dd, J = 14.0, 6.0 Hz, 
1H), 3.95 (s, 2H), 3.71 (s, 3H), 3.10-2.99 (m, 2H), 1.41 (s, 9H). 13C NMR (CDCl3, 125.8 MHz): δ 
= 172.4, 155.2, 141.0, 139.0, 133.8, 129.5, 129.2, 129.0, 128.5, 126.2, 100.0, 79.9, 54.5, 52.2, 41.6, 
38.0, 28.4. IR:  = 3363, 2978, 2362, 1745, 1715, 1494, 1366, 1166 cm-1. HRMS (ESI) m/z calc. 
for C22H27NO4Na (M+Na) 392.1838, found 392.1822. Chiral SFC (ChiralPak AD-H column: 10% 
MeOH in CO2, 5.0 mL/min) tr = 2.017 (major peak). 
 
4-Benzylbenzaldehyde (37): obtained as a colorless oil (79 mg, 81%). 1H NMR (CDCl3, 500 
MHz):  = 9.98 (s, 1H), 7.81 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.31 (dd, J = 7.5, 7.0 
Hz, 2H), 7.24 (t, J = 7.0 Hz, 1H), 7.19 (d, J = 7.5 Hz, 2H), 4.06 (s, 2H). 13C NMR (CDCl3, 125.8 
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MHz):  = 192.1, 148.6, 139.9, 134.8, 130.2, 129.7, 129.1, 128.8, 126.7, 42.2. Characterization 
data matched that reported in the literature.9 
 
 
4-Benzylbenzonitrile (38): obtained as a white crystalline solid (86 mg, 89%); gram scale (1029 
mg, 97%), mp = 47-50 °C. 1H NMR (CDCl3, 500 MHz): δ = 7.57 (d, J = 8.5 Hz, 2H), 7.25-7.32 
(m, 5H), 7.17 (d, J = 7.5 Hz, 2H), 4.04 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 146.9, 139.5. 
132.4, 129.8, 129.1, 128.9, 126.8, 119.1, 110.2, 42.1. Characterization data matched that reported 
in the literature.30  
 
 
4-(1-(benzyloxy)-3-phenylpropyl)benzonitrile (40): prepared using the general procedure for 
primary benzyl cross-couplings, obtained as a colorless oil (106 mg, 65%). 1H NMR (CDCl3, 500 
MHz): δ = 7.67 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.40-7.37 (m, 2H), 7.34-7.32 (m, 3H), 
7.30-7.26 (m, 2H), 7.22-7.18 (m, 1H), 7.14 (d, J = 7.5 Hz, 2H), 4.46 (d, J = 11.5 Hz, 1H), 4.38 (dd, 
J = 8.5, 4.5 Hz, 1H), 4.29 (d, J = 11.5 Hz, 1H), 2.83-2.77 (m, 1H), 2.72-2.67 (m, 1H), 2.19-2.14 
(m, 1H), 1.97-1.92 (m, 1H). 13C NMR (CDCl3, 125.8 MHz): δ = 148.2, 141.3, 137.9, 132.4, 128.5, 
128.40, 128.38, 127.78, 127.76, 127.3, 125.9, 118.8, 111.4, 79.8, 71.0, 39.8, 31.8. IR:  = 3028, 
2924, 2228, 1607, 1496, 1094, 853, 698, 737 cm-1 HRMS (ESI) m/z calc. 328.1701 for (M+H), 
found 328.1709. 
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Methyl 3-(1-Phenylethyl)benzoate (41): obtained as a colorless oil (62 mg, 52%). 1H NMR 
(CDCl3, 500 MHz): δ = 7.96 (m, 1H), 7.87 (m, 1H), 7.41-7.28 (m, 4H), 7.22-7.18 (m, 3H), 4.21 (q, 
J = 7.5 Hz, 1H), 3.90 (s, 3H), 1.67 (d, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ = 167.4, 
146.9, 145.9, 132.5, 130.4, 128.8, 128.64, 128.61, 127.7, 127.6, 126.4, 52.2, 44.8, 21.9. [αD]25 = -
4.4 (CDCl3, c = 1.0 mg/mL). Chiral SFC (ChiralPak OJ-H column: 5% iPrOH in CO2, 2.0 mL/min) 
tr = 8.37 (minor peak) tr = 9.17 (major peak) Absolute configuration of the major enantiomer was 
assigned as (S) based on literature data. Characterization data matched that reported in the 
literature.31 
 
 
4-(Naphthalen-2-ylmethyl)benzonitrile (42): obtained as a white solid (121 mg, 99%), Mp = 105-
110 °C. 1H NMR (CDCl3, 500 MHz): δ = 7.83-7.77 (m, 3H), 7.62 (s, 1H), 7.58 (m, 2H), 7.48 (m, 
2H), 7.33 (d, J = 8.0 Hz, 2H), 7.27-7.25 (m, 1H), 4.20 (s, 2H). 13C NMR (CDCl3, 125.8 MHz): δ = 
146.5, 136.8, 133.6, 132.3, 129.7, 128.5, 127.7, 127.5, 127.4, 126.3, 125.8, 119.0, 110.1, 42.1. 
Characterization data matched that reported in the literature.32 
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4-(3,5-Dimethoxybenzyl)benzonitrile (43): obtained as a colorless oil (108 mg, 86%). 1H NMR 
(CDCl3, 500 MHz): δ = 7.57 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.34 (s, 1H), 6.30 (s, 
2H), 3.95 (s, 2H,), 3.76 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ = 161.2, 146.5, 141.7, 132.4, 
129.7, 119.1, 110.2, 107.4, 98.4, 55.4, 42.3. IR:  = 2937, 2838, 2358, 2227, 1594, 1461, 1430, 
1205, 1156, 1065, 822 cm-1. HRMS (ESI) m/z calc. for C16H16NO2 (M+H) 254.1181, found 
254.1182. 
 
 
 
Potassium (Benzo[d][1,3]dioxol-5-ylmethyl)trifluoroborate (S5): prepared following general 
procedure A, obtained as a white solid (498 mg, 41%), mp = 258 °C (dec.). 1H NMR (acetone-d6, 
500 MHz): δ = 6.65 (s, 1H), 6.54-6.50 (m, 2H), 5.79 (s, 2H), 1.55 (br s, 2H). 13C NMR (DMSO-d6, 
125.8 MHz): δ = 146.8, 143.1, 141.2, 121.2, 109.8, 107.7, 100.3. 19F NMR (acetone-d6, 282.4 
MHz): δ = -136.3 (q, J = 70.6 Hz). 11B NMR (acetone-d6, 128.4 MHz): δ = 4.12 (q, J = 50.2 Hz) 
IR:  = 3067, 1482, 1436, 1230, 1040, 960, 775, 630 cm-1. HRMS (ESI) m/z calc. for C8H7O2BF3 
(M-) 203.0491, found 203.0486. 
 
Potassium Trifluoro(4-(methoxycarbonyl)benzyl)borate (S6): prepared following general 
procedure B, obtained as a white solid (706 mg, 55%), mp = 205°C (dec.). 1H NMR (acetone-d6, 
500 MHz): δ = 7.73 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 3.81 (s, 3H), 1.75 (br s, 2H). 13C 
NMR (acetone-d6, 125.8 MHz): δ = 166.9, 153.7, 128.5, 128.3, 124.3, 50.7. 19F NMR (acetone-d6, 
470.8 MHz): δ = -140.7 (q, J = 55.6 Hz). 11B NMR (acetone-d6, 128.4 MHz): δ = 4.70 (q, J = 57.9 
52 
Hz). IR:  = 3038, 1690, 1607, 1444, 1293, 1233, 1056, 993, 959, 782, 720, 642. HRMS: (ESI) 
m/z calc. for C9H9O2BF3 (M-) 217.0648, found 217.0647. 
 
 
Potassium Trifluoro(2-methylbenzyl)borate (S7): prepared following general procedure A, 
obtained as a white solid (850 mg, 80%), mp = 230 °C (dec.). 1H NMR (acetone-d6, 500 MHz): δ 
= 7.05 (d, J = 8.0 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.90-6.87 (m, 1H), 6.81-6.78 (m, 1H), 2.24 (s, 
3H), 1.66 (br s, 2H). 13C NMR (acetone-d6, 125.8 MHz): δ = 145.0, 135.3, 129.4, 129.0, 124.8, 
122.5, 19.9. 19F NMR (acetone-d6, 470.8 MHz): δ = -138.3. 11B NMR (acetone-d6, 128.4 MHz): δ = 
5.27 (q, J = 51.0 Hz). IR:  = 2941, 1488, 1228, 1049, 975, 781, 734, 636 cm-1. HRMS (ESI) m/z 
calc. for C8H9BF3 (M-) 173.0749, found 173.0753. 
 
Potassium (2,4-Difluorobenzyl)trifluoroborate (S8): prepared following general procedure A, 
obtained as a white solid (422 mg, 36%), mp = 225-227 °C. 1H NMR (acetone-d6, 500 MHz):  = 
7.23 (q, J = 7.5 Hz, 1H), 6.70-6.66 (m, 2H), 1.59 (br s, 2H). 13C NMR (acetone-d6, 125.8 MHz):  
= 160.7 (dd, J = 131, 11 Hz), 158.8 (dd, J = 129, 11 Hz), 131.7 (t, J = 8 Hz), 128.0 (d, J = 17 Hz), 
109.7 (dd, J = 20, 3 Hz), 102.0 (dd, J = 28, 25 Hz), 18.5. 19F NMR (acetone-d6, 470.8 MHz):  = -
114.9, -119.4, -139.9. 11B NMR (acetone-d6, 128.4 MHz):  = 4.98. IR:  = 2928, 1622, 1601, 1504, 
1253, 1087, 1071, 986, 949, 846 cm-1. HRMS (ESI) m/z calc. for C7H5BF5 (M-) 195.0404, found 
195.0402. 
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Potassium Trifluoro(naphthalen-2-ylmethyl)borate (S9): prepared following general procedure 
A, obtained as a white solid (323 mg, 26%), mp: 199-202 °C. 1H NMR (acetone-d6, 500 MHz):  
= 7.70 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 7.38 (d, 
J = 8.5 Hz, 1H), 7.35-7.28 (m, 1H), 7.27-7.21 (m, 1H), 1.81 (br s, 2H). 13C NMR (acetone-d6, 125.8 
MHz):  = 144.0, 134.0, 130.9, 129.4, 127.3, 126.8, 126.3, 125.4, 124.9, 123.3. 19F NMR (acetone-
d6, 470.8 MHz):  = -139.1. 11B NMR (acetone-d6, 128.4 MHz):  = 5.34. IR:  = 3054, 2891, 1631, 
1597, 1505, 1239, 1074, 953, 746. HRMS (ESI) m/z calc. for C11H9BF3 (M-) 209.0749, found 
209.0749. 
 
Potassium (3,5-Dimethoxybenzyl)trifluoroborate (S10): prepared following general procedure 
A, obtained as a white solid (809 mg, 63%), mp: 220-222 °C. 1H NMR (DMSO-d6, 500 MHz):  = 
6.16 (s, 2H), 6.02 (s, 1H), 3.64 (s, 6H), 1.40 (br s, 2H). 13C NMR (DMSO-d6, 125.8 MHz):  = 
159.4, 149.3, 106.7, 94.5, 54.6. 19F NMR (DMSO-d6, 470.8 MHz):  = -136.3. 11B NMR (DMSO-
d6, 128.4 MHz):  = 4.20. IR:  = 2837, 1614, 1588, 1315, 1240, 1156, 1147, 1068, 978, 934 cm-1. 
HRMS (ESI) m/z calc. for C9H11BF3O2 (M-) 219.0804, found 219.0812. 
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Potassium (3,5-Dimethoxybenzyl)trifluoroborate (S11): reaction performed on 3 mmol scale 
according to general procedure A, obtained as a white solid (466 mg, 55%), mp = 165-168 °C. 1H 
NMR (acetone-d6, 500 MHz):  = 7.16 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 1.66 (br s, 
2H). 13C NMR (acetone-d6, 125.8 MHz):  = 146.7, 145.0, 130.0, 120.9 (q, J = 253 Hz), 119.8. 19F 
NMR (acetone-d6, 470.8 MHz):  = -59.0, -141.0 (q, J = 62 Hz). 11B NMR (acetone-d6, 128.4 
MHz):  = 4.88. Characterization data matched that reported in the literature.17 
 
Potassium Trifluoro(4-methoxybenzyl)borate (S12): prepared following general procedure A, 
obtained as a white solid (403 mg, 35%), mp = 162-165 °C. 1H NMR (acetone-d6, 500 MHz):  = 
7.01 (d, J = 8.0 Hz, 2H), 6.64 (d, J = 8.0 Hz, 2H), 3.68 (s, 3H), 1.56 (br s, 2H). 13C NMR (acetone-
d6, 125.8 MHz):  = 156.4, 138.0, 129.8, 113.3, 54.9. 19F NMR (acetone-d6, 470.8 MHz):  = -
140.7 (q, J = 58.9 Hz). 11B NMR (acetone-d6, 128.4 MHz):  = 5.14. Characterization data matched 
that reported in the literature.8 
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Appendix A1. 1H, 13C, 11B, and 19F NMR Spectra Relevant to Chapter 2 
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Figure A1.1. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(4-methoxybenzyl)benzonitrile (12) 
Figure A1.1. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(4-methoxybenzyl)benzonitrile (12) 
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Figure A1.3. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,4-difluorobenzyl)benzonitrile (13) 
Figure A1.4. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(2,4-difluorobenzyl)benzonitrile (13) 
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Figure A1.5. 13C NMR (CDCl3, 470.8 MHz) spectrum of 4-(2,4-difluorobenzyl)benzonitrile (13) 
Figure A1.6. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2-methylbenzyl)benzonitrile (14) 
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Figure A1.7. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(2-methylbenzyl)benzonitrile (14) 
 
Figure A1.8. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-(4-cyanobenzyl)benzoate (15) 
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Figure A1.9. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-(4-cyanobenzyl)benzoate (15) 
Figure A1.10. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(4-
(trifluoromethoxy)benzyl)benzonitrile (16) 
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Figure A1.11. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(4-
(trifluoromethoxy)benzyl)benzonitrile (16)  
 
Figure A1.12. 19F NMR (CDCl3, 470.8 MHz) spectrum of 4-(4-
(trifluoromethoxy)benzyl)benzonitrile (16) 
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Figure A1.13. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(benzo[d][1,3]dioxol-5-
ylmethyl)benzonitrile (17) 
Figure A1.14. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(benzo[d][1,3]dioxol-5-
ylmethyl)benzonitrile (17) 
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Figure A1.15. 1H NMR (CDCl3, 500 MHz) spectrum of 1-benzyl-4-methoxybenzene (18) 
Figure A1.16. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-benzyl-4-methoxybenzene (18) 
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Figure A1.17. 1H NMR (CDCl3, 500 MHz) spectrum of 1-benzyl-2-methylbenzene (19) 
 
Figure A1.18. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-benzyl-2-methylbenzene (19) 
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Figure A1.19. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 3-benzylbenzoate (20) 
Figure A1.20. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 3-benzylbenzoate (20) 
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Figure A1.21. 1H NMR (CDCl3, 500 MHz) spectrum of 1-benzyl-4-(trifluoromethyl)benzene 
(21) 
Figure A1.22. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-benzyl-4-
(trifluoromethyl)benzene (21) 
70 
Figure A1.23. 19F NMR (CDCl3, 470.8 MHz) spectrum of 1-benzyl-4-
(trifluoromethyl)benzene (21) 
Figure A1.24. 1H NMR (CDCl3, 500 MHz) spectrum of 1-benzyl-4-vinylbenzene (22) 
71 
Figure A1.25. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-benzyl-4-vinylbenzene (22)  
Figure A1.26. 1H NMR (CDCl3, 500 MHz) spectrum of 4-benzylphenol (23) 
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Figure A1.27. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-benzylphenol (23) 
 
Figure A1.28. 1H NMR (CDCl3, 500 MHz) spectrum of N-(4-benzylphenyl)acetamide (24) 
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Figure A1.29. 13C NMR (CDCl3, 125.8 MHz) spectrum of N-(4-benzylphenyl)acetamide (24)  
Figure A1.30. 1H NMR (CDCl3, 500 MHz) spectrum of 3-benzyl-5-methoxypyridine (25) 
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Figure A1.31. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-benzyl-5-methoxypyridine (25) 
Figure A1.32. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(4-benzylphenyl)-1,3,4-oxadiazole 
(26) 
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Figure A1.33. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(4-benzylphenyl)-1,3,4-
oxadiazole (26) 
Figure A1.34. 1H NMR (CDCl3, 500 MHz) spectrum of 5-benzylquinoline (27) 
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Figure A1.35. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-benzylquinoline (27) 
Figure A1.36. 1H NMR (CDCl3, 500 MHz) spectrum of 5-(3-benzylphenyl)-1H-pyrazole (28) 
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Figure A1.37. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-(3-benzylphenyl)-1H-pyrazole 
(28) 
Figure A1.38. 1H NMR (CDCl3, 500 MHz) spectrum of 5-benzyl-1H-indole (29) 
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Figure A1.39. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-benzyl-1H-indole (29) 
Figure A1.40. 1H NMR (CDCl3, 500 MHz) spectrum of 5-benzylthiophene-2-sulfonamide 
(30) 
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Figure A1.41. 13C NMR (CDCl3,125.8 MHz) spectrum of 5-benzylthiophene-2-sulfonamide 
(30) 
Figure A1.42. 1H NMR (CDCl3, 500 MHz) spectrum of 5-benzylthiophene-2-carbaldehyde 
(31) 
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Figure A1.43. 13C NMR (CDCl3,125.8 MHz) spectrum of 5-benzylthiophene-2-carbaldehyde 
(31) 
Figure A1.44. 1H NMR (CDCl3, 500 MHz) spectrum of 5-benzylpicolinonitrile (32) 
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Figure A1.45. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-benzylpicolinonitrile (32) 
Figure A1.46. 1H NMR (CDCl3, 500 MHz) spectrum of 2-benzyl-5-(trifluoromethyl)pyridine 
(33) 
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Figure A1.47. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-benzyl-5-
(trifluoromethyl)pyridine (33) 
Figure A1.48. 1H NMR (CDCl3, 500 MHz) spectrum of 4-benzyl-2-methylpyridine (34) 
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Figure A1.49. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-benzyl-2-methylpyridine (34) 
Figure A1.50. 1H NMR (CDCl3, 500 MHz) spectrum of 5-benzylpyrimidine (35) 
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Figure A1.51. 13C NMR (CDCl3,125.8 MHz) spectrum of 5-benzylpyrimidine (35) 
Figure A1.52. 1H NMR (CDCl3, 500 MHz) spectrum of methyl (S)-3-(4-benzylphenyl)-2-((tert-
butoxycarbonyl)amino)propanoate (36) 
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Figure A1.53. 13C NMR (CDCl3,125.8 MHz) spectrum of methyl (S)-3-(4-benzylphenyl)-2-
((tert-butoxycarbonyl)amino)propanoate (36) 
Figure A1.54. 1H NMR (CDCl3, 500 MHz) spectrum of 4-benzylbenzaldehyde (37) 
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Figure A1.55. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-benzylbenzaldehyde (37) 
Figure A1.56: 1H NMR (CDCl3, 500 MHz) spectrum of 4-benzylbenzonitrile (38) 
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Figure A1.57: 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-benzylbenzonitrile (38) 
Figure A1.58: 1H NMR (CDCl3, 500 MHz) spectrum of 4-(1-(benzyloxy)-3-
phenylpropyl)benzonitrile (39) 
88 
Figure A1.59: 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(1-(benzyloxy)-3-
phenylpropyl)benzonitrile (39) 
Figure A1.60: 1H NMR (CDCl3, 500 MHz) spectrum of methyl 3-(1-phenylethyl)benzoate 
(41)
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Figure A1.61: 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 3-(1-phenylethyl)benzoate 
(41) 
Figure A1.62: 1H NMR (CDCl3, 500 MHz) spectrum of 2-(2,4-difluorophenyl)-5-
(trifluoromethyl)pyridine (S3) 
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Figure A1.63: 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(2,4-difluorophenyl)-5-
(trifluoromethyl)pyridine (S3) 
Figure A1.64: 19F NMR (CDCl3, 470.8 MHz) spectrum of 2-(2,4-difluorophenyl)-5-
(trifluoromethyl)pyridine (S3) 
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Figure A1.65: 1H NMR (acetone-d6, 500 MHz) spectrum of potassium (benzo[d][1,3]dioxol-
5-ylmethyl)trifluoroborate (S5) 
Figure A1.66: 13C NMR (acetone-d6, 125.8 MHz) spectrum of potassium 
(benzo[d][1,3]dioxol-5-ylmethyl)trifluoroborate (S5) 
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Figure A1.67: 19F NMR (acetone-d6, 282.4 MHz) spectrum of potassium 
(benzo[d][1,3]dioxol-5-ylmethyl)trifluoroborate (S5) 
Figure A1.68: 11B NMR (acetone-d6, 128.4 MHz) spectrum of potassium 
(benzo[d][1,3]dioxol-5-ylmethyl)trifluoroborate (S5) 
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Figure A1.69. 1H NMR (acetone-d6, 500 MHz) spectrum potassium trifluoro(4-
(methoxycarbonyl)benzyl)borate (S6) 
 
Figure A1.70. 13C NMR (acetone-d6, 125.8 MHz) spectrum potassium trifluoro(4-
(methoxycarbonyl)benzyl)borate (S6) 
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Figure A1.71. 19F NMR (acetone-d6, 470.8 MHz) spectrum potassium trifluoro(4-
(methoxycarbonyl)benzyl)borate (S6) 
 
Figure A1.72. 11B NMR (acetone-d6, 128.4 MHz) spectrum potassium trifluoro(4-
(methoxycarbonyl)benzyl)borate (S6) 
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Figure A1.73. 1H NMR (acetone-d6, 500 MHz) spectrum of potassium trifluoro(2-
methylbenzyl)borate (S7) 
Figure A1.74. 13C NMR (acetone-d6, 125.8 MHz) spectrum of potassium trifluoro(2-
methylbenzyl)borate (S7) 
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Figure A1.75. 11B NMR (acetone-d6, 128.4 MHz) spectrum of potassium trifluoro(2-
methylbenzyl)borate (S7) 
Figure A1.76. 19F NMR (acetone-d6, 470.8 MHz) spectrum of potassium trifluoro(2-
methylbenzyl)borate (S7) 
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Figure A1.77. 1H NMR (acetone-d6, 500 MHz) spectrum of potassium (2,4-
difluorobenzyl)trifluoroborate (S8) 
Figure A1.78. 13C NMR (acetone-d6, 125.8 MHz) spectrum of potassium (2,4-
difluorobenzyl)trifluoroborate (S8) 
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Figure A1.79. 11B NMR (acetone-d6, 128.4 MHz) spectrum of potassium (2,4-
difluorobenzyl)trifluoroborate (S8) 
Figure A1.80. 19F NMR (acetone-d6, 470.8 MHz) spectrum of potassium (2,4-
difluorobenzyl)trifluoroborate (S8) 
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Figure A1.81. 1H NMR (acetone-d6, 500 MHz) spectrum of potassium trifluoro(naphthalen-
2-ylmethyl)borate (S9) 
Figure A1.82. 13C NMR (acetone-d6, 125.8 MHz) spectrum of potassium 
trifluoro(naphthalen-2-ylmethyl)borate (S9) 
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Figure A1.83. 11B NMR (acetone-d6, 128.4 MHz) spectrum of potassium 
trifluoro(naphthalen-2-ylmethyl)borate (S9) 
Figure A1.84. 19F NMR (acetone-d6, 400.7 MHz) spectrum of potassium 
trifluoro(naphthalen-2-ylmethyl)borate (S9) 
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Figure A1.85. 1H NMR (DMSO-d6, 500 MHz) spectrum of potassium (3,5-
dimethoxybenzyl)trifluoroborate (S10) 
Figure A1.86. 13C NMR (DMSO-d6, 125.8 MHz) spectrum of potassium (3,5-
dimethoxybenzyl)trifluoroborate (S10) 
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Figure A1.87. 11B NMR (DMSO-d6, 128.4 MHz) spectrum of potassium (3,5-
dimethoxybenzyl)trifluoroborate (S10) 
Figure A1.88. 19F NMR (DMSO-d6, 470.8 MHz) spectrum of potassium (3,5-
dimethoxybenzyl)trifluoroborate (S10) 
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Figure A1.89. 1H NMR (acetone-d6, 500 MHz) spectrum of potassium trifluoro(4-
(trifluoromethoxy)benzyl)borate (S11) 
Figure A1.90. 13C NMR (acetone-d6, 125.8 MHz) spectrum of potassium trifluoro(4-
(trifluoromethoxy)benzyl)borate (S11) 
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Figure A1.91. 11B NMR (acetone-d6, 128.4 MHz) spectrum of potassium trifluoro(4-
(trifluoromethoxy)benzyl)borate (S11) 
Figure A1.92. 19F NMR (acetone-d6, 470.8 MHz) spectrum of potassium trifluoro(4-
(trifluoromethoxy)benzyl)borate (S11) 
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Figure A1.93. 1H NMR (acetone-d6, 500 MHz) spectrum of potassium trifluoro(4-
methoxybenzyl)borate (S12) 
Figure A1.94. 13C NMR (acetone-d6, 125.8 MHz) spectrum of potassium trifluoro(4-
methoxybenzyl)borate (S12) 
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Figure A1.95. 19F NMR (acetone-d6, 470.8 MHz) spectrum of potassium trifluoro(4-
methoxybenzyl)borate (S12) 
Figure A1.96. 11B NMR (acetone-d6, 128.4 MHz) spectrum of potassium trifluoro(4-
methoxybenzyl)borate (S12) 
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Figure A1.97. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(naphthalen-2-
ylmethyl)benzonitrile (42) 
Figure A1.98. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(naphthalen-2-
ylmethyl)benzonitrile (42) 
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Figure A1.99. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(3,5-dimethoxybenzyl)benzonitrile 
(43) 
Figure A1.99. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(3,5-
dimethoxybenzyl)benzonitrile (43) 
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Chapter 3. Extension to Activated Primary Systems 
3.1 Introduction 
Moving forward from the initial success in benzylic couplings, it was anticipated that 
success might be realized more broadly with an array of primary and secondary alkyl 
trifluoroborates. However, access to these radicals from alkyl precursors is not as trivial a process 
as one might expect. First off, primary, unactivated systems, such as n-hexyl trifluoroborate, exhibit 
prohibitively high oxidation potentials (1.9 V vs SCE)1 for direct incorporation into the developed 
photoredox/Ni catalytic cycle. Although incorporation of unactivated, primary alkyl systems 
appeared inaccessible with the current technology, the use of stabilizing groups had enabled the 
generation of benzylic systems previously,2 so the use of alternative stabilized moieties was 
considered to allow efficient radical generation. 
Radical stability, similar to carbocation stability, can be influenced by a number of factors. 
As a singularly occupied orbital, these species tend to be electron-poor and benefit from any 
interaction that can donate electron density into the radical center. Three of the most well 
recognized phenomena for achieving this donation are hyperconjugative stabilization,3 resonance 
stabilization,4 and adjacent lone pair donation (Figure 3.1).5   
 
Figure 3.1: Stabilization of radicals  
Given the stabilization afforded by α-heteroatom substitution, it was anticipated that the use 
of α-alkoxymethyltrifluoroborates would significantly lower the oxidation potential required to 
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access these radical species. Access to these radical synthons would serve to complement existing 
anionic approaches in cross-coupling.i Prior work on α-alkoxy anions6,7 has included methods 
employing alkoxymethylzincs,8,9 alkoxymethylstannanes,10–13 and alkoxymethylboron 
derivatives.14,15 However, the current methods are severely limited by the use of toxic and/or air- 
and moisture-sensitive reagents under often harsh conditions that inhibit the incorporation of 
reactive functional groups. As such, improved methods in this arena would allow access to benzylic 
ethers, which are an important motif in pharmaceutical16–18 and supramolecular chemical 
architectures.19,20  
3.2 Results and Discussion 
At the start of this optimization, direct application of previously developed conditions 
afforded trace amounts of the desired α-alkoxymethyl cross-coupling product (Eq. 3.1). However, 
the alkyltrifluoroborate used in this initial investigation was deemed only sparingly soluble in room 
temperature acetone.  
Eq 3.1. Previously optimized conditions with α-alkoxymethyltrifluoroborates 
 
To overcome this issue, an extensive solvent screen was commenced to enhance contact 
between the photocatalyst and the alkyltrifluoroborate in solution (see Experimental). Solubility is 
                                                     
i Reproduced in part from Org. Lett., 2015, 17, 3294 
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particularly important for these reactions as insoluble material disrupts light penetration and can 
serve to decouple the integrated catalytic cycles. In our experience, maintaining the homogeneity 
of the reaction mixture has always led to significant improvements. Using methyl 4-
bromobenzoate, potassium [(benzyloxy)methyl]trifluoroborate (1.2 equiv), NiCl2•dme (5.0 mol 
%), dtbbpy (5.0 mol %), Ir cat 1 (2.0 mol %), and a cosolvent system consisting of dioxane with 
added DMA was determined to provide the right balance of solubility and reactivity for the dual 
catalytic cross-coupling.  
An investigation of additives, proposed to be key for sequestering generated BF3 during 
trifluoroborate oxidation, also improved the yields significantly. Without added base, the reactions 
tend to stall out around 40-60% conversion (~10 h), leading us to suspect that byproduct inhibition 
is principally responsible. Among those bases examined, K2HPO4 led to full consumption of the 
starting material after 16 h.  
With reasonably effective conditions in hand, alternate ligands and Ni sources were 
examined to identify scaffolds that might be useful in extending this chemistry. Although a number 
of these Ni sources and ligands served as competent catalysts (see Experimental), our model ligand 
remained a clear front-runner in both conversion and yield. Considering the commercial availability 
and low cost of this established catalytic system (NiCl2•dme, dtbbpy), we moved forward with this 
combination to evaluate the full scope of this reaction. 
Beginning with the aryl bromide partner, it was important to emphasize the ability of this 
catalyst system to engage a range of electronically differentiated aryl bromides. Reaction with 
electron-withdrawing 4-bromoacetophenone and electron-neutral 4-bromotoluene led to isolation 
of 4 and 13 in 86% and 62% yields, respectively. Even electron-rich bromides were competent 
electrophiles, as reaction with 4-bromoanisole gave rise to product 12, albeit in a modest 52% yield.  
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ortho-Substitution was tolerated in trifluoromethyl-, cyano-, methyl-, and methoxy- 
substituted aryl bromides, leading to ethers 6-9. Selective cross-coupling was observed exclusively 
at the bromide for both a bifunctional aryl triflate and a heteroaryl chloride, affording products 10 
and 17, respectively. Aldehydes contained in products 3 and 16 survived the reaction untouched.  
 
Figure 3.2. α-Alkoxymethyltrifluoroborate photoredox cross-coupling: halide scope 
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Considering the sensitivity of aldehydes to reduction under Pd-catalysis21 as well as their 
electrophilicity toward harsher organometallic nucleophiles in cross-coupling, this method 
provides the opportunity to circumvent protection and/or oxidation-reduction sequences that may 
be required to access the same structural architecture. To ensure the scalability of this 
transformation, a gram-scale reaction was performed with 4-bromoacetophenone using reduced 
catalyst loadings (1.0 mol % Ir cat. 1 and 1.5 mol % NiCl2•dme). Although extended reaction times 
were required for full conversion (48 h), the desired ether 4 was obtained in good yield (72%). The 
generality for the cross-coupling with heteroaryl substructures makes this method particularly 
attractive for late-stage diversification. In addition to the products derived from well-behaved 
benzofuran- and benzothiophene-containing bromides (14, 15), more challenging pyrazine-, 
pyrimidine-, quinoline-, and isoquinoline-containing bromides gave the desired products in excel-
lent yield (22-25). Bromopyridines substituted at all regioisomeric positions were used to access 
products 17-21 in good yields.  Even 8-bromocaffeine allowed access to product 28 in excellent 
yield. Unfortunately, protection was required for indazole- and azaindole-containing bromides, 
affording products 26 and 27, respectively. Although satisfactory methods for cross-coupling of 
these protic heteroaryl bromides remain elusive, it should be noted that previous Pd-catalyzed 
conditions [3 mol % Pd(OAc)2, 6 mol % RuPhos, 3 equiv Cs2CO3, dioxane/H2O, 100° C] have 
proved wholly ineffective or low yielding for a number of the heteroaryl bromides shown.14 
Therefore, this method represents a marked improvement over the current state of the art. 
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Figure 3.3. α-Alkoxymethyltrifluoroborate photoredox cross-coupling: Organotrifluoroborate 
scope 
To highlight further the heteroaryl tolerance of this coupling, 5-bromopyrimidine was used 
as an electrophile to evaluate the alkoxymethyltrifluoroborate scope (Figure 3.3). To this end, a 
pyridyl-containing organotrifluoroborate was successfully employed to yield compound 30 in 
reasonable yield – showing tolerance of a heteroaryl functional unit in both reaction partners.  Aryl 
chlorides were also tolerated on the trifluoroborate partner to give the dichlorinated arene 31 with 
no competitive reaction at the chlorides. 
As expected, ethers were tolerated throughout the functionalized organotrifluoroborate 
core to give products such as 32, 34, and 35. For 35, the ability to incorporate PEG linkers on target 
molecules at a late stage could serve as a means to modulate in vivo drug solubility.22 Steric bulk, 
although distal from the reacting radical, led to isolation of menthol derivative 33 and tert-butyl 
ether product 44 (Figure 3.4) in acceptable yields.  
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Beyond the largely aliphatic functional groups shown, amides and alkyl chlorides were 
untouched under the reaction conditions, leaving a site for further manipulation in products 37 and 
39. Also to be noted is that products containing alkenes and alkynes were isolated in excellent 
yields (40-42). Considering the intermediacy of radical intermediates during this process, the 
tolerance of these functional handles for later derivatization is particularly intriguing.  
As a final testament to the utility of this transformation, a variety of α-
alkoxymethyltrifluoroborates substituted with simple protecting groups were prepared (Figure 
3.4). Currently, the facile preparation of many benzylic alcohols is predicated on commercial access 
to the corresponding esters and aldehydes. Even in cases where these precursors are readily 
available, the generated alcohols can be sensitive to ambient oxidation to afford a mixture of 
alcohol, aldehyde, and other oxidation byproducts.23,24 Consequently, a method for the preparation 
of protected benzylic alcohol variants from the far more widely available aryl- and heteroaryl 
halides serves as an attractive method for reliable synthesis and long-term storage. To that end, 
allyl-, para-methoxybenzyl-, tert-butyl-, and trimethylsilylethyl-protected α-
alkoxymethyltrifluoroborates were synthesized and employed as cross-coupling partners to give 
products 42-45. Subsequent deprotection of these protected alcohols allows the formation of 
benzylic alcohols in two steps from readily accessible bromoarenes. 
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Figure 3.4. α-Alkoxy photoredox cross-coupling: formation of protected alcohols 
3.3 Conclusion 
In summary, room temperature conditions for the cross-coupling of α-
alkoxymethyltrifluoroborates with an array of aryl bromides has been communicated. Previous 
reports for the cross-coupling of these substrates with aryl chlorides have taken place at 100 ºC in 
the presence of strong aqueous base and have suffered from significant limitations in scope when 
applied to both heteroaryl chlorides and -bromides. Consequently, the developed couplings address 
key substrate limitations of the former methods. Furthermore, the delineated procedures provide a 
method for the synthesis of benzylic ethers that can be readily deprotected to afford the 
corresponding alcohols – many of which are challenging to access in high purity.  
Finally, although the products derived from these reactions can often be made by other 
means, the use of these reagents serves to validate further the photoredox cross-coupling manifold 
as a means of engaging Csp3 nucleophiles in alkyl transfer under mild conditions. Most importantly, 
the ability to cross-couple late stage bromides with an ever-expanding library of Csp3 hybridized 
nucleophiles using a single robust catalyst system is anticipated to enable practitioners to diversify 
synthetic molecular architecture quickly and expand three-dimensional chemical space. 
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3.4 Experimental 
 
General considerations 
 
 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless otherwise 
noted. Dioxane (99.9%, extra dry) and dimethyl acetamide (purity, extra dry) were used as received. 
K2HPO4 was used as received. IrCl3·xH2O, and NiCl2•dme were purchased from commercial 
sources. All other reagents were purchased commercially and used as received. Photoredox 
reactions were irradiated with two to three standard 26 W compact fluorescent light bulbs. Melting 
points (°C) are uncorrected. NMR spectra were recorded on a 500 or 400 MHz spectrometer. 19F 
NMR chemical shifts were referenced to external CFCl3 (0.0 ppm). 11B NMR spectra were obtained 
on a spectrometer equipped with the appropriate decoupling accessories. All 11B NMR chemical 
shifts were referenced to an external BF3·OEt2 (0.0 ppm) with a negative sign indicating an upfield 
shift. Data are presented as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet), coupling constant J (Hz) and integration. The 13C signal of the 
carbon bonded to boron was not observed in some cases due to quadrupolar relaxation. 
 
Synthesis of -alkoxymethyltrifluoroborates: 
 
Most potassium -alkoxymethyltrifluoroborates were purchased commercially. In cases where the 
desired potassium organotrifluoroborate was unavailable, the corresponding alcohol derivative was 
converted to the trifluoroborate by the following procedure. 
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General procedure for -alkoxymethyltrifluoroborate synthesis: 
 
NaH (96 mg, 4 mmol) was added to a 50 mL 2-neck round-bottom-flask and purged with N2 three 
times. The content was diluted with dry THF (10 mL) and precursor alcohol (4.0 mmol) was then 
added dropwise to the reaction mixture at 0 oC under N2. After stirring for 15 min at 0 oC, the 
temperature was increased to rt and further stirred for 30 min. Bromomethyltrifluoroborate (267 
mg, 1.33 mmol) was added in one portion to the suspension at 0 oC, and the reaction was stirred at 
rt for 3 h. The reaction was quenched by adding 4.5 M KHF2 (pH 6, ~ 4.5 mL).  The final mixture 
was stirred for 30 min and then concentrated and dried overnight under high vacuum to remove 
trace solvent. The crude residue was suspended in hot acetone (3 x 50 mL) and filtered. The filtrate 
was concentrated to a minimal volume (5 – 10 mL) and Et2O (~150 mL) was added to precipitate. 
The white precipitate was isolated by filtration, washing with hexanes (~30 mL) and CH2Cl2 (~30 
mL), to give the desired trifluoroborate in good yield. 
 
 
Potassium (((6-Chlorohexyl)oxy)methyl)trifluoroborate (S1): Obtained as a white solid (296 
mg, 87%). mp = 177-181 oC, 1H NMR (DMSO, 500 MHz): 3.60-3.58 (m, 2H), 3.15-3.14 (m, 2H), 
2.46-2.45 (m, 2H), 1.69-1.66 (m, 2H), 1.41-1.40 (m, 2H), 1.34-1.33 (m, 2H), 1.25-1.24 (m, 2H), 
13C NMR (DMSO, 126 MHz) δ 73.9, 46.0, 32.6, 29.9, 26.9, 25.7, 19F NMR (DMSO, 471 MHz) δ 
-141.5, 11B NMR (DMSO, 128 MHz) δ 3.1, IR:  = 2936, 2856, 1444, 1402, 1353, 1230, 1221, 
1068, 1008, 961, 920, 804, 732 cm-1, HRMS (ESI) m/z calc. for C7H14BClF3O (M-) 217.0767, 
found 217.0773. 
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Potassium ((Pyridin-2-ylmethoxy)methyl)trifluoroborate (S2): Obtained as a white solid (213 
mg, 70%), mp = 162-164 oC, 1H NMR (DMSO, 500 MHz) δ 8.45-8.44 (m, 1H), 7.74 (t, J = 7.5 Hz, 
1H), 7.39 (d, J = 7.8 Hz, 1H), 7.25 – 7.14 (m, 1H), 4.35 (s, 2H), 2.62 (s, 2H), 13C NMR (DMSO, 
126 MHz) δ 160.7, 149.2, 136.9, 122.5, 121.5, 76.4, 19F NMR (DMSO, 471 MHz) δ -141.4, 11B 
NMR (DMSO, 128 MHz) δ 3.2, IR:  = 3773, 2834, 1593, 1435, 1352, 1304, 1234, 1121, 1060, 
1022, 985, 918, 801 cm-1, HRMS (ESI) m/z calc. for C7H8BF3NO (M-) 190.0657, found 190.0653. 
 
 
Potassium ((2-Ethoxyethoxy)methyl)trifluoroborate (S3): Obtained as a colorless oil, 5 mmol 
scale (610 mg, 58%), 1H NMR (500 MHz, (CD3)2CO) δ 1H NMR (acetone-d6, 500 MHz,) δ 3.58 – 
3.50 (m, 4H), 3.49-3.46 (m, 2H), 2.80 (s, 2H), 1.16 (t, J = 7.0 Hz, 3H), 13C NMR (acetone-d6, 126 
MHz) δ 72.9, 69.2, 66.0, 14.4, 19F NMR (acetone-d6, 471 MHz) δ -145.0, 11B NMR (acetone-d6, 
128 MHz) δ -4.8, IR:  = 3606, 3054, 2977, 2870, 2305, 1712, 1608, 1447, 1265, 1072, 735 cm-1, 
HRMS (ESI) m/z calc. for C5H11BF3O2 (M-) 171.0804, found 171.0806. 
 
Potassium ((Methoxy)methyl)pyrrolidin-2-onetrifluoroborate (S4): Obtained as a white solid 
(256 mg, 82%), mp = 120-123 oC 1H NMR (DMSO, 500 MHz) δ 3.36-3.35 (m, 4H), 3.25 (s, 4H), 
2.18-2.16 (m, 2H), 1.88-1.87 (m, 2H), 13C NMR (DMSO, 126 MHz) δ 174.5, 71.0, 47.5, 42.3, 30.8, 
17.8, 19F NMR (DMSO, 471 MHz) δ 141.8, 11B NMR (DMSO, 128 MHz) δ 3.3, IR:  = 3053, 
120 
2987, 2305, 1669, 1422, 1265, 1071, 895, 739, 705 cm-1, HRMS (ESI) m/z calc. for C7H12BF3NO2 
(M-) 210.0913, found 210.0914. 
Selected reaction optimization studies
 
A 1:1 ratio of Ni source and ligand were dissolved in THF in a 1 gram reaction vial equipped with 
a Teflon coated magnetic stir bar. After stirring about 10 min, the solvent was removed in vacuo. 
Other solid additives were weighed into the vials. The vials were then brought into the glovebox 
where a stock solution of aryl bromide (0.1 mmol), alkoxymethyltrifluoroborate, Ir catalyst 1, and 
internal standard were then added by syringe and stirred for 24 h in front of a single 26 W CFL at 
an ambient temperature of ~35  C. Reactions were analyzed using GC and compared within sets 
by crude product to internal standard (P/IS) ratios. Note: P/IS can only be compared within each 
table; fresh stock solutions were prepared for each screen. 
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Figure 3.5. Comparison of Solvents 
Conditions: 0.1 mmol Ph-Br, 1.2 equiv R-BF3K, 2.0 % Ir(dFCF3ppy)2bpy•PF6,  
5.0 % NiCl2•dme/dtbbpy, 0.05 M in solvent 
 
 
Figure 3.6. Comparison of Solvents and Bases 
Conditions: 0.1 mmol Ph-Br, 1.2 equiv R-BF3K, 2.0 % Ir(dFCF3ppy)2bpy•PF6, 
5.0 % NiCl2•dme/dtbbpy, 1.0 equiv base, 0.05 M in solvent 
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 Figure 3.7. Comparison of Solvent Mixtures 
 Conditions: 0.1 mmol Ph-Br, 1.2 equiv R-BF3K, 2.0 % Ir(dFCF3ppy)2bpy•PF6,  
 5.0 % NiCl2•dme/dtbbpy, 1.0 equiv K2HPO4, 0.05 M in solvent 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 Figure 3.8. Comparison of Solvent Mixture and Base Ratios  
 Conditions: 0.1 mmol Ph-Br, 1.2 equiv R-BF3K, 2.0 % Ir(dFCF3ppy)2bpy•PF6, 5.0 % 
NiCl2•dme/dtbbpy, 0.05 M in solvent 
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 Figure 3.9. Comparison of Ligands  
 Conditions: 0.1 mmol Ph-Br, 1.2 equiv R-BF3K, 2.0 % Ir(dFCF3ppy)2bpy•PF6,  
 5.0 % NiCl2•dme/ligand, 3.0 equiv K2HPO4, 0.05 M in solvent 
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 Figure 3.10. Comparison of Ni Sources  
 Conditions: 0.1 mmol Ph-Br, 1.2 equiv R-BF3K, 2.0 % Ir(dFCF3ppy)2bpy•PF6,  
 5.0 % Ni source / dtbbpy, 3.0 equiv K2HPO4, 0.05 M in solvent 
 
Ni(DMGO) = Nickel(II) dimethylglyoxime; Ni(TMHD)2 = Nickel(II) bis(2,2,6,6-tetramethyl-3,5-
heptanedionate); NiCl2py4 = Nickel(II) chloride tetrapyridine 
 
 
 Figure 3.11. Comparison of NiCl2•dme/dtbbpy loadings 
 Conditions: 0.1 mmol Ph-Br, 1.2 equiv R-BF3K, 2.0 % Ir(dFCF3ppy)2bpy•PF6, 
 3.0 equiv K2HPO4, 0.05 M in solvent 
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General Procedure for Photoredox Cross-Coupling Reactions 
4,4’-di-tert-Butyl-2,2’-bipyridine (4.0 mg, 0.015 mmol) and NiCl2•dme (3.3 mg, 0.015 mmol) were 
weighed into a 20 mL oven-dried, long, thin (~20 mL) glass vial. Approximately 1 mL of dry, 
degassed THF was added and the mixture was heated briefly until obtaining a pale green solution. 
The solvent was then removed under vacuum to yield a ligated nickel complex that was pale 
evergreen color. Next, aryl bromide (0.5 mmol, 1 equiv) (liquid aryl bromides were added with 
solvent), alkoxymethyltrifluoroborate (0.6 mmol, 1.2 equiv), Ir[dFCF3ppy]2(bpy)•PF6 1 (10.1 mg, 
0.02 mmol) and K2HPO4 (261 mg, 1.5 mmol) were added sequentially. Afterwards, the tube was 
sealed and subsequently purged and evacuated four times. Dioxane/DMA (5:1) (12 mL) was next 
added under inert atmosphere. The resulting mixture was stirred for 24 h approximately 4 cm away 
from two 26 W fluorescent light bulbs while a fan was blown across the reaction setup to maintain 
an ambient temperature of 24 oC. The crude reaction mixture was filtered through a cylindrical plug 
of Celite and rinsed with CH2Cl2 and EtOAc (10-20 mL). The resulting solution was concentrated, 
and the residue was purified by column chromatography on silica gel, eluting with EtOAc and 
hexanes, to obtain products in pure form.   
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Figure 3.12. Photoredox cross-coupling reaction set-up (0.5 mmol scale) 
 
 
Gram scale reaction: To a ~125 mL long, thin-walled vacuum flask equipped with a Teflon-coated 
magnetic stir bar was added NiCl2•dme (16.5 mg, 0.075 mmol, 0.015 equiv) and 4,4'-di-tert-butyl-
2,2'-bipyridine (20 mg, 0.075, 0.015 equiv), and 5.0 mL of THF. The vial was capped, and the 
resulting suspension was heated briefly with a heat gun until the nickel and ligand were fully 
solubilized, yielding a pale green solution. The solvent was then removed under vacuum to give a 
fine coating of the ligated nickel complex (pale evergreen in color). Once fully evacuated, 1-(4-
bromophenyl)ethan-1-one (1.000 g, 5.025 mmol, 1.00 equiv), potassium 
(benzyloxy)methyltrifluoroborate (1.37 g, 6.03 mmol, 1.20 equiv), Ir[dFCF3ppy]2(bpy)•PF6 1 (53 
mg, 0.0525 mmol, 0.01 equiv), and K2HPO4 (2.6 g, 15.07 mmol, 3.0 equiv) was added. The vial 
was then capped with a rubber septum and purged and evacuated four times. Under inert 
atmosphere, dioxane (92 mL) and DMA (18 mL) was introduced. The vial containing all the 
reagents was further sealed with parafilm and stirred vigorously (a small vortex should be observed 
toward the top of the reaction mixture) for 48 h approximately 4 cm away from three 26 W 
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fluorescent light bulbs. A fan was blown across the reaction setup to maintain an ambient 
temperature around 24 oC. After completion, the crude reaction mixture was filtered through an 
approximately 4 cm x 2 cm cylindrical plug of Celite, washing with EtOAc (40 mL). The resulting 
solution was concentrated, and the residue was purified by column chromatography on silica gel, 
eluting with EtOAc and hexanes, to obtain product in pure form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Gram scale photoredox cross-coupling reaction set-up (4.65 mmol) 
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Compound Characterization Data 
 
1-((Benzyloxy)methyl)-3,5-dimethoxybenzene (2): Obtained as a colorless oil (111 mg, 86%), 1H 
NMR (CDCl3, 500 MHz): δ 7.42-7.37 (m, 4H), 7.34-7.33 (m, 1H), 6.59 (s, 2H), 6.45 (s, 1H), 4.59 
(s, 2H), 4.55 (s, 2H), 3.82 (s, 6H), 13C NMR (CDCl3, 126 MHz): δ 161.1, 141.0, 138.4, 128.6, 
128.0, 127.8, 105.6, 99.9, 72.3, 72.2, 55.5, IR:  = 2838, 1597, 1455, 1430, 1358, 1320, 1204, 1153, 
1098, 1065, 1055, 833, 737, 698 cm-1; HRMS (ESI) m/z calc. for  C16H18O3Na (M+Na) 281.1154, 
found 281.1162. 
 
3-((Benzyloxy)methyl)benzaldehyde (3): Obtained as a semi solid (97 mg, 86%), 1H NMR 
(CDCl3, 500 MHz): δ 10.03 (s, 1H), 7.89 (s, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.65 (d, J = 7.6 Hz, 1H), 
7.53 (t, J = 7.6 Hz, 1H), 7.41 – 7.35 (m, 4H), 7.33-7.31 (m, 1H), 4.63 (s, 2H), 4.61 (s, 2H), 13C 
NMR (CDCl3, 126 MHz): δ 192.4, 139.7, 138.0, 136.7, 133.7, 129.3, 129.1, 128.9, 128.7, 128.0, 
128.0, 72.7, 71.5, IR:  = 2856, 1694, 1606, 1590, 1453, 1285, 1203, 1099, 1072, 1028, 750, 697 
cm-1; HRMS (ESI) m/z calc. for C15H14O2Na (M+Na) 249.0891, found 249.0896. 
 
1-(4-(Benzyloxy)methyl)phenyl)ethan-1-one (4): Obtained as a colorless oil (114 mg, 95%) On 
gram scale with 1% Ir cat. 1 and 1.5% NiCl2•dme/dtbbpy (868 mg, 72% yield), 1H NMR (CDCl3, 
500 MHz): δ 7.96 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.40 – 7.35 (m, 4H), 7.33-7.30 (m, 
129 
1H), 4.62 (s, 2H), 4.60 (s, 2H), 2.60 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 197.9, 144.0, 138.1, 
136.6, 128.7, 128.6, 128.0, 127.9, 127.6, 72.7, 71.6, 26.8, IR:  = 2919, 2851, 1682, 1609, 1413, 
1358, 1267, 1092, 1073, 1016, 957, 820, 699 cm-1; HRMS (ESI) m/z calc. for C16H16O2Na (M+Na) 
263.1048, found 263.1035. 
 
N-((4-(Benzyloxy)methyl)phenyl)acetamide (5): Obtained as a white solid (108 mg, 85%), mp = 
84-85 oC, 1H NMR (CDCl3, 500 MHz): 8.06 (s, 1H), 7.50 (d, J = 8.2 Hz, 2H), 7.45 – 7.26 (m, 7H), 
4.54 (s, 2H), 4.51 (s, 2H), 2.12 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 169.0, 138.3, 137.7, 134.2, 
128.7, 128.5, 127.9, 127.8, 120.1, 72.2, 71.8, 24.5, IR:  = 3309, 2866, 2342, 1614, 1611, 1555, 
1544, 1517, 1358, 1326, 1270, 1091, 1073, 824, 730 cm-1; HRMS (ESI) m/z calc. for C16H17NO2Na 
(M+Na) 278.1157, found 278.1147. 
 
1-(Benzyloxy)methyl)-2-(trifluoromethyl)benzene (6): Obtained as a colorless oil (112 mg, 
84%), 1H NMR (CDCl3, 500 MHz): δ 7.80 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.59 (m, 
1H), 7.42-7.39 (m, 5H), 7.35-7.32 (m, 1H), 4.81 (s, 2H), 4.66 (s, 2H), 13C NMR (CDCl3, 126 MHz): 
δ 138.1, 137.3, 132.1, 129.1, 128.6, 127.9, 127.9, 127.5, 125.8 (q, J = 5.7 Hz), 124.6 (q, J = 273.6 
Hz), 73.0, 68.4 (q, J = 2.7 Hz), 19F NMR (471 MHz, CDCl3) δ -59.97, IR:  = 2854, 1451, 1365, 
1314, 1163, 1117, 1059, 1038, 769, 697 cm-1; HRMS (ESI) m/z calc. for C15H14F3O (M+H) 
267.0997, found 267.0992. 
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2-((Benzyloxy)methyl)benzonitrile (7): Obtained as a colorless oil (105 mg, 94%), 1H NMR 
(CDCl3, 500 MHz): δ 7.66-7.58 (m, 3H), 7.43-7.37 (m, 5H), 7.34-7.31 (m, 1H), 4.76 (s, 2H), 4.67 
(s, 2H), 13C NMR (CDCl3, 126 MHz): δ  142.2, 137.8, 133.0, 132.9, 128.8, 128.7, 128.2, 128.1, 
128.1, 117.5, 111.7, 73.37, 70.0, IR:  = 2919, 2850, 2225, 1600, 1453, 13612, 1214, 1111, 1075, 
763, 738, 698 cm-1; HRMS (ESI) m/z calc. for C15H14NO (M+H) 224.1075, found 224.1077. 
 
1-((Benzyloxy)methyl)-2-methoxybenzene (8): Obtained as a colorless oil (49 mg, 43%), 1H 
NMR (CDCl3, 500 MHz): δ 7.48 – 7.36 (m, 5H), 7.33-7.27 (m, 2H), 7.01-6.98 (m, 1H), 6.91-6.89 
(m, 1H), 4.64 (s, 4H), 3.85 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 157.1, 138.5, 128.9, 128.6, 
128.3, 127.7, 127.4, 126.6, 120.4, 110.1, 72.3, 66.9, 55.2, IR:  = 3865, 2838, 1603, 1494, 1464, 
1361, 1244, 1092, 1029, 753 cm-1; HRMS (ESI) m/z calc. for C15H16O2 (M+) 228.1150, found 
228.1143. 
 
1-((Benzyloxy)methyl)-2-methylbenzene (9): Obtained as a colorless oil (77 mg, 73%), 1H NMR 
(CDCl3, 500 MHz): δ 7.41-7.37 (m, 5H), 7.34-7.32 (m, 1H), 7.26 – 7.18 (m, 3H), 4.61 (s, 2H), 4.59 
(s, 2H), 2.37 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 138.3, 136.7, 136.0, 130.2, 128.6, 128.3, 
127.8, 127.7, 127.6, 125.7, 72.2, 70.5, 18.8, IR:  = 3029, 2855, 1605, 1495, 1454, 1358, 1213, 
1090, 1072, 742, 697 cm-1; HRMS (ESI) m/z calc. for C15H15O (M-H) 211.1123, found 211.1129. 
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4-((Benzyloxy)methyl)phenyl trifluoromethanesulfonate (10): Obtained as a colorless oil (160 
mg, 92%), 1H NMR (CDCl3, 500 MHz): δ 7.48-7.26 (m, 2H), 7.41-7.38 (m, 4H), 7.36-7.33 (m, 
1H), 7.31-7.27 (m, 2H), 4.62 (s, 2H), 4.59 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 149.0, 139.2, 
138.0, 129.4, 128.7, 128.0, 128.0, 121.4, 119.0 (q, J = 320.8 Hz), 72.8, 71.1, 19F NMR (471 MHz, 
CDCl3) δ -72.76, IR:  = 2853, 1501, 1422, 1249, 1210, 1139, 1094, 1017, 887, 697 cm-1; HRMS 
(ESI) m/z calc. for C15H13F3O4SNa (M+Na) 369.0384, found 369.0383. 
 
1-((Benzyloxy)methyl)-2,4-difluorobenzene (11): Obtained as a colorless oil (71 mg, 61%), 1H 
NMR (CDCl3, 500 MHz): δ 7.45-7.41 (m, 1H), 7.39 – 7.35 (m, 4H), 7.31-7.30 (m, 1H), 6.91 – 6.85 
(m, 1H), 6.84 – 6.78 (m, 1H), 4.59 (s, 2H), 4.58 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 162.8 
(dd, J = 220.7, 12.1 Hz), 160.9 (dd, J = 221.8, 12.2 Hz) 138.1, 131.2 (dd, J = 9.7, 5.6 Hz), 128.6, 
127.9, 121.5 (dd, J = 15.3, 3.5 Hz), 111.3 (dd, J = 21.0, 3.6 Hz), 103.8 (dd, J = 25.4, 25.4 Hz), 72.7, 
65.3 (d, J = 3.4 Hz), 19F NMR (CDCl3, 471 MHz): δ -110.9 (d, J = 7.4 Hz), -114.6 (d, J = 7.4 Hz), 
IR:  = 2864, 1620, 1606, 1505, 1454, 1430, 1277, 1139, 1101, 1072, 1029, 962, 849, 735, 697 cm-
1; HRMS (ESI) m/z calc. for C14H12F2O (M+) 234.0856, found 234.0857. 
 
1-((Benzyloxy)methyl)-4-methoxybenzene (12): Obtained as a colorless oil (60 mg, 52%), 1H 
NMR (CDCl3, 500 MHz): δ 7.41 – 7.35 (m, 4H), 7.32 (m, 3H), 6.92 (d, J = 8.6 Hz, 2H), 4.56 (s, 
2H), 4.52 (s, 2H), 3.83 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 159.1, 138.3, 130.3, 129.4, 128.3, 
127.7, 127.5, 113.7, 71.7, 71.6, 55.2, IR:  = 3893, 2853, 1652, 1513, 1454, 1360, 1302, 1247, 
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1172, 1088, 1071, 1034, 822, 737, 697 cm-1; HRMS (ESI) m/z calc. for C15H16O2 (M+) 228.1150, 
found 228.1155. 
 
1-((Benzyloxy)methyl)-4-methylbenzene (13): Obtained as a colorless oil (66 mg, 62%), 1H NMR 
(CDCl3, 500 MHz): δ 7.46 – 7.38 (m, 4H), 7.36-7.33 (m, 3H), 7.23-7.22 (m, 2H), 4.60 (s, 2H), 4.58 
(s, 2H), 2.41 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 138.3, 137.3, 135.2, 129.1, 128.3, 127.9, 
127.7, 127.5, 71.9, 71.8, 21.2, IR:  = 3028, 2854, 1615, 1516, 1496, 1453, 1359, 1204, 1092, 1073, 
1028, 803, 735, 697 cm-1; HRMS (ESI) m/z calc. for C15H15O (M-H) 211.1123, found 211.1124. 
 
2-((Benzyloxy)methyl)benzo[b]thiophene (14): Obtained as a white solid, mp = 51-53 oC (98 mg, 
77%), 1H NMR (CDCl3, 500 MHz): δ 7.87 (d, J = 7.3 Hz, 1H), 7.78 (d, J = 7.2 Hz, 1H), 7.45 – 
7.31 (m, 7H), 7.26 (s, 1H), 4.85 (s, 2H), 4.65 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 142.2, 140.2, 
139.4,  137.7, 128.4, 127.9, 127.8, 126.3, 124.2, 123.4, 122.6, 122.4, 71.8, 67.2,  IR:  = 3031, 
2923, 2851, 1496, 1455, 1355, 1140, 1129, 1086, 1070, 1061, 841, 746, 727, 696 cm-1; HRMS 
(ESI) m/z calc. for C16H14OSNa (M+Na) 277.0663, found 277.0673. 
 
5-((Benzyloxy)methyl)benzofuran (15): Obtained as a colorless oil (86 mg, 72%), 1H NMR 
(CDCl3, 500 MHz): δ 7.65-7.64 (m, 2H), 7.53-7.51 (m, 1H), 7.46 – 7.37 (m, 4H), 7.36 – 7.29 (m, 
2H), 6.79-6.78 (m, 1H), 4.68 (s, 2H), 4.61 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 154.8, 145.5, 
138.5, 133.0, 128.6, 128.0, 127.8, 127.7, 124.7, 120.9, 111.4, 106.8, 72.5, 72.1, IR:  = 2854, 1538, 
133 
1496, 1469, 1453, 1444, 1362, 1264, 1126, 1108, 1089, 1070, 1031, 884, 760, 734 cm-1; HRMS 
(ESI) m/z calc. for C16H14O2Na (M+Na) 261.0891, found 261.0899. 
 
5-((Benzyloxy)methyl)thiophene-2-carbaldehyde (16): Obtained as a colorless oil (65 mg, 56%), 
1H NMR (CDCl3, 500 MHz): 9.87 (s, 1H), 7.66 (d, J = 3.8 Hz, 1H), 7.37 (d, J = 4.4 Hz, 4H), 7.34 
– 7.26 (m, 1H), 7.09 (d, J = 3.7 Hz, 1H), 4.73 (s, 2H), 4.61 (s, 2H), 13C NMR (CDCl3, 126 MHz): 
δ 183.1, 152.6, 143.5, 137.5, 136.6, 128.7, 128.2, 128.0, 126.6, 72.7, 66.9,  IR:  = 2854, 1713, 
1668, 1464, 1454, 1359, 1227, 1206, 1086, 816, 738, 698 cm-1; HRMS (ESI) m/z calc. for 
C13H12O2SNa (M+Na) 255.0456, found 255.0462. 
 
1-((Benzyloxy)methyl)-3-chlorobenzene (17): Obtained as a colorless oil (75 mg, 64%), 1H NMR 
(CDCl3, 500 MHz): δ 8.52 (m, 1H), 8.46 (s, 1H), 7.73 (s, 1H), 7.38 (m, 4H), 7.34 (m, 1H), 4.61 (s, 
2H), 4.56 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 147.9, 146.6, 137.3, 135.1, 134.9, 132.0, 128.5, 
127.9, 127.7, 72.7, 68.6, IR:  = 2921, 1566, 1336, 1265, 1165, 1059, 1035, 911, 732,  cm-1; HRMS 
(ESI) m/z calc. for C13H13ClNO (M+H) 234.0686, found 234.0685. 
 
4-((Benzyloxy)methyl)-2-fluoropyridine (18): Obtained as a colorless oil (102 mg, 94%), 1H 
NMR (CDCl3, 500 MHz): δ 8.17 (d, J = 5.1 Hz, 1H), 7.39-7.38 (m, 4H), 7.35-7.32 (m, 1H), 7.15-
7.14 (m, 1H), 6.97 (s, 1H), 4.63 (s, 2H), 4.59 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 165.0, 163.1, 
153.7 (d, J = 7.6 Hz), 147.5 (d, J = 15.1 Hz), 137.3, 128.5, 127.8 (d, J = 32.9 Hz), 119.2 (d, J = 4.1 
Hz), 107.2 (d, J = 38.2 Hz), 72.9, 69.7 (d, J = 2.9 Hz), 19F NMR  (471 MHz, CDCl3) δ -68.1, IR:  
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= 2858,1615, 1570, 1453, 1411, 1359, 1277, 1148, 1097, 958, 830, 737, 698 cm-1; HRMS (ESI) 
m/z calc. for C13H13FNO (M+H) 218.0981, found 218.0977. 
 
2-((Benzyloxy)methyl)-5-methylpyridine (19): Obtained as a colorless oil (91 mg, 86%), 1H 
NMR (CDCl3, 500 MHz): δ 8.40 (s, 1H), 7.51-7.49 (m, 1H), 7.40-7.34 (m, 5H), 7.31-7.29 (m, 1H), 
4.67 (s, 2H), 4.64 (s, 2H), 2.33 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 155.4, 149.4, 138.0, 137.1, 
131.7, 128.3, 127.7, 127.6, 121.0, 73.0, 72.7, 18.1, IR:  = 2922, 2855, 1603, 1573, 1490, 1454, 
1356, 1099, 1030, 824, 734, 698 cm-1; HRMS (ESI) m/z calc. for C14H15NONa (M+Na) 236.1051, 
found 236.1062.  
 
3-((Benzyloxy)methyl)-5-methoxypyridine (20): Obtained as a colorless oil (87 mg, 76%), 1H 
NMR (CDCl3, 500 MHz): δ 8.25-8.24 (m, 1H), 8.18 (s, 1H), 7.37-7.36 (m, 4H), 7.34 – 7.28 (m, 
1H), 7.24 (s, 1H), 4.58 (s, 2H), 4.55 (s, 2H), 3.85 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 155.9, 
141.4, 137.9, 137.3, 134.5, 128.7, 128.0, 128.0, 119.7, 72.7, 69.4, 55.7, IR:  = 2840, 1591, 1468, 
1429, 1287, 1192, 1178, 1097, 1051, 865, 740, 701 cm-1; HRMS (ESI) m/z calc. for C14H16NO2 
(M+H) 230.1181, found 230.1185. 
 
3-((Benzyloxy)methyl)-4-methylpyridine (21): Obtained as a colorless oil (90 mg, 85%), 1H 
NMR (CDCl3, 500 MHz): δ 8.48 (s, 1H), 8.41 (d, J = 4.9 Hz, 1H), 7.35-7.32 (m, 4H), 7.29 (dd, J 
= 8.6, 4.2 Hz, 1H), 7.07 (d, J = 4.9 Hz, 1H), 4.55 (s, 2H), 4.53 (s, 2H), 2.33 (s, 3H),  13C NMR 
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(CDCl3, 126 MHz): δ 150.0, 149.6, 146.7, 138.0, 132.0, 128.6, 128.0, 127.9, 125.4, 72.7, 68.3, 
18.5, IR:  = 3052, 2861, 1597, 1559, 1506, 1496, 1456, 1362, 1265, 1076, 738 cm-1, HRMS (ESI) 
m/z calc. for C14H16NO (M+H) 214.1232, found 214.1230. 
 
5-((Benzyloxy)methyl)pyrimidine (22): Obtained as a colorless oil (82 mg, 82%), 1H NMR 
(CDCl3, 500 MHz): δ 9.14 (s, 1H), 8.71 (s, 2H), 7.38 – 7.33 (m, 4H), 7.31-7.39 (m, 1H), 4.60 (s, 
2H), 4.53 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 158.3, 156.4, 137.4, 131.7, 128.7, 128.2, 128.0, 
73.1, 67.3, IR:  = 2917, 2851, 1722, 1564, 1410, 1271, 1164, 1109, 1092, 1074, 728 cm-1; HRMS 
(ESI) m/z calc. for C12H13N2O (M+H) 201.1028, found 201.1027. 
 
2-((Benzyloxy)methyl)-5-(methylthio)pyrazine (23): Obtained as a colorless oil (103 mg, 84%), 
1H NMR (CDCl3, 500 MHz): δ 8.52-8.51 (m, 1H), 8.41-8.40 (m, 1H), 7.40 – 7.33 (m, 4H), 7.31-
7.29 (m, 1H), 4.65 (s, 2H), 4.64 (s, 2H), 2.56 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ  156.3, 148.0, 
142.9, 142.4, 137.8, 128.6, 128.0, 128.0, 73.1, 71.0, 12.8, IR:  = 3030, 2856, 1497, 1463, 1357, 
1317, 1116, 1023, 736, 698 cm-1; HRMS (ESI) m/z calc. for C13H15N2OS (M+H) 247.0905, found 
247.0903. 
 
4-((Benzyloxy)methyl)isoquinoline (24): Obtained as a colorless oil (89 mg, 72%), 1H NMR 
(CDCl3, 500 MHz): δ  9.24 (s, 1H), 8.52 (s, 1H), 8.13 (d, J = 8.3 Hz, 1H), 7.99 (d, J = 8.3 Hz, 1H), 
7.75-7.72 (m, 1H), 7.63-7.61 (m, 1H), 7.39 – 7.34 (m, 4H), 7.33 – 7.28 (m, 1H), 4.95 (s, 2H), 4.62 
(s, 2H), 13C NMR (CDCl3, 126 MHz): δ 153.6, 143.3, 138.0, 134.9, 130.8, 128.7, 128.3, 128.1, 
136 
128.0, 127.4, 127.0, 123.6, 72.5, 68.4, IR:  = 3053, 2985, 2861, 2305, 1624, 1420, 1362, 1265, 
1075, 896, 738, 703 cm-1, HRMS (ESI) m/z calc. for C17H16NO (M+H) 250.1232, found 250.1235. 
 
4-((Benzyloxy)methyl)quinoline (25): Obtained as a semisolid (116 mg, 93%), 1H NMR (CDCl3, 
500 MHz): δ 8.91 (d, J = 4.2 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.73-7.71 
(m, 1H), 7.60-7.51 (m, 2H), 7.39 (m, 4H), 7.33 (m, 1H), 5.01 (s, 2H), 4.68 (s, 2H), 13C NMR 
(CDCl3, 126 MHz): δ 150.3, 148.0, 143.5, 137.6, 130.1, 129.1, 128.5, 127.8, 127.7, 126.5, 126.1, 
123.1, 119.4, 72.8, 68.5, IR:  = 2863, 1712, 1596, 1510, 1453, 1352, 1242, 1109, 852, 758, 737 
cm-1; HRMS (ESI) m/z calc. for C17H16NO (M+H) 250.1232, found 250.1238. 
 
4-((Benzyloxy)methyl)-1-methyl-1H-indazole (26): Obtained as a colorless oil (92 mg, 73%), 1H 
NMR (CDCl3, 500 MHz): δ 8.12 (s, 1H), 7.42 – 7.34 (m, 6H), 7.33-7.30 (m, 1H), 7.14 (d, J = 5.8 
Hz, 1H), 4.90 (s, 2H), 4.61 (s, 2H), 4.10 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 140.1, 138.0, 
131.8, 131.6, 128.4, 127.8, 127.6, 126.0, 122.8, 119.4, 108.5, 72.2, 70.3, 35.5 ,  IR:  = 2854, 2358, 
2340, 1611, 1453, 1354, 1275, 1162, 1093, 1074, 980, 781, 735, 698 cm-1; HRMS (ESI) m/z calc. 
for C16H16N2ONa (M+Na) 275.1160, found 275.1161. 
 
(tert-Butyl 5-(Benzyloxy)methyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (27): Obtained as a 
colorless oil (98 mg, 58%), 1H NMR (CDCl3, 500 MHz): δ 8.47 (d, J = 1.9 Hz, 1H), 7.90 (d, J = 
137 
1.9 Hz, 1H), 7.64 (d, J = 4.0 Hz, 1H), 7.35 (d, J = 4.3 Hz, 4H), 7.30-7.28 (m, 1H), 6.48 (d, J = 4.1 
Hz, 1H), 4.65 (s, 2H), 4.55 (s, 2H), 1.66 (s, 9H), 13C NMR (CDCl3, 126 MHz): δ 148.3, 148.0, 
145.3, 138.1, 129.0, 128.6, 128.0, 127.9, 127.2, 123.1, 104.6, 84.2, 72.2, 70.0, 28.2, IR:  = 2860, 
1753, 1729, 1532, 1477, 1392, 1370, 1318, 1254, 1159, 1092, 1028, 734 cm-1; HRMS (ESI) m/z 
calc. for C20H23N2O3 (M+H) 339.1725, found 339.1719. 
 
8-((Benzyloxy)methyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione (28): Obtained as a 
white solid, mp = 124-125 oC (146 mg, 93%), 1H NMR (CDCl3, 500 MHz): δ  7.37 – 7.23 (m, 5H), 
4.62 (s, 2H), 4.55 (s, 2H), 3.94 (s, 3H), 3.53 (s, 3H), 3.36 (s, 3H),  13C NMR (CDCl3, 126 MHz): δ 
155.5, 151.7, 149.3, 147.5, 137.0, 128.7, 128.3, 128.2, 108.6, 73.2, 63.7, 32.4, 29.8, 28.1, IR:  = 
3055, 2359, 2343, 1705, 1660, 1544, 1457, 1265, 1073, 849, 738, 703 cm-1, HRMS (ESI) m/z calc. 
for C16H19N4O3 (M+H) 315.1457, found 315.1457.  
 
 
5-((benzyloxy)methyl)-2-(1H-imidazol-1-yl)pyrimidine (29): Obtained as a white solid, mp = 
59-61 oC (111 mg, 83%), 1H NMR (CDCl3, 500 MHz): δ 8.68 – 8.59 (m, 3H), 7.89 (s, 1H), 7.42 – 
7.30 (m, 5H), 7.17 (s, 1H), 4.60 (s, 2H), 4.52 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ  158.9, 158.3, 
154.5, 137.3, 130.9, 129.3, 128.8, 128.3, 128.0, 119.1, 73.1, 66.8, IR:  = 3051, 2925, 2859, 2305, 
1700, 1573, 1476, 1454, 1266, 1097, 1052, 981, 737 cm-1, HRMS (ESI) m/z calc. for C15H15N4O 
(M+H) 267.1246, found 267.1247. 
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5-((Pyridin-2-ylmethoxy)methyl)pyrimidine (30): Obtained as a white solid, mp = 38-39 oC (71 
mg, 71%), 1H NMR (CDCl3, 500 MHz): δ 9.13 (s, 1H), 8.73 (s, 2H), 8.54-8.53 (m, 1H), 7.70-7.68 
(m, 1H), 7.42-7.40 (m, 1H), 7.23 – 7.15 (m, 1H), 4.71 (s, 2H), 4.64 (s, 2H),  13C NMR (CDCl3, 126 
MHz): δ 158.4, 157.5, 156.4, 149.4, 137.0, 131.4, 122.9, 121.7, 74.0, 68.1, IR:  = 2858, 1718, 
1590, 1564, 1439, 1412, 1111, 1046, 1029, 764, 729 cm-1; HRMS (ESI) m/z calc. for C11H11N3ONa 
(M+Na) 224.0800, found 224.0807. 
 
5-(((2,6-Dichlorobenzyl)oxy)methyl)pyrimidine (31): Obtained as a white solid, mp = 77-78 oC 
(95 mg, 71%), 1H NMR (CDCl3, 500 MHz): δ 9.13 (s, 1H), 8.74 (s, 2H), 7.32-7.30 (m, 2H), 7.20-
7.17 (m, 1H), 4.86 (s, 2H), 4.62 (s, 2H), 13C NMR (CDCl3, 126 MHz): δ 158.4, 156.4, 137.0, 132.8, 
131.5, 130.5, 128.6, 67.9, 67.5, IR:  = 2923, 2853, 1184, 1565, 1436, 1407, 1104, 1090, 1080, 
941, 792, 760, 729 cm-1; HRMS (ESI) m/z calc. for C12H11Cl2N2O (M+H) 269.0248, found 
269.0248. 
 
5-((Tetrahydro-2H-pyran-4-yl)methoxy)methyl)pyrimidine (32): Obtained as a colorless oil 
(61 mg, 58%), 1H NMR (CDCl3, 500 MHz): δ 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H), 8.69 (s, 
2H), 4.50 (s, 2H), 3.98 – 3.92 (m, 2H), 3.44 – 3.30 (m, 4H), 1.93 – 1.83 (m, 1H), 1.68 – 1.60 (m, 
2H), 1.41 – 1.28 (m, 2H), 13C NMR (CDCl3, 126 MHz): δ 158.3, 156.2, 131.8, 76.2, 68.4, 67.7, 
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35.6, 30.0,  IR:  = 2918, 2847, 1728, 1564, 1442, 1407, 1288, 1237, 1148, 1111, 1091, 728 cm-1; 
HRMS (ESI) m/z calc. for C11H17N2O2 (M+H) 209.1290, found 209.1287. 
 
5-(((1S)-2-Isopropylcyclohexyl)oxy)methyl)pyrimidine (33): Obtained as a colorless oil (78 mg, 
63%), 1H NMR (CDCl3, 500 MHz): δ  9.11 (s, 1H), 8.69 (s, 2H), 4.66 (d, J = 12.1 Hz, 1H), 4.37 
(d, J = 12.1 Hz, 1H), 3.20-3.15 (m, 1H), 2.24 – 2.09 (m, 2H), 1.66-1.60 (m, 2H), 1.37-1.33 (m, 1H), 
1.29-1.24 (m, 1H), 0.93-0.80 (m, 9H), 0.71 (d, J = 7.0 Hz, 3H),  13C NMR (CDCl3, 126 MHz): δ 
158.1, 156.3, 132.5, 79.9, 65.7, 48.3, 40.3, 34.5, 31.6, 25.8, 23.4, 22.4, 21.0, 16.2, IR:  = 3354, 
2959, 2871, 1565, 1453, 1410, 1370, 1161, 1110, 953, 727 cm-1; HRMS (ESI) m/z calc. for 
C15H25N2O (M+H) 249.1967, found 249.1978. 
 
5-(((2-Methyloxetan-2-yl)methoxy)methyl)pyrimidine (34): Obtained as a colorless oil (72 mg, 
74%), 1H NMR (CDCl3, 500 MHz): δ  9.13 (s, 1H), 8.69 (s, 2H), 4.56 (s, 2H), 4.47 (d, J = 5.6 Hz, 
2H), 4.34-4.33 (m, 2H), 3.56 (s, 2H), 1.29 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 158.2, 156.1, 
131.4, 79.9, 76.2, 68.6, 39.9, 21.3,  IR:  = 2868, 1729, 1584, 1564, 1407, 1290, 1111, 1093, 1045, 
977, 833, 727 cm-1; HRMS (ESI) m/z calc. for C10H15N2O2 (M+H) 195.1134, found 195.1133. 
 
5-((2-Ethoxyethoxy)methyl)pyrimidine (35): Obtained as a colorless oil (55 mg, 60%), 1H NMR 
(CDCl3, 500 MHz): δ 9.11 (s, 1H), 8.70 (s, 2H), 4.57 (s, 2H), 3.66-3.64 (m, 2H), 3.60-3.58 (m, 2H), 
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3.49 (q, J = 7.0 Hz, 2H), 1.18 (t, J = 7.0 Hz, 3H),  13C NMR (CDCl3, 126 MHz): δ 158.0, 156.1, 
131.4, 70.3, 69.7, 68.4, 66.7, 15.0, IR:  = 3053, 2980, 2873, 2306, 1734, 1565, 1410, 1265, 1110, 
896, 739 cm-1, HRMS (ESI) m/z calc. for C9H14N2O2Na (M+Na) 205.0953, found 205.0958. 
 
5-((2-Methoxyethoxy)methyl)pyrimidine (36): Obtained as a colorless oil (80 mg, 95%), 1H 
NMR (CDCl3, 500 MHz): δ 9.09 (s, 1H), 8.68 (s, 2H), 4.54 (s, 2H), 3.69-3.67 (m, 2H), 3.58-3.57 
(m, 2H), 3.33 (s, 3H), 13C NMR (CDCl3, 126 MHz): δ 158.2, 156.4, 131.6, 72.0, 70.4, 68.6, 59.2, 
IR:  = 3420, 2894, 1628, 1568, 1410, 1111, 1092, 847, 727, 630 cm-1; HRMS (ESI) m/z calc. for 
C8H12N2O2Na (M+Na) 191.0796, found 191.0799. 
 
5-((Cyclopropylmethoxy)methyl)pyrimidine (37): Obtained as a colorless oil (45 mg, 55%), 1H 
NMR (CDCl3, 500 MHz): δ 9.14 (s, 1H), 8.72 (s, 2H), 4.54 (s, 2H), 3.37 (d, J = 6.9 Hz, 2H), 1.14 
– 1.04 (m, 1H), 0.59 – 0.52 (m, 2H), 0.23-0.20 (m, 2H), 13C NMR (CDCl3, 126 MHz): δ 158.0, 
156.1, 131.7, 75.7, 67.6, 10.3, 3.0, IR:  = 2858, 1586, 1564, 1440, 1409, 1376, 1110, 1089, 1045, 
728 cm-1; HRMS (ESI) m/z calc. for C9H13N2O (M+H) 165.1028, found 165.1026. 
 
1-(2-(Pyrimidin-5-ylmethoxy)ethyl)pyrrolidin-2-one (38): Obtained as a colorless oil (74 mg, 
67%), 1H NMR (CDCl3, 500 MHz): δ 9.12 (s, 1H), 8.66 (s, 2H), 4.50 (s, 2H), 3.65-3.63 (m, 2H), 
3.50-3.48 (m, 2H), 3.45-4.42 (m, 2H), 2.35-2.42 (m, 2H), 2.02-1.94 (m, 2H),13C NMR (CDCl3, 126 
MHz): δ  175.4, 158.3, 156.2, 131.4, 69.2, 68.2, 48.7, 42.4, 30.9, 18.2, IR:  = 2923, 2870, 2239, 
141 
1677, 1566, 1408, 1289, 1115, 912, 728 cm-1, HRMS (ESI) m/z calc. for C11H15N3O2Na (M+Na) 
244.1062, found 244.1059. 
 
5-((5-Chloropentyl)oxy)methyl)pyrimidine (39): Obtained as a colorless oil (90 mg, 79%), 1H 
NMR (CDCl3, 500 MHz): δ 9.10 (s, 1H), 8.67 (s, 2H), 4.47 (s, 2H), 3.50-3.46 (m, 4H), 1.76-1.70 
(m, 2H), 1.63-1.57 (m, 2H), 1.45-1.35 (m, 4H), 13C NMR (CDCl3, 126 MHz): δ 158.2, 156.2, 131.9, 
71.1, 68.2, 45.1, 32.6, 29.6, 26.7, 25.5, IR:  = 2934, 2860, 1727, 1564, 1440, 1406, 1112, 1095, 
727 cm-1; HRMS (ESI) m/z calc. for C11H18ClN2O (M+H) 229.1108, found 229.1112. 
 
5-((Hex-5-en-1-yloxy)methyl)pyrimidine (40): Obtained as a colorless oil (67 mg, 70%), 1H 
NMR (CDCl3, 500 MHz): δ 9.13 (s, 1H), 8.69 (s, 2H), 5.82 – 5.72 (m, 1H), 5.00-4.91 (m, 2H), 4.49 
(s, 2H), 3.52-3.49 (m, 2H), 2.12 – 2.02 (m, 2H), 1.69 – 1.57 (m, 2H), 1.52 – 1.41 (m, 2H), 13C NMR 
(CDCl3, 126 MHz): δ 158.2, 156.2, 138.6, 131.9, 114.8, 71.2, 68.2, 33.6, 29.1, 25.5, IR:  = 3391, 
2968, 2934, 2861, 1731, 1643, 1565, 1408, 1112, 1099, 952, 910, 728 cm-1; HRMS (ESI) m/z calc. 
for C11H17N2O (M+H) 193.1341, found 193.1345. 
 
5-((Prop-2-yn-1-yloxy)methyl)pyrimidine (41): Obtained as a white semi-solid (58 mg, 78%), 
1H NMR (CDCl3, 500 MHz): δ 9.15 (s, 1H), 8.72 (s, 2H), 4.61 (s, 2H), 4.23 (s, 2H), 2.51 (s, 1H),  
13C NMR (CDCl3, 126 MHz): δ 158.5, 156.5, 131.0, 78.8, 75.8, 66.8, 58.1, IR:  = 3276, 1566, 
1444, 1409, 1388, 1276, 1233, 1164, 1107, 1091, 1046, 724 cm-1; HRMS (ESI) m/z calc. for 
C8H9N2O (M+H) 149.0715, found 149.0712. 
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5-((Allyloxy)methyl)pyrimidine (42): Obtained as a colorless oil (57 mg, 76%), 1H NMR (CDCl3, 
500 MHz): δ 9.11 (s, 1H), 8.69 (s, 2H), 5.96 – 5.83 (m, 1H), 5.30-5.20 (m, 2H), 4.49 (s, 2H), 4.04 
(d, J = 5.6 Hz, 2H),  13C NMR (CDCl3, 126 MHz): δ 158.3, 156.3, 134.0, 131.7, 118.1, 72.0, 67.3, 
IR:  = 3050, 2982, 2858, 1588, 1564, 1410, 1267, 1086, 931, 737 cm-1, HRMS (ESI) m/z calc. for 
C8H11N2O (M+H) 151.0871, found 151.0867. 
 
5-(((4-Methoxybenzyl)oxy)methyl)pyrimidine (43): Obtained as a colorless oil (71 mg, 62%), 
1H NMR (CDCl3, 500 MHz): δ 9.19 (s, 1H), 8.76 (s, 2H), 7.30 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 8.5 
Hz, 2H), 4.57 (s, 2H), 4.54 (s, 2H), 3.83 (s, 3H),13C NMR (CDCl3, 126 MHz): δ 159.7, 158.3, 
156.4, 132.0, 129.7, 129.4, 114.1, 72.8, 67.0, 55.4, IR:  = 3047, 2859, 1613, 1586, 1564, 1514, 
1441, 1410, 1302, 1249, 1174, 1082, 1034, 820, 728 cm-1, HRMS (ESI) m/z calc. for C13H15N2O2 
(M+H) 231.1134, found 231.1126. 
 
5-(Tert-butoxymethyl)pyrimidine (44): Obtained as a colorless oil (59 mg, 71%), 1H NMR 
(CDCl3, 500 MHz): δ 9.09 (s, 1H), 8.67 (s, 2H), 4.43 (s, 2H), 1.27 (s, 9H), 13C NMR (CDCl3, 126 
MHz): δ 157.9, 156.1, 133.0, 74.3, 59.7, 27.6, IR:  = 2974, 2359, 2341, 1723, 1564, 1490, 1392, 
1365, 1197, 1082, 877, 727 cm-1; HRMS (ESI) m/z calc. for C9H15N2O (M+H) 167.1184, found 
167.1183. 
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5-(2-(Trimethylsilyl)ethoxy)methyl)pyrimidine (45): Obtained as a colorless oil (85 mg, 81%), 
1H NMR (CDCl3, 500 MHz): δ 9.09 (s, 1H), 8.67 (s, 2H), 4.45 (s, 2H), 3.57 (dd, J = 11.1, 5.2 Hz, 
2H), 0.95 (dd, J = 11.1, 5.42 Hz, 2H), -0.03 (s, 9H), 13C NMR (CDCl3, 126 MHz): δ 158.1, 156.2, 
132.0, 68.7, 67.6, 18.3, -1.3, IR:  = 2953, 1563, 1409, 1360, 1249, 1182, 1110, 1087, 859, 836, 
727 cm-1; HRMS (ESI) m/z calc. for C10H18N2OSiNa (M+Na) 233.1079, found 233.1076. 
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Appendix A2. 1H, 13C, 11B, and 19F NMR Spectra Relevant to Chapter 3 
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Figure A2.1. 1H NMR (CDCl3, 500 MHz) spectrum of 1-((benzyloxy)methyl)-3,5-
dimethoxybenzene (2) 
 
Figure A2.2. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-((benzyloxy)methyl)-3,5-
dimethoxybenzene (2) 
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Figure A2.3. 1H NMR (CDCl3, 500 MHz) spectrum of 3-((benzyloxy)methyl)benzaldehyde (3) 
 
Figure A2.4. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-((benzyloxy)methyl)benzaldehyde (3) 
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Figure A2.5. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(4-(benzyloxy)methyl)phenyl)ethan-1-one 
(4) 
Figure A2.6. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(4-(benzyloxy)methyl)phenyl)ethan-1-one 
(4) 
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Figure A2.7. 1H NMR (CDCl3, 500 MHz) spectrum of N-((4-(benzyloxy)methyl)phenyl)acetamide 
(5) 
Figure A2.8. 13C NMR (CDCl3, 125.8 MHz) spectrum of N-((4-
(benzyloxy)methyl)phenyl)acetamide (5) 
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Figure A2.9. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(benzyloxy)methyl)-2-
(trifluoromethyl)benzene (6) 
 
Figure A2.10. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(benzyloxy)methyl)-2-
(trifluoromethyl)benzene (6)  
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Figure A2.11. 19F NMR (CDCl3, 470.8 MHz) spectrum of 1-(benzyloxy)methyl)-2-
(trifluoromethyl)benzene (6) 
Figure A2.12. 1H NMR (CDCl3, 500 MHz) spectrum of 2-((benzyloxy)methyl)benzonitrile 
(7)  
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Figure A2.13. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-((benzyloxy)methyl)benzonitrile 
(7)  
 
Figure A2.14. 1H NMR (CDCl3, 500 MHz) spectrum of 1-((benzyloxy)methyl)-2-
methoxybenzene (8) 
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Figure A2.15. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-((benzyloxy)methyl)-2-
methoxybenzene (8) 
Figure A2.16. 1H NMR (CDCl3, 500 MHz) spectrum of 1-((benzyloxy)methyl)-2-methylbenzene 
(9) 
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Figure A2.17. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-((benzyloxy)methyl)-2-
methylbenzene (9) 
Figure A2.18. 1H NMR (CDCl3, 500 MHz) spectrum of 4-((benzyloxy)methyl)phenyl 
trifluoromethanesulfonate (10) 
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Figure A2.19. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-((benzyloxy)methyl)phenyl 
trifluoromethanesulfonate (10) 
Figure A2.20. 19F NMR (CDCl3, 470.8 MHz) spectrum of 4-((benzyloxy)methyl)phenyl 
trifluoromethanesulfonate (10)  
157 
Figure A2.21. 1H NMR (CDCl3, 500 MHz) spectrum of 1-((benzyloxy)methyl)-2,4-
difluorobenzene (11) 
Figure A2.22. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-((benzyloxy)methyl)-2,4-
difluorobenzene (11) 
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Figure A2.23. 19F NMR (CDCl3, 470.8 MHz) spectrum of 1-((benzyloxy)methyl)-2,4-
difluorobenzene (11) 
Figure A2.24. 1H NMR (CDCl3, 500 MHz) spectrum of 1-((benzyloxy)methyl)-4-
methoxybenzene (12) 
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Figure A2.25. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-((benzyloxy)methyl)-4-
methoxybenzene (12) 
Figure A2.26. 1H NMR (CDCl3, 500 MHz) spectrum of 1-((benzyloxy)methyl)-4-methylbenzene 
(13) 
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Figure A2.27. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-((benzyloxy)methyl)-4-
methylbenzene (13) 
Figure A2.28. 1H NMR (CDCl3, 500 MHz) spectrum of 2-((benzyloxy)methyl)benzo[b]thiophene 
(14) 
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Figure A2.29. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-
((benzyloxy)methyl)benzo[b]thiophene (14) 
Figure A2.30. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((benzyloxy)methyl)benzofuran (15) 
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Figure A2.31. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((benzyloxy)methyl)benzofuran (15) 
Figure A2.32. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((benzyloxy)methyl)thiophene-2-
carbaldehyde (16) 
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Figure A2.33. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((benzyloxy)methyl)thiophene-2-
carbaldehyde (16) 
 Figure A2.34. 1H NMR (CDCl3, 500 MHz) spectrum of 1-((benzyloxy)methyl)-3-
chlorobenzene (17) 
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Figure A2.35. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-((benzyloxy)methyl)-3-
chlorobenzene (17) 
Figure A2.36. 1H NMR (CDCl3, 500 MHz) spectrum of 4-((benzyloxy)methyl)-2-
fluoropyridine (18) 
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Figure A2.37. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-((benzyloxy)methyl)-2-
fluoropyridine (18)  
Figure A2.38. 1H NMR (CDCl3, 470.8 MHz) spectrum of 4-((benzyloxy)methyl)-2-
fluoropyridine (18) 
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Figure A2.39. 1H NMR (CDCl3, 500 MHz) spectrum of 2-((benzyloxy)methyl)-5-
methylpyridine (19) 
Figure A2.40. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-((benzyloxy)methyl)-5-
methylpyridine (19) 
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Figure A2.41. 1H NMR (CDCl3, 500 MHz) spectrum of 3-((benzyloxy)methyl)-5-
methoxypyridine (20) 
Figure A2.42. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-((benzyloxy)methyl)-5-
methoxypyridine (20) 
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Figure A2.43. 1H NMR (CDCl3, 500 MHz) spectrum of 3-((benzyloxy)methyl)-4-
methylpyridine (21) 
Figure A2.44. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-((benzyloxy)methyl)-4-
methylpyridine (21) 
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Figure A2.45. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((benzyloxy)methyl)pyrimidine (22) 
Figure A2.46. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((benzyloxy)methyl)pyrimidine 
(22) 
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Figure A2.47. 1H NMR (CDCl3, 500 MHz) spectrum of 2-((benzyloxy)methyl)-5-
(methylthio)pyrazine (23) 
Figure A2.48. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-((benzyloxy)methyl)-5-
(methylthio)pyrazine (23) 
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Figure A2.49. 1H NMR (CDCl3, 500 MHz) spectrum of 4-((benzyloxy)methyl)isoquinoline 
(24) 
Figure A2.50. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-((benzyloxy)methyl)isoquinoline 
(24) 
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Figure A2.51. 1H NMR (CDCl3, 500 MHz) spectrum of 4-((benzyloxy)methyl)quinoline (25) 
Figure A2.52. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-((benzyloxy)methyl)quinoline 
(25) 
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Figure A2.53. 1H NMR (CDCl3, 500 MHz) spectrum of 4-((benzyloxy)methyl)-1-methyl-1H-
indazole (26) 
Figure A2.54. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-((benzyloxy)methyl)-1-methyl-
1H-indazole (26) 
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Figure A2.55. 1H NMR (CDCl3, 500 MHz) spectrum of  (tert-butyl 5-(benzyloxy)methyl)-1H-
pyrrolo[2,3-b]pyridine-1-carboxylate (27) 
Figure A2.56. 13C NMR (CDCl3, 125.8 MHz) spectrum of  (tert-butyl 5-(benzyloxy)methyl)-1H-
pyrrolo[2,3-b]pyridine-1-carboxylate (27) 
175 
Figure A2.57. 1H NMR (CDCl3, 500 MHz) spectrum of 8-((benzyloxy)methyl)-1,3,7-trimethyl-
3,7-dihydro-1H-purine-2,6-dione (28) 
Figure A2.58 13C NMR (CDCl3, 125.8 MHz) spectrum of 8-((benzyloxy)methyl)-1,3,7-
trimethyl-3,7-dihydro-1H-purine-2,6-dione (28) 
176 
Figure A2.59. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((benzyloxy)methyl)-2-(1H-imidazol-1-
yl)pyrimidine (29) 
Figure A2.60. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((benzyloxy)methyl)-2-(1H-imidazol-1-
yl)pyrimidine (29) 
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Figure A2.61. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((pyridin-2-
ylmethoxy)methyl)pyrimidine (30) 
Figure A2.62. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((pyridin-2-
ylmethoxy)methyl)pyrimidine (30) 
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Figure A2.63. 1H NMR (CDCl3, 500 MHz) spectrum of 5-(((2,6-
dichlorobenzyl)oxy)methyl)pyrimidine (31) 
Figure A2.64. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-(((2,6-
dichlorobenzyl)oxy)methyl)pyrimidine (31) 
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Figure A2.65. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((tetrahydro-2H-pyran-4-
yl)methoxy)methyl)pyrimidine (32) 
Figure A2.66. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((tetrahydro-2H-pyran-4-
yl)methoxy)methyl)pyrimidine (32) 
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Figure A2.67. 1H NMR (CDCl3, 500 MHz) spectrum of 5-(((1S)-2-
isopropylcyclohexyl)oxy)methyl)pyrimidine (33) 
Figure A2.68. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-(((1S)-2-
isopropylcyclohexyl)oxy)methyl)pyrimidine (33) 
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Figure A2.69. 1H NMR (CDCl3, 500 MHz) spectrum of 5-(((2-methyloxetan-2-
yl)methoxy)methyl) (34) 
Figure A2.70. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-(((2-methyloxetan-2-
yl)methoxy)methyl) (34) 
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Figure A2.71. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((2-
methoxyethoxy)methyl)pyrimidine (35) 
Figure A2.72. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((2-
methoxyethoxy)methyl)pyrimidine (35) 
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Figure A2.73. 1H NMR (CDCl3, 500 MHz) spectrum of 5-
((cyclopropylmethoxy)methyl)pyrimidine (36) 
Figure A2.74. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-
((cyclopropylmethoxy)methyl)pyrimidine (36) 
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Figure A2.75. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(2-(pyrimidin-5-
ylmethoxy)ethyl)pyrrolidin-2-one (37) 
Figure A2.76. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(2-(pyrimidin-5-
ylmethoxy)ethyl)pyrrolidin-2-one (37) 
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Figure A2.77. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((2-ethoxyethoxy)methyl)pyrimidine 
(38) 
Figure A2.78. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((2-
ethoxyethoxy)methyl)pyrimidine (38) 
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Figure A2.79. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((5-
chloropentyl)oxy)methyl)pyrimidine (39) 
Figure A2.80. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((5-
chloropentyl)oxy)methyl)pyrimidine (39) 
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Figure A2.81. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((hex-5-en-1-
yloxy)methyl)pyrimidine (40) 
Figure A2.82. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((hex-5-en-1-
yloxy)methyl)pyrimidine (40) 
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Figure A2.83. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((prop-2-yn-1-
yloxy)methyl)pyrimidine (41) 
Figure A2.84. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((prop-2-yn-1-
yloxy)methyl)pyrimidine (41) 
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Figure A2.85. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((allyloxy)methyl)pyrimidine (42) 
Figure A2.86. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((allyloxy)methyl)pyrimidine (42) 
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Figure A2.87. 1H NMR (CDCl3, 500 MHz) spectrum of 5-(((4-
methoxybenzyl)oxy)methyl)pyrimidine (43) 
Figure A2.88. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-(((4-
methoxybenzyl)oxy)methyl)pyrimidine (43) 
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Figure A2.89. 1H NMR (CDCl3, 500 MHz) spectrum of 5-(tert-butoxymethyl)pyrimidine (44) 
Figure A2.90. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-(tert-butoxymethyl)pyrimidine 
(44) 
 
192 
Figure A2.91. 1H NMR (CDCl3, 500 MHz) spectrum of 5-((tetrahydro-2H-pyran-4-
yl)methoxy)methyl)pyrimidine (45) 
Figure A2.92. 13C NMR (CDCl3, 125.8 MHz) spectrum of 5-((tetrahydro-2H-pyran-4-
yl)methoxy)methyl)pyrimidine (45) 
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Figure A2.93. 1H NMR (CDCl3, 500 MHz) spectrum of Potassium (((6-
chlorohexyl)oxy)methyl)trifluoroborate (S1) 
Figure A2.94. 13C NMR (CDCl3, 125.8 MHz) spectrum of Potassium (((6-
chlorohexyl)oxy)methyl)trifluoroborate (S1) 
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Figure A2.95. 11B NMR (CDCl3, 128.4 MHz) spectrum of Potassium (((6-
chlorohexyl)oxy)methyl)trifluoroborate (S1) 
Figure A2.96. 19F NMR (CDCl3, 470.8 MHz) spectrum of Potassium (((6-
chlorohexyl)oxy)methyl)trifluoroborate (S1) 
195 
Figure A2.97. 1H NMR (CDCl3, 500 MHz) spectrum of Potassium ((pyridin-2-
ylmethoxy)methyl)trifluoroborate (S2) 
Figure A2.98. 13C NMR (CDCl3, 125.8 MHz) spectrum of Potassium ((pyridin-2-
ylmethoxy)methyl)trifluoroborate (S2) 
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Figure A2.99. 11B NMR (CDCl3, 128.4 MHz) spectrum of Potassium ((pyridin-2-
ylmethoxy)methyl)trifluoroborate (S2) 
Figure A2.100. 19F NMR (CDCl3, 470.8 MHz) spectrum of Potassium ((pyridin-2-
ylmethoxy)methyl)trifluoroborate (S2) 
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Figure A2.101. 1H NMR (CDCl3, 500 MHz) spectrum of Potassium ((2-
ethoxyethoxy)methyl)trifluoroborate (S3) 
Figure A2.102. 13C NMR (CDCl3, 125.8 MHz) spectrum of Potassium ((2-
ethoxyethoxy)methyl)trifluoroborate (S3) 
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Figure A2.103. 11B NMR (CDCl3, 128.4 MHz) spectrum of Potassium ((2-
ethoxyethoxy)methyl)trifluoroborate (S3) 
Figure A2.104. 19F NMR (CDCl3, 470.8 MHz) spectrum of Potassium ((2-
ethoxyethoxy)methyl)trifluoroborate (S3) 
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Figure A2.105. 1H NMR (CDCl3, 500 MHz) spectrum of Potassium 
((methoxy)methyl)pyrrolidin-2-onetrifluoroborate (S4) 
Figure A2.106. 13C NMR (CDCl3, 125.8 MHz) spectrum of Potassium 
((methoxy)methyl)pyrrolidin-2-onetrifluoroborate (S4) 
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Figure A2.107. 11B NMR (CDCl3, 128.4 MHz) spectrum of Potassium 
((methoxy)methyl)pyrrolidin-2-onetrifluoroborate (S4) 
Figure A2.108. 19F NMR (CDCl3, 470.8 MHz) spectrum of Potassium 
((methoxy)methyl)pyrrolidin-2-onetrifluoroborate (S4) 
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Chapter 4. Unactivated Secondary Alkyltrifluoroborates as Radical 
Precursors 
4.1 Introduction 
At this point in the development of this new cross-coupling paradigm, all successful radical 
partners (benzylic, α-alkoxymethyl) had been previously employed in Pd cross-coupling via their 
analogous carbon-centered anion intermediates. Although the scope of the photoredox Ni catalyzed 
variants often far exceeded and surpassed that of previously recorded methods, many of the 
products obtained in these coupling could be accessed by alternative strategies – cross-coupling or 
otherwise. The true test of a new method should be whether it can overcome or complement 
weaknesses in the current state of the art and, in the case of organoboron cross-coupling, the truest 
limitation has always been sterically hindered secondary and tertiary alkyl nucleophiles. 
Given these classical restraints, the expectation from the outset of this research was to 
surmount the far greater challenge of secondary alkyl coupling.i As alluded to in Chapter 1, the 
most challenging aspect of traditional alkylboron cross-coupling is the slow rate of 
transmetalation,1–3 a problem innate to the two-electron nature of the process. Because of the 
inherently low nucleophilicity of organoboron reagents and the associated high energy of activation 
in the transmetalation, general approaches to secondary alkyl cross-coupling have defaulted to the 
more reactive alkylboranes,1 alkylzincs,4,5 alkyl Grignard reagents,6 and alkyllithiums.7 Although 
                                                     
i Reproduced in part from J. Am. Chem. Soc., 2015, 137, 2195 
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these reagents can normally be cross-coupled in high yields, their poor shelf life and lack of 
functional group tolerability limits their widespread application - particularly in the context of 
parallel synthesis for medicinal chemistry. 
Among the more preferable organoboron reagents, a number of substrate-specific secondary 
alkyl cross-coupling reactions have been reported, but these have always required electronic or 
functional group stabilization (β-carbonyl,8 α-boryl,9 α-alkoxy,10 benzylic,11,12 or allylic13) to allow 
effective reaction.14 A few isolated examples of cross-coupling with unactivated boronic acid 
derivatives exist, but these do not comprise a general strategy for alkyl cross-coupling.15,16 The 
most universal transformations to date have involved cross-coupling with alkyltrifluoroborates or 
boronic acids under rigorous reaction conditions (3 equiv K2CO3, 60 – 100 ⁰C, 24 – 48 h).17–19 Most 
importantly, these methods are uniformly ineffective for more highly substituted systems such as 2-
methylcycloalkylboron reagents. 
 
Figure 4.1. Comparison between traditional and radical cross-coupling 
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Here, our approach to transmetalation was anticipated to circumvent the traditional four-
coordinate transition structure20 and replace alkyl transfer with a series of SET processes,21,22 
enabling cross-coupling at room temperature. It was recognized that this method had profound 
implications for Csp3-Csp2 cross-coupling because of the mild nature of the reaction conditions. 
Instead of a high activation energy transmetalation, alkyl transfer could be effected through radical 
combination with a transition metal-based catalyst complex – a nearly barrierless energetic 
process.23 In such a transformation, excitation of the photocatalyst serves as a targeted energy 
shuttle to enable the transmetalation event, alleviating the necessity to heat the reactions. These 
conditions were anticipated to increase yields by limiting the side reactions that have doomed 
previous alkyl Suzuki couplings. A comparison between the two strategies is summarized in Figure 
4.1 
4.2 Results and Discussion 
 
Direct application of the previously reported SET strategy to secondary alkyltrifluoroborates 
was recognized as challenging because of their relatively high oxidation potentials (+1.50 V vs 
SCE)24 as compared to that of their benzylic counterparts (+1.10 V vs SCE).24 Exceeding the 
electrochemical potentials of highly oxidizing photocatalyst Ir(dFCF3ppy)2bpy PF6 (+1.32 V vs 
SCE),25 these substrates appeared to be destined for failure because of their high electrochemical 
demands. Nevertheless, encouragement was found in cases where thermodynamically unfavorable 
single electron transfers occur – particularly within the context of an irreversible oxidation or 
reduction.24,26 Thus, only a small portion of the oxidation wave need overlap with the potential of 
the photocatalyst for the reaction to proceed, driven forward by irreversible C-B bond 
fragmentation. 
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Initially, attempts to apply previous conditions for the cross-coupling of benzylic and 
secondary -alkoxyalkyltrifluoroborates [2.0 mol % Ir[dFCF3ppy]2(bpy)PF6 1, 3.0 mol % 
Ni(COD)2/dtbbpy, acetone/MeOH (10:1), 3.5 equiv of lutidine] proved ineffective (<10% yield). 
The low yields achieved using that protocol appeared to be a consequence of the differing nature 
of the unstabilized, secondary alkyl radicals, where radical alkylation of arenes27 and H-atom 
abstraction from the solvent28 could outcompete combination with the nickel catalyst, which was 
present in low concentration.  Using knowledge of established H-atom abstraction rates,29 
suppression of these side reactions could be achieved by the use of dioxane as solvent with careful 
monitoring of the reaction temperature. Next, various additives were determined to have a profound 
effect on the rate of the reaction and the amount of protodehalogenation side product observed. Of 
those additives screened, Cs2CO3 was the best for maximizing productive cross-coupling while 
limiting side reactions. Although the precise role of the base has not been defined, rate studies have 
revealed that BF3 appears to inhibit the reaction. Its removal by added base allows reactions to 
proceed to completion in a more timely manner. Application of these conditions to the cross-
coupling of methyl 4-bromobenzoate with potassium cyclopentyltrifluoroborate furnished product 
14 in a satisfactory 92% yield (see experimental). Control experiments in the absence of nickel, 
iridium, and light all confirmed the dual catalytic nature of this cross-coupling. 
With suitable conditions [2.5 mol % Ir cat 1, 5 mol % NiCl2•dme, 5 mol % dtbbpy, 1.5 equiv 
Cs2CO3, dioxane, 26-Watt compact fluorescent lightbulb (CFL), 24 ºC, 24 h] in hand, an 
exploration of the scope of the alkyltrifluoroborate component was initiated (Table 1). 
Organoboron reagents possessing various ring sizes were coupled in good to excellent yields.  To 
ensure the scalability and efficiency of this secondary alkyl coupling, a gram scale reaction 
generating 2 was performed with reduced loadings of iridium and nickel catalyst. Importantly, only 
1.0 mol % of the photoredox catalyst and 2.0 mol % of the nickel catalyst was required, and under 
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these conditions the cross-coupling of methyl 4-bromobenzoate with potassium 
cyclohexyltrifluoroborate was accomplished to afford 2 in 73% yield after 36 h.  
When moving to smaller ring sizes, particularly cyclobutyl- and cyclopropyl systems, where 
occupying an orbital with greater s-character destabilizes the resultant radical, yields suffered. In 
fact, for the cyclopropyl substrate, no reaction was observed. This poor reactivity serves to highlight 
the complementary nature of this method when compared to established methods for Csp2- and Csp2-
like cross-coupling; an area where the two-electron transmetalation regime has proven quite 
effective.30 Isopropyl- and sec-butyltrifluoroborates were also coupled in good yields. For these 
substrates, where isomerization would lead to different products, only the desired regioisomer was 
observed. 
To probe further the limits of the isomeric fidelity observed in this transformation, several 
more bulky secondary alkyltrifluoroborates were explored. Gratifyingly, products derived from 2-
methylcyclopentyl and 2-methylcyclohexyl substrates were also isolated without rearrangement. In 
addition, the products were exclusively the trans diastereomer.  Remarkably, an even more 
sterically demanding pinene derivative could be coupled to afford 12. 
Aliphatic heterocyclic ring systems containing oxygen (11) and protected nitrogen (10), 
which have proven to be recalcitrant in previous cross-coupling methods,18 did not significantly 
reduce yields under the photoredox cross-coupling protocol. In particular, aryl piperidines 
structurally analogous to 10, which are highly desired for incorporation into pharmaceutical 
libraries,31 could be accessed in excellent yield. To explore the scope of functional group tolerance, 
attention was turned to the screening of substituted aryl bromides (Table 4.2). During this process, 
a variety of trifluoroborates were used, particularly those that were both unsymmetrical and 
sterically encumbered in an effort to showcase the mild nature of these cross-couplings.  In previous 
work under palladium catalysis, 2-methylcycloalkylborons were observed to isomerize during the 
reaction, leading to a complex mixture where cross-coupling at the less sterically crowded positions 
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was preferred.18,19 In contrast, the ability to couple even more crowded trifluoroborates with a range 
of aryl bromides under the current paradigm serves to highlight the mechanistic differences 
between a traditional transmetalation and the radical-mediated alkyl transfer described herein. 
 
Figure 4.2. Scope of secondary alkyltrifluoroborates and aryl halides in 
 Ni/photoredox cross-coupling 
 
For the aryl bromide component, both electron-poor (13) and electron-rich systems (14) were 
coupled in good to excellent yields. Substitution ortho to the halide in 15 and 18 was tolerated 
without significant reduction in yield. Selective cross-coupling was observed in compounds with 
multiple electrophilic handles; both bifunctional aryl chlorides (leading to 15 and 17) and an aryl 
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triflate, providing 27, coupled exclusively at the bromide. Ketones and esters (24 and 30), which 
can be intolerant of Kumada-type conditions, could be embedded within substrates to afford 
products in excellent yields. Further, nitrile-substituted bromides 13 and 25, which were unreactive 
under the previously developed Pd chemistry for alkyltrifluoroborates,18 served as competent 
reaction partners.  
Protic groups did not diminish reactivity for the acetanilide substrate leading to 20. A number 
of N-heterocyclic bromides, providing privileged substructures of use in medicinal chemistry,31 
readily participated in the cross-coupling. Pyridines (17, 19, 21, 25, 28), pyrimidine (23), and 
protected heterocycles (indazole 18, azaindole 22) were all accessed in acceptable yields. In 
addition to the more desirable N-heterocycles, a bromobenzothiophene was also reactive under the 
conditions, returning coupled product 29 in reasonable yield. Overall, the functional group 
tolerance for bromides shown here rivals or exceeds that of any previously developed method for 
secondary alkyl Suzuki cross-coupling – particularly within the context of heteroaryl substrates.  
4.3 Conclusion 
 
In summary, extremely mild conditions (rt, 1.5 equiv base, 26 W CFL irradiation) for the 
cross coupling of secondary alkyltrifluoroborates with aryl bromides have been developed.  The 
best previously reported, palladium-catalyzed conditions for secondary alkylboron coupling18,19 
have required significant excess of base and elevated temperatures  to achieve less general overall 
results. Moreover, extensive Pd source, ligand, and reaction condition screening have so far failed 
to identify satisfactory results for systems such as 2-methyl-substituted cycloalkylboron reagents. 
In contrast, only slight modification of the initially reported conditions for benzylic coupling were 
required to extend both the nucleophilic and electrophilic scope of secondary alkyl cross-couplings 
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with the photoredox/cross-coupling dual catalytic system. The ease of this transformation across a 
broad array of radical precursors (-amino,32 -alkoxy,32,33 benzylic,33 and now secondary alkyl) 
speaks to the power of the SET-mediated approach. Further investigations into Ni precatalysts and 
ligands (entities that have yielded vast improvements in analogous Pd chemistry34,35) can arguably 
afford similar gains when applied to this system. With proper screening and catalyst design, 
extensions to extremely hindered electrophiles and aryl chlorides appear feasible.  
Finally, it should be noted that several Pd-catalyzed processes allow the conversion of 
enantiomerically enriched organoboron reagents to cross-coupled products with high 
stereochemical fidelity.7,17,19-22  Although such a process is clearly not feasible under the current 
paradigm, where radical intermediates are generated from the organoboron precursors, the prochiral 
radicals generated can be engaged in stereoconvergent transformations by employing 
enantioenriched ligands around the Ni catalyst.33,36,37 The fine tuning of stereoconvergent protocols 
by ligand development and screening has the potential to provide a unique and significant 
advancement to the field by eliminating the need to synthesize optically active organometallic 
reagents, approaches to which are often long, tedious, and intolerant of sensitive functional 
groups.38–40 
Possibly the most attractive feature of the reported photoredox cross-coupling is its 
operational simplicity. By eliminating the need to prepare sensitive organometallics, titrate 
reagents, or use glovebox techniques, these methods greatly enhance the approachability of 
secondary alkyl cross-couplings.  Consequently, the methods described herein provide a significant 
advancement to Csp3-Csp2 cross-coupling. 
 
4.4 Experimental 
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General considerations 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless otherwise 
noted. Dioxane (99.9%, extra dry) was used as received. Cs2CO3 was used as received. IrCl3·xH2O, 
and NiCl2•dme were purchased from commercial sources. All other reagents were purchased 
commercially and used as received. Photoredox reactions were irradiated with two or three standard 
26 W compact fluorescent light bulbs. Melting points (°C) are uncorrected. NMR spectra were 
recorded on a 500- or 400 MHz spectrometer. 19F NMR chemical shifts were referenced to external 
CFCl3 (0.0 ppm). 11B NMR spectra were obtained on a spectrometer equipped with the appropriate 
decoupling accessories. Data are presented as follows: chemical shift (ppm), multiplicity (s = 
singlet, d = doublet, t = triplet, sept = septet, m = multiplet, br = broad), coupling constant J (Hz) 
and integration.  
 
Synthesis of Secondary Alkyltrifluoroborates: 
 
Most potassium organotrifluoroborates were purchased commercially. In cases where the desired 
potassium organotrifluoroborate was unavailable, the corresponding boronic acid derivative was 
converted to the trifluoroborate by the following procedure. 
 
General Procedure for conversion of boronic acid to trifluoroborate: 
 
To a solution of boronic acid derivative in acetone or MeOH (0.1 M) at 0 oC was added saturated 
aq KHF2 (4.5 M) dropwise over 30 min. The resulting suspension was concentrated under reduced 
pressure. H2O was azeotropically removed by suspension in toluene (100-150 mL) followed by 
rotary evaporation. The remaining solid was dried under high vacuum and then suspended in hot 
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acetone (3 x 100 mL) and filtered. The filtrate was concentrated to a minimal volume (5 – 20 mL) 
and hexane or Et2O (~200 mL) were added to yield a white precipitate. The precipitate was isolated 
by filtration, washing with hexanes (~30 mL) and CH2Cl2 (~30 mL), to afford the desired secondary 
alkyltrifluoroborate. 
 
Selected reaction optimization studies 
 
Procedure for reaction screening at 0.10 or 0.05 mmol scale: To a reaction vial equipped with a 
Teflon-coated magnetic stir bar in a glovebox was added a soln of nickel source and ligand (1:1) 
dissolved in THF. The solvent was removed in vacuo under an inert atmosphere. Additives were 
weighed into the vials (liquid additives were added after the stock solution). A stock solution of 
aryl bromide, secondary alkyltrifluoroborate, Ir catalyst 1, and internal standard were then added 
by syringe and stirred for 16-24 h in front of a single 26 W CFL. Aliquots were then taken, diluted, 
and analyzed by HPLC or GC/MS. Reactions were compared within sets by crude product to 
internal standard (P/IS) ratios. 
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Figure 4.3. Comparison of Solvents 
Conditions: 0.1 mmol Ar-Br, 1.5 equiv RBF3K, 2.0 %  
Ir(dFCF3ppy)2bpy PF6, 10.0 % Ni/dtbbpy, K2CO3 (1.0 equiv), 0.05 M  
 
 
 
in solvent 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Nickel Sources 
Conditions: 0.1 mmol Ar-Br, 1.5 equiv RBF3K, 2.0%  
Ir(dFCF3ppy)2bpy PF6, 10.0 % Ni source/dtbbpy, K2CO3 (1.0 equiv), 0.05 M in dioxane 
 
 
Figure 4.5. Nickel Loadings 
Conditions: 0.1 mmol Ar-Br, 1.5 equiv RBF3K, 2.0%  
Ir(dFCF3ppy)2bpy PF6, 1.5 equiv K2CO3 0.05 M in dioxane 
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MeCN
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DMA
DMPU
DMF
P/IS: Solvent Screen
0 0.2 0.4 0.6 0.8
2% Ni cat.
5% Ni cat.
10% Ni cat.
P/IS: Nickel Loadings
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P/IS: Nickel Sources
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Figure 4.6. Comparison of Carbonate Bases and Cesium Salts 
Conditions: 0.1 mmol Ar-Br, 1.5 equiv RBF3K, 2.5%  
Ir(dFCF3ppy)2bpy PF6, 5.0% Ni/dtbbpy, 1.5 equiv additive, 0.05 M in dioxane 
 
General procedure for photoredox cross-coupling reactions 
 
 
 
 
 
 
 
 
 
 
 
To a long, thin (~20 mL) borosilicate glass vial equipped with a Teflon-coated magnetic stir bar 
was added 4,4’-di-tert-butyl-2,2’-bipyridine (6.7 mg, 0.025 mmol) and NiCl2•dme (5.5 mg, 0.025 
mmol) and 1.0 mL THF. The vial was capped and the resulting suspension was heated briefly with 
a heat gun until the nickel and ligand were fully solubilized, yielding a pale green solution. The 
solvent was then removed under vacuum to give a fine coating of the ligated nickel complex (pale 
evergreen in color). Once dry, aryl bromide (0.5 mmol, 1 equiv) (liquid aryl bromides were added 
with solvent), secondary alkyltrifluoroborate (0.75 mmol, 1.5 equiv), Ir[dFCF3ppy]2(bpy)PF6 1 
(12.8 mg, 0.025 mmol) and Cs2CO3 (243 mg, 0.75 mmol) were added in succession. The vial was 
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
P/IS: Additive Screen
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then capped and purged and evacuated four times. Under inert atmosphere, dioxane (10 mL) was 
introduced. The vial containing all the reagents was further sealed with parafilm and stirred for 24 
hours approximately 4 cm away from two 26 W fluorescent light bulbs. A fan was blown across 
the reaction setup to maintain an ambient temperature around 24 oC. After 16-24 h, an aliquot was 
taken and analyzed on a GC/MS to monitor reaction completion and confirm formation of a single 
regioisomer (when applicable). Then, the crude reaction mixture was filtered through an 
approximately 2 cm x 2 cm cylindrical plug of Celite, washing with EtOAc (10–20 mL). The 
resulting solution was concentrated and the residue was purified by column chromatography on 
silica gel, eluting with EtOAc and hexanes, to obtain products in pure form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Photoredox cross-coupling reaction set-up (0.5 mmol scale) 
 
Gram scale reaction: To a ~125 mL long thin-walled vacuum flask equipped with a Teflon-coated 
magnetic stir bar was added NiCl2•dme (20 mg, 0.093 mmol, 0.02 equiv) and 4,4'-di-tert-butyl-
2,2'-bipyridine (25 mg, 0.093, 0.02 equiv) and 5.0 mL of THF. The vial was capped and the 
resulting suspension was heated briefly with a heat gun until the nickel and ligand were fully 
solubilized, yielding a pale green solution. The solvent was then removed under vacuum to give a 
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fine coating of the ligated nickel complex (pale evergreen in color). Once dry, methyl 4-
bromobenzoate (1.000 g, 4.65 mmol, 1.00 equiv), potassium cyclohexyltrifluoroborate (1.325 g, 
6.98 mmol, 1.50 equiv), Ir[dFCF3ppy]2(bpy)PF6 1 (47.0 mg, 0.047 mmol, 0.01 equiv), and Cs2CO3 
(2.267 g, 6.98 mmol, 1.50 equiv) was added. The vial was then capped with a rubber septum and 
purged and evacuated four times. Under inert atmosphere, dioxane (95 mL, 0.05 M) was 
introduced. The vial containing all the reagents was further sealed with parafilm and stirred 
vigorously (a small vortex should be observed toward the top of the reaction mixture) for 36 h 
approximately 4 cm away from three 26 W fluorescent light bulbs. A fan was blown across the 
reaction setup to maintain an ambient temperature around 24 oC. After completion, the crude 
reaction mixture was filtered through an approximately 4 cm x 2 cm cylindrical plug of Celite, 
washing with EtOAc (60 mL). The resulting solution was concentrated and the residue was purified 
by column chromatography on silica gel, eluting with EtOAc and hexanes, to obtain product in 
pure form. 
 
Figure 4.8. Gram scale photoredox cross-coupling reaction set-up (4.65 mmol) 
215 
Compound Characterization Data 
 
 
 
Methyl 4-cyclohexylbenzoate (2): obtained as a white crystalline solid (76 mg, 70%), on gram 
(4.65 mmol) scale (740 mg, 73%), mp = 38-40 oC. 1H NMR (CDCl3, 500 MHz): δ 7.97 (d, J = 8.0 
Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 3.90 (s, 3H), 2.58-2.54 (m, 1H), 1.87 (m, 4H), 1.77 (d, J = 12.5 
Hz, 1 H), 1.48-1.31 (m, 4H), 1.29-1.25 (m, 1H). 13C NMR (CDCl3, 125.8 MHz): δ 167.1, 153.4, 
129.6, 127.7, 126.8, 51.8, 44.6, 34.0, 26.7, 26.0. IR:  = 2926, 2852, 1720, 1436, 1276, 1180, 1112, 
1101, 1019, 762, 706 cm-1. HRMS (ESI) m/z calc. for C14H18O2Na (M+Na) 241.1204, found 
241.1214. 
 
Methyl 4-cyclopentylbenzoate (3): obtained as a white amorphous solid (94 mg, 92%), mp = 32-
33 °C. 1H NMR (CDCl3, 500 MHz): δ 7.95 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 3.89 (s, 
3H), 3.04 (q, J = 8.5 H, 1H), 2.08 (m, 2H), 1.82-1.59 (m, 6H) – a small amount of methyl 4-
bromobenzoate (<5%) was inseparable from the starting material after column chromatography. 
13C NMR (CDCl3, 125.8 MHz): δ 167.1, 152.1, 129.5, 127.6, 127.0, 51.8, 45.9, 34.4, 25.5 
Characterization data matched that reported in the literature.41 
 
Methyl 4-cyclobutylbenzoate (4): obtained as a pale yellow oil (57 mg, 60%). 1H NMR (CDCl3, 
500 MHz): δ 7.96 (d, J = 8.5, 2H), 7.26 (d, J = 8.5, 2H) 3.90 (s, 3H), 3.59 (m, 1H), 2.39-2.34 (m, 
2H), 2.20-2.00 (m, 3H), 1.90-1.84 (m, 1H). 13C NMR (CDCl3, 125.8 MHz): δ 167.3, 151.8, 129.7, 
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127.8, 126.4, 52.1, 40.4, 29.7, 18.4. IR:  = 2951, 1721, 1609, 1435, 1276, 1108, 1020, 768, 646 
cm-1. HRMS (ESI) m/z calc. for C12H15O2 (M+H) 191.1072, found 191.1065. 
 
Methyl trans-4-(2-methylcyclohexyl)benzoate (6): obtained as a colorless oil (110 mg, 95%) 
1H NMR (CDCl3, 500 MHz): δ 7.95 (d, J = 8.0, 2H), 7.22 (d, J = 8.0, 2H), 3.89 (s, 3H), 2.16-2.11 
(m, 1H), 1.84-1.76 (m, 4H), 1.64-1.58 (m, 1H), 1.46-1.32 (m, 3H), 1.12-1.10 (m, 1H), 0.64 (d, J = 
6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 167.1, 152.4, 129.6, 127.7, 127.5, 52.5, 51.8, 37.4, 
35.5, 35.2, 26.7, 26.5, 20.6. IR:  = 2924, 2853, 1722, 1609, 1435, 1276, 1180, 1112, 1102, 772, 
708 cm-1. HRMS (ESI) m/z calc. for C15H21O2 (M+H) 233.1542, found 233.1539. GCMS analysis 
of the reaction mixture after 16 hours confirms formation of a single regioisomer. 
 
Methyl trans-4-(2-methylcyclopentyl)benzoate (7): obtained as a pale yellow oil (99 mg, 91%) 
1H NMR (CDCl3, 500 MHz): δ 7.96 (d, J = 8.0, 2H), 7.27 (d, J = 8.0, 2H), 3.90 (s, 3H), 2.50-2.44 
(m, 1H) 2.10-2.08 (m, 1H), 2.00-1.92 (m, 2H), 1.78-1.71 (m, 3H), 1.34-1.30 (m, 1H), 0.91 (d, J = 
6.5 Hz, 3H) 13C NMR (CDCl3, 125.8 MHz): δ 167.3, 151.4, 129.8, 128.0, 127.7, 54.7, 52.1, 43.4, 
35.4, 34.9, 24.1, 18.6. IR:  = 2951, 2868, 1723, 1610, 1435, 1278, 1179, 1112, 770 cm-1 
HRMS (ESI) m/z calc. for C14H19O2 (M+H) 219.1385, found 219.1394. GCMS analysis of the 
reaction mixture after 16 hours confirms presence of a single regioisomer. 
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Methyl 4-(sec-butyl)benzoate (8): obtained as a colorless oil (73 mg, 76%). 1H NMR (CDCl3, 500 
MHz):  7.96 (m, 2H), 7.25 (m, 2H), 3.89 (s, 3H), 2.65 (m, 1H), 1.61 (m, 2H), 1.24 (m, 3H), 0.81 
(m, 3H). 13C NMR (CDCl3, 125.8 MHz):  167.3, 153.3, 129.8, 127.9, 127.2, 52.1, 41.9, 31.1, 21.7, 
12.3. GCMS analysis of the reaction mixture after 24 hours confirms presence of a single 
regioisomer. Characterization data matched that reported in the literature. 42 
 
 
 
Methyl 4-isopropylbenzoate (9): obtained as a colorless oil (68 mg, 76%). 1H NMR (CDCl3, 500 
MHz):  7.96 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 3.90 (s, 3H), 2.96 (sept, J = 7.0 Hz, 
1H), 1.26 (d, J = 7.0 Hz, 6H). 13C NMR (CDCl3, 125.8 MHz):  167.3, 153.3, 129.8, 127.9, 127.2, 
52.1, 41.9, 31.1, 21.7, 12.3. Characterization data matched that reported in the literature.43 
 
 
 
 
tert-Butyl 4-(4-(methoxycarbonyl)phenyl)piperidine-1-carboxylate (10): obtained as a white 
amorphous solid (147 mg, 92%), mp = 118-120 ºC. 1H NMR (CDCl3, 500 MHz): δ 7.95 (d, J = 8.5 
Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 4.23 (bs, 2H), 3.87 (s, 3H), 2.80-2.65 (m, 3H), 1.81-1.78 (m, 
2H), 1.62-1.58 (m, 2H), 1.46 (s, 9H). 13C NMR (CDCl3, 125.8 MHz): δ 167.1, 154.9, 151.2, 130.0, 
128.4, 127.0, 79.7, 52.1, 44.3 (br), 42.9, 33.0, 28.6, 24.9. IR:  = 2845, 1701, 1421, 1365, 1268, 
1229, 1155, 1126, 1012, 770 cm-1. HRMS (ESI) m/z calc. for C18H25NO4Na (M+Na) 342.1681, 
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found 342.1685. GC analysis of the crude mixture after 24h confirms the formation of a single 
regioisomer.  
 
 
Methyl 4-(tetrahydro-2H-pyran-4-yl)benzoate (11): obtained as a white crystalline solid (91 mg, 
83%), mp = 74-75 °C. 1H NMR (CDCl3, 500 MHz): δ 7.97 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 
2H), 4.08 (d, J = 10.5 Hz, 2H), 3.89 (s, 3H), 3.52 (t, J = 11.5 Hz, 2H), 2.82-2.78 (m, 1H), 1.83-1.74 
(m, 4H). 13C NMR (CDCl3, 125.8 MHz): δ 167.2, 151.2, 130.0, 128.4, 126.9, 68.3, 52.2, 41.8, 33.7. 
IR:  = 2964, 2932, 2862, 1718, 1609, 1440, 1275, 1109, 1098, 1017, 764 cm-1. HRMS (ESI) m/z 
calc. for C13H17O3 (M+H) 221.1178, found 221.1179. 
 
 
 
Methyl 4-((1R*,2R*,3R*,5R*)-3,6,6-trimethylbicyclo[3.1.1]heptan-2-yl)benzoate (12): 
obtained as a yellow oil (80 mg, 59%). 1H NMR (CDCl3, 500 MHz): δ 7.99 (d, J = 8.5 Hz, 2H), 
7.37 (d, J = 8.5 Hz, 2H), 3.91 (s, 3H), 3.10-3.06 (m, 1H), 2.53-2.51 (m, 1H), 2.45-2.42 (m, 1H), 
2.09-2.04 (m, 2H), 1.92-1.87 (m, 2H), 1.29 (s, 3H), 1.17-1.15 (m, 4H), 1.00 (d, J = 7.0 Hz, 3H). 
13C NMR (CDCl3, 125.8 MHz): δ 167.1, 154.8, 129.6, 128.3, 127.5, 51.8, 47.9, 45.6, 44.9, 41.7, 
39.1, 37.2, 34.8, 28.4, 22.9, 20.8. IR:  = 2950, 2904, 1723, 1610, 1434, 1278, 1112, 1019, 770, 
707 cm-1. HRMS (ESI) m/z calc. for C18H25O2 (M+H) 273.1855, found 273.1850. 
 
 
219 
4-Cyclopentylbenzonitrile (13): obtained as a colorless oil (81 mg, 95%). 1H NMR (CDCl3, 500 
MHz): δ 7.56 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 3.04 (q, J = 8.0 Hz, 1H), 2.10-2.08 (m, 
2H), 1.84-1.81 (m, 2H), 1.73-1.70 (m, 2H), 1.60-1.57 (m, 2H). 13C NMR (CDCl3, 125.8 MHz): δ 
152.5, 132.2, 128.1, 119.4, 109.6, 46.1, 34.6, 25.7. IR:  = 2955, 2869, 2227, 1607, 1504, 1451, 
1416, 1178, 830, 657 cm-1. HRMS: (ESI) m/z calc. for C12H13N (M+) 171.1048, found 171.1044. 
 
 
 
 
1-Cyclopentyl-4-methoxybenzene (14): obtained as a colorless oil (63 mg, 72%). 1H NMR 
(CDCl3, 500 MHz): δ 7.19 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 9.0 Hz, 2H), 3.81 (s, 3H), 3.00-2.93 (m, 
1H), 2.10-2.04 (m, 2H), 1.83-1.55 (m, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 157.8, 138.7, 128.1, 
113.8, 55.4, 45.3, 34.9, 25.6. IR:  = 2950, 2866, 1612, 1513, 1463, 1245, 1178, 1033, 826 cm-1. 
HRMS: (ESI) m/z calc. for C12H16O (M+) 176.1201, found 176.1199. 
 
1-Chloro-2-cyclopentylbenzene (15): obtained as a yellow oil (80 mg, 89%). 1H NMR (CDCl3, 
500 MHz): δ 7.36-7.22 (m, 2H), 7.13-7.10 (m, 2H), 3.46 (q, J = 9 Hz, 1H), 2.16-2.07 (m, 2H), 1.83-
1.72 (m, 4H), 1.59-1.57 (m, 2H). 13C NMR (CDCl3, 125.8 MHz): δ 143.8, 134.3, 129.5, 127.2, 
127.0, 126.9, 42.3, 33.3, 25.6. IR:  = 2951, 2868, 1475, 1442, 1355, 1035, 744 cm-1. HRMS: (ESI) 
m/z calc. for C11H13Cl (M+) 180.0706, found 180.0711. 
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4-Cyclopentyl-1,1'-biphenyl (16): obtained as a pale yellow semi-solid (98 mg, 88%). 1H NMR 
(CDCl3, 500 MHz): δ 7.67-7.65 (m, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.51-7.48 (m, 2H), 7.41-7.38 
(m, 3H) 3.11 (q, J = 7.5 Hz, 1H), 2.19-2.17 (m, 2H), 2.00-1.90 (m, 2H) 1.80-1.70 (m, 4H). 13C 
NMR (CDCl3, 125.8 MHz): δ 145.9, 141.4, 138.9, 129.0, 127.8, 127.23, 127.22, 127.17 45.9, 34.9, 
25.8. IR:  = 2952, 2869, 1598, 1486, 831, 764, 735, 698 cm-1. HRMS: (ESI) m/z calc. for C17H18 
(M+) 222.1409, found 222.1406. 
 
3-Chloro-5-cyclopentylpyridine (17): obtained as a pale yellow oil (80 mg, 88%). 1H NMR 
(CDCl3, 500 MHz): δ 8.39 (d, J = 2.5 Hz, 1H), 8.37 (d, J = 1.5 Hz, 1H), 7.53-7.52 (dd, J = 2.5, 1.5 
Hz, 1H), 3.00 (m, 1H), 2.13-2.10 (m, 2H), 1.85-1.83 (m, 2H), 1.75-1.69 (m, 2H), 1.59-1.52 (m, 
2H). 13C NMR (CDCl3, 125.8 MHz): δ 146.9, 146.0, 143.0, 134.0, 131.7, 42.8, 34.2, 25.3. IR:  = 
2954, 2868, 2361, 1580, 1440, 1420, 1295, 1233, 1107, 1022, 935, 879, 709 cm-1. HRMS: (ESI) 
m/z calc. for C10H13NCl (M+H) 182.0737, found 182.0740. 
 
 
 
7-Cyclopentyl-1-methyl-1H-indazole (18): obtained as a dark yellow oil (80 mg, 80%). 1H NMR 
(CDCl3, 500 MHz): δ 8.08 (s, 1H), 7.35-7.32 (m, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.03 (d, J = 7.0 Hz, 
1H), 4.07 (s, 3H), 3.46 (m, 1H), 2.22-2.18 (m, 2H), 1.90-1.78 (m, 6H). 13C NMR (CDCl3, 125.8 
MHz): δ 140.2, 140.0, 131.7, 126.3, 123.5, 116.8, 106.4, 43.6, 35.5, 33.6, 25.6. IR:  = 2950, 2868, 
1606, 1508, 1447, 1272, 1237, 982, 783, 740 cm-1. HRMS: (ESI) m/z calc. for C13H17N2 (M+H) 
201.1392, found 201.1390. 
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trans-2-Methyl-4-(2-methylcyclopentyl)pyridine (19): obtained as a yellow oil (62 mg, 71%). 1H 
NMR (CDCl3, 500 MHz): δ 8.36 (d, J = 5.0 Hz, 1H), 6.97 (s, 1H), 6.91 (d, J = 5.0 Hz, 1H), 2.51 
(s, 3H), 2.35 (m, 1H), 2.07-1.90 (m, 3H), 1.77-1.67 (m, 3H), 1.33-1.28 (m, 1H), 0.91 (d, J = 6.5 
Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 158.3, 155.1, 149.1, 122.6, 120.2, 53.9, 42.9, 34.9, 24.6, 
24.1, 18.6. IR:  = 2934, 2837, 1698, 1611, 1512, 1247, 1173, 1096, 1034, 818 cm-1. HRMS (ESI) 
m/z calc. for C12H18N (M+H) 176.1439, found 176.1439. 
 
trans-N-(4-(2-Methylcyclopentyl)phenyl)acetamide (20): obtained as a white crystalline solid 
(90 mg, 83%), mp = 118-124 °C. 1H NMR (CDCl3, 500 MHz): δ 7.60 (br s, 1H), 7.41 (d, J = 8.0 
Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 2.37 (q, J = 9.0 Hz, 1H), 2.15 (s, 3H), 2.05-1.72 (m, 6H), 1.31-
1.27 (m, 1H), 0.90 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 168.6, 141.7, 135.8, 128.0, 
120.3, 54.2, 43.2, 35.5, 34.8, 24.6, 23.9, 18.7. IR:  = 3246, 3123, 2946, 2865, 1661, 1610, 1557, 
1512, 1413, 1369, 1327, 826 cm-1. HRMS (ESI) m/z calc. for C14H20NO (M+H) 218.1545, found 
218.1545. 
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trans-3-Methoxy-5-(2-methylcyclopentyl)pyridine (21): obtained as a yellow oil (61 mg, 64%). 
1H NMR (CDCl3, 500 MHz): δ 8.12 (d, J = 2.5 Hz, 1H), 8.07 (m, 1H), 7.02-7.01 (m, 1H), 3.84 (s, 
3H), 2.43-2.38 (m, 1H), 2.09-2.07 (m, 1H), 2.00-1.98 (m, 1H), 1.94-1.89 (m, 1H), 1.76-1.69 (m, 
3H), 1.31-1.29 (m, 1H), 0.91 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 155.8, 142.2, 
141.6, 134.8, 119.6, 55.6, 51.7, 43.2, 35.3, 34.8, 24.0, 18.5. IR:  = 2953, 2868, 1587, 1454, 1427, 
1318, 1296, 1176, 1164, 1049, 867, 714 cm-1. HRMS: (ESI) m/z calc. for C12H18NO (M+H) 
192.1388, found 192.1386. 
 
 
tert-Butyl trans-5-(2-methylcyclopentyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (22): 
obtained as a yellow oil (115 mg, 77%). 1H NMR (CDCl3, 500 MHz): δ 8.34 (d, J = 2.0 Hz, 1H), 
7.68 (d, J = 2.0 Hz, 1H), 7.58 (d, J = 4.0 Hz, 1H), 6.43 (d, J = 4.0Hz, 1H), 2.53-2.47 (m, 1H), 2.12-
2.10 (m, 1H), 2.02-1.90 (m, 2H), 1.81-1.72 (m, 3H), 1.65 (s, 9H), 0.90 (d, J = 6.5 Hz, 3H). 13C 
NMR (CDCl3, 125.8 MHz): δ 148.2, 147.4, 145.5, 135.4, 127.4, 126.7, 123.1, 104.5, 83.9, 52.0, 
43.6, 35.7, 34.8, 28.3, 23.9, 18.4. IR:  = 2951, 2868, 1757, 1728, 1532, 1472, 1398, 1356, 1318, 
1253, 1145, 1092, 730 cm-1. HRMS (ESI) m/z calc. for C19H25N2O2 (M+H) 301.1916, found 
301.1905. 
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trans-2-(1H-Imidazol-1-yl)-5-(2-methylcyclopentyl)pyrimidine (23): obtained as a dark yellow 
oil (79 mg, 69%). 1H NMR (CDCl3, 500 MHz): δ 8.63 (s, 1H), 8.52 (s, 2H), 7.88 (s, 1H), 7.17 (s, 
1H), 2.48-2.42 (m, 1H), 2.20-2.13 (s, 1H), 2.10-2.03 (m, 1H), 1.98-1.92 (m, 1H), 1.87-1.71 (m, 
3H), 1.42-1.34 (m, 1H), 0.98 (d, J = 6.5 Hz, 3H).13C NMR (CDCl3, 125.8 MHz): δ 159.4, 157.6, 
136.0, 135.6, 130.3, 116.4, 48.9, 43.0, 34.7, 34.4, 23.6, 18.2. IR:  = 3127, 2947, 2866, 1568, 1477, 
1450, 1314, 1097, 931, 795, 754, 651 cm-1. HRMS (ESI) m/z calc. for C13H17N4 (M+H) 229.1453, 
found 229.1453. 
 
trans-2-Fluoro-4-(2-methylcyclopentyl)pyridine (24): obtained as a pale yellow oil (70 mg, 
78%). 1H NMR (CDCl3, 500 MHz): δ 8.09 (d, J = 5.0 Hz, 1H), 7.01-6.99 (m, 1H), 6.75 (s, 1H), 
2.49-2.43 (m, 1H), 2.15-2.08 (m, 1H), 2.04-1.89 (m, 2H),  1.83-1.65 (m, 3H), 1.37-1.29 (m, 1H), 
0.94 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 164.1 (d, J = 237.7 Hz), 160.9 (d, J = 
7.4 Hz), 147.2 (d, J = 15.4 Hz), 120.6 (d, J = 3.6 Hz), 108.0 (d, J =36.6 Hz), 53.6 (d, J = 2.6 Hz), 
42.9, 34.7, 34.6, 23.9, 18.3.IR:  = 2953, 2869, 1610, 1563, 1482, 1414, 1273, 996, 974, 832 cm-1 
HRMS (ESI) m/z calc. for C11H15NF (M+H) 180.1189, found 180.1189. 
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trans-5-(2-Methylcyclohexyl)picolinonitrile (25): Reaction was run on 0.40 mmol scale; obtained 
as a pale yellow oil (68 mg, 85%). 1H NMR (CDCl3, 500 MHz): δ 8.52 (s, 1H), 7.63-7.59 (m, 2H), 
2.22-2.17 (m, 1H), 1.87-1.77 (m, 4H), 1.62-1.58 (m, 1H), 1.44-1.33 (m, 3H), 1.15-1.10 (m, 1H), 
0.65 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 151.3, 146.5, 135.6, 131.6, 128.5, 117.6, 
50.1, 37.5, 35.5, 35.2, 26.6, 26.4, 20.7. IR:  = 2925, 2854, 2234, 1566, 1470, 1024, 845, 652, 632 
cm-1. HRMS (ESI) m/z calc. for C13H17N2 (M+H) 201.1392, found 201.1385. 
 
 
trans-1-(2-Methylcyclohexyl)-4-(trifluoromethyl)benzene (26): obtained as a colorless oil (90 
mg, 74%). 1H NMR (CDCl3, 500 MHz): δ 7.53 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H), 2.17-
2.12 (m, 1H), 1.82-177 (m, 4H), 1.61-1.57 (m, 1H), 1.45-1.35 (m, 3H), 1.13-1.10 (m, 1H), 0.65 (d, 
J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 151.1, 128.2 (q, J = 32.1 Hz), 128.0, 125.3 (q, 
J = 3.9 Hz), 124.6 (q, J = 271.6 Hz), 52.6, 37.7, 35.7, 35.6, 26.9, 26.7, 20.8. 19F NMR (CDCl3, 470 
MHz): δ -62.2. IR:  = 2928, 2858, 1618, 1325, 1163, 1124, 1069, 1020, 830 cm-1.HRMS (ESI) 
m/z calc. for C14H17F3 (M+) 242.1282, found 242.1283. 
 
 
trans-4-(2-Methylcyclohexyl)phenyl trifluoromethanesulfonate (27): obtained as a colorless oil 
(120 mg, 75%). 1H NMR (CDCl3, 500 MHz): δ 7.22 (d, J = 8.5 Hz, 2H), 7.17 (d, J = 8.5 Hz, 2H), 
2.14-2.09 (m, 1H), 1.85-1.78 (m, 4H), 1.60-1.53 (m, 1H), 1.44-1.35 (m, 3H), 1.13-1.06 (m, 1H), 
0.65 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 147.5, 147.3, 129.0, 120.9, 118.7 (q, J 
= 320.7 Hz), 51.8, 37.6, 35.5, 35.4, 26.7, 26.4, 20.5. 19F NMR (CDCl3, 470 MHz): δ -72.9. IR:  = 
225 
3339, 2970, 2929, 1426, 1379, 1213, 1142, 1131, 952, 883, 817 cm-1.HRMS (ESI) m/z calc. for 
C14H16O3F3S (M-H) 321.0772, found 321.0787. 
 
 
trans-Methyl 3-(2-methylcyclohexyl)benzoate (28): obtained as a colorless oil (100 mg, 86%). 
1H NMR (CDCl3, 500 MHz): δ 7.87-7.86 (m, 2H), 7.36-7.34 (m, 2H), 3.92 (s, 3H), 2.17-2.15 (m, 
1H), 2.13-1.80 (m, 4H), 1.64-1.62 (m, 1H), 1.51-1.28 (m, 3H), 1.14-1.06 (m, 1H), 0.66 (d, J = 6.5 
Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 167.3, 147.1, 132.2, 130.0, 128.5, 128.2, 127.0, 52.3, 
51.9, 37.5, 35.6, 35.5, 26.8, 26.5, 20.6. IR:  = 2923, 2852, 1723, 1445, 1432, 1285, 1196, 1107, 
1086, 752, 698 cm-1. HRMS (ESI) m/z calc. for C15H21O2 (M+H) 233.1542, found 233.1553. 
 
 
trans-2-(2-Methylcyclohexyl)benzo[b]thiophene (29): obtained as a colorless crystal (73 mg, 
63%). 1H NMR (CDCl3, 500 MHz): δ 7.78 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.33-7.24 
(m, 2H), 7.01 (s, 1H), 2.52-2.47 (m, 1H), 2.02 (dd, J = 3.0, 1.0 Hz, 1H), 1.85-1.78 (m, 3H), 1.60-
1.36 (m, 4H), 1.15-1.13 (m, 1H), 0.83 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 152.1, 
140.1, 139.0, 124.1, 123.4, 122.8, 122.4, 119.8, 48.4, 39.3, 36.8, 35.7, 26.9, 26.5, 21.0 
IR:  = 2923, 2851, 1445, 1443, 1309, 1128, 819, 744, 655, 636 cm-1. HRMS (ESI) m/z calc. for 
C15H19S (M+H) 231.1207, found 231.1208. 
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trans-1-(4-(2-Methylcyclohexyl)phenyl)ethan-1-one (30): obtained as a colorless oil (89 mg, 
82%).1H NMR (CDCl3, 500 MHz): δ 7.78-7.77 (m, 2H), 7.38-7.37 (m, 2H), 2.61 (s, 3H), 2.19-2.14 
(m, 1H), 1.86-1.78 (m, 4H), 1.65-1.62 (m, 1H), 1.49-1.27 (m, 3H), 1.14-1.08 (m, 1H), 0.66 (d, J = 
6.5 Hz, 3H). 13C NMR (CDCl3, 125.8 MHz): δ 198.4, 147.4, 137.1, 132.4, 128.4, 127.1, 126.0, 
52.3, 37.5, 35.6, 35.5, 26.8, 26.6, 26.5, 20.6.IR:  = 2922, 2853, 1685, 1600, 1444, 1359, 1266, 
1229, 1186, 799, 698 cm-1. HRMS (ESI) m/z calc. for C15H21O (M+H) 217.1592, found 217.1586. 
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Appendix A3. 1H, 13C, 11B, and 19F NMR Spectra Relevant to Chapter 4 
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Figure A3.1. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-cyclohexylbenzoate (2) 
Figure A3.2. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-cyclohexylbenzoate (2) 
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Figure A3.3. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-cyclopentylbenzoate (3) 
 
Figure A3.4. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-cyclopentylbenzoate (3) 
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Figure A3.5. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-cyclobutybenzoate (4) 
 
Figure A3.6. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-cyclobutybenzoate (4) 
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Figure A3.7. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-(2-methylcyclohexyl)benzoate (6) 
Figure A3.8. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-(2-methylcyclohexyl)benzoate 
(6) 
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Figure A3.9. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-(2-methylcyclopentyl)benzoate (7) 
Figure A3.10. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-(2-methylcyclopentyl)benzoate 
(7) 
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Figure A3.11. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-(sec-butyl)benzoate (8) 
 
Figure A3.12. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-(sec-butyl)benzoate (8) 
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Figure A3.13. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-isopropylbenzoate (9) 
Figure A3.14. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-isopropylbenzoate (9) 
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Figure A3.15. 1H NMR (CDCl3, 500 MHz) spectrum of tert-butyl 4-(4-
(methoxycarbonyl)phenyl)piperidine-1-carboxylate (10) 
Figure A3.16. 13C NMR (CDCl3, 125.8 MHz) spectrum of tert-butyl 4-(4-
(methoxycarbonyl)phenyl)piperidine-1-carboxylate (10) 
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Figure A3.17. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-(tetrahydro-2H-pyran-4-
yl)benzoate (11) 
Figure A3.18. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-(tetrahydro-2H-pyran-4-
yl)benzoate (11) 
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Figure A3.19. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-((3,6,6-
trimethylbicyclo[3.1.1]heptan-2-yl)benzoate (12) 
Figure A3.20. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-((3,6,6-
trimethylbicyclo[3.1.1]heptan-2-yl)benzoate (12) 
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Figure A3.21. 1H NMR (CDCl3, 500 MHz) spectrum of 4-cyclopentylbenzonitrile (13) 
 
Figure A3.22. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-cyclopentylbenzonitrile (13) 
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Figure A3.23. 1H NMR (CDCl3, 500 MHz) spectrum of 1-cyclopentyl-4-methoxybenzene (14) 
 
Figure A3.24. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-cyclopentyl-4-methoxybenzene (14) 
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Figure A3.25. 1H NMR (CDCl3, 500 MHz) spectrum of 1-chloro-2-cyclopentylbenzene (15) 
Figure A3.26. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-chloro-2-cyclopentylbenzene (15) 
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Figure A3.27. 1H NMR (CDCl3, 500 MHz) spectrum of 4-cyclopentyl-1,1'-biphenyl (16) 
Figure A3.28. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-cyclopentyl-1,1'-biphenyl (16) 
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Figure A3.29. 1H NMR (CDCl3, 500 MHz) spectrum of 3-chloro-5-cyclopentylpyridine (17) 
Figure A3.30. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-chloro-5-cyclopentylpyridine (17) 
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Figure A3.31. 1H NMR (CDCl3, 500 MHz) spectrum of 7-cyclopentyl-1-methyl-1H-indazole 
(18) 
Figure A3.32. 13C NMR (CDCl3, 125.8 MHz) spectrum of 7-cyclopentyl-1-methyl-1H-indazole 
(18) 
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Figure A3.33. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-2-methyl-4-(2-
methylcyclopentyl)pyridine (19) 
Figure A3.34. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-2-methyl-4-(2-
methylcyclopentyl)pyridine (19) 
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Figure A3.35. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans -N-(4-(2-
methylcyclopentyl)phenyl)acetamide (20) 
Figure A3.36. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans -N-(4-(2-
methylcyclopentyl)phenyl)acetamide (20) 
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Figure A3.37. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-3-methoxy-5-(2-
methylcyclopentyl)pyridine (21) 
Figure A3.38. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-3-methoxy-5-(2-
methylcyclopentyl)pyridine (21) 
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Figure A3.39. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-tert-butyl trans-5-(2-
methylcyclopentyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (22) 
Figure A3.40. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-tert-butyl trans-5-(2-
methylcyclopentyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (22) 
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Figure A3.41. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-2-(1H-Imidazol-1-yl)-5-(2-
methylcyclopentyl)pyrimidine (23) 
Figure A3.42. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-2-(1H-Imidazol-1-yl)-5-(2-
methylcyclopentyl)pyrimidine (23) 
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Figure A3.43. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-2-fluoro-4-(2-
methylcyclopentyl)pyridine (24) 
Figure A3.44. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-2-fluoro-4-(2-
methylcyclopentyl)pyridine (24) 
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Figure A3.45. 19F NMR (CDCl3, 470.8 MHz) spectrum of (±)-trans-2-fluoro-4-(2-
methylcyclopentyl)pyridine (24) 
Figure A3.46. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-5-(2-
methylcyclopentyl)picolinonitrile (25) 
254 
Figure A3.47. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-5-(2-
methylcyclopentyl)picolinonitrile (25) 
Figure A3.48. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-1-(2-methylcyclohexyl)-4-
(trifluoromethyl)benzene (26) 
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Figure A3.49. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-1-(2-methylcyclohexyl)-4-
(trifluoromethyl)benzene (26) 
Figure A3.50. 19F NMR (CDCl3, 470.8 MHz) spectrum of (±)-trans-1-(2-methylcyclohexyl)-4-
(trifluoromethyl)benzene (26) 
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Figure A3.51. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-4-(2-methylcyclohexyl)phenyl 
trifluoromethanesulfonate (27) 
Figure A3.52. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-4-(2-methylcyclohexyl)phenyl 
trifluoromethanesulfonate (27) 
257 
Figure A3.53. 19F NMR (CDCl3, 470.8 MHz) spectrum of (±)-trans-4-(2-methylcyclohexyl)phenyl 
trifluoromethanesulfonate (27) 
Figure A3.54. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-methyl 3-(2-
methylcyclohexyl)benzoate (28) 
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Figure A3.55. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-methyl 3-(2-
methylcyclohexyl)benzoate (28) 
Figure A3.56. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-2-(2-
Methylcyclohexyl)benzo[b]thiophene (29) 
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Figure A3.57. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-2-(2-
Methylcyclohexyl)benzo[b]thiophene (29) 
Figure A3.58. 1H NMR (CDCl3, 500 MHz) spectrum of (±)-trans-1-(4-(2-
Methylcyclohexyl)phenyl)ethan-1-one (30) 
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Figure A3.59. 13C NMR (CDCl3, 125.8 MHz) spectrum of (±)-trans-1-(4-(2-
Methylcyclohexyl)phenyl)ethan-1-one (30) 
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Chapter 5. Synthesis of 1,1’-Diaryl-2,2,2-trifluoroethanes via 
Photoredox/Nickel Dual Catalytic Cross-Coupling 
5.1 Introduction 
The importance of fluorinated molecules in diverse applications has driven interest in the 
development of methods for accessing unexplored chemical space in hopes of providing new 
molecular architectures with desirable physical and biological properties. Toward this end, it was 
anticipated that α-trifluoromethylated alkylboron reagents would be broadly reactive in established 
protocols for organoboron elaboration. Indeed, these compounds were found to participate in a 
variety of C-B bond functionalization reactions, including oxidation, halogenation, ethyl 
diazoacetate (EDA) insertion, and protodemetalation (Figure 5.1).1 
 
Figure 5.1. C-B bond functionalization reactions of α-trifluoromethylated alkylborons 
 
These reagents were next examined in Suzuki cross-coupling with aryl halides. This 
process was particularly attractive as currently, 1,1-diaryl-2,2,2-trifluoroethane substructures can 
only be accessed through methods that require multiple steps and/or are severely limited in scope. 
In fact, at the outset of this project, less than 20 compounds had been reported in the literature with 
only one compound reported with full characterization. Among known methods, two main 
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strategies predominate: (1) deoxygenation of diaryltrifluoromethylcarbinols (Eq 5.1, Eq 5.2)2 and 
(2) Friedel-Crafts alkylation of arenes with aryltrifluoroethyl cations derived from ionization of the 
corresponding benzylic alcohols (Eq 5.3, Eq 5.4).3 The harsh conditions employed in these 
transformations significantly limit functional group tolerance, and reactions are often low yielding. 
Furthermore, approaches based on Friedel-Crafts alkylation are typically limited to electron rich 
arenes, suffer from regiochemical restrictions, and usually afford mixtures of ortho- and para-
alkylated products.  
Eq 5.1. Published in 1960 
 
Eq 5.2. Published in 1982 
 
Eq 5.3. Published in 1985 
 
Eq 5.4. Published in 2011 
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Notwithstanding these challenges, diaryltrifluoroethanes remain attractive targets in 
medicinal and agricultural chemistry. The addition of a trifluoromethyl functional group onto a 
biologically active diarylmethane skeleton could prove a viable strategy for reduction of metabolic 
susceptibility in this class of drug candidates.4 Moreover, as fluoro-analogs of 1,1,1-trichloro-2,2-
bis(p-chlorophenyl)ethane (DDT), these compounds serve as potential alternatives to the 
environmentally harmful DDT, in which case the ability to manipulate their structures would be 
crucial in altering their physical properties. 
In pursuit of conditions for achievement of the desired Suzuki cross-coupling,i microscale 
high throughput experimentation techniques5 were employed to screen a variety of Pd sources, 
ligands, bases, solvents, and temperatures. Despite significant efforts to identify optimal conditions, 
only trace amounts (less than 5%) of the cross-coupled product were detected by HPLC analysis of 
the crude reaction mixtures. Furthermore, this insignificant conversion was invariably accompanied 
by side products arising from protodeboronation, C-B bond oxidation, and β-fluoride elimination 
to afford the corresponding difluoroalkene. 
These outcomes suggested that application of these reagents in conventional Pd-catalyzed 
cross-coupling is hindered by two principal challenges rooted in the two-electron nature of 
alkylboron transmetalation. First and foremost, the low nucleophilicity of these electron-poor, 
secondary alkylboron reagents necessitates both high temperature and strong base for efficient 
transmetalation. Second, the strong affinity of transition metal complexes for fluoride leads to β-
fluoride elimination from the intermediate organopalladium in preference to the desired reductive 
elimination.6 Notably, in analogy to the related β-hydride elimination, this side reaction is likely to 
                                                     
i Reproduced in part from Chem. Eur. J. 2016, 22, 120. 
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be exacerbated at the elevated temperatures required for efficient transmetalation. This unfortunate 
dichotomy of reactivity was feared to preclude this useful class of reagents from participating in all 
types of transition metal-catalyzed C-C bond forming reactions. 
Although these novel organoboron reagents proved unreactive in conventional cross-
coupling protocols, productive reactivity was anticipated to result through application of the 
mechanistically distinct single-electron transmetalation manifold developed recently in our 
laboratory.7 Here, the problematic high energy transition state associated with transmetalation of 
the secondary alkylboron is, in effect, replaced by a lower energy pathway involving oxidative 
fragmentation of the trifluoroborate followed by capture at a transition metal center. This low 
barrier, odd-electron pathway was anticipated to permit cross-coupling to occur at room 
temperature, thereby reducing the problematic side reactions that had doomed previous efforts 
(Figure 5.2). 
 
Figure 5.2. Comparison between traditional and single-electron transmetalations 
 
5.2 Results and Discussion 
Iridium complex 1 was expected to be sufficiently oxidizing to fragment the C-B bond of 
2 to generate the corresponding α-trifluoromethyl radical 3, which would rapidly add to a ligated 
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Ni0 complex 5. The resultant alkylnickel(I) complex was then expected to engage an aryl bromide 
in oxidative addition to afford high-valent diorganonickel(III) complex 8 which was predicted to 
exist in equilibrium with Ni(II) complex 9 and free radical 3.8 Reductive elimination from 8 was 
then expected to afford the desired diaryltrifluoroethane 10 and Ni-Br species 11. Subsequent 
reduction of the complex 11 by the reduced form of the photocatalyst then completes both catalytic 
cycles simultaneously (Figure 5.3). 
 
Figure 5.3. Proposed catalytic cycle with depiction of possible side reactions 
 
It is worth noting that this proposed catalytic cycle is rife with challenges and potential 
deleterious side reactions. Both the feasibility of generating the putative benzylic α-trifluoromethyl 
radicals and their affinity for transition metal complexes were uncertain at the outset of this study. 
Furthermore, it was not clear if reductive elimination from Ni(III) complex 8 would be favored 
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over the β-fluoride elimination observed under palladium catalysis. Even if the rate of β-fluoride 
elimination were slowed sufficiently by the milder reaction temperatures, slow reductive 
elimination could result in excessive homocoupling of the trifluoroborate fragment through 
reversible homolysis of the Ni(III) intermediate followed by radical-radical coupling (Figure 5.3). 
Undaunted, investigations were initiated with measurement of the single-electron oxidation 
potential of organotrifluoroborate 2 (Ar1 = p-methoxyphenyl) via cyclic voltammetry. Expectedly, 
the electronic influence of the trifluoromethyl group affords an organoboron intermediate much 
less susceptible to oxidation (ERed = + 1.17 V vs SCE, see Appendix A8) than related non-
fluorinated reagents (ERed = + 1.10 V and + 0.91 V vs SCE for benzyltrifluoroborate and 1-
phenylethyltrifluoroborate, respectively). Nonetheless, this data suggested that the oxidation is 
thermodynamically feasible based on the reported reduction potential of the excited state of 
photocatalyst 1 (ERed = + 1.32 V vs SCE),9 providing support for the viability of the proposed cross-
coupling. 
Reaction optimization began with investigation of the cross-coupling of 
organotrifluoroborate 2 with methyl 4-bromobenzoate (Table 5.1). Dioxane was quickly 
recognized as the solvent of choice with 2,2’-bisoxazoline ligand L1 inducing promising levels of 
the desired reactivity (entry 1). Screening of various additives revealed the beneficial effect of 
fluoride bases and Cs2CO3, with a mixture of KF and Cs2CO3 ultimately proving optimal (entry 9). 
In this case, the additives appear to be primarily responsible for reducing the prevalence of products 
arising from β-fluoride elimination and homocoupling of radical 3. The nature of this effect has yet 
to be identified, although it is reasonable to suggest that these anionic additives may act as transient 
ligands, occupying coordination sites on the Ni center to retard the β-fluoride elimination process. 
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Table 5.1. Optimization table 
 
A variety of novel 2,2’-bisoxazoline ligands (L2-L7) were synthesized10 and tested in the 
cross-coupling, but benzyl derivative L1 exhibited the best performance among the ligands 
analyzed. This observation underscores the challenges associated with this particular cross-
coupling, as the ligand must satisfy a highly delicate balance of electronic and steric effects to 
promote the desired reactivity while simultaneously suppressing numerous detrimental side 
reactions. 
Exchange of Ni(COD)2 for Ni(II) sources such as NiBr2•dme in combination with reduced 
Ni loading and higher ligand/Ni ratio (1.5:1) was effective in decreasing homocoupling of the aryl 
bromide and providing increased conversion to product (entries 3-4). Adventitious water from 
hygroscopic Cs2CO3 (entry 8) and increased reaction temperature (entry 10) proved detrimental to 
the desired reactivity. 
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Concentration proved an important variable in achieving high yields (entry 5), as reactions 
performed at higher dilution exhibited significantly faster rates and fewer side products. We 
attribute this concentration dependence primarily to increased penetration of light into the reaction 
mixture, because reactions at higher concentration suffer from decreased light input per unit area 
because of inner filter effects.11 A brief exploration of alternative photocatalysts revealed other 
related derivatives to be inferior to 1 for this cross-coupling. 
With optimized conditions in hand, a variety of aryl bromides were engaged in cross-
coupling with trifluoroborate 2 (Figure 5.4).  
 
Figure 5.4. Substrate scope of aryl bromides 
 
Both electronically activated and electron neutral bromides smoothly participated in cross-
coupling to afford the corresponding unsymmetrical 1,1-diaryl-2,2,2-trifluoroethanes. Selective 
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cross-coupling of the C-Br bond was observed in preference to both triflates and aryl chlorides 
(products 10a and 10c). In addition, numerous functional groups, including esters 10f, nitriles 10g, 
and ketones 10i, were well tolerated. Protected alcohol derivatives also afforded products in good 
yield (10h). Tolerance of medicinally and agrochemically relevant heterocyclic bromides was 
demonstrated in the cross-coupling of 4-pyridyl (10j) and protected indolyl (10k) substrates. 
Unfortunately, some nitrogen-containing aryl bromides (e.g., 4-acetamido, 4-dimethylamino, etc.) 
proved unreactive under the reported conditions, affording only trace amounts of product even with 
prolonged reaction times.  
Attention was next turned to the compatibility of this reaction manifold with electronically 
and structurally diverse trifluoroborates (Figure 5.5). Expectedly, substrates adorned with electron 
donating groups (11c, 11d) afforded products in the highest yields, presumably because of the 
greater stability of the intermediate radical. Electron neutral substrates (11a, 11e) were also 
engaged in cross-coupling in moderate yields. Although electron poor substrates were generally 
sluggish – requiring extended reaction times, diarylethane 11b was generated in 43% yield despite 
the presence of the electron-withdrawing 4-fluoro substituent. Heteroaromatic fragments were also 
coupled, affording products 11f and 11g.  
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Figure 5.5. Substrate scope of trifluoroborates 
 
Some degree of enantioselectivity was observed in several of the products generated via 
reaction in the presence of L1 (0-60% ee, see 5.4 Experimental and Appendix A7). According to 
the mechanistic studies, enantioselectivity arises from Ni(III) complex 8 where one of the two 
equilibrating diastereomeric Ni(III) complexes undergoes reductive elimination at a faster rate.8 In 
this study, reaction conditions were optimized purely on yields, and no attempt was made to identify 
conditions under which higher levels of enantioinduction could be afforded. 
Although the yields afforded by the methods reported herein are often moderate, it is 
noteworthy that all of the reported compounds are entirely new chemical entities (only 10a has 
been synthesized previously with only elemental analysis provided for characterization 2a). This 
fact effectively highlights both the difficulties associated with synthesis of these materials using 
conventional methods and the vast, untapped chemical space that these products occupy. 
Furthermore, the variety of useful functional groups demonstrated to be compatible in this novel 
cross-coupling permit rapid diversification and complexity building operations, thereby 
multiplying the quantity of readily accessible molecular architectures. 
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5.3 Conclusion 
 
The first general synthesis of differentially substituted 1,1-diaryl-2,2,2-trifluoroethanes 
through photoredox/nickel dual catalytic cross-coupling of α-trifluoromethylated trifluoroborates 
with (hetero)aryl bromides has been developed. Key to the success of this method is the exploitation 
of a mechanistically distinct activation mode for transmetalation of these alkylboron reagents that 
avoids the high temperatures and strong bases that have thwarted attempts to effect their cross-
coupling using conventional protocols. These dual catalytic cross-couplings occur under mild 
conditions, in satisfactory yields, and demonstrate tolerance of a variety of useful functional groups. 
In addition to the significant synthetic value offered by the reported method, the success of the 
single-electron transmetalation manifold in a case where conventional approaches have failed 
entirely stands as a testament to the power of this complementary reactivity mode in realizing the 
cross-coupling of conventionally challenging substructures. 
 
5.4 Experimental 
 
General considerations 
 
New bottles of Cs2CO3 and KF were opened in the glove box and stored within. Dioxane was stored 
over 3Å molecular sieves overnight and purged with argon for 1 h prior to being brought into the 
glove box. NiBr2•dme was stored in the desiccator under vacuum. 
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The cross-coupling reactions were performed on a 0.1 mmol scale. Reactions performed on larger 
scales gave a lower conversion to the desired products. Three separate 0.1 mmol reactions were run 
for each substrate and then combined prior to purification in order to get accurate isolated yields 
(yields were calculated accordingly). 
Photocatalyst 17 and potassium trifluoro(2,2,2-trifluoro-1-arylethyl)borates 21 were synthesized 
according to previous reports. 
The compounds were purified using an ISCO CombiFlash system equipped with 254 nm, 280 nm, 
and ELS detectors. All pure compounds were characterized by 1H, 13C, and 19F NMR spectroscopy, 
IR spectroscopy, high-resolution mass spectrometry (HRMS), chiral SFC, and melting point (for 
solids). 1H, 13C, and 19F NMR spectra were recorded at 500.4, 125.8, and 470.8 MHz, respectively. 
Procedure for photoredox cross-coupling reactions – varying (het)aryl bromides: 
 
To a 2-dram vial (8 mL) equipped with a Teflon-coated magnetic stir bar was added L1 (0.0024 g, 
0.0075 mmol) and NiBr2•dme (0.0015 g, 0.005 mmol) and 1.0 mL THF (from a JC Meyer solvent 
system). The resulting suspension was heated briefly with a heat gun until the nickel and ligand 
273 
were fully solubilized, yielding an orange solution. The solvent was then removed under vacuum 
to give a fine coating of the ligated nickel complex, and the vial was placed under high vacuum. 
Once dry, (het)aryl bromide (0.1 mmol, 1 equiv) (liquid aryl bromides were added in the glove box 
after adding the solvent), potassium trifluoro[2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl]borate 
(0.0592 g, 0.2 mmol), and Ir(dFCF3ppy)2(bpy)PF6 1 (0.0030 g, 0.0030 mmol) were added. The vial 
was then transported into the glove box where Cs2CO3 (0.0130 g, 0.4 mmol) and KF (0.0058 g, 0.1 
mmol) and dioxane (5 mL) were added, and the vial was then sealed tightly with a PTFE-lined PP 
storage cap. Once brought out of the glove box, the vial was further sealed with Parafilm and placed 
in front of two 26 W fluorescent light bulbs with a fan blowing across to maintain an ambient 
temperature around 24 °C. After stirring for 48 h, the crude reaction mixture was filtered through 
a plug of Celite, washed with CH2Cl2, and then concentrated under vacuum. Purification of the 
mixture by column chromatography, eluting with EtOAc and hexanes, was performed to obtain 
products in pure form. 
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1-Chloro-4-(2,2,2-trifluoro-1-phenylethyl)benzene (10a): Pale yellow oil (63%); IR (KBr) 3052, 
2987, 2306, 1424, 1269, 1260, 897, 757, 708 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.33-7.24 (m, 
8H), 4.60 (q, J = 9.8 Hz, 1H), 3.80 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 159.5, 134.4, 134.0, 
130.5, 130.3, 129.0, 127.1, 126.8 (q, J = 280.6 Hz), 114.3, 55.4, 54.3 (q, J = 27.7 Hz); 19F NMR 
(471 MHz, CDCl3) δ -66.3; HRMS (ESI-TOF) m/z calcd. for C15H12OF3Cl [M]+ 300.0529, found 
300.0529; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 8.16 min 
(61%), 9.00 min (39%). 
 
1-Methoxy-3-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)benzene (10b): Pale yellow oil (68%); 
IR (KBr) 3438, 3055, 2987, 2306, 1611, 1515, 1263, 1158, 896, 752, 706 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.32–7.27 (m, 3H), 6.97 (d, J = 7.8 Hz, 1H), 6.95–6.82 (m, 4H), 4.61 (q, J = 9.9 Hz, 1H), 
3.80 (s, 3H), 3.80 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 159.6, 159.1, 137.0, 130.1, 129.6, 127.3, 
126.4 (q, J = 280.6 Hz), 121.2, 115.1, 114.0, 112.7, 55.2, 55.1, 54.6 (q, J = 27.7 Hz); 19F NMR 
(471 MHz, CDCl3) δ -66.0; HRMS (ESI-TOF) m/z calcd. for C16H15O2F3 [M]+ 296.1024, found 
296.1021; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 10.78 min 
(47%), 14.00 min (53%). 
 
4-(2,2,2-Trifluoro-1-(4-methoxyphenyl)ethyl)phenyl trifluoromethanesulfonate (10c): 
Colorless oil (56%); IR (KBr) 3052, 2983, 2302, 1422, 1263, 1181, 1140, 895, 738, 704 cm-1; 1H 
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NMR (500 MHz, CDCl3) δ 7.46 (d, J = 8.9 Hz, 2H), 7.28-7.25 (m, 4H), 6.91 (d, J = 8.8 Hz, 2H), 
4.68 (q, J = 9.7 Hz, 1H), 3.81 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 159.4, 148.9, 136.2, 130.8, 
130.1, 126.3, 125.8 (q, J = 280.2 Hz), 121.5, 118.6 (q, J = 320.5 Hz), 114.2, 55.2, 54.0 (q, J = 27.7 
Hz); 19F NMR (471 MHz, CDCl3) δ -66.2, -72.8; HRMS (ESi-TOF) m/z calcd. for C16H12O4F6S 
[M]+ 414.0361, found 414.0361; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 
mL/min) tr = 4.08 min (75%), 5.23 min (25%). 
 
4-(2,2,2-Trifluoro-1-(4-methoxyphenyl)ethyl)-1,1'-biphenyl (10d): White solid (61%): mp 69-
71 oC; IR (KBr) 3052, 2983, 2366, 1422, 1267, 895, 749, 706 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.60 (d, J = 7.7 Hz, 4H), 7.47-7.44 (m, 4H), 7.39 - 7.34 (m, 3H), 6.92 (d, J = 8.0 Hz, 2H), 4.71 (q, 
J = 9.9 Hz, 1H), 3.82 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 159.3, 140.7, 140.5, 134.7, 130.3, 
129.4, 128.8, 127.5, 127.5, 127.4, 127.1, 126.3 (q, J = 280.6 Hz), 114.2, 55.3 (q, J = 3.8 Hz), 54.5 
(q, J = 27.7 Hz); 19F NMR (471 MHz, CDCl3) δ -66.0; HRMS (ESI-TOF) m/z calcd. for C21H17OF3 
[M]+ 342.1232, found 342.1231; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 
mL/min) tr = 4.25 min (58%), 8.75 min (42%). 
 
2-(2,2,2-Trifluoro-1-(4-methoxyphenyl)ethyl)naphthalene (10e): Pale yellow solid (66%): mp 
57-59; IR (KBr) 3052, 2983, 2301, 1512, 1422, 1267, 1153, 897, 740, 704 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.90 (s, 1H), 7.87-7.82 (m, 3H), 7.53-7.49  (m, 2H), 7.45 (d, J = 8.5 Hz, 1H), 7.35 
(d, J = 8.3 Hz, 2H), 6.91 (d, J = 7.8 Hz, 2H), 4.84 (q, J = 9.9 Hz, 1H), 3.81 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 159.4, 133.4, 133.3, 132.8, 130.5, 128.6, 128.2, 128.1, 127.8, 127.6, 126.9, 126.6, 
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126.5 (q, J = 280.6 Hz), 126.5, 114.3, 55.4, 55.0 (q, J = 27.7 Hz); 19F NMR (471 MHz, CDCl3) δ -
65.8; HRMS (ESI-TOF) m/z calcd. for C19H15OF3 [M]+ 316.1075, found 316.1075; Chiral SFC 
(ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 28.85 min (57%), 33.15 min (43%). 
 
4-(2,2,2-Trifluoro-1-(4-methoxyphenyl)ethyl)benzoate (10f): Pale yellow oil (78%); IR (KBr) 
3052, 2983, 2306, 1723, 1516, 1439, 1265, 1159, 1108, 899, 740, 706 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 8.02 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 
8.7 Hz, 2H), 4.69 (q, J = 9.8 Hz, 1H), 3.91 (s, 3H), 3.79 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
166.7, 159.6, 140.8, 130.4, 130.1, 129.8, 129.1, 126.8, 126.1 (q, J = 280.6 Hz), 114.4, 55.4, 54.8 
(q, J = 27.7 Hz), 52.3; 19F NMR (471 MHz, CDCl3) δ -66.0;HRMS (ESI-TOF) m/z calcd. for 
C17H15O3F2 [M]+ 324.0973, found 324.0973; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in 
CO2, 1.5 mL/min) tr = 9.48 min (50%), 11.23 min (50%). 
 
4-(2,2,2-Trifluoro-1-(4-methoxyphenyl)ethyl)benzonitrile (10g): Pale yellow oil (76%); IR 
(KBr) 3056, 2987, 2306, 2233, 1613, 1512, 1422, 1263, 1162, 895, 738, 706 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.64 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 6.89 
(d, J = 8.8 Hz, 2H), 4.69 (q, J = 9.6 Hz, 1H), 3.80 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 159.5, 
140.8, 132.4, 130.1, 129.7, 125.9, 125.6 (q, J = 280.2 Hz), 118.3, 114.3, 111.9, 55.2, 54.6 (q, J = 
28.1 Hz); 19F NMR (471 MHz, CDCl3) δ -66.0; HRMS (ESI-TOF) m/z calcd. for C16H12NOF3 [M]+ 
291.0871, found 291.0871; Chiral SFC (ChiralPak OD-H column: 5% i-PrOH in CO2, 1.5 mL/min) 
tr = 9.16 min (60%), 10.08 min (40%). 
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tert-Butyldimethyl(4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)phenethoxy)silane (10h): 
Pale yellow oil (64%); IR (KBr) 3056, 2953, 2310, 1514, 1422, 1265, 895, 738, 704 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.31–7.26 (m, 4H), 7.20 (d, J = 7.3 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.62 (q, 
J = 9.7 Hz, 1H), 3.82-3.79 (m, 5H), 2.82 (t, J = 7.0 Hz, 2H), 0.87 (s, 9H), -0.02 (s, 6H); 13C NMR 
(126 MHz, CDCl3) δ 159.0, 138.8, 133.4, 130.1, 129.4, 128.7, 127.6, 126.2 (q, J = 280.6 Hz), 113.9, 
64.2, 55.1, 54.3 (q, J = 27.3 Hz), 39.0, 25.8, 18.2, -5.5; 19F NMR (471 MHz, CDCl3) δ -66.2; HRMS 
(ESI-TOF) m/z calcd. for C23H32O2F3Si [M+H]+ 425.2124, found 425.2140; Chiral SFC (ChiralPak 
OJ-H column: 3% i-PrOH in CO2, 1.5 mL/min) tr = 9.42 min (55%), 11.97 min (45%). 
 
1-(3-(2,2,2-Trifluoro-1-(4-methoxyphenyl)ethyl)phenyl)ethan-1-one (10i): Pale yellow oil 
(68%); IR (KBr) 3056, 2841, 1686, 1516, 1267, 1159, 1103, 740, 706 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.97 (s, 1H), 7.89 (d, J = 7.5 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H), 
7.28 (d, J = 8.3 Hz, 2H), 6.89 (d, J = 6.7 Hz, 2H), 4.71 (q, J = 9.8 Hz, 1H), 3.79 (s, 3H), 2.59 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ 197.8, 159.5, 137.7, 136.6, 133.5, 130.3, 129.2, 128.9, 128.1, 
126.9, 126.2 (q, J = 280.6 Hz), 114.4, 55.4 (q, J = 6.3 Hz), 54.7 (q, J = 27.7 Hz), 26.8; 19F NMR 
(471 MHz, CDCl3) δ -66.1; HRMS (ESI-TOF) m/z calcd. for C17H16O2F3 [M+H]+ 309.1102, found 
309.1100; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 12.40 min 
(38%), 14.65 min (62%). 
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2-Fluoro-4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)pyridine (10j): Pale yellow oil (51%); IR 
(KBr) 3052, 2987, 2302, 1613, 1514, 1422, 1267, 1166, 895, 734, 706 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 8.20 (d, J = 6.6 Hz, 1H), 7.22 (d, J = 7.9 Hz, 2H), 7.17 (d, J = 5.2 Hz, 1H), 6.94 (s, 1H), 
6.90 (d, J = 10.3 Hz, 2H), 4.65 (q, J = 9.5 Hz, 1H), 3.80 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
164.2 (d, J = 239.1 Hz), 159.9, 150.2 (d, J = 7.6 Hz), 148.2 (d, J = 15.1 Hz), 130.5, 125.2, 124.0 
(q, J = 280.2 Hz), 121.8 (d, J = 3.8 Hz), 114.6, 110.1 (d, J = 39.0 Hz), 55.4, 54.1 (q, J = 27.7 Hz); 
19F NMR (471 MHz, CDCl3) δ -66.0, -66.9; HRMS (ESI-TOF) m/z calcd. for C14H12NOF4 [M+H]+ 
286.0855, found 286.0854; Chiral SFC (ChiralPak OD-H column: 3% i-PrOH in CO2, 1.5 mL/min) 
tr = 11.68 min (80%), 19.58 min (20%). 
 
tert-Butyl 5-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)-1H-indole-1-carboxylate (10k): Pale 
yellow oil (56%); IR (KBr) 3056, 2987, 2301, 1733, 1512, 1265, 1155, 895, 736, 706 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 8.09 (s, 1H), 7.59 (d, J = 15.4 Hz, 2H), 7.32-7.28 (m, 3H), 6.87 (d, J = 
7.5 Hz, 2H), 6.55 (d, J = 3.8 Hz, 1H), 4.74 (q, J = 10.0 Hz, 1H), 3.79 (s, 3H), 1.66 (s, 9H); 13C 
NMR (126 MHz, CDCl3) δ 159.2, 149.8, 134.6, 130.9, 130.3, 130.2, 128.1, 126.7, 126.6 (q, J = 
280.2 Hz), 125.4, 121.5, 115.5, 114.2, 107.4, 84.0, 55.4 (q, J = 3.8 Hz), 54.7 (q, J = 27.7 Hz), 28.3; 
19F NMR (471 MHz, CDCl3) δ -66.1; HRMS (ESI-TOF) m/z calcd. for C22H23NO3F3 [M+H]+ 
406.1630, found 406.1637; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) 
tr = 14.19 min (35%), 16.06 min (65%). 
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Procedure for photoredox cross-coupling reactions – varying RBF3K’s: 
 
To a 2-dram vial vial (8 mL) equipped with a Teflon-coated magnetic stir bar was added L1 (0.0024 
g, 0.0075 mmol) and NiBr2•dme (0.0015 g, 0.005 mmol) and 1.0 mL THF (from a JC Meyer solvent 
system). The resulting suspension was heated briefly with a heat gun until the nickel and ligand 
were fully solubilized, yielding an orange solution. The solvent was then removed under vacuum 
to give a fine coating of the ligated nickel complex, and the vial was placed under high vacuum. 
Once dry, 4-bromobenzaldehyde (0.0185 g, 0.1 mmol, 1 equiv), potassium trifluoro(2,2,2-trifluoro-
1-arylethyl)borates (0.2 mmol, 2 equiv), and Ir(dFCF3ppy)2(bpy)PF6 1 (0.0040 g, 0.0040 mmol) 
were added. The vial was then transported into the glove box where Cs2CO3 (0.0130 g, 0.4 mmol) 
and KF (0.0058 g, 0.1 mmol) and dioxane (5 mL) were added, and the vial was then sealed tightly 
with a PTFE-lined PP storage cap. Once brought out of the glove box, the vial was further sealed 
with parafilm and placed in front of two 26 W fluorescent light bulbs with a fan blowing across to 
maintain an ambient temperature around 24 °C. After stirring for 60 h, the crude reaction mixture 
was filtered through a plug of Celite, washed with CH2Cl2, and then concentrated under vacuum. 
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Purification of the mixture by column chromatography, eluting with EtOAc and hexanes, was 
performed to obtain products in pure form. 
 
4-(2,2,2-Trifluoro-1-phenylethyl)benzaldehyde (11a): Pale yellow oil (45%); IR (KBr) 3943, 
3688, 3054, 2987, 2305, 1704, 1422, 1266, 1161, 910, 738, 705 cm-1; 1H NMR (500 MHz, CDCl3) 
δ 10.02 (s, 1H), 7.87 (d, J = 6.2 Hz, 2H), 7.55 (d, J = 7.8 Hz, 2H), 7.39-7.33 (m, 5H), 4.77 (q, J = 
9.5 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 191.7, 142.1, 136.0, 134.6, 130.2, 130.0, 129.3, 129.1, 
128.5, 125.9 (q, J = 280.6 Hz), 55.72 (q, J = 27.7 Hz); 19F NMR (471 MHz, CDCl3) δ -65.6; HRMS 
(ESI-TOF) m/z calcd. for C15H10OF3 [M-H]- 263.0684, found 263.0673; Chiral SFC (ChiralPak OJ-
H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 12.24 min (46%), 15.68 min (54%). 
 
4-(2,2,2-Trifluoro-1-(4-fluorophenyl)ethyl)benzaldehyde (11b): Yellow oil (43%); IR (KBr) 
3607, 3054, 2987, 2306, 1702, 1421, 1266, 1162, 896, 739, 705 cm-1; 1H NMR (500 MHz, CDCl3) 
δ 10.02 (s, 1H), 7.88 (dd, J = 8.3, 1.8 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.34–7.31 (m, 2H), 7.08-
7.04 (m, 2H), 4.77 (q, J = 9.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 191.7, 162.5 (d, J = 124.1 
Hz), 141.7, 136.1, 131.0 (d, J = 8.8 Hz), 130.4 (d, J = 2.5 Hz), 130.2, 129.8, 125.8 (q, J = 280.6 
Hz), 116.1 (d, J = 21.4 Hz), 54.9 (q, J = 28.1 Hz); 19F NMR (471 MHz, CDCl3) δ -65.9, -113.3; 
HRMS (ESI-TOF) m/z calcd. for C15H10OF4 [M]+ 282.0668, found 282.0673; Chiral SFC 
(ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 7.00 min (39%), 7.93 min (61%). 
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4-(2,2,2-Trifluoro-1-(p-tolyl)ethyl)benzaldehyde (11c): Yellow oil (70%); IR (KBr) 3435, 3047, 
2983, 2310, 1703, 1421, 1264, 895, 740, 704 cm-1; 1H NMR (500 MHz, CDCl3) δ 10.01 (s, 1H), 
7.87 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 7.9 Hz, 2H), 7.25 (d, J = 7.9 Hz, 2H), 7.18 (d, J = 7.9 Hz, 
2H), 4.74 (q, J = 9.7 Hz, 1H), 2.35 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 191.8, 142.3, 138.4, 
135.9, 131.6, 130.1, 129.9, 129.8, 129.1, 126.0 (q, J = 280.6 Hz), 55.4 (q, J = 27.7 Hz), 21.2; 19F 
NMR (471 MHz, CDCl3) δ -65.7; HRMS (ESI-TOF) m/z calcd. for C16H13OF3 [M]+ 278.0918, 
found 278.0920; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 12.81 
min (46%), 17.34 min (54%). 
 
4-(2,2,2-Trifluoro-1-(4-methoxyphenyl)ethyl)benzaldehyde (11d): Pale yellow oil (75%); IR 
(KBr) 3436, 3054, 2987, 2306, 1703, 1422, 1266, 1160, 896, 740, 706 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 10.02 (s, 1H), 7.88 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 6.7 Hz, 2H), 
6.90 (d, J = 8.8 Hz, 2H), 4.73 (q, J = 9.7 Hz, 1H), 3.81 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
191.8, 159.6, 142.4, 135.9, 130.4, 130.1, 129.8, 126.6, 126.0 (q, J = 280.6 Hz), 114.4, 55.4, 54.9 
(q, J = 27.7 Hz); 19F NMR (471 MHz, CDCl3) δ -65.9; HRMS (ESI-TOF) m/z calcd. for C16H13O2F3 
[M]+ 294.0868, found 294.0864; Chiral SFC (ChiralPak OJ-H column: 3% i-PrOH in CO2, 1.5 
mL/min) tr = 37.48 min (49%), 40.63 min (51%). 
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4-(2,2,2-Trifluoro-1-(naphthalen-2-yl)ethyl)benzaldehyde (11e): Pale yellow oil (53%); IR 
(KBr) 3686, 3054, 2986, 2305, 1708, 1421, 1266, 1159, 896, 741, 706 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 10.02 (s, 1H), 7.89–7.83 (m, 6H), 7.60 (d, J = 8.0 Hz, 2H), 7.54-7.50 (m, 2H), 7.40 (d, J 
= 8.6 Hz, 1H), 4.95 (q, J = 9.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 191.7, 142.0, 136.0, 133.3, 
133.0, 131.9, 130.2, 130.1, 128.9, 128.5, 128.2, 127.8, 126.9, 126.8, 126.6, 126.0 (q, J = 280.6 Hz), 
55.8 (q, J = 27.7 Hz); 19F NMR (471 MHz, CDCl3) δ -65.3; HRMS (ESI-TOF) m/z calcd. for 
C19H13OF3 [M]+ 314.0918, found 314.0915; Chiral SFC (ChiralPak OJ-H column: 10% i-PrOH in 
CO2, 1.5 mL/min) tr = 15.95 min (59%), 17.67 min (41%). 
 
4-(2,2,2-Trifluoro-1-(thiophen-3-yl)ethyl)benzaldehyde (11f): Pale yellow oil (64%); IR (KBr) 
2836, 1705, 1610, 1265, 1160, 1108, 826, 781, 738, 703 cm-1; 1H NMR (500 MHz, CDCl3) δ 10.02 
(s, 1H), 7.88 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 7.7 Hz, 2H), 7.35-7.33 (m, 1H), 7.27 (s, 1H), 7.01 (d, 
J = 5.0 Hz, 1H), 4.86 (q, J = 9.4 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 191.7, 141.6, 136.2, 
134.2, 130.2, 130.1, 127.9, 126.7, 125.7 (q, J = 280.6 Hz), 124.3, 51.6 (q, J = 28.5 Hz); 19F NMR 
(471 MHz, CDCl3) δ -66.8; HRMS (ESI-TOF) m/z calcd. for C13H9OF3S [M]+ 270.0326, found 
270.0326; Chiral SFC (ChiralPak OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) tr = 10.95 min 
(51%), 13.41 min (49%). 
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4-(2,2,2-Trifluoro-1-(1-methyl-1H-indol-5-yl)ethyl)benzaldehyde (11g): Red oil (32%); IR 
(KBr) 3054, 2987, 2325, 1708, 1265, 1166, 896, 741, 706 cm-1; 1H NMR (500 MHz, CDCl3) δ 
10.00 (s, 1H), 7.86 (d, J = 6.5 Hz, 2H), 7.67–7.57 (m, 3H), 7.30 (d, J = 8.5 Hz, 1H), 7.16 (d, J = 
8.5 Hz, 1H), 7.08 (d, J = 3.2 Hz, 1H), 6.48 (d, J = 3.1 Hz, 1H), 4.87 (q, J = 9.8 Hz, 1H), 3.78 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ 191.9, 143.2, 136.4, 135.7, 130.1, 130.0, 129.9, 128.8, 126.3 
(q, J = 280.6 Hz), 125.4, 122.7, 121.8, 109.8, 101.4, 55.8 (q, J = 27.7 Hz), 33.1; 19F NMR (471 
MHz, CDCl3) δ -65.6; HRMS (ESI-TOF) m/z calcd. for C18H15NOF3 [M+H]+ 318.1106, found 
318.1105; Chiral SFC (ChiralPak AS-H column: 10% i-PrOH in CO2, 1.5 mL/min) tr = 8.22 min 
(53%), 9.42 min (47%). 
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Appendix A4. Cyclic Voltammetry (CV) Data Relevant to Chapter 5 
 
Electrochemical measurements were recorded on a CH Instruments: Model 600E Series 
Electrochemical Analyzer (observed in 0.002 M MeCN; [N(Bu)4](PF6) = 0.1 M; Ag/AgCl = 
electrode; reported in SCE based on a ferrocene internal standard).  
 
 
 
 
 
 
 
 
 
-9.00E-05
-8.00E-05
-7.00E-05
-6.00E-05
-5.00E-05
-4.00E-05
-3.00E-05
-2.00E-05
-1.00E-05
0.00E+00
1.00E-05
0.30.50.70.91.11.31.51.7
CV: Compound 2 (Ar1 = p-methoxyphenyl)
1.17 V 
Potential (V vs SCE) 
-1.00E-04
-8.00E-05
-6.00E-05
-4.00E-05
-2.00E-05
0.00E+00
2.00E-05
0.20.40.60.811.21.4
CV: Potassium 1-Phenylethyltrifluoroborate
Potential (V vs SCE) 
0.91 V 
286 
Appendix A5. Chiral SFC Chromatograms Relevant to Chapter 5 
 
 
 
 
Figure A5.1. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 1-chloro-4-
(2,2,2-trifluoro-1-phenylethyl)benzene (10a) 
 
 
 
Figure A5.2. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 1-methoxy-3-
(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)benzene (10b) 
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Figure A5.3. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(4-methoxyphenyl)ethyl)phenyl trifluoromethanesulfonate (10c) 
 
 
Figure A5.4. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(4-methoxyphenyl)ethyl)-1,1'-biphenyl (10d) 
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Figure A5.5. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 2-(2,2,2-
trifluoro-1-(4-methoxyphenyl)ethyl)naphthalene (10e) 
 
 
Figure A5.6. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of methyl 4-
(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)benzoate (10f) 
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Figure A5.7. Chiral SFC (OD-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(4-methoxyphenyl)ethyl)benzonitrile (10g) 
 
 
Figure A5.8. Chiral SFC (OJ-H column: 3% i-PrOH in CO2, 1.5 mL/min) chromatogram of tert-
butyldimethyl(4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)phenethoxy)silane (10h)  
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Figure A5.9. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 1-(3-(2,2,2-
trifluoro-1-(4-methoxyphenyl)ethyl)phenyl)ethan-1-one (10i) 
 
 
Figure A5.10-1.  Chiral SFC (OD-H column: 3% i-PrOH in CO2, 1.5 mL/min) chromatogram of 2-fluoro-
4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)pyridine (10j) 
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Figure A5.10-2.  Chiral SFC (OD-H column: 3% i-PrOH in CO2, 1.5 mL/min) chromatogram of 2-fluoro-
4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)pyridine (1j) from a racemic reaction
 
 
Figure A5.11. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of tert-butyl 5-
(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)-1H-indole-1-carboxylate (10k) 
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Figure A5.12. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-phenylethyl)benzaldehyde (11a) 
 
 
Figure A5.13. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(4-fluorophenyl)ethyl)benzaldehyde (11b) 
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Figure A5.14. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(p-tolyl)ethyl)benzaldehyde (11c) 
 
 
Figure A5.15. Chiral SFC (OJ-H column: 3% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(4-methoxyphenyl)ethyl)benzaldehyde (11d) 
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Figure A5.16. Chiral SFC (OJ-H column: 10% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(naphthalen-2-yl)ethyl)benzaldehyde (11e) 
 
 
Figure A5.17. Chiral SFC (OJ-H column: 5% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(thiophen-3-yl)ethyl)benzaldehyde (11f) 
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Figure A5.18. Chiral SFC (AS-H column: 10% i-PrOH in CO2, 1.5 mL/min) chromatogram of 4-(2,2,2-
trifluoro-1-(1-methyl-1H-indol-5-yl)ethyl)benzaldehyde (11g) 
296 
Appendix A6. 1H, 13C, and 19F NMR Spectra Relevant to Chapter 5 
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Figure A6.1. 1H NMR (CDCl3, 500 MHz) spectrum of 1-chloro-4-(2,2,2-trifluoro-1-phenylethyl)benzene 
(10a) 
 
 
Figure A6.2. 13C NMR (CDCl3, 126 MHz) spectrum of 1-chloro-4-(2,2,2-trifluoro-1-phenylethyl)benzene 
(10a) 
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Figure A6.3. 19F NMR (CDCl3, 471 MHz) spectrum of 1-chloro-4-(2,2,2-trifluoro-1-phenylethyl)benzene 
(10a) 
 
 
Figure A6.4. 1H NMR (CDCl3, 500 MHz) spectrum of 1-methoxy-3-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzene (10b)  
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Figure A6.5. 13C NMR (CDCl3, 126 MHz) spectrum of 1-methoxy-3-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzene (10b) 
 
 
Figure A6.6. 19F NMR (CDCl3, 471 MHz) spectrum of 1-methoxy-3-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzene (10b) 
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Figure A6.7. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)phenyl 
trifluoromethanesulfonate (10c) 
 
 
Figure A6.8. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)phenyl trifluoromethanesulfonate (10c) 
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Figure A6.9. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)phenyl 
trifluoromethanesulfonate (10c) 
 
 
Figure A6.10. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)-1,1'-
biphenyl (10d)  
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Figure A6.11. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)-1,1'-
biphenyl (10d) 
 
 
Figure A6.12. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-methoxyphenyl)ethyl)-1,1'-
biphenyl (10d) 
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Figure A6.13. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)naphthalene (10e)  
 
 
Figure A6.14. 13C NMR (CDCl3, 126 MHz) spectrum of 2-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)naphthalene (10e) 
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Figure A6.15. 19F NMR (CDCl3, 471 MHz) spectrum of 2-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)naphthalene (10e) 
 
 
Figure A6.16. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzoate (10f)  
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Figure A6.17. 13C NMR (CDCl3, 126 MHz) spectrum of methyl 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzoate (10f) 
 
 
Figure A6.18. 19F NMR (CDCl3, 471 MHz) spectrum of methyl 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzoate (10f) 
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Figure A6.19. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzonitrile (10g)  
 
 
Figure A6.20. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzonitrile (10g) 
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Figure A6.21. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzonitrile (10g) 
 
 
Figure A6.22. 1H NMR (CDCl3, 500 MHz) spectrum of tert-butyldimethyl(4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)phenethoxy)silane (10h)  
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Figure A6.23. 13C NMR (CDCl3, 126 MHz) spectrum of tert-butyldimethyl(4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)phenethoxy)silane (10h) 
 
 
Figure A6.24. 19F NMR (CDCl3, 471 MHz) spectrum of tert-butyldimethyl(4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)phenethoxy)silane (10h) 
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Figure A6.25. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(3-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)phenyl)ethan-1-one (10i)  
 
 
Figure A6.26. 13C NMR (CDCl3, 126 MHz) spectrum of 1-(3-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)phenyl)ethan-1-one (10i) 
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Figure A6.27. 19F NMR (CDCl3, 471 MHz) spectrum of 1-(3-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)phenyl)ethan-1-one (10i) 
 
 
Figure A6.28. 1H NMR (CDCl3, 500 MHz) spectrum of 2-fluoro-4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)pyridine (10j)  
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Figure A6.29. 13C NMR (CDCl3, 126 MHz) spectrum of 2-fluoro-4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)pyridine (10j) 
 
 
Figure A6.30. 19F NMR (CDCl3, 471 MHz) spectrum of 2-fluoro-4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)pyridine (10j) 
312 
 
Figure A6.31. 1H NMR (CDCl3, 500 MHz) spectrum of tert-butyl 5-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)-1H-indole-1-carboxylate (10k)  
 
 
Figure A6.32. 13C NMR (CDCl3, 126 MHz) spectrum of tert-butyl 5-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)-1H-indole-1-carboxylate (10k) 
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Figure A6.33. 19F NMR (CDCl3, 471 MHz) spectrum of tert-butyl 5-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)-1H-indole-1-carboxylate (10k) 
 
 
Figure A6.34. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-phenylethyl)benzaldehyde 
(11a)  
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Figure A6.35. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-phenylethyl)benzaldehyde 
(11a) 
 
 
Figure A6.36. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-phenylethyl)benzaldehyde 
(11a) 
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Figure A6.37. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)benzaldehyde (11b)  
 
 
Figure A6.38. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)benzaldehyde (11b) 
316 
 
Figure A6.39. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)benzaldehyde (11b) 
 
 
Figure A6.40. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(p-tolyl)ethyl)benzaldehyde 
(11c)  
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Figure A6.41. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(p-tolyl)ethyl)benzaldehyde 
(11c) 
 
 
Figure A6.42. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(p-tolyl)ethyl)benzaldehyde 
(11c) 
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Figure A6.43. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzaldehyde (11d)  
 
 
Figure A6.44. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzaldehyde (11d) 
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Figure A6.45. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(4-
methoxyphenyl)ethyl)benzaldehyde (11d) 
 
 
Figure A6.46. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(naphthalen-2-
yl)ethyl)benzaldehyde (11e)  
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Figure A6.47. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(naphthalen-2-
yl)ethyl)benzaldehyde (11e) 
 
 
Figure A6.48. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(naphthalen-2-
yl)ethyl)benzaldehyde (11e) 
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Figure A6.49. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(thiophen-3-
yl)ethyl)benzaldehyde (11f)  
 
 
Figure A6.50. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(thiophen-3-
yl)ethyl)benzaldehyde (11f) 
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Figure A6.51. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(thiophen-3-
yl)ethyl)benzaldehyde (11f) 
 
 
Figure A6.52. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2,2,2-trifluoro-1-(1-methyl-1H-indol-5-
yl)ethyl)benzaldehyde (11g)  
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Figure A6.53. 13C NMR (CDCl3, 126 MHz) spectrum of 4-(2,2,2-trifluoro-1-(1-methyl-1H-indol-5-
yl)ethyl)benzaldehyde (11g) 
 
 
Figure A6.54. 19F NMR (CDCl3, 471 MHz) spectrum of 4-(2,2,2-trifluoro-1-(1-methyl-1H-indol-5-
yl)ethyl)benzaldehyde (11g)  
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Chapter 6. Construction of Quaternary Centers via Radical Mediated Alkyl Transfer 
6.1 Introduction 
 
The installation of quaternary centers has been a long-standing challenge going back to the 
earliest days in the art of steroid synthesis.i Woodward and coworkers succeeded in setting some 
of the first all-carbon stereocenters through cycloaddition chemistry over 60 years ago.1 Although 
methods have evolved dramatically, there are still relatively few ways to install these centers 
reliably across a broad array of functionalized partners.2–4 Among the most commonly employed 
methods, three predominate: 1) alkylation of 1,1-disubstituted allylic leaving groups,5 2) conjugate 
addition to α,β-unsaturated carbonyls,6 and 3) alkylation of substituted enolate equivalents.7 In 
many cases, each of these subclasses can cleanly access the requisite quaternary center, but are 
constrained by the requirement and natural reactivity pattern for a particular structural element 
(e.g., α,β-unsaturated carbonyls, allyl, or carbonyl systems). Most notably, none of these methods 
adequately address the synthesis of arylated quaternary centers.  
In addition to these common approaches, a variety of niche metal-catalyzed reactions have 
also been developed for installing such centers between various nucleophile and electrophile 
combinations. Key contributions to highlight include Tsuji-Trost allylations,8a Heck couplings,8b 
Pauson-Khand cyclizations,8c redox relay arylations,8d and carbene C-H insertion reactions.8e These 
examples are by no means comprehensive, but represent landmark catalytic approaches to the 
installation of challenging quaternary centers. 
                                                     
i Reproduced in part from Journal of the American Chemical Society, manuscript accepted. 
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Although other metal-mediated catalytic reactions have enabled access to quaternary centers, 
there are, by contrast, vanishingly few examples of tertiary nucleophiles in classical cross-coupling 
chemistry. Seminal contributions from the Biscoe9a and Glorius9b groups have highlighted the 
success of Grignard reagents with N-heterocyclic carbene-ligated nickel complexes. Unfortunately, 
these strongly basic nucleophiles are poorly tolerant of electrophilic and protic functional groups 
and are often accompanied by isomerization, generating byproducts when the temperature of these 
reactions is not carefully controlled. Beyond these seminal reports, there are additional isolated 
examples using Kumada10 or Negishi11 reagents; however, these do not represent a unified strategy 
for tertiary cross-couplings. Particularly from a diversification perspective, approaches using these 
sensitive, pyrophoric reagents are wholly impractical when applied to a wide array of tertiary 
nucleophiles paired with an equally broad palette of aryl electrophiles. The clear absence of 
methods predicated on the use of bench-stable partners inspired the laboratory to explore tertiary 
organoboron nucleophiles more closely – especially given the recent surge in methods for their 
preparation.13  
 
6.2 Results and Discussion 
 
Studies were initiated using tert-butyltrifluoroborate 13 as the chosen nucleophile with 4’-
bromoacetophenone as the aryl electrophile. Application of conditions14 (Figure 6.1A) successful 
in previous studies proved completely ineffective for achieving the desired cross-coupling. For all 
bipyridyl ligands, only starting material or protodehalogenation products were observed. 
Furthermore, the alkyltrifluoroborate was often minimally consumed after 24 h. Given the lack of 
conversion under our initially developed conditions, we sought to understand in a more 
comprehensive manner the divergent reactivity of these tertiary radical precursors.  
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Figure 6.1. Plausible catalytic cycle and key mechanistic experiments  
 
First, oxidation of the reagent was considered (Figure 6.1B). Notably, in previous work, 
static quenching of alkyltrifluoroborates in the presence of a cationic photocatalysts has been 
observed15 – indicating the formation of a salt pre-complex that precedes a single-electron transfer 
(SET) event. Because of the enhanced steric bulk of these tertiary precursors, it seemed prudent to 
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confirm these reagents were indeed generating radical intermediates. Gratifyingly, both cyclic 
voltammetry analysis of the alkyltrifluoroborate (Ered1/2 = +1.26 V vs SCE) and Giese-type trapping 
experiments16 confirmed the viability of this oxidation, the latter affording the desired alkylated 
product 14 in 74% yield.   
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Constrained cyclic alkyltrifluoroborates in cross-coupling  
using slightly modified reaction conditions 
 
Next, attention was turned to the key bond-forming reductive elimination step in these 
couplings (Figure 1C) Here, the desired NiIII intermediate was deemed to be accessible through the 
use of a preformed NiII(dtbbpy) oxidative addition complex 15 in the presence of 
alkyltrifluoroborate 13 and an appropriate oxidant. Surprisingly, stoichiometric experiments 
exposing this complex to a variety of oxidant combinations in the presence of alkyltrifluoroborate 
13 failed to afford any of the desired coupling product even under prolonged reaction times. The 
only products observed were THF-adduct 18 (known to be generated under the reaction conditions 
through C-H abstraction17 or halide abstraction pathways18) and protodehalogenation. Given these 
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results, it appeared unlikely that the established bipyridyl ligand systems for primary and secondary 
alkyl radicals would be broadly applicable to their tertiary counterparts.   
Although daunted by the failures here, we did achieve targeted success with 
adamantyltrifluoroborate and other constrained ring systems because of their unique structural 
properties. As a tied back (tetrahedral) radical possessing no sites for possible β-hydride 
elimination, slight modification of the previously developed conditions allowed access to an array 
of compounds (Figure 2). Electron-poor (19–23 , 25), electron-rich (24) and heteroaryl halides (20) 
all proved viable. Unfortunately, this rather niche reactivity was not unprecedented19,12a and by no 
means represented a general solution to tertiary radical coupling.  
To identify a set of more robust general conditions, a screening effort was initiated to evaluate 
a wide variety of ligand classes that might be amenable to tertiary radical progenitors. 
Representative ligands from the Ni cross-coupling literature ranging from phosphines,20 
pyridines,21 terpyridines,22 amino alcohols,23 N-heterocyclic carbenes,9 olefins,24 to 1,3-diketones25 
were all introduced to both a Ni(0) and Ni(II) source in parallel. The reactions were then followed 
by UPLC to observe the desired coupling product (see Supporting Information for full details). 
Across all ligand classes, only diketonate-type species showed significant product formation. 
Interestingly, these ligands have seen use in mechanistically analogous reductive coupling 
chemistry reported by the Gong group in 2015.25 
Further optimization of this ligand architecture identified a more bulky 
tetramethylheptanedione (TMHD) scaffold as being suitable for promoting the desired coupling. 
Additional evaluation of bases showed that the addition of inorganic bases served to reduce 
protodehalogenation byproducts and increase yield. A solvent screen showed that DMA was 
essential for coupling success. Use of other polar aprotic solvents such as DMF, DMSO, or NMP 
resulted in poorer conversions. Use of ZnBr2 and other Lewis acids were tested as additives to 
facilitate the coupling. Although these additives were deemed non-essential, rate studies show that 
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these salts reduce the initial induction period observed for the coupling, particularly at larger 
reaction scales. A summary of the effect of deviations from the optimized conditions can be found 
in Table 1. It should be noted that although reactions run in front of the low wattage LEDs were 
sluggish (48–72 h), increasing the light intensity through the use of blue aquarium lamps as in 
Figure 1, entries 27 and 35, substantially reduced the reaction times (24 h).   
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1. Optimized conditions for tert-butyltrifluoroborate cross-coupling and effects of 
deviation from standard conditions. aCzIPN = ;2,4,5,6-Tetra-9H-carbazol-9-yl-1,3-
benzenedicarbonitrile 
 
With suitable conditions in hand, an evaluation of this coupling across an array of aryl 
bromides was undertaken (Figure 3). The use of numerous electron-poor aryl bromides resulted in 
moderate to excellent yields. (26–34). Of note, a number of electrophilic functional groups that are 
intolerant of more reactive Kumada conditions could be employed to afford nitrile 27, aldehyde 28, 
sulfonyl fluoride 30, amide 34, and ketones 26 and 36. A bromo sulfonamide could also be engaged 
in the coupling to give 31, demonstrating tolerance of some protic functional groups. A heteroaryl 
thiophene and benzofuran were also acceptable partners to give products 35 and 36. Unfortunately, 
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the more highly desirous N-heteroaryl bromides were ineffective under the coupling conditions 
(see 37). At this time, we surmise that the pyridine serves to ligate the metal center competitively, 
inhibiting the active catalyst. This is supported by doping experiments where addition of 10 mol % 
of pyridine to the active catalyst mixture arrests conversion to desired product (see Supporting 
Information).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Aryl bromide scope in the cross-coupling of potassium tert-butyltrifluoroborate under 
the developed conditions. ‡Reactions irradiated with four H150 blue LED Kessil lamps. 
 
To evaluate the scope further, an enone-derived alkyltrifluoroborate 38 was used to ease 
separation of reactions with incomplete conversion (Figure 4). Here, electron-poor systems worked 
well to give products 39–44. Meta substitution was tolerated, giving compounds 43 and 46 in 
moderate yields. Overall, the use of electron-neutral bromides resulted in poorer yields (45–46) and 
331 
truly electron-rich systems such as 4-bromoanisole afforded trace product (47) under the developed 
conditions.   
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Further aryl bromide scope evaluation with enone derived alkyltrifluoroborate 38 
With this survey of electrophiles established, we next turned our attention to more complex 
tertiary alkyltrifluoroborate precursors using electron-poor bromides as model electrophiles 
(Figure 6.5A).  Cyclohexanone- and cyclopentanone- based ring systems could be coupled with an 
array of substituted aryl bromides (aldehydes, sulfones, ketones) to afford products 48–51. Notably, 
the products obtained from the coupling of these enone- and enoate-derived trifluoroborates are 
analogous to those accessed through 1,4 addition chemistry of aryl nucleophiles to α,β-unsaturated 
carbonyl systems.26As such, the coupling here represent an umpolung approach to these methods 
where the carbon β to the carbonyl has been rendered nucleophilic (Figure 6.5B). Considering the 
far greater number of commercially-available aryl electrophiles in comparison to the corresponding 
aryl nucleophiles, this alternative approach has clear advantages for diversity oriented synthesis. 
Other functionalized trifluoroborates could be employed to give quaternary centers in products 52–
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56. Here, ester-, ether-, and ketone-containing trifluoroborates all work well in the established 
protocol. The incorporation of an amide in a nearby position shut down the reaction, returning only 
β-hydride elimination and reduction products (see 57), suggesting that changes in the ligation 
around the nickel have drastic effects on the reaction profile for this tertiary cross-coupling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. (A) Tertiary alkyltrifluoroborate scope with electron poor aryl bromides. (B) 
Comparison of enone and enoate derived trifluoroborate cross-coupling to metal catalyzed 1,4-
addition chemistry. 
 
 
 
 
333 
6.3 Conclusion 
 
In summary, the first general method for the cross-coupling of tertiary organotrifluoroborates 
has been described. The development of this protocol hinged on the use of photoredox high-
throughput screening technology to identify a new ligand architecture amenable to more bulky 
tertiary radical nucleophiles. Using the conditions identified therein, an array of functionalized, 
unactivated tertiary organoboron reagents have been employed in transition metal-catalyzed cross-
coupling for the first time.27 These reactions generate notoriously challenging to access quaternary 
centers that are typically forged in cross-coupling through the use of highly reactive Kumada and 
Negishi partners. In contrast, these mild conditions are tolerant of a number of electrophilically-
sensitive functional groups such as aldehydes, ketones, esters, and amides. 
At present, a few key limitations of this protocol still remain, as the aryl bromide scope for 
this cross-coupling is currently limited to electron-poor and electron-neutral systems. From the 
standpoint of organoboron coupling, this limitation actually serves to complement existing metal-
free tertiary coupling work by Aggarwal and others, wherein tertiary alkyl pinacol boronates can 
be best coupled with electron-rich arene systems.28 The current method also exhibits a notable 
absence of N-containing heteroaryl partners. In some ways, this failure of heteroaryl systems is 
mitigated by the successful implementation of tertiary alkyltrifluoroborates in Minisci processes,29 
but extension to other electrophilic sites on heteroaryl compounds would still have significant 
value. Further refinement to the ligand scaffold and conditions will likely address these two 
limitations; efforts in the laboratory toward this end are an ongoing endeavor. 
Given the growing suite of methods for the synthesis of tertiary organoboron compounds,13 
this photoredox cross-coupling serves as a timely addition, enabling tertiary organoboron reagents 
as partner in the installation of arylated quaternary centers. Although limitations remain, the ligand 
screening data and mechanistic interrogation will allow practitioners seeking to employ other 
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tertiary radical feedstocks (carboxylic acids, halides, aldehydes, silicates, etc.) to channel these 
lessons into developing new tertiary alkyl cross-couplings of broad interest. Taken together, these 
findings introduce tertiary alkyl radicals to the photoredox cross-coupling portfolio. 
6.4 Experimental 
 
General considerations 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless otherwise 
noted. DMA was purchased as 99.9%, extra dry. K2HPO4 was stored and dispensed in a dry 
glovebox. IrCl3·xH2O, and Ni(TMHD)2 were purchased from commercial sources. All other 
reagents were purchased commercially and used as received. Photoredox reactions were irradiated 
by 1.2 W/ft. blue LED (420 nm) light strips, coiled in a circular setup approximately 38 inches in 
length. To accelerate the reactions, irradiation with 2–4 Kessil H150 blue LED flood lamps can 
also be used to complete reactions in under 24 h. Melting points (°C) are uncorrected. NMR spectra 
were recorded on a 500 MHz spectrometer. 19F NMR chemical shifts were referenced to external 
CFCl3 (0.0 ppm). 11B NMR spectra were obtained on a spectrometer equipped with the appropriate 
decoupling accessories. All 11B NMR chemical shifts were referenced to an external BF3·OEt2 (0.0 
ppm) with a negative sign indicating an upfield shift. Data are presented as follows: chemical shift 
(ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant 
J (Hz) and integration. The 13C signal of the carbon bonded to boron was not observed in all cases 
because of quadrupolar relaxation. 
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General Procedure for Conversion of Boronic Acid Derivatives to Alkyltrifluoroborate: 
 
To a solution of boronic acid derivative in MeOH (0.1 M) at 0 oC was added saturated aq KHF2 
(4.5 M) dropwise over 30 min and then subsequently stirred for 3 h to rt. The resulting suspension 
was concentrated under reduced pressure. H2O was azeotropically removed by suspension in 
toluene (100–150 mL) followed by rotary evaporation. The remaining solid was dried under high 
vacuum overnight. The resultant solid was resuspended in hot acetone and filtered. The filtrate was 
then concentrated to minimal volume, and the trifluoroborates were precipitated by the addition of 
cold Et2O, CH2Cl2, and/or pentanes. 
 
General Enone Borylation Procedure: 
 
Following a slightly modified literature procedure,30 a flask was charged with CuBr (14.8 mg, 0.1 
mmol), CyJohnPhos (35 mg, 0.1 mmol), bisboronic acid (537.9 mg, 6 mmol) and NaOt-Bu (144.2 
mg, 1.5 mmol). The flask was evacuated and purged 3 times with argon.  EtOH (50  mL)  and enone 
(5.0  mmol) were added via syringe,  and  the  mixture  was  stirred  for 21 h.  The reaction mixture 
was filtered through a plug of Celite and then rinsed with EtOAc (3 x 40 mL). The filtrate was 
concentrated, and the resultant oil was dissolved in MeOH (50 mL). This solution was cooled in an 
ice-bath, and then a solution of saturated KHF2 (42.5 mmol, 4.5 M) was added dropwise.  The 
mixture was warmed to rt and was stirred for 3.5 h. The suspension was then evaporated to dryness. 
The resultant solid was triturated and sonicated with hot acetone and filtered three times.  The 
filtrate was then concentrated to a minimal volume, and the alkyltrifluoroborates were precipitated 
through dropwise addition of cold Et2O (10–50   mL). The mixture was filtered, washed with cold 
Et2O (5–20 mL), and dried on high vacuum overnight to yield the desired β-trifluoroboratoester or 
–ketone.  
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Potassium (4-(2-Ethoxy-2-oxoethyl)tetrahydro-2H-pyran-4-yl)trifluoroborate (S1) prepared 
from ethyl 2-(tetrahydro-4H-pyran-4-ylidene)acetate (5 mmol) and obtained in 32% yield, 445 mg 
as a white crystalline solid, mp = 187 – 190 ⁰C. 1H NMR (500 MHz, acetone-d6) δ 4.01 (q, J = 7.1 
Hz, 2H), 3.72 – 3.64 (m, 2H), 3.55 – 3.49 (m, 2H), 2.15 (s, 2H), 1.73 – 1.62 (m, 2H), 1.33 – 1.25 
(m, 2H), 1.17 (t, J = 7.1 Hz, 3H). 13C NMR (125.8 MHz, acetone-d6) δ 175.3, 64.4, 58.9, 42.2, 33.5, 
13.9. 19F NMR (XXX MHz, acetone-d6) -146.8. 11B NMR (400 MHz, acetone-d6) δ 5.42. IR (ATR): 
ν = 1720, 1688, 1308, 1228, 1088, 1016, 999, 964, 533 cm-1. HRMS (ESI) m/z calc. for 
C9H15BF3O3- (M-) 238.1103, found 238.1095. 
 
Reductive Alkene Coupling Procedure: 
 
Based on a slightly modified literature procedure,13b to a solution of 4,4,5,5-tetramethyl-2-(prop-1-
en-2-yl)-1,3,2-dioxaborolane (5.0 mmol) in 20 mL of EtOH was added anhydrous Na2HPO4 (2.12 
g, 10.0 mmol), Fe(acac)3 (177 mg, 10 mol %), acceptor olefin (15.0 mmol), and PhSiH3 (1.62 g, 
15.0 mmol). The resulting mixture was heated in an oil bath preheated to 60 °C with stirring (until 
GC analysis indicated the consumption of starting material boronate ester, usually 2–4 h). The 
reaction mixture was then cooled to rt and diluted with brine (20 mL) and EtOAc (20 mL). The 
organic layer was separated, and the aqueous layer was extracted with EtOAc (3 x 10 mL). The 
organic layers were combined, washed with brine (20 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The resulting crude product was then purified by silica gel 
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flash column chromatography. The pinacol boronate obtained after column chromatography was 
dissolved in MeOH (10–20 mL) and converted to the alkyltrifluoroborate by addition of saturated 
aq KHF2 (12 mL, 4.5 M, 54 mmol) at 0 oC. The mixture was then warmed to rt and stirred for 3.5 
h. The suspension was then evaporated to dryness. The resultant solid was triturated and sonicated 
with warm acetone and filtered three times.  The filtrate was then concentrated to a minimal volume, 
and the alkyltrifluoroborate was precipitated through dropwise addition of cold Et2O and/or 
pentanes (10–30 mL). The mixture was filtered, washed with cold Et2O (5–10 mL), and then dried 
on high vacuum overnight to yield the desired alkyltrifluoroborates. 
 
 
Potassium Trifluoro(5-methoxy-2-methyl-5-oxopentan-2-yl)borate (S2) prepared using methyl 
methacrylate as the olefin acceptor and obtained in 44% yield, 522 mg as an off-white solid, mp = 
129 – 131 ⁰C. 1H NMR (500 MHz, acetone-d6) δ 3.55 (s, 3H), 2.47 – 2.17 (m, 2H), 1.55 – 1.30 (m, 
2H), 0.68 (s, 6H). 13C NMR (126 MHz, acetone-d6) δ 175.6, 137.0, 50.1, 36.0, 30.3, 24.1. 11B NMR 
(128.4 MHz, acetone-d6) δ 6.19. 19F NMR (470.8 MHz, acetone-d6) δ -150.5. IR (ATR): : ν = 1732, 
1646, 1236, 1174, 1026, 981, 937, 750, 567 cm-1. HRMS (ESI) m/z calc. for C7H13BF3O2- (M-) 
196.0997, found 196.1975.  
 
Potassium Trifluoro(2-methyl-5-oxohexan-2-yl)borate (S3) prepared using methyl vinyl ketone 
as the olefin acceptor, 45% yield, 497 mg as a colorless, viscous oil. 1H NMR (500 MHz, acetone-
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d6) δ 2.47 – 2.28 (m, 2H), 2.03 (s, 3H), 1.37 – 1.30 (m, 2H), 0.67 (s, 6H) 
13C NMR (125.8 MHz, acetone-d6) δ 210.5, 40.1, 34.9, 28.6, 24.2. 11B NMR (128.4 MHz, acetone-
d6) δ 6.15 (with residual BF4). 19F NMR (470.8 MHz, acetone-d6) δ -149.0 (with residual BF4). IR 
(ATR): : ν = 1696, 1471, 1296, 1254, 1016, 749, 480 cm-1. HRMS (ESI) m/z calc. for C7H13BF3O- 
(M-) 181.1012, found 181.1029. 
 
Potassium Trifluoro(2-methyl-5-morpholino-5-oxopentan-2-yl)borate (S4) prepared using 1-
morpholinoprop-2-en-1-one as the olefin acceptor, 53% yield, 764 mg as a white crystalline solid, 
mp = 164 – 166 ⁰C. 1H NMR (500 MHz, CD3CN) δ 3.76–3.63 (m, 4H), 3.57 (s, 4H), 2.49–2.39 (m, 
2H), 1.46–1.35 (m, 2H), 0.78 (s, 6H). 13C NMR (125.8 MHz, CD3CN) δ 174.2, 66.5, 46.0, 41.4, 
36.8, 29.8, 24.2. 11B NMR (128.4 MHz, CD3CN) δ 6.00. 19F NMR (470.8 MHz, CD3CN) δ -149.7. 
IR (ATR): ν = 1645, 1482, 1429, 1281, 1114, 1038, 1017, 963, 935, 524 cm-1. HRMS (ESI) m/z 
calc. for C10H18BF3NO2- (M-) 252.1388, found 252.1383. 
Trifluoroborates below were synthesized according to known literature procedures: 
 
 
  
Spectral data matched that reported in the literature literature16,29-31 
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Selected reaction optimization studies: 
High Throughput Experimentation was performed at the Penn/Merck Center for High Throughput 
Experimentation at the University of Pennsylvania. The screens were analyzed by UPLC with 
addition of an internal standard. The areas for the internal standard (IS), aryl bromide (ArBr), and 
product (P) from each of the screens are shown in the tables below. The ratios calculated are 
pertinent only to that specific screen; the ratios from one screen should not be quantitatively 
compared to those from a different screen. The results of the screens are illustrated in a heat map. 
The information conveyed in these heat maps is two-fold. First, the size of the circle corresponds 
to the amount of product. The larger the circle, the more product formed during the reaction. 
Secondly, the shade of the circle corresponds to the amount of starting material, in this case aryl 
bromide, remaining. The lighter the circle, the less aryl bromide remaining after 24 h. Therefore, 
for a reaction resulting in high conversion and product formation, the circle will be both large and 
light. 
Procedure for screening at 10 μmol scale:  
To a 96 well plate reactor containing 1 mL reaction vials equipped with a Teflon-coated magnetic 
stir bar in a glovebox was added sequentially: 1) solution of Ni source (0.1 equiv) dissolved in THF 
for [Ni(COD)2] or DMA [for all Ni(II) sources], and 2) ligand (0.1 equiv) in DMA. After addition, 
the plate was sealed and the vials were allowed to stir at 60 ⁰C for 1 h to ensure complexation of 
ligand to the catalyst. Then, 100 μL of a stock solution containing potassium tert-
butyltrifluoroborate (1.5 equiv), aryl bromide (1.0 equiv – 10 μmol), photocatalyst (0.03 equiv), 
and internal standard (0.1 equiv) was added to each vial. The vials were sealed and stirred over 
blue LED lights at rt (~24 ⁰C). After 24 h the reactions were opened to air and diluted with 500 μL 
of MeCN. After stirring, the diluted block for fifteen minutes15 min, 25 μL aliquots were then 
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taken from the reaction vials and dosed into a 96-well UPLC block. These aliquots were further 
diluted by the addition of 700 μL of MeCN. The reaction mixtures were then analyzed by UPLC.  
Note: If examining the effect of solid additives, these were added as slurries in THF or DCE (0.1 
M) followed by solvent removal by Genovac evaporation before the following steps. If looking at 
the effect of liquid additives, these were added as stock solutions in DMA (1.0 M) after dosing all 
other ingredients. 
 
 
 
 
 
 
Conditions: 3 mol % Ir cat 1, 10 mol % Ni, 10 mol % ligand, no base, 0.05 M DMA 
 
 
 
 
 
 
 
 
 
Figure 6.6. Broad Ligand Screening for Baseline Conversion 
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Optimizing Precomplexed Diketonate Ligand Scaffold 
 
 
 
 
 
 
 
 
 
     Conditions: 3 mol % Ir cat. 1, 10 mol % Ni, 10 mol % ligand, 20 mol % additive, 1 equiv base, 0.05 M DMA 
Figure 6.7. Effects of ligand structure, additives, NHC additives, and bases on overall yield 
 
Procedure for screening at 0.1 mmol scale:  
To a 1 dram vial containing a Teflon coated magnetic stir bar was added a stock solution of 
potassium tert-butyltrifluoroborate (2.0 equiv), aryl halide (1 equiv), photocatalyst 1 (3 mol %), 
and internal standard 4,4’-di-tert-butylbiphenyl (10 mol %) in THF. The solvent was then removed 
under high vacuum. To the reaction mixture was then added any additional base (1.0 equiv). The 
vial was then brought into a nitrogen filled glovebox and Ni(TMHD)2 (10 mol %) was dosed in the 
reaction solvent of choice. The reactions were then monitored by GC analysis after stirring for 24 
h with the product/IS ratios given below 
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Figure 6.8: Benchtop Screening of Solvents and Bases 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9. Similar Structures Examined as Ligands with Relative Conversion  
 (Red: <5%, Yellow: 5–50 %, Green: >50%) 
 
Procedure for nickel complexation with above ligands: 
 
Based on an adapted literature procedure,6 2.0 equiv of ligand (0.2 mmol) were dosed into a vial 
Ni(OAc)2 x 4H2O (1.8 mg, 0.1 mmol) . To the vial was added 0.5 mL of MeOH. The vial was then 
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capped and stirred at 50 ºC overnight to induce complexation of the ligand to the nickel center. The 
solvent was then removed under high vacuum to afford green to purple solids or semi-solids. The 
residual solid material was then dissolved in DMA and dosed as a 0.1 M stock solution. 
 
 
Figure 6.10. Nickel to Photocatalyst Ratio Array  
 (P/IS ratios under standard conditions after 24 h) 
 
 
 
 
 
 
 
Figure 6.11. Deviation from Standard Conditions (HPLC ratios after 48 h) 
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General procedure A for adamantyltrifluoroborates photoredox cross-coupling reactions: 
 
 
 
 
 
To a 4 dram borosilicate glass vial equipped with a Teflon-coated magnetic stir bar was added 
adamantyltrifluoroborate S5 (181 mg, 0.75 mmol, 1.5 equiv), Ir[dFCF3ppy]2(bpy)PF6 1 (15.0 mg, 
0.03 equiv), Ni(dtbbpy)(H2O)4Cl2 (7.0 mg, 0.05 equiv), Na2CO3 (1.0 mmol, 2 equiv) and aryl 
bromide (0.5 mmol, 1 equiv) (liquid aryl bromides were added with solvent). The vial was then 
purged and evacuated 3x under argon atmosphere. To the vial was then added dioxane/DMA in a 
(6 mL in 5:1 mixture). The entire mixture was then sparged for 10 min with argon and then placed 
on a stir plate 4 cm away from 4 Kessil H150 blue flood lamps for 24 h. Two fans were placed 
above the reaction setup (shown below) to maintain an ambient temperature of 28–30 oC. After 
completion, the reaction mixture was diluted with an equal volume of H2O and extracted with 
EtOAc (3 x 5 mL). The organic layer was then dried (Na2SO4), filtered, concentrated onto silica, 
and then purified by silica gel chromatography, eluting with EtOAc and hexanes to obtain the 
products in pure form. 
 
General procedure B for tertiary photoredox cross-coupling reactions 
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To a 4 dram borosilicate glass vial equipped with a Teflon-coated magnetic stir bar was added 
tertiary alkyltrifluoroborate (1.0 mmol, 2 equiv), Ir[dFCF3ppy]2(bpy)PF6 1 (5.0 mg, 0.01 equiv), 
and aryl bromide (0.5 mmol, 1 equiv) (liquid aryl bromides were added with solvent). The vial was 
then transferred into a glove box where Ni(TMHD)2 (21.2 mg, 0.05 mmol), ZnBr2 (11.3 mg, 0.05 
mmol), and anhydrous K2HPO4 (87 mg, 0.5 mmol) were added. The vial was then capped and 
removed from the glovebox. Anhydrous DMA (5 mL) was added to the vial via syringe under inert 
atmosphere. The vial was then sparged with argon for 10 min. The vial containing all the reagents 
was further sealed with parafilm and Teflon tape and stirred for 48–72 h approximately 4 cm away 
from a ring of blue LED lights strips (see below). A fan was blown across the reaction setup to 
maintain an ambient temperature around 27 oC. After completion, the crude reaction mixture was 
diluted with H2O (10 mL) and extracted with Et2O (2 X 10 mL) EtOAc (5 mL). The organic layer 
was then washed with saturated aq NaCl (5 mL) and dried (Na2SO4). The resulting organics were 
then concentrated, and the residue was purified by column chromatography on silica gel, eluting 
with EtOAc and hexanes, to obtain products in pure form. 
 
General procedure C for tertiary photoredox cross-couplings 
 
Setup for these reactions remains the same as procedure B, however, the reactions are instead 
irradiated with 4 Kessil H150 blue flood lamps at 30 oC for 24 h. The greater light intensity in these 
systems significantly accelerates reaction progress and mirrors acceleration seen in other systems.33 
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Figure 6.12. Procedure B photoredox cross-coupling reaction set-up (0.50 mmol scale) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13. Procedure A and C Kessil lamp setup for shortened reaction times (0.25 – 0.50 
mmol scale)  
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Cyclic Voltammetry (CV) Data  
 
Electrochemical measurements were recorded on a CH Instruments: Model 600E Series 
Electrochemical Analyzer (observed in 0.002 M MeCN; [N(Bu)4](PF6) = 0.1 M; Ag/AgCl = 
electrode; reported in SCE based on a ferrocene internal standard). 
 
 
 
 
 
 
Figure 6.14. Oxidation Potential of Tertiary Alkyltrifluoroborate 13 
 
Alkyltrifluoroborate Oxidation Experiment 
 
Based on a literature procedure reported by Akita,5 a one dram vial equipped with a Teflon coated 
magnetic stir bar was charged with alkyltrifluoroborate 13 (82 mg, 0.50 mmol) and 
Ir[dFCF3ppy]2(bpy)PF6 1 (10 mg, 0.01 mmol), then acetone (5.0 mL), MeOH (0.5 mL) and methyl 
vinyl ketone (140 mg, 2.0 mmol) were added under inert atmosphere. The vessel was degassed by 
Ar sparging for 10 min. The vial was then exposed to the blue LED setup in procedure B (vide 
supra) at rt for 24 h. The resulting mixture was extracted with CH2Cl2, and the combined organic 
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layers were dried (Na2SO4) and filtered. The filtrate was concentrated under vacuum, and the 
residue was purified by flash column chromatography on silica gel to afford 14 as a colorless oil 
(47 mg, 73%). 1H NMR (500 MHz, CDCl3) δ 2.44-2.40 (m, 2H), 2.18 (s, 3H), 1.52-1.48 (m, 2H), 
0.91 (s, 9H). 13C NMR (125.8 MHz, CDCl3): δ 209.2, 39.1, 37.0, 29.5, 29.1, 28.8. Spectroscopic 
data matches that previously reported.34  
 
 
Compound Characterization Data 
 
 
4-(Adamantan-1-yl)benzonitrile (19): obtained as a white amorphous solid using procedure A at 
0.50 mmol scale (76 mg, 64%), mp = 125–128 ⁰C. 1H NMR (500 MHz, CDCl3) δ 7.60 (d, J = 8.2 
Hz, 2H), 7.45 (d, J = 8.3 Hz, 2H), 2.12 (s, 3H), 1.90 (s, 6H), 1.83 – 1.72 (m, 6H). 13C NMR (126 
MHz, CDCl3) δ 156.8, 132.2, 126.0, 119.4, 109.4, 42.9, 37.0, 36.7, 28.8. IR (ATR): ν = 2916, 2898, 
2847, 2233, 1506, 1343, 1101, 849, 806, 563 cm-1. HRMS (EI) m/z calc. for C17H19N (M+) 
237.1517, found 237.1501. 
 
1-(4-((3r,5r,7r)-Adamantan-1-yl)phenyl)ethan-1-one (20): obtained as a white solid using 
procedure A at 0.50 mmol scale (97 mg, 76%), mp = 108–110 ⁰C. 1H NMR (500 MHz, CDCl3) δ 
7.92 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 2.59 (s, 3H), 2.12 (s, 3H), 1.92 (s, 6H), 1.83 – 
1.72 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 198.1, 157.1, 134.8, 128.5, 125.3, 43.0, 36.8, 36.8, 
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28.9, 26.7. IR (ATR): ν = 2907, 2848, 1678, 1602, 1359, 1267, 1245, 832, 804, 596 cm-1. HRMS 
(EI) m/z calc. for C18H22O (M+) 254.1671, found 254.1675. 
 
4-((3r,5r,7r)-Adamantan-1-yl)-2-methylpyridine (21): obtained as a pale yellow semi-solid 
using procedure A at 0.25 mmol scale (29 mg, 51%). 1H NMR (500 MHz, CDCl3) δ 8.40 (d, J = 
5.4 Hz, 1H), 7.11 (s, 1H), 7.06 (d, J = 5.4 Hz, 1H), 2.55 (s, 3H), 2.11 (s, 3H), 1.89 (s, 6H), 1.83 – 
1.75 (m, 6H). 13C NMR (125.8 MHz, CDCl3) δ 160.1, 158.0, 148.9, 119.7, 117.4, 42.3, 36.5, 36.0, 
28.6, 24.5. IR (ATR): ν = 2901, 2848, 1602, 1550, 1449, 1397, 1296, 1038, 976, 837, 806 cm-1. 
HRMS (EI) m/z calc. for C16H21N (M+) 227.1674, found 227.1665. 
 
1-(3-((3r,5r,7r)-Adamantan-1-yl)phenyl)ethan-1-one (22): obtained as a colorless semi-solid 
with procedure A at 0.25 mmol scale (43 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 7.98 (s, 1H), 
7.77 (d, J = 7.6 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.41 (dd, J = 7.6, 7.8 Hz, 1H), 2.61 (s, 3H), 2.12 
(s, 3H), 1.94 (s, 6H), 1.82 – 1.75 (m, 6H).13C NMR (125.8 MHz, CDCl3) δ 193.8, 152.0, 137.2, 
130.1, 128.5, 126.0, 124.8, 43.2, 36.8, 36.5, 29.0, 26.9. IR (ATR): ν = 2900, 1847, 1682, 1426, 
1355, 1270, 963, 789, 695, 588 cm-1. HRMS (EI) m/z calc. for C18H23O (M+H) 255.1743, found 
255.1748. 
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1-(4-(Methylsulfonyl)phenyl)adamantane (23): obtained as a white amorphous solid with 
procedure A at 0.25 mmol scale (66 mg, 91%), mp = 167–170 ⁰C. 1H NMR (500 MHz, CDCl3) δ 
7.87 (d, J = 8.6 Hz, 2H), 7.55 (d, J = 8.6 Hz, 2H), 3.04 (s, 3H), 2.13 (s, 3H), 1.92 (s, 6H), 1.83 – 
1.72 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 157.8, 137.7, 127.4, 126.2, 44.7, 43.0, 37.0, 36.7, 
28.8. IR (ATR): ν = 2902, 2848, 1596, 1449, 1308, 1291, 1148, 1090, 954, 777, 558, 473 cm-1 
HRMS (EI) m/z calc. for C17H22O2S (M+) 290.1341, found 290.1341. 
 
(3r,5r,7r)-1-(4-Methoxyphenyl)adamantane (24) obtained as a pale yellow oil using procedure 
A at 0.25 mmol scale (12 mg, 20%). 1H NMR (500 MHz, DMSO-d6) δ 7.24 (d, J = 8.8 Hz, 2H), 
6.83 (d, J = 8.8 Hz, 2H), 3.69 (s, 3H), 2.01 (s, 3H), 1.80 (s, 6H), 1.70 (s, 6H). 13C NMR (125.8 
MHz, DMSO-d6) δ 157.4, 143.4, 125.9, 113.8, 55.3, 43.2, 36.6, 35.4, 28.7. HRMS (EI) m/z calc. 
for C17H16O (M+) 242.1671, found 242.1677. Spectroscopic data matches with previously reported 
data.35  
 
1-(4-(1-Phenylcyclopropyl)phenyl)ethan-1-one (25): obtained as a colorless oil with procedure 
A at 0.25 mmol scale (55 mg, 93% yield). 1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 8.4 Hz, 2H), 
7.34 – 7.19 (m, 7H), 2.57 (s, 3H), 1.43 – 1.32 (m, 4H). 13C NMR (125.8 MHz, CDCl3) δ 197.9, 
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151.9, 144.6, 135.0, 129.1, 128.6, 128.6, 128.0, 126.6, 30.2, 26.7, 17.2. IR (ATR): ν = 3143, 2950, 
1678, 1603, 1404, 1265, 957, 821, 760, 699, 598 cm-1. HRMS (EI) m/z calc. for C17H16O (M+) 
236.1201, found 236.1206. 
 
1-(4-(tert-Butyl)phenyl)ethan-1-one (26): obtained as a colorless oil with procedure B (80 mg, 
90%). 1H NMR (CDCl3, 500 MHz): δ 7.90 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 2.58 (s, 
3H), 1.36 (s, 9H). 13C NMR (CDCl3, 125.8 MHz): δ 198.0, 157.0, 134.8, 128.4, 125.7, 35.2, 31.2. 
Spectroscopic data matches with previously reported data.25 
 
4-(tert-Butyl)benzonitrile (27): obtained as a colorless oil with procedure B (71 mg, 89%); with 
C (66 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 
1.34 (s, 9H). 13C NMR (125.8 MHz, CDCl3) δ 156.6, 131.9, 126.1, 119.0, 109.2, 35.2, 30.8. HRMS 
(ESI) m/z calc. for C11H14N (M+H) 160.1126, found 160.1123. Spectroscopic data matches with 
previously reported data.25 
 
4-(tert-Butyl)benzaldehyde (28): obtained as a crystalline solid with procedure B (74 mg, 91%) (with <5% 
protodehalogenation). 1H NMR (CDCl3, 500 MHz): δ 9.98 (s, 1H), 7.83 – 7.80 (m, 2H), 7.56 – 7.54 (m, 
2H), 1.36 (s, 9H). 13C NMR (CDCl3, 125.8 MHz): δ 192.2, 158.6, 134.2, 129.8, 126.1, 125.6, 35.5, 31.2. 
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HRMS (ESI) m/z calc. for C11H15O (M+H) 163.1123, found 163.1129. Spectroscopic data matches with 
previously reported data.25  
 
1-(4-(tert-Butyl)phenyl)-2,2,2-trifluoroethan-1-one (29): obtained as a colorless oil with 
procedure B (109 mg, 96%). 1H NMR (CDCl3, 500 MHz): δ 8.02 (d, J = 8.0 Hz, 2H), 7.57 – 7.55 
(m, 2H), 1.37 (s, 9H). 13C NMR (125.8 MHz, CDCl3) δ 180.2 (q, J = 34.7 Hz), 160.0, 130.3 (q, J = 
2.5 Hz), 127.5, 126.3, 116.9 (q, J = 291.4 Hz), 35.58, 31.02. 19F NMR (CDCl3, 282.4 MHz): δ -
71.3. HRMS (ESI) m/z calc. for C12H16O (M+) 230.0918, found 230.0904. Spectroscopic data 
matches with previously reported data.36  
 
4-(tert-Butyl)-3-fluorobenzenesulfonyl fluoride (30): obtained as a colorless oil with procedure 
B (69 mg, 59%). 1H NMR (CDCl3, 500 MHz): δ 7.87 (m, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.33 (dd, 
J = 11.5, 1.5 Hz, 1H), 1.36 (s, 9H). 13C NMR (CDCl3, 125.8 MHz): δ 182.0, 163.8 (d, J = 7.5 Hz), 
160.7, 130.6, 122.1 (d, J = 3.3 Hz), 115.0 (d, J = 20.6 Hz), 36.0, 30.9. 19F NMR (CDCl3, 470.8 
MHz): δ 106.8(1), 106.8(3). IR (ATR): ν = 2970, 1607, 1571, 1420, 1215, 1203, 781, 644, 535 cm-
1.HRMS (EI) m/z calc. for C10H12F2O2S (M+) 234.0526, found 234.0534. 
 
1-(tert-Butyl)-4-(methylsulfonyl)benzene (32): obtained as a colorless oil with procedure B (88 mg, 83%),.  
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1H NMR (CDCl3, 500 MHz): δ 7.85 – 7.83 (m, 2H), 7.56 – 7.54 (m, 2H), 3.02 (s, 3H), 1.33 (s, 9H). 13C NMR 
(CDCl3, 125.8 MHz): δ 157.7, 137.8, 127.3, 126.5, 44.7, 35.4, 31.2. HRMS (ESI) m/z calc. for C11H16O2S 
(M+) 212.0871, found 212.0863. Spectroscopic data matches with previously reported data.25  
 
 
1-(tert-Butyl)-4-(methylsulfonyl)benzene (32): obtained as a colorless oil with procedure B (88 
mg, 83%), 1H NMR (CDCl3, 500 MHz): δ 7.85 – 7.83 (m, 2H), 7.56 – 7.54 (m, 2H), 3.02 (s, 3H), 
1.33 (s, 9H). 13C NMR (CDCl3, 125.8 MHz): δ 157.7, 137.8, 127.3, 126.5, 44.7, 35.4, 31.2. HRMS 
(ESI) m/z calc. for C11H16O2S (M+) 212.0871, found 212.0863. Spectroscopic data matches with 
previously reported data.10 
 
1-(tert-Butyl)-4-(trifluoromethyl)benzene (33) obtained as a pale yellow oil with procedure B (96 mg, 
95%). 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 1.35 (s, 9H). 13C 
NMR (CDCl3, 125.8 MHz): δ 155.3, 127.9 (q, J = 31.4 Hz), 125.8, 125.1 (q, J = 3.8 Hz), 124.5 (q, J = 271.8 
Hz), 35.1, 31.3 (residual ligand peaks, less than 5% at 27.5, 90.9, 201.6). 19F NMR (CDCl3, 282.4 MHz): δ 
62.3. HRMS (ESI) m/z calc. for C11H13F3 (M+) 202.0969, found 202.0958. Spectroscopic data matches with 
previously reported data.38  
 
4-(tert-Butyl)-N-methoxy-N-methylbenzamide (34) obtained as yellow oil with procedure B (43 mg, 39%). 
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1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 3.59 (s, 3H), 3.36 (s, 3H), 
1.34 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 169.9, 153.9, 131.0, 128.0, 124.9, 60.9 34.8, 33.9, 31.0. HRMS 
(ESI) m/z calc. for C13H20NO2 (M+H) 222.1494, found 222.1492. Spectroscopic data matches with 
previously reported data.38  
 
2-(tert-Butyl)benzofuran (35): obtained as a colorless oil with procedure C (46 mg, 53%).1H NMR (500 
MHz, CDCl3) δ 7.50 (d, J = 7.4 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.25 – 7.14 (m, 2H), 6.37 (s, 1H), 1.40 (s, 
9H). 13C NMR (126 MHz, CDCl3) δ 167.1, 154.5, 128.8, 123.0, 122.2, 120.2, 110.7, 98.8, 32.9, 28.8. 
Spectroscopic data matches with previously reported data.39  
 
1-(5-(tert-Butyl)thiophen-2-yl)ethan-1-one (36): obtained as a yellow oil with procedure B (60 mg, 66%). 
1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 3.9 Hz, 1H), 6.88 (d, J = 3.9 Hz, 1H), 2.52 (s, 3H), 1.41 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 190.6, 167.2, 141.2, 132.5, 122.8, 35.1, 32.1, 26.4. HRMS (ESI) m/z calc. 
for C10H15OS (M+H) 183.0844, found 183.0821. Spectroscopic data matches with previously reported data.40  
 
 
 
4-(4-Acetylphenyl)-4-methylpentan-2-one (39): obtained as a colorless oil with procedure B (73 
mg, 67%).1H NMR (CDCl3, 500 MHz): δ 7.93 – 7.91 (m, 2H), 7.47 – 7.44 (m, 2H), 2.82 (s, 2H), 
2.59 (s, 3H), 1.89 (s, 3H), 1.45 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 206.9, 197.6, 153.9, 
134.9, 128.3, 125.7, 56.2, 37.4, 31.6, 28.8, 26.4. IR (ATR): ν = 2964, 1715, 1678, 1605, 1406, 
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1356, 1269, 1014, 958, 596 cm-1. HRMS (ESI) m/z calc. for C14H18O2Na (M+Na) 241.1204, found 
241.1210. 
 
4-Methyl-4-(4-(trifluoromethyl)phenyl)pentan-2-one (40): obtained as a clear oil, procedure B 
(89 mg, 73%). 1H NMR (CDCl3, 500 MHz): δ 7.57 (d, J = 7.5 Hz, 2H), 7.47 (d, J = 7.5 Hz, 2H), 
2.81 (s, 2H), 1.91 (s, 3H), 1.45 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 206.8, 152.4 128.2, 125.8, 
125.1 (q, J =3.8 Hz), 124.1 (q, J = 275.5 Hz) 56.1, 37.2, 31.6, 28.3. 19F NMR (CDCl3, 470.8 MHz): 
δ -62.4. IR (ATR): ν = 2967, 1718, 1618, 1409, 1325, 1112, 1104, 1068, 1014, 838, 530 cm-1. 
HRMS (ESI) m/z calc. for C13H15OF3 (M+) 244.1075, found 244.1072. 
 
Methyl 4-(2-Methyl-4-oxopentan-2-yl)benzoate (41): obtained as a colorless oil with procedure B (93 mg, 
82%).  1H NMR (CDCl3, 500 MHz): δ 7.98 – 7.95 (m, 2H), 7.43 – 7.40 (m, 2H), 3.88 (s, 3H), 2.78 (s, 2H), 
1.84 (s, 3H), 1.42 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 207.3, 167.1, 153.9, 129.7, 128.0, 125.7, 56.6, 
52.1, 37.6, 31.8, 29.0. HRMS (ESI) m/z calc. for C14H19O3 (M+H) 235.1334, found 235.1340. Spectroscopic 
data matches with previously reported data.25  
 
4-(4-(1,3,4-Oxadiazol-2-yl)phenyl)-4-methylpentan-2-one (42): obtained as a yellow oil with 
procedure B (73 mg, 60%). 1H NMR (CDCl3, 500 MHz): δ 8.45 (s, 1H), 8.02 (d, J = 7.5 Hz, 2H), 
356 
7.51 (d, J = 7.5 Hz, 2H), 2.82 (s, 2H), 1.90 (s, 3H), 1.46 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 
207.1, 164.8, 153.0, 152.6, 127.2, 126.5, 121.3, 56.5, 37.6, 31.8, 29.0. IR (ATR): ν = 3250, 2965, 
1714, 1616, 1494, 1380, 1097, 954, 713, 640 cm-1. HRMS (ESI) m/z calc. for C14H17N2O2 (M+H) 
245.1290, found 245.1282. 
 
3-(2-Methyl-4-oxopentan-2-yl)benzaldehyde (43): obtained as a colorless oil with procedure C 
(62 mg, 61%). 1H NMR (CDCl3, 500 MHz): δ 10.02 (s, 1H), 7.88 (s, 1H), 7.72 – 7.70 (m, 1H), 7.66 
– 7.63 (m, 1H), 7.51 – 7.48 (m, 1H), 2.82 (s, 2H), 1.90 (s, 3H), 1.46 (s, 6H). 13C NMR (CDCl3, 
125.8 MHz): δ 207.1, 192.7, 149.8, 136.6, 132.0, 129.1, 128.1, 126.5, 56.4, 37.4, 31.9, 29.1. IR 
(ATR): ν = 2964, 1694, 1603, 1361, 1261, 1177, 1083, 801, 697 cm-1. HRMS (ESI) m/z calc. for 
C13H16O2 (M+) 204.1150, found 204.1149. 
 
4-(2-Methyl-4-oxopentan-2-yl)benzonitrile (44): obtained as a colorless oil with procedure C (73 mg, 
73%). 1H NMR (CDCl3, 500 MHz): δ 7.59 (d, J = 7.0 Hz, 2H), 7.45 (d, J = 7.0 Hz, 2H), 2.81 (s, 2H), 1.93 
(s, 3H), 1.42 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 206.6, 154.2, 132.2, 126.5, 119.1, 109.9, 56.1, 37.6, 
31.7, 29.0. HRMS (ESI) m/z calc. for C13H16NO (M+H) 202.1232, found 202.1240. Spectroscopic data 
matches with previously reported data.41  
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4-([1,1'-Biphenyl]-4-yl)-4-methylpentan-2-one (45): obtained as a viscous oil with procedure C 
(54 mg, 43%). 1H NMR (CDCl3, 500 MHz): δ 7.61 – 7.53 (m, 4H), 7.45 – 7.40 (m, 4H), 7.35 – 
7.31 (m, 1H), 2.79 (s, 2H), 1.86 (s, 3H), 1.47 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 208.1, 
147.5, 140.9, 138.9, 128.9, 127.3, 127.1(1), 127.0(8), 126.1, 57.0, 37.3, 32.0, 29.1. IR (ATR): ν = 
2962, 2927, 1715, 1702, 1487, 1356, 1161, 765, 697 cm-1. HRMS (ESI) m/z calc. for C18H20O (M+) 
252.1514, found 252.1521. 
 
4-(3,5-Dimethoxyphenyl)-4-methylpentan-2-one (46): obtained as a colorless oil with procedure 
B (40 mg, 34%). 1H NMR (CDCl3, 500 MHz): δ 6.52 (d, J = 2.0 Hz, 2H), 6.33 (d, J = 2.0 Hz, 1H), 
3.81 (s, 6H), 2.71 (s, 2H), 1.86 (s, 3H), 1.40 (s, 6H). 13C NMR (CDCl3, 125.8 MHz): δ 207.9, 160.6, 
150.9, 104.4, 97.1, 56.7, 55.1, 37.5, 31.7, 28.8. IR (ATR): ν = 2961, 1838, 1703, 1594, 1423, 1315, 
1203, 1154, 1052, 700 cm-1. HRMS (ESI) m/z calc. for C14H20O3Na (M+Na) 259.1310, found 
259.1313. 
 
3-(4-Acetylphenyl)-3-methylcyclohexan-1-one (48): obtained as a colorless oil with procedure C (97 mg, 
75%). 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 7.9 Hz, 2H), 7.41 (d, J = 7.9 Hz, 2H), 2.89 (d, J = 14.2 Hz, 
1H), 2.57 (s, 3H), 2.46 (d, J = 14.2 Hz, 1H), 2.37 – 2.13 (m, 3H), 2.00 – 1.83 (m, 2H), 1.63 (bs, 1H), 1.33 (s, 
3H).13C NMR (125.8 MHz, CDCl3) δ 210.9, 197.8, 153.0, 135.4, 128.8, 126.1, 53.0, 43.4, 40.8, 37.9, 29.9, 
26.7, 22.1. HRMS (ESI) m/z calc. for C15H19O2 (M+H) 231.1385, found 231.1372. Spectroscopic data 
matches with previously reported data.42 
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3-Methyl-3-(4-(methylsulfonyl)phenyl)cyclohexan-1-one (49): obtained as a colorless oil with 
procedure C (87 mg, 65%). 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.6 
Hz, 2H), 3.05 (s, 3H), 2.89 (d, J = 14.2 Hz, 1H), 2.50 (d, J = 14.2 Hz, 1H), 2.38 – 2.19 (m, 3H), 
1.97 (d, J = 12.6 Hz, 2H), 1.68 – 1.62 (m, 1H), 1.35 (s, 3H). 13C NMR (125.8 MHz, CDCl3) δ 210.2, 
153.7, 138.4, 127.6, 126.7, 52.6, 44.4, 43.3, 40.6, 37.6, 29.7, 21.9.  IR (ATR): ν = 2929, 1705, 
1596, 1305, 1146, 1094, 954, 727, 538 cm-1. HRMS (ESI) m/z calc. for C14H18O3S (M+) 266.0977, 
found 266.0987. 
  
4-(1-Methyl-3-oxocyclohexyl)benzaldehyde (50): obtained as a colorless oil with procedure C 
(63 mg, 58%). 1H NMR (500 MHz, CDCl3) δ 9.99 (s, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 
8.4 Hz, 2H), 2.90 (d, J = 14.1 Hz, 1H), 2.49 (d, J = 14.1 Hz, 1H), 2.38 – 2.18 (m, 3H), 2.02 – 1.85 
(m, 2H), 1.70 – 1.62 (m, 1H), 1.35 (s, 3H). 13C NMR (125.8 MHz, CDCl3) δ 210.5, 191.7, 154.4, 
134.6, 129.9, 126.3, 52.7, 43.4, 40.6, 37.7, 29.6, 21.9. IR (ATR): ν = 2936, 1701, 1608, 1226, 825 
cm-1. HRMS (ESI) m/z calc. for C14H16O2 (M+) 216.1150, found 216.1146. 
359 
 
3-(4-Acetylphenyl)-3-methylcyclopentan-1-one (51): obtained as a white semi-solid with 
procedure C (72 mg, 67%).1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 8.6 
Hz, 2H), 2.64 (d, J = 17.5 Hz, 1H), 2.59 (s, 3H), 2.54 – 2.28 (m, 5H), 1.40 (s, 3H). 13C NMR (125.8 
MHz, CDCl3) δ 217.8, 197.8, 154.1, 135.5, 128.9, 125.9, 52.0, 44.2, 36.7, 35.7, 29.3, 26.7. IR 
(ATR): ν = 2960, 1739, 1679, 1605, 1406, 1271, 1156, 958, 836, 601 cm-1. HRMS (ESI) m/z calc. 
for C14H16O2 (M+) 216.1150, found 216.1165. 
 
Ethyl 3-(4-Acetylphenyl)-3-methylbutanoate (52) obtained as a colorless oil with procedure C 
(62 mg, 50 %). 1H NMR (500 MHz, CDCl3) δ 7.91 (dd, J = 6.7, 1.8 Hz, 2H), 7.46 (dd, J = 6.7, 1.8 
Hz, 2H), 3.97 (q, J = 7.1 Hz, 2H), 2.64 (s, 2H), 2.58 (s, 3H), 1.47 (s, 6H), 1.08 (t, J = 7.1 Hz, 3H). 
13C NMR (125.8 MHz, CDCl3) δ 198.0, 171.3, 154.0, 135.1, 128.4, 126.0, 60.2, 48.2, 37.6, 29.0, 
26.7, 14.2. IR (ATR): ν = 2971, 1730, 1682, 1606, 1406, 1366, 1270, 1034, 837 cm-1. HRMS (EI) 
m/z calc. for C15H20O3 (M+) 248.1412, found 248.1416. 
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Ethyl 2-(4-(4-Acetylphenyl)tetrahydro-2H-pyran-4-yl)acetate (53) obtained as a colorless oil 
with procedure C (60 mg, 41%). 1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8.5 Hz, 2H), 7.42 (d, J 
= 8.5 Hz, 2H), 3.89 – 3.76 (m, 4H), 3.66 – 3.48 (m, 2H), 2.65 (s, 2H), 2.59 (s, 3H), 2.34 – 2.22 (m, 
2H), 2.12 – 1.98 (m, 2H), 0.98 (t, J = 7.1 Hz, 3H). 13C NMR (125.8 MHz, CDCl3) δ 197.9, 170.6, 
150.0, 135.5, 128.6, 127.1, 64.2, 60.3, 46.9, 39.0, 36.2, 26.8, 14.1. IR (ATR): ν = 2956, 1727, 1682, 
1605, 1407, 1358, 1114, 1030, 831 cm-1. HRMS (EI) m/z calc. for C17H22O4 (M+) 290.1518, found 
290.1537. 
 
1-(4-(2-Methyl-1-phenylpropan-2-yl)phenyl)ethan-1-one (54) obtained as a colorless oil using 
procedure C (68 mg 54%). 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 
Hz, 2H), 7.15 – 7.10 (m, 3H), 6.84 – 6.72 (m, 2H), 2.89 (s, 2H), 2.60 (s, 3H), 1.35 (s, 6H). 13C 
NMR (125.8 MHz, CDCl3) δ 197.9, 154.6, 138.1, 134.7, 130.2, 128.0, 127.5, 126.4, 126.0, 50.7, 
39.2, 28.0, 26.5. IR (ATR): ν = 3028, 2966, 2926, 1682, 1605, 1357, 1269, 1015, 838, 702 cm-1. 
HRMS (EI) m/z calc. for C18H20O (M+) 252.1514, found 252.1529. 
 
Methyl 4-(4-Acetylphenyl)-4-methylpentanoate (55) obtained as a colorless oil with procedure 
C (76 mg, 61 %). 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.3 Hz, 2H), 
3.60 (s, 3H), 2.60 (s, 3H), 2.18 – 1.92 (m, 4H), 1.35 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 198.0, 
174.3, 154.0, 135.1, 128.6, 126.2, 51.7, 38.8, 37.9, 30.0, 28.7, 26.7. IR (ATR): ν = 2963, 1736, 
361 
1682, 1606, 1566, 1435, 1357, 1269, 1118, 958, 601 cm-1. HRMS (EI) m/z calc. for C15H20O3 (M+) 
248.1412, found 248.1413. 
 
5-(4-Acetylphenyl)-5-methylhexan-2-one (56) obtained as a colorless oil with procedure C (40 
mg, 34%). 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 2.60 
(s, 3H), 2.16 (t, J = 8.0 Hz, 2H), 2.04 (s, 3H), 1.95 (t, J = 8.0 Hz, 2H), 1.34 (s, 6H). 13C NMR (125.8 
MHz, CDCl3) δ 208.5, 197.7, 154.0, 134.8, 128.3, 126.0, 39.3, 37.5, 37.2, 29.8, 28.6, 26.4. IR 
(ATR): ν = 2964, 1713, 1682, 1606, 1271, 838, 640, 556 cm-1. HRMS (EI) m/z calc. for C15H20O2 
(M+) 232.1463, found 232.1460. 
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Appendix A7. 1H, 13C, 11B, and 19F NMR Spectra Relevant to Chapter 6 
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Figure A7.1. 1H NMR (CDCl3, 500 MHz) of 4-(adamantan-1-yl)benzonitrile (19)  
Figure A7.2. 13C NMR (CDCl3, 125.8 MHz) of 4-(adamantan-1-yl)benzonitrile (19) 
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Figure A7.3. 1H NMR (CDCl3, 500 MHz) of 1-(4-((3r,5r,7r)-Adamantan-1-yl)phenyl)ethan-1-one (20) 
Figure A7.4. 13C NMR (CDCl3, 125.8 MHz) of 1-(4-((3r,5r,7r)-Adamantan-1-yl)phenyl)ethan-1-one 
(20) 
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Figure A7.5. 1H NMR (CDCl3, 500 MHz) spectrum of  4-((3r,5r,7r)-adamantan-1-yl)-2-
methylpyridine (21)  
Figure A7.6. 13C NMR (CDCl3, 125.8 MHz) spectrum of  4-((3r,5r,7r)-adamantan-1-yl)-2-
methylpyridine (21) 
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Figure A7.7. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(3-((3r,5r,7r)-Adamantan-1-yl)phenyl)ethan-
1-one (22)  
Figure A7.8. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(3-((3r,5r,7r)-Adamantan-1-
yl)phenyl)ethan-1-one (22) 
370 
Figure A7.9. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(4-(methylsulfonyl)phenyl)adamantane (23)  
Figure A7.10. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(4-(methylsulfonyl)phenyl)adamantane 
(23) 
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Figure A7.11. 1H NMR (CDCl3, 500 MHz) spectrum of(3r,5r,7r)-1-(4-methoxyphenyl)adamantane 
(24)  
Figure A7.12. 13C NMR (CDCl3, 125.8 MHz) spectrum of (3r,5r,7r)-1-(4-
methoxyphenyl)adamantane (24) 
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Figure A7.13. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(4-(1-phenylcyclopropyl)phenyl)ethan-1-
one (25)  
Figure A7.14. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(4-(1-phenylcyclopropyl)phenyl)ethan-
1-one (25) 
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Figure A7.15. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(4-(tert-Butyl)phenyl)ethan-1-one (26)  
Figure A7.16. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(4-(tert-Butyl)phenyl)ethan-1-one (26) 
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Figure A7.17. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(tert-Butyl)benzonitrile (27)  
Figure A7.18. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(tert-Butyl)benzonitrile (27) 
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Figure A7.19. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(tert-Butyl)benzaldehyde (28)  
Figure A7.20. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(tert-Butyl)benzaldehyde (28) 
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Figure A7.21. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(4-(tert-butyl)phenyl)-2,2,2-trifluoroethan-
1-one (29)  
Figure A7.22. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(4-(tert-butyl)phenyl)-2,2,2-
trifluoroethan-1-one (29) 
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Figure A7.23. 19F NMR (CDCl3, 470.8 MHz) spectrum of 1-(4-(tert-butyl)phenyl)-2,2,2-
trifluoroethan-1-one (29)  
Figure A7.24. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(tert-butyl)-3-fluorobenzenesulfonyl 
fluoride (30) 
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Figure A7.25. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(tert-butyl)-3-fluorobenzenesulfonyl 
fluoride (30) 
Figure A7.26. 19F NMR (CDCl3, 470.8 MHz) spectrum of of 4-(tert-butyl)-3-fluorobenzenesulfonyl 
fluoride (30) 
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Figure A7.27. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(tert-Butyl)benzenesulfonamide (31)  
Figure A7.28. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(tert-Butyl)benzenesulfonamide (31) 
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Figure A7.29. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(tert-Butyl)-4-(methylsulfonyl)benzene 
(32)  
Figure A7.30. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(tert-Butyl)-4-(methylsulfonyl)benzene 
(32) 
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Figure A7.31. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(tert-butyl)-4-(trifluoromethyl)benzene 
(33)  
Figure A7.32. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(tert-butyl)-4-(trifluoromethyl)benzene 
(33) 
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Figure A7.33. 19F NMR (CDCl3, 125.8 MHz) spectrum of 1-(tert-butyl)-4-(trifluoromethyl)benzene 
(33) 
Figure A7.34. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(tert-butyl)-N-methoxy-N-
methylbenzamide (34)  
383 
Figure A7.35. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(tert-butyl)-N-methoxy-N-
methylbenzamide (34) 
Figure A7.36. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-Butyl)benzofuran (35)  
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Figure A7.37. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-Butyl)benzofuran (35) 
Figure A7.38. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(5-(tert-butyl)thiophen-2-yl)ethan-1-one 
(36)  
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Figure A7.39. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(5-(tert-butyl)thiophen-2-yl)ethan-1-one 
(36) 
Figure A7.40. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(4-Acetylphenyl)-4-methylpentan-2-one 
(39)  
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Figure A7.41. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(4-Acetylphenyl)-4-methylpentan-2-one 
(39) 
Figure A7.42. 1H NMR (CDCl3, 500 MHz) spectrum of 4-Methyl-4-(4-
(trifluoromethyl)phenyl)pentan-2-one (40)  
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Figure A7.43. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-Methyl-4-(4-
(trifluoromethyl)phenyl)pentan-2-one (40) 
Figure A7.44. 19F NMR (CDCl3, 470.8 MHz) spectrum of 4-Methyl-4-(4-
(trifluoromethyl)phenyl)pentan-2-one (40) 
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Figure A7.45. 1H NMR (CDCl3, 500 MHz) spectrum of Methyl 4-(2-methyl-4-oxopentan-2-
yl)benzoate (41)  
Figure A7.46. 13C NMR (CDCl3, 125.8 MHz) spectrum of Methyl 4-(2-methyl-4-oxopentan-2-
yl)benzoate (41) 
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Figure A7.47. 1H NMR (CDCl3, 500 MHz) spectrum of  4-(4-(1,3,4-Oxadiazol-2-yl)phenyl)-4-
methylpentan-2-one (42) 
Figure A7.48. 13C NMR (CDCl3, 125.8 MHz) spectrum of  4-(4-(1,3,4-Oxadiazol-2-yl)phenyl)-4-
methylpentan-2-one (42) 
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Figure A7.49. 1H NMR (CDCl3, 500 MHz) spectrum of 3-(2-Methyl-4-oxopentan-2-yl)benzaldehyde 
(43)  
Figure A7.50. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-(2-Methyl-4-oxopentan-2-
yl)benzaldehyde (43) 
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Figure A7.51. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(2-Methyl-4-oxopentan-2-yl)benzonitrile 
(44)  
Figure A7.52. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(2-Methyl-4-oxopentan-2-
yl)benzonitrile (44) 
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Figure A7.53. 1H NMR (CDCl3, 500 MHz) spectrum of 4-([1,1'-Biphenyl]-4-yl)-4-methylpentan-2-
one (45)  
Figure A7.54. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-([1,1'-Biphenyl]-4-yl)-4-methylpentan-
2-one (45) 
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Figure A7.55. 1H NMR (CDCl3, 500 MHz) spectrum of  4-(3,5-Dimethoxyphenyl)-4-methylpentan-
2-one (46)  
Figure A7.56. 13C NMR (CDCl3, 125.8 MHz) spectrum of  4-(3,5-Dimethoxyphenyl)-4-
methylpentan-2-one (46) 
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Figure A7.57. 1H NMR (CDCl3, 500 MHz) spectrum of 3-(4-acetylphenyl)-3-methylcyclohexan-1-
one (48) 
Figure A7.58. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-(4-acetylphenyl)-3-methylcyclohexan-1-
one (48) 
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Figure A7.59. 1H NMR (CDCl3, 500 MHz) spectrum of 3-methyl-3-(4-
(methylsulfonyl)phenyl)cyclohexan-1-one (49) 
Figure A7.60. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-methyl-3-(4-
(methylsulfonyl)phenyl)cyclohexan-1-one (49) 
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Figure A7.61. 1H NMR (CDCl3, 500 MHz) spectrum of 4-(1-Methyl-3-oxocyclohexyl)benzaldehyde 
(50) 
Figure A7.62. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-(1-Methyl-3-
oxocyclohexyl)benzaldehyde (50) 
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Figure A7.63. 1H NMR (CDCl3, 500 MHz) spectrum of 3-(4-Acetylphenyl)-3-methylcyclopentan-1-
one (51) 
Figure A7.64. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-(4-Acetylphenyl)-3-methylcyclopentan-
1-one (51) 
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Figure A7.65. 1H NMR (CDCl3, 500 MHz) spectrum of ethyl 3-(4-acetylphenyl)-3-methylbutanoate 
(52) 
Figure A7.66. 13C NMR (CDCl3, 125.8 MHz) spectrum of ethyl 3-(4-acetylphenyl)-3-
methylbutanoate (52) 
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Figure A7.67. 1H NMR (CDCl3, 500 MHz) spectrum of ethyl 2-(4-(4-acetylphenyl)tetrahydro-2H-
pyran-4-yl)acetate (53) 
Figure A7.68. 13C NMR (CDCl3, 125.8 MHz) spectrum of ethyl 2-(4-(4-acetylphenyl)tetrahydro-2H-
pyran-4-yl)acetate (53) 
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Figure A7.69. 1H NMR (CDCl3, 500 MHz) spectrum of XX (54) 
Figure A7.70. 13C NMR (CDCl3, 125.8 MHz) spectrum of XX (54) 
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Figure A7.71. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 4-(4-acetylphenyl)-4-
methylpentanoate (55) 
Figure A7.72. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 4-(4-acetylphenyl)-4-
methylpentanoate (55) 
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Figure A7.73. 1H NMR (CDCl3, 500 MHz) spectrum of XX (56) 
Figure A7.74. 13C NMR (CDCl3, 125.8 MHz) spectrum of XX (56) 
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Figure A7.75. 1H NMR (acetone-d6, 500 MHz) of potassium (4-(2-ethoxy-2-oxoethyl)tetrahydro-2H-
pyran-4-yl)trifluoroborates (S1) 
Figure A7.76. 13C NMR (acetone-d6, 500 MHz) of potassium (4-(2-ethoxy-2-oxoethyl)tetrahydro-2H-
pyran-4-yl)trifluoroborates (S1) 
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Figure A7.77. 11B NMR (acetone-d6, 500 MHz) of potassium (4-(2-ethoxy-2-oxoethyl)tetrahydro-2H-
pyran-4-yl)trifluoroborates (S1) 
Figure A7.78. 19F NMR (acetone-d6, 500 MHz) of potassium (4-(2-ethoxy-2-oxoethyl)tetrahydro-2H-
pyran-4-yl)trifluoroborates (S1) 
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Figure A7.79. 1H NMR (acetone-d6, 500 MHz) of potassium trifluoro(5-methoxy-2-methyl-5-oxopentan-
2-yl)borate (S2) 
Figure A7.80. 13C NMR (acetone-d6, 500 MHz) of potassium trifluoro(5-methoxy-2-methyl-5-
oxopentan-2-yl)borate (S2) 
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Figure A7.81. 11B NMR (acetone-d6, 500 MHz) of potassium trifluoro(5-methoxy-2-methyl-5-
oxopentan-2-yl)borate (S2) 
Figure A7.82. 19F NMR (acetone-d6, 500 MHz) of potassium trifluoro(5-methoxy-2-methyl-5-
oxopentan-2-yl)borate (S2) 
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Figure A7.83. 1H NMR (acetone-d6, 500 MHz) of potassium trifluoro(2-methyl-5-oxohexan-2-yl)borate 
(S3) 
Figure A7.84. 13C NMR (acetone-d6, 500 MHz) of potassium trifluoro(2-methyl-5-oxohexan-2-yl)borate 
(S3) 
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Figure A7.85. 11B NMR (acetone-d6, 500 MHz) of potassium trifluoro(2-methyl-5-oxohexan-2-yl)borate 
(S3) 
Figure A7.86. 19F NMR (acetone-d6, 500 MHz) of potassium trifluoro(2-methyl-5-oxohexan-2-yl)borate 
(S3) 
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Figure A7.87. 1H NMR (CD3CN, 500 MHz) of potassium trifluoro(2-methyl-5-morpholino-5-
oxopentan-2-yl)borate (S4) 
Figure A7.88. 13C NMR (CD3CN, 500 MHz) of potassium trifluoro(2-methyl-5-morpholino-5-
oxopentan-2-yl)borate (S4) 
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Figure A7.89. 11B NMR (CD3CN, 500 MHz) of potassium trifluoro(2-methyl-5-morpholino-5-
oxopentan-2-yl)borate (S4) 
Figure A7.90. 19F NMR (CD3CN, 500 MHz) of potassium trifluoro(2-methyl-5-morpholino-5-
oxopentan-2-yl)borate (S4) 
411 
 
Chapter 7. Hypervalent Silicates as Alternative Radical Precursors  
7.1 Introduction 
 
Having demonstrated the use of alkyltrifluoroborates extending from benzylic systems all 
the way to the highly congested tertiary variants, we became interested in developing a palette of 
potential radical feedstocks to complement the existing protocols. In much the same way as cross-
coupling benefits from a diverse collection of organometallic nucleophiles (Negishi, Kumada, 
Suzuki, etc), in the single electron transmetalation paradigm, no one particular radical source is 
best in all cases. In certain situations, an organoboron reagent may be easier to access, more 
reactive/selective, or inexpensive. In others, a competing reagent may be more suitable.   
For alkyltrifluoroborates, a number of notable shortcomings currently exist. First, in the SET 
cross-coupling reaction, an expensive Ir-based photocatalyst is required because of the high 
oxidation potentials of the boron reagents, and consequently primary alkyl radicals are inaccessible 
because the trifluoroborate precursor (E0  ~ +1.90 V vs SCE)1 is not readily oxidized by 
photoexcited Ir catalysts (E0 = +1.32 V vs SCE).2 Second, the initial oxidation of the 
alkyltrifluoroborates releases BF3, which is corrosive on scale and has been demonstrated to be an 
inhibitor of reactivity, thereby requiring addition of excess base. Finally, alkyltrifluoroborates are 
often minimally soluble in many organic solvents, thus obstructing the transmission of light in 
photoredox reactions.i 
                                                     
i Reproduced in part from J. Am. Chem. Soc., 2016, 138, 475. 
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In our quest to find new coupling partners able to address these issues, we considered that 
the alkylborate anion present in trifluoroborates has striking similarities to hypercoordinate silicate 
complexes that are often invoked as intermediates in Hiyama type cross-couplings.3 Therefore, we 
wondered if this hypercoordinate complex (Figure 7.1) or some stable isolable complex thereof 
could be generated and oxidized in the presence of an appropriate photocatalyst.  
 
v 
Figure 7.1. Similarities between organoborates and silicate intermediates 
 
Examination of the literature identified a number of stable, isolable hypercoordinate silicon 
complexes that had been reported going back as early as the 1960s.4,5 Follow-up investigations into 
these complexes were largely focused on their structural features, particularly the well-defined 
square pyramidal structure adopted by the bis-catecholatosilicate structures. It was not until the mid 
1990s that these structures were used in productive synthetic chemistry. DeShong was the first to 
employ the aryl structures in aryl-aryl cross-couplings.6 
Most excitingly, in our quest to identify new silicate coupling partners, we noted the seminal 
studies of Nishigaishi et al. on the allylation of nitrile-containing arenes using photoexcited, 
hypercoordinate tetramethylammonium allylbis(catecholato)silicate. These investigations were 
suggestive that these complexes were a ready and easily oxidized source of alkyl radicals.7 Most 
notably, these bis(catecholato)silicates appeared amenable to photoredox/Ni dual catalysis and 
were intriguing because the benign byproducts generated from their fragmentation 
(biscatecholsilane and tetramethylammonium bromide) would obviate the need for basic additives 
required in all heretofore reported SET mediated cross-couplings. 
413 
During the course of our investigations into these hypercoordinate reagents, the groups of 
Fensterbank and Goddard described the use of related potassium organobis(catecholato)silicates as 
alkyl radical precursors.8 This contribution demonstrated that, as expected, both primary and 
secondary alkyl radicals could be generated from the corresponding pentacoordinate silicon species 
and employed in a number of transformations. In addition, six such silicates were used in dual 
photoredox/nickel-catalyzed cross-coupling with a single aryl halide. Unfortunately, this brief 
study did not fully outline the advantages or potential of such synthons. For example, in these 
protocols, an expensive Ir catalyst was utilized, whereas the oxidation potentials of the silicates (E0 
= +0.75 V vs SCE for 1º alkylsilicate 5, Figure 7.2)9 lie in the range of the less expensive, 
photoexcited [Ru(bpy)3](PF6)2 catalyst (E0 = +0.77 V vs SCE) (bpy: 2,2'-bipyridine).
10 Secondly, 
the use of potassium as a counterion forced the authors to employ the cost-prohibitive 18–crown–
6 as both stabilizer and solubilizer,11,12 making the corresponding silicates unusable for practical 
large scale/industrial purposes. Given these restrictions, we hoped to improve the synthesis and 
application of these silicates in photoredox cross-coupling protocols. 
7.2 Results and Discussion 
 
Prior to the publication of the Fensterbank/Goddard study, we had begun our own 
investigation with the synthesis of alkylbis(catecholato)silicate derivatives having a 
triethylammonium cation, using modified literature reaction conditions.5 Reaction of a 
substoichiometric amount of catechol with benzyltrimethoxysilane in refluxing THF using 
triethylamine as base afforded the corresponding silicate 1 in 92% yield (cation = Et3NH, Figure 
7.2). This economical ($90/Kg of catechol, $80/Kg of triethylamine) and straightforward, 
multigram scale reaction could be extended to secondary (2, 3) and other primary (4-6, 11, 13) 
alkyltrimethoxysilanes without modification of the reaction conditions. In some cases, an 
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improvement of the yield was observed by using the higher boiling dioxane instead of THF (7-10). 
Interestingly, we noticed a significant decrease in the solubility of the corresponding silicates (3, 
8-10, 12) in ethereal solvents when replacing triethylamine with diisopropylamine as base, allowing 
the isolation of the latter salts as fine, fluffy powders (R1 = H, R2 = i–Pr). In the case of the primary 
alkylamine 14, the amine group serves as both base and counterion. All these silicate derivatives 
are non-hygroscopic, colorless, bench stable powders that can be stored at room temperature under 
air without noticeable decomposition even after 5 months (see Experimental). 
 
 
 
Figure 7.2. Preparation of Primary and Secondary Ammonium Alkylbis(catecholato)silicates. 
 
With a suitable library of substrates in hand, attention was turned to the development of a 
practical photoredox/Ni dual catalyzed cross-coupling using aryl bromide electrophiles. Screening 
of the reaction conditions using 4-bromobenzonitrile and triethylammonium 
cyclohexylbis(catecholato)silicate 2 indicated that the catalyst system previously established for 
the cross-coupling of secondary alkyltrifluoroborate13 {5.0 mol % of [NiCl2(dme)], 5.0 mol % of 
415 
4,4'-di-tert-butyl-2,2'-bipyridine (dtbbpy), and 2.0 mol % of [Ir(dFCF3ppy)2(bpy)]PF6, using a 26 
W compact fluorescent lightbulb (CFL)} could be applied almost directly to 
alkylbis(catecholato)silicates [dFCF3ppy: 2-(2,4-difluorophenyl)-5-(trifluoromethyl)pyridine]. 
However, the use of DMF as solvent at higher concentration (0.1 M instead of 0.05 M) led to 
significantly improved conversions (see Experimental). Whereas additives have proven to be 
crucial in previously reported photoredox/Ni and conventional cross-couplings with 
organotrifluoroborates, their use here proved detrimental. Various photocatalysts were assessed to 
replace the expensive Ir photocatalysts, and, as anticipated from the low oxidation potential of 
organobis(catecholato)silicate,9 the [Ru(bpy)3](PF6)2 could be substituted without any loss in yield 
(see Supporting Information). 
 
 
Figure 7.3. Photoredox Cross-coupling of Ammonium Alkylbis(catecholato)silicates with 
Bromoanisole. 
 
Using these reaction conditions with the electron rich 4-bromoanisole and 1, coupled 
product 15 was obtained in 77% isolated yield (Figure 7.3). The study was extended to all other 
silicates synthesized, affording coupled products in good to excellent yield with both 2º and 1º 
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alkylsilicates. These reactions, which involve highly reactive 1º and 2º alkyl radicals, proved to be 
applicable in sterically demanding systems (17) and tolerant of reactive functional groups such as 
esters (27) and lactams/ureas (23). Remarkably, substrates containing coordinating groups such as 
pyridine (25) and primary alkylamines (28) coupled in good yields. Furthermore, to the best of our 
knowledge, substrate 14 represents the first successful example of an alkylmetallic cross-coupling 
partner bearing a free primary alkylamine functional group. As the introduction of primary 
alkylamines is a common method for increasing solubility and/or biocompatibility of lead 
candidates in medicinal chemistry, this tolerance is highly relevant for diversification efforts in 
drug discovery.14 Also noteworthy, very few examples of the cross-coupling of free secondary 
alkylamine-containing nucleophiles have been reported in the literature.15 Of further importance, 
the use of the less highly oxidizing Ru photocatalyst allows the incorporation of oxidizable amines 
such as that found in aniline 24 (E0 = +0.76 V vs SCE).16 Unfortunately, silicates 4, 6, and 8 failed 
to give any cross-coupling product. We suspect this is likely because of the high oxidation 
potentials and greater reactivity of the generated radicals, favoring C-H abstraction and aryl 
addition pathways. 
 
Figure 7.4. Aryl- and Heteroaryl Bromide Scope with Primary Amine-Containing Silicate 14. 
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To assess the limitations of the primary amine coupling reaction, silicate 14 was reacted 
with various aryl- and heteroaryl electrophiles using unmodified reaction conditions (Figure 7.4). 
Electron-rich (33, 34), electron-poor (29–32), and ortho-substituted (30) cross-coupled products 
were accessed in good to excellent yield. In particular, the presence of further protic functional 
groups such as those found in acetanilide 33, benzyl alcohol 34, and unprotected pyrazole 35 and 
indole 37 did not affect the reaction, which is surprising because these substrates have proven 
recalcitrant coupling partners under previous cross-coupling protocols.13,17 Nitrogen-containing 
heterocycles (35–38), which represent important substructures in pharmaceutical libraries,18 were 
well tolerated and afforded the corresponding coupling products in reasonable (38) to excellent 
(36) yields. Although poorer reactivity was observed in accessing 38, the remaining mass balance 
could be accounted for as unreacted aryl halide after 16 h. To confirm the scalability of this primary 
alkylamine cross-coupling, a gram-scale reaction was performed and afforded coupled product 32 
in 97% isolated yield after only 4 h. This increase in reaction rate when compared to that of 
organotrifluoroborates was achieved through the use of high-intensity, broadband white LEDs, 
accompanied with a slight increase in reaction temperature (36 ºC, see Experimental). 
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Figure 7.5. Aryl- and Heteroaryl Bromide Scope with both Primary and Secondary Ammonium 
Alkylbis(catecholato)silicate. 
 
The scope of the reaction was next extended to sterically encumbered 2º alkyl- (3) as well 
as 1º alkylsilicates bearing acetoxy (13) or secondary alkylamine (10) functional groups (Figure 
7.5). The use of 2º alkylsilicon reagents in cross-coupling is perhaps unremarkable in light of our 
previous success with 2º alkylboron reagents, but it still represents the first time that unactivated 
secondary Hiyama-type reagents19–21 have been widely employed in cross-coupling.22 Furthermore, 
the far lower oxidation potentials and/or higher solubility of these reagents in organic media leads 
in many cases to reactions that are complete in dramatically shorter time-frames (as short as 2 h for 
pyridyl derivative 41) than their trifluoroborate or carboxylic acid counterparts,23,24 and even those 
previously developed by Fensterbank/Goddard (24 h).8  
A wide variety of aryl- and heteroaryl bromides were assessed to highlight the broad 
compatibility of these extremely mild cross-coupling conditions. Coupled products bearing 
electron-withdrawing (49, 51, 52) or electron-donating groups (44, 46) were easily accessed, as 
well as more sterically encumbered systems (44) or those bearing a potential competitive site for 
oxidative addition (51). Nitrogen heterocycles (39, 41, 43, 48, 53) could be acquired in the process 
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in good to excellent yield (even for the challenging aminopyridine 43). Oxygen- (47) and sulfur- 
(42) containing heteroaryls could be procured as well. Furthermore, target structures bearing protic 
groups (43, 45, 46, 48, 50) were readily synthesized. Overall, the success of ammonium 
organobis(catechol)silicates makes them partners of choice for metal-catalyzed carbon-carbon 
bond-forming reactions, as both their functional group tolerance and reactivity outperform 
previously reported photoredox/Ni dual catalysis methods and conventional Hiyama/Suzuki cross-
couplings.3  
As a final showcase of these hypercoordinate silicates, two successive, photoredox/Ni dual 
cross-couplings were carried out with dibrominated arenes 54 and 56 (Figure 7.6). In both cases, 
an initial cross-coupling with a 2º alkyltrifluoroborate was first performed under conditions 
previously optimized in our laboratory using the iridium photoredox catalyst. After filtration of the 
resulting salts in air, concentration, solvent switch, and addition of a primary silicate 13 (1 for aryl 
56), a second cross-coupling was then completed to provide functionalized arenes 55 and 57. Most 
notably, these transformations require no intermediate isolation and can be performed without the 
further addition of either the photoredox or cross-coupling catalyst, underlining the robustness of 
both dual catalysis systems. This chemistry has the potential to be applied to successive one-pot 
cross-coupling operations in either batch or photo-flow systems. Furthermore, given the reports by 
Burke and co-workers on successive MIDA boronate cross-couplings25 and our own on 
mechanistically orthogonal boron couplings,26 innumerable opportunities exist for rapid 
complexity-building operations without isolation of intermediates. 
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Figure 7.6 Successive Photoredox/Ni Dual Cross Couplings Using Organotrifluoroborate then 
Organobis(catecholato)silicate Nucleophiles. 
 
7.3 Conclusion 
 
In summary, we have developed a synthetic procedure for the photoredox cross-coupling of 
ammonium organobis(catecholato)silicates that is operationally simple and does not require the use 
of expensive crown ether additives. These silicates represent ideal radical precursors because of 
their low oxidation potentials, excellent physical properties, and the innocuous byproducts formed 
upon oxidation. Further, these silicates have been demonstrated for the first time as 1º and 2º alkyl 
radical precursors in the dual catalytic Ru/Ni cross-coupling. The conditions developed herein are 
general, functional group tolerant and, when dealing with protic functional groups, unmatched by 
competing alkyltrifluoroborate13 and carboxylic acid protocols.24,23 
Most remarkably, the use of these reagents allows the selective coupling of an alkylmetallic 
reagent in the presence of primary amines for the first time – representing an expansion into new 
reactivity space. Whereas traditional two-electron cross-couplings of alkylmetallics feature 
strongly basic reagents and/or additives that favor amine deprotonation and coordination,32 the use 
of a base-free, odd-electron transmetalation manifold inhibits competitive metal-catalyzed 
amination. Considering the absence of a single-step method for the introduction of primary 
alkylamines onto (hetero)aryl halide cores, aminoalkylsilicates have the potential to improve the 
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late stage introduction of primary amines into bioactive compounds. Taken together, these findings 
introduce alkylsilicates as key players in the photoredox/Ni dual catalytic cross-coupling regime. 
 
7.4 Experimental 
 
General considerations 
 
 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless otherwise 
noted. DMF (99.9%, extra dry) was used as received. Triethylamine and diisopropylamine were 
distilled prior to use and stored over activated molecular sieves. Catechol (99%) was sublimed prior 
to use. [NiCl2(dme)] was purchased from commercial sources and all other reagents were purchased 
commercially and used as received, unless otherwise noted. Column chromatography was 
performed by Combiflash(R) using RediSep Rf Gold Normal-Phase Silica(R) columns. Photoredox 
reactions were irradiated with a standard 26 W compact fluorescent light bulb and the temperature 
was controlled using an external fan. Melting points (°C) are uncorrected. Mass spectra (ESI-TOF) 
were recorded using CH2Cl2, MeCN or MeOH as the solvent. NMR spectra were recorded with 
Bruker FT spectrometers. 1H (500.4 MHz) and 13C {1H} (125.8 MHz) NMR chemical shifts are 
reported relative to internal TMS (δ = 0.00 ppm) or to residual protiated solvent, and 19F {1H} NMR 
(470.8 MHz) chemical shifts were referenced to external CFCl3 (0.0 ppm). Data are presented as 
follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, sept = 
septet, m = multiplet, br = broad), coupling constant J (Hz) and integration. 
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Procedure for the synthesis of alkyltrimethoxysilanes from alkyltrichlorosilanes 
 
 
To an oven-dried double neck round bottom flask equipped with an inert gas inlet, an addition 
funnel and a stir bar were successively introduced organotrichlorosilane (1 equiv) and THF (0.3 
M). The resulting solution was cooled to –20 °C, then MeOH (4 equiv) and pyridine (4 equiv) were 
placed into the addition funnel and added dropwise to the trichlorosilane solution under vigorous 
stirring, resulting in an immediate precipitation of pyridinium chloride salt. After addition, the 
reaction mixture was allowed to reach rt for 1 h before being diluted with chilled H2O (same volume 
as THF) and extracted with Et2O (3 × THF volume). The combined organic extracts were dried 
(MgSO4) and concentrated under vacuum, affording a colorless oil. The latter was finally distilled 
under reduced pressure to obtain the product in pure form. 
 
Procedure for the synthesis of alkylbis(catechol)silicates 
 
 
Catechol (1.95 equiv) was introduced into a microwave vial with a stirring bar. The vial was sealed 
with a Teflon-coated septum cap then purged with N2 and evacuated four times. THF or 1,4–
dioxane (0.5 M) and the corresponding amine (1.2 equiv) were introduced, and the resulting light 
pink solution was stirred at rt for 15 min before addition of alkyltrimethoxysilane derivative (1 
equiv) (note: no amine base was needed for the synthesis of 14). The reaction mixture was refluxed 
for 16 h, then an aliquot was taken and analyzed by 1H NMR. In the case of an incomplete reaction, 
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the vial was cooled to rt and the reaction mixture concentrated to a glue (to remove MeOH formed 
during the reaction) before the amine (0.5 equiv) and solvent (1.0 M) were introduced, and the vial 
was heated at reflux for another 16 h. The vial was finally cooled to rt and the reaction mixture 
concentrated to a glue before the Et2O (0.1 M) was introduced. The mixture was then sonicated 15 
min to allow the corresponding product to precipitate as a white powder. Note that for some 
silicates, evaporation in vacuo for a prolonged period of time (16 h) was required before sonication. 
The vial was finally unsealed and the precipitate was collected by vacuum filtration. The filter cake 
was washed with Et2O to afford the desired silicate. In some cases, a trace amount (less than 5%) 
of tris(catechol)silicate could be detected in the final product, but the latter did not affect the 
efficiency of the dual photoredox/nickel catalyzed cross coupling. If desired, the product could be 
purified by dissolving in CH2Cl2 followed by precipitation with pentane and filtration. 
 
 
Synthesis of photocatalyst [Ru(bpy)3](PF6)2 
 
 
The synthesis of photocatalyst [Ru(bpy)3](PF6)2 has been realized using a modified method of the 
literature.27 
 
 
2,2'-Bipyridyl (968 mg, 6.20 mmol) and RuCl3•6H2O (316 mg, 1.00 mmol) were introduced in a 
microwave vial with a stirring bar. The vial was sealed with a Teflon-coated septum cap then 
purged with N2 and evacuated four times. The content was solved in degassed EtOH (40 mL) then 
stirred at reflux for 16 h. After cooling to rt, the vial was unsealed and NH4PF6 (1.63 g, 10 mmol) 
was added, resulting in an immediate precipitation of an orange suspension. The mixture was 
heated 15 min at 40 °C then cooled to 0 °C in an ice bath. After 2 h, the precipitate was collected 
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by vacuum filtration and the cake washed thoroughly with H2O (~200 mL) then EtOH (~100 mL) 
and finally Et2O (~100 mL) to afford the title compound as a brick red solid (710 mg, 83%). mp 
>250 °C. Characterization data for this compound matched that reported in the literature.1 
 
High Throughput Experimentation Information 
 
 
High Throughput Experimentation was performed at the Penn/Merck Center for High Throughput 
Experimentation at the University of Pennsylvania. The screens were run on a 0.01 mmol scale 
(relative to ArBr) and analyzed by HPLC with addition of 4,4′-di-tert-butylbiphenyl (0.1 equiv) as 
internal standard (IS). The graphs depicted hereafter represent product or starting material to 
internal standard ratios (P/IS or SM/IS, respectively). The ratios calculated are pertinent only to 
that specific screen; the ratios from one screen should not be quantitatively compared to those from 
a different screen.  
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General Procedure for Screens 
 
Reactions were run in glass vials in 24 or 96 well plate reactor blocks having hollowed bottoms, 
and the vials were equipped with Teflon coated magnetic stir bar (Figure 1). The plate was placed 
in a glovebox, then the various compounds (silicates, ArBr, ligands, metallic precursors, 
photoredox catalyst) were added as solutions using micropipettes. If needed, carrying solvents were 
removed using a centrifugal evaporator. The plate was sealed with a screwed top lid equipped with 
a PTFE gasket then removed from the glovebox and placed on an LED (white or blue) plate on the 
top a magnetic stirrer (500 rpm). After 16 h, the plate was unsealed and reaction mixtures were 
diluted with MeCN (0.50 mL). Aliquots (25 μL) were taken and introduced into a 96 well HPLC 
plate, diluted with MeCN (0.70 mL) and finally analyzed by HPLC. 
 
 
 
Figure 7.6. Hollow bottom 96 well plate reactor block equipped with glass vials and blue LED 
plate. 
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Screens using HTE Screening Center 
Screen 1. Optimization of metal catalyzed photoredox cross-coupling using 
cyclohexylbis(catecholato)silicate•HNEt3 (2) – Variation of solvents, metal sources and ligands. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7. Optimization of metal catalyzed photoredox cross-coupling using 
cyclohexylbis(catecholato)silicate•HNEt3 and various metal sources, ligands and solvents. 
Note: [Ir]PF6 stands for [Ir(dFCF3ppy)2(bpy)]PF6 (dFCF3ppy = 2-(2,4- difluorophenyl)-5-
(trifluoromethyl)pyridine; bpy = bipyridine)  
Solvent Metal source Ligand [Ni] Ligand [Pd] 
    
THF [Ni(COD)2] dppe 
DMF [NiCl2(dme)] PPh3 
 [Pd2(dba)3] P(Cy)3 
 [Pd(OAc)2] dppf 
  P(t-Bu)3 
  PhOx 
  dppp IMes  
  dppbz  DuPhos 
  P(o-Tol)3 CyJohnPhos 
  blank XPhos 
  bphen RuPhos 
  dtbBpy Cataxcium A 
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Screen 2. Optimization of metal catalyzed photoredox cross-coupling using 
cyclohexylbis(catecholato)silicate•HNEt3 (2) – Variation of Ni(II) sources and solvents. 
 
  
Nickel (II) source  Solvent 
[NiCl2(dme)] THF 
[Ni(NO3)2]6H2O MeCN 
 2-methylbutan-2-ol 
 DMA 
 DMF 
 DMSO 
 DCE 
 AcOEt 
 CPME 
 MeTHF 
 DME 
 dimethylcarbonate 
 
 
Figure 7.8. Optimization of metal catalyzed photoredox cross-coupling using 
cyclohexylbis(catecholato)silicate•HNEt3. and various Nickel (II) sources and solvents. 
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Screen 3. Optimization of metal catalyzed photoredox cross-coupling using 
organobis(catecholato)silicate•HNEt3 – Variation of photoredox catalysts.  
 
  
 
Silicate  Photoredox catalyst 
1 [Ir(dFCF3ppy)2(bpy)]PF6 
2 [Ru(bpy)3]2PF6 
14 [Ru(phen)3]2PF6 
5 [Ru(bpz)3]2PF6 
 [Ru(bpm)3]2PF6 
 EosinY 
 
 
Figure 7.9. Screening of photoredox catalyst for the cross-coupling of various 
organobis(catecholato)silicates with bromobenzonitrile. SM/IS graph.  
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General procedure for photoredox cross-coupling reactions 
 
 
 
0.5 mmol scale reaction: To a 2-dram clear glass vial equipped with a Teflon-coated magnetic stir 
bar was added 4,4’-di-tert-butyl-2,2’-bipyridine (6.7 mg, 0.025 mmol), and [NiCl2(dme)] (5.5 mg, 
0.025 mmol). The vial was capped and purged with nitrogen, then 1.5 mL THF was introduced. 
The resulting suspension was heated briefly with a heat gun until the nickel and ligand were fully 
solubilized, yielding a pale green solution. The solution was cooled in an ice bath, resulting in the 
immediate precipitation of an evergreen solid. Solvents were then evaporated in vacuo to give a 
fine coating of the ligated nickel complex. Once dry, aryl bromide (0.5 mmol, 1.0 equiv) (liquid 
aryl bromides were added with solvent), aalkylsilicates (0.6 mmol, 1.2 equiv), and [Ru(bpy)3]2PF6 
(8.6 mg, 0.01 mmol) were added in succession. The vial was then capped and purged four times. 
Under inert atmosphere, DMF (5 mL) was introduced. The vial containing all the reagents was 
further sealed with Parafilm and stirred approximately 4 cm away from a 26 W fluorescent light 
bulb. A fan was blown across the reaction setup to suppress the heat generated by the latter (the 
reaction temperatures were estimated to be ~30 °C). After 16-24 h, an aliquot was taken and 
analyzed by HPLC to monitor reaction completion. 
 
General work up: The crude reaction mixture was poured in a separatory funnel and diluted with 
H2O (20 mL). The resulting suspension was extracted with Et2O (3 × 30 mL), and the combined 
organic extracts were washed with a saturated solution of Na2CO3 (2 × 20 mL) then H2O (20 mL), 
dried (MgSO4) and concentrated. The residue was purified by column chromatography on silica 
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gel, eluting with EtOAc and hexanes (or with CH2Cl2 and i–PrOH, when needed), to obtain 
products in pure form. 
 
Special work up for amine-containing compounds: After completion, the crude reaction mixture 
was diluted with EtOAc (10 mL), filtered through an approximately 6 cm x 4 cm cylindrical plug 
of Celite, washing with EtOAc (50 mL). The resulting solution was concentrated, retaken in EtOAc 
(20 mL), poured in a separatory funnel and washed with a saturated solution of Na2CO3 (2 × 10 
mL) then H2O (10 mL), dried (MgSO4) and concentrated. The residue was purified by column 
chromatography on silica gel, eluting with MeOH and CH2Cl2 containing NH4OH (1 %, v/v), to 
obtain the product in pure form.  
 
 
 
Gram scale reaction: To a 100 mL Schlenk flask equipped with a Teflon-coated magnetic stir bar 
was added [NiCl2(dme)] (55 mg, 0.25 mmol) and 4,4'-di-tert-butyl-2,2'-bipyridine (67 mg, 0.25). 
The flask was capped and purged with nitrogen, then 5.0 mL THF was introduced. The resulting 
suspension was heated briefly with a heat gun until the nickel and ligand were fully solubilized, 
yielding a pale green solution. The solution was cooled in an ice bath, resulting in the immediate 
precipitation of an evergreen solid. Solvents were then evaporated in vacuo to give a fine coating 
of the ligated nickel complex. Once dry, methyl 4-bromobenzoate (1.075 g, 5.00 mmol), silicate 
14 (1.325 g, 6.00 mmol) and [Ru(bpy)3]2PF6 (86 mg, 0.10 mmol) were added in succession. The 
vial was then capped and purged four times. Under inert atmosphere, DMF (80 mL) was introduced. 
The vial containing all the reagents was further sealed with Parafilm and stirred in the "light 
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chamber" depicted below. Two fans were blown across the reaction setup to suppress the heat 
generated by the LEDs, reaching 36 °C after 1 h. Reaction completion was monitored by taking 
aliquots of the reaction mixture and analyzing them by HPLC. After completion (4 h), the crude 
reaction mixture was diluted with EtOAc (50 mL), filtered through an approximately 6 cm x 4 cm 
cylindrical plug of Celite, washing with EtOAc (150 mL). The resulting solution was concentrated, 
retaken in EtOAc (100 mL), poured into a separatory funnel and washed with a saturated solution 
of Na2CO3 (2 × 50 mL) then H2O (50 mL), dried (MgSO4) and concentrated. The residue was 
purified by column chromatography on silica gel, eluting with MeOH and CH2Cl2 containing 
NH4OH (1 %, v/v), to obtain methyl 4-(3-aminopropyl)benzoate in pure form (891 mg, 92%). 
 
  
Figure 7.10. 0.5 mmol (left) and gram (right) scale photoredox cross-coupling reaction set-up.  
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General procedure for successive photoredox cross-coupling reactions 
 
To a 4-dram clear glass vial equipped with a Teflon-coated magnetic stir bar was added 4,4’-di-
tert-butyl-2,2’-bipyridine (6.7 mg, 0.025 mmol), and [NiCl2(dme)] (5.5 mg, 0.025 mmol). The vial 
was capped and purged with nitrogen, then 1.5 mL THF was introduced. The resulting suspension 
was heated briefly with a heat gun until the nickel and ligand were fully solubilized, yielding a pale 
green solution. The solution was cooled in an ice bath, resulting in the immediate precipitation of 
an evergreen solid. Solvents were then evaporated in vacuo to give a fine coating of the ligated 
nickel complex. Once dry, aryl bromide (0.5 mmol, 1.0 equiv) (liquid aryl bromides were added 
with solvent), alkyltrifluoroborate (0.51 mmol, 1.05 equiv), and [Ir(dFCF3ppy)2(bpy)]PF6 (10.1 mg, 
0.01 mmol) were added in succession. The vial was then capped and purged four times. Under inert 
atmosphere, dioxane (10 mL) was introduced. The vial containing all the reagents was further 
sealed with Parafilm and stirred approximately 4 cm away from a 26 W fluorescent light bulb. A 
fan was blown across the reaction setup to suppress the heat generated by the latter (the reaction 
temperatures were estimated to be ~30 °C). After 48 h, the crude reaction mixture was filtered 
through an approximately 2 cm x 2 cm cylindrical plug of Celite in air, washing with dioxane (10 
mL). The resulting solution was concentrated to approximately 0.5 mL in vacuo, then alkylsilicate 
(0.6 mmol, 1.2 equiv) and DMF (5 mL) were added successfully. The resulting solution was then 
capped and flushed with inert gas. The vial was further sealed with Parafilm and stirred 
approximately 4 cm away from a 26 W fluorescent light bulb for 16 h. Finally, the crude reaction 
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mixture was poured in a separatory funnel and diluted with H2O (20 mL). The resulting suspension 
was extracted with Et2O (3 × 30 mL), and the combined organic extracts were washed with a 
saturated solution of Na2CO3 (2 × 20 mL) then H2O (20 mL), dried (MgSO4) and concentrated. The 
residue was purified by column chromatography on silica gel, eluting with EtOAc and hexanes, to 
obtain products in pure form. 
 
Compound Characterization Data 
 
 
Triethylammonium benzylbis(catecholato)silicate (1): obtained as a white powder using THF as 
solvent (1.89 g, 92%), mp = 118 °C; 1H NMR (CDCl3, 500.4 MHz): δ 7.00 (t, J = 7.7 Hz, 2 H), 
6.90 (t, J = 7.7 Hz, 1 H), 6.85 (d, J = 7.7 Hz, 2 H), 6.72–6.66 (m, 8 H), 3.07 (q, J = 7.2 Hz, 6 H), 
2.25 (s, 2 H), 1.14 (t, J = 7.6 Hz, 9 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): δ 149.3, 142.0, 
129.0, 127.2, 122.9, 118.7, 110.7, 46.1, 26.0, 8.4 ppm; IR:  = 3031, 2928, 1528, 1482, 1235, 816, 
739, 695 cm-1; HRMS (ESI) m/z calc. for C19H15O4Si [M – HNEt3]– 335.0740, found 335.0744; Epa 
= + 0.70 V vs SCE. 
 
 
Triethylammonium cyclohexylbis(catecholato)silicate (2): obtained as a white powder using 
THF as solvent (1.14 g, 96%), mp 158 °C; 1H NMR (CDCl3, 500.4 MHz): δ 6.74–6.68 (m, 4 H), 
6.67–6.62 (m, 4 H), 3.24 (q, J = 7.2 Hz, 6 H), 1.63 (d, J = 14.0 Hz, 2 H), 1.54–1.51 (m, 3 H), 1.30 
(t, J = 7.6 Hz, 9 H), 1.22–1.12 (m, 2 H), 1.12–1.01 (m, 3 H), 0.92–0.82 (tt, J = 12.2, 3.3 Hz, 1 H) 
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ppm; 13C NMR {1H} (CDCl3, 125.8 MHz): δ 150.0, 118.4, 110.3, 46.1, 29.4, 28.4, 28.1, 30.0, 8.53 
ppm; IR:  = 3030, 2944, 1486, 1458, 1357, 1262, 1231, 1205, 1101, 1015, 816, 742, 731, 685 cm-
1; HRMS (ESI) m/z calc. for C18H19O4Si [M – HNEt3]– 327.1053, found 327.1055; Epa = + 0.74 V 
vs SCE. 
  
 
Diisopropylammonium exo-2-bicyclo[2.2.1]heptylbis(catecholato)silicate (3): obtained as a 
white powder using THF as solvent (1.14 g, 81%), mp 188 °C; 1H NMR (CDCl3, 500.4 MHz): δ 
6.74–6.68 (m, 4 H), 6.67–6.62 (m, 4 H), 3.24 (q, J = 7.2 Hz, 6 H), 2.22 (br s, 1 H), 2.02 (br s, 1 H), 
1.65–1.58 (m, 1 H), 1.37–1.31 (m, 2 H), 1.28 (t, J = 7.5 Hz, 9 H), 1.22–1.16 (m, 1 H), 1.09–1.01 
(m, 3 H), 0.91 (dt, J = 8.7, 2.6 Hz, 1 H), 0.79–0.74 (m, 1 H) ppm; 13C {1H} NMR (CDCl3, 125.8 
MHz): δ 149.9, 149.7, 118.5, 118.4, 110.5, 110.4, 46.1, 38.4, 38.3, 36.6, 33.3, 32.9, 31.1, 29.1, 8.6 
ppm; IR:  = 3025, 2941, 1485, 1262, 1241, 1207, 1191, 1101, 1017, 816, 732, 704 cm-1; HRMS 
(ESI) m/z calc. for C19H19O4Si [M – i-Pr2NH2]– 339.1058, found 339.1062. 
 
 
 
Triethylammonium methylbis(catecholato)silicate (4): obtained as a gray powder using THF as 
solvent (1.63 g, 73%), mp 168 °C; 1H NMR (CDCl3, 500.4 MHz): δ 6.74–6.71 (m, 4 H), 6.69–6.64 
(m, 4 H), 3.23 (q, J = 7.5 Hz, 6 H), 1.29 (t, J = 7.5 Hz, 9 H), 0.14 (s, 3 H) ppm; 13C {1H} NMR 
(CDCl3, 125.8 MHz): δ 149.2, 118.6, 110.7, 46.1, 8.5, –1.1 ppm; IR:  = 3045, 1598, 1483, 1354, 
1277, 1240, 1225, 1153, 1098, 1013, 826, 740 cm-1; HRMS (ESI) m/z calc. for C13H11O4Si [M – 
HNEt3]– 259.0432, found 259.0435. 
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Triethylammonium hexylbis(catecholato)silicate (5): obtained as a white powder using THF as 
solvent (1.21 g, 88%), mp 116 °C; 1H NMR (CDCl3, 500.4 MHz): δ 6.74–6.68 (m, 4 H), 6.67–6.62 
(m, 4 H), 3.24 (q, J = 7.2 Hz, 6 H), 1.34–1.25 (m, 11 H), 1.18–1.10 (m, 6 H), 0.78 (t, J = 7.0 Hz, 3 
H), 0.69–0.64 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): δ 149.9, 118.7, 110.8, 46.3, 
33.2, 31.8, 24.5, 22.8, 17.1, 14.3, 8.9 ppm; IR:  = 3035, 2924, 1484, 1355, 1239, 1100, 1014, 818, 
734 cm-1; HRMS (ESI) m/z calc. for C18H21O4Si [M – HNEt3]– 329.1215, found 329.1212; Epa = + 
0.75 V vs SCE. 
 
 
Triethylammonium chloromethylbis(catecholato)silicate (6): obtained as a light brown powder 
using THF as solvent (2.16 g, 93%), mp 108 °C; 1H NMR (CDCl3, 500.4 MHz): δ 6.76–6.73 (m, 4 
H), 6.72–6.68 (m, 4 H), 3.32 (q, J = 7.1 Hz, 6 H), 2.90 (s, 2 H), 1.37 (t, J = 7.1 Hz, 9 H) ppm; 13C 
{1H} NMR (CDCl3, 125.8 MHz): δ 149.0, 119.0, 110.8, 46.4, 30.4, 8.5 ppm; IR:  = 2995, 1483, 
1390, 1351, 1239, 1221, 1172, 1153, 1101, 1060, 1012, 829, 783, 771, 739 cm-1; HRMS (ESI) m/z 
calc. for C13H10ClO4Si [M – HNEt3]– 293.0037, found 293.0032. 
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Triethylammonium 2-(3-cyclohexenyl)ethylbis(catecholato)silicate (7): obtained as a white 
powder using 1,4–dioxane as solvent (1.70 g, 86%), mp 102 °C; 1H NMR (CDCl3, 500.4 MHz): δ 
6.75–6.70 (m, 4 H), 6.68–6.64 (m, 4 H), 5.59–5.55 (m, 2 H), 3.27 (q, J = 7.3 Hz, 6 H), 2.01–1.85 
(m, 3 H), 1.64–1.58 (m, 1 H), 1.51–1.43 (m, 1 H), 1.31 (t, J = 7.3 Hz, 9 H), 1.29–1.24 (m, 3 H), 
1.07–0.97 (m, 1 H), 0.73–0.68 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): δ 149.6, 149.5, 
127.0, 126.8, 118.5, 118.4, 110.6, 46.1, 36.2, 31.6, 31.0, 28.5, 25.4, 13.7, 8.4 ppm; IR:  = 2913, 
1484, 1390, 1356, 1261, 1241, 1227, 1205, 1014, 817, 759, 733, 679 cm-1; HRMS (ESI) m/z calc. 
for C20H21O4Si [M – HNEt3]– 353.1215, found 353.1217. 
 
 
Diisopropylammonium 2-(3,4-epoxycyclohexyl)ethylbis(catecholato)silicate (8): obtained as a 
white powder using 1,4–dioxane as solvent (3.29 g, 86%), mp 140 °C; 1H NMR (DMSO–d6, 500.4 
MHz): δ 6.52–6.47 (m, 4 H), 6.44–6.40 (m, 4 H), 3.33 (sept, J = 6.4 Hz, 2 H), 3.19–3.15 (d, J = 10 
Hz, 0.5 H), 3.00–2.93 (m, 1.5 H), 1.91–1.79 (m, 1.5 H), 1.58–1.48 (m, 1 H), 1.37–1.24 (m, 1 H), 
1.18 (d, J = 6.4 Hz, 12 H), 1.14–0.99 (m, 4 H), 0.99–0.88 (m, 0.5 H), 0.82–0.63 (m, 1 H), 0.46–
0.40 (m, 2 H) ppm; 13C {1H} NMR (DMSO–d6, 125.8 MHz): δ 151.1, 151.0, 117.4, 117.3, 109.8, 
52.4, 52.0, 51.3, 51.2, 46.7, 35.1, 32.3, 31.8, 31.5, 30.9, 30.7, 26.7, 25.4, 24.4, 23.4, 19.4, 15.6, 
15.4 ppm; IR:  = 2986, 2919, 1485, 1238, 891, 813, 736 cm-1; HRMS (ESI) m/z calc. for 
C20H21O5Si [M – i-Pr2NH2]– 369.1164, found 369. 1169. 
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Diisopropylammonium N-[5-(bis(catecholato)silicate)-2-aza-1-oxopentyl]caprolactam (9): 
obtained as a white powder using 1,4–dioxane as solvent (2.74 g, 83%), mp 146 °C; 1H NMR 
(CD3CN, 500.4 MHz): δ 9.10 (br s, 1 H), 6.67–6.62 (m, 4 H), 6.58–6.53 (m, 4 H), 3.89 (t, J = 4.5 
Hz, 2 H), 3.53 (tt, J = 6.7, 6.7 Hz, 2 H), 3.03 (sept, J = 6.4 Hz, 2 H), 2.67–2.61 (m, 2 H), 1.73–1.65 
(m, 4 H), 1.63–1.54 (m, 2 H), 1.46–1.37 (m, 2 H), 1.31 (d, J = 6.4 Hz, 12 H), 0.58–0.50 (m, 2 H) 
ppm; 13C {1H} NMR (DMSO-d6, 125.8 MHz): δ 179.3, 154.3, 150.9, 117.5, 109.9, 46.7, 43.4, 43.0, 
39.3, 28.6, 28.3, 25.0, 23.3, 19.4, 15.9 ppm; IR:  = 2928, 1698, 1485, 1239, 813, 738 cm-1; HRMS 
(ESI) m/z calc. for C22H25N2O6Si [M – i-Pr2NH2]– 441.1446, found 441.1441. 
 
  
 
Diisopropylammonium 3-(phenylamino)propylbis(catecholato)silicate (10): obtained as a 
white powder using 1,4–dioxane as solvent (3.50 g, 89%), crystallized with 0.25 equiv 1,4–dioxane 
and a trace amount of Et2O, mp 154 °C; 1H NMR (DMSO-d6, 500.4 MHz): δ 8.01 (br s, 2 H), 6.99 
(t, J = 7.3 Hz, 2 H), 6.54–6.51 (m, 4 H), 6.45–6.41 (m, 7 H), 5.32 (t, J = 5.1 Hz, 1 H), 3.34 (sept, J 
= 6.4 Hz, 2 H), 2.79 (td, J = 7.9, 5.1 Hz, 2 H), 1.46 (tt, J = 7.9, 7.9 Hz, 2 H), 1.19 (d, J = 6.4 Hz, 
12 H), 0.54 (t, J = 7.9 Hz, 2 H) ppm; 13C {1H} NMR (DMSO-d6, 125.8 MHz): δ 151.0, 145.5, 
129.1, 117.5, 115.2, 112.1, 109.9, 66.7, 16.8, 46.6, 24.7, 19.2, 16.2 ppm; IR:  = 2859, 1601, 1484, 
1239, 1149, 813, 739 cm-1; HRMS (ESI) m/z calc. for C21H20NO4Si [M – i-Pr2NH2]– 378.1167, 
found 378.1167. 
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Triethylammonium 2-(pyridin-2-yl)ethylbis(catecholato)silicate (11): obtained as a white 
powder using THF as solvent (3.54 g, 91%), together with 8% of SM, mp = 168 °C; 1H NMR 
(CDCl3, 500.4 MHz): δ 9.53 (br s, 1 H), 8.34 (d, J = 5.4 Hz, 1 H), 7.48 (dd, J = 7.9, J = 6.3 Hz, 1 
H), 7.10 (d, J = 7.9 Hz, 1 H), 6.98 (dd, J = 6.3, J = 5.3 Hz, 1 H), 6.71–6.67 (m, 4 H), 6.65–6.60 (m, 
4 H), 3.12 (q, J = 6.5 Hz, 6 H), 2.84 (m, 2 H), 1.22 (t, J = 6.5 Hz, 9 H), 1.12–1.07 (m, 2 H) ppm; 
13C {1H} NMR (CDCl3, 125.8 MHz): δ 149.6, 147.6, 136.7, 125.5, 120.6, 118.4, 114.8, 110.7, 46.0, 
32.6, 16.7, 9.2 ppm; IR:  = 2859, 1601, 1484, 1239, 813, 739, 692 cm-1; HRMS (ESI) m/z calc. 
for C19H16NO4Si [M – HNEt3]– 350.0854, found 350.0851. 
 
 
Diisopropylammonium 3,3,4,4,5,5,6,6,6-nonafluorohexylbis(catecholato)silicate (12): 
obtained as a white powder using THF as solvent (1.48 g, 92%), mp 65 °C; 1H NMR (CDCl3, 500.4 
MHz): δ 6.76–6.73 (m, 4 H), 6.69–6.66 (m, 4 H), 3.34 (sept, J = 6.6 Hz, 2 H), 2.16–2.02 (m, 2 H), 
1.41 (d, J = 6.6 Hz, 12 H), 0.95–0.88 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): δ 149.3, 
119.2, 111.0, 46.4, 26.4 (t, J = 22 Hz), 8.6, 5.9 ppm; 19F {1H} NMR (CDCl3, 470.8 MHz): –81.1, 
–116.4, –124.4, –126.1 ppm; IR:  = 3049, 1599, 1484, 1352, 1238, 121, 1129, 1101, 1059, 1013, 
877, 822, 792, 737, 690 cm-1; HRMS (ESI) m/z calc. for C18H12F9O4Si [M – i-Pr2NH2]– 491.0361, 
found 491.0361. 
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Triethylammonium 3-acetoxypropylbis(catecholato)silicate (13): obtained as a white powder 
using THF as solvent (1.92 g, 95%), mp 88 °C; 1H NMR (CDCl3, 500.4 MHz): δ 6.75–6.73 (m, 4 
H), 6.68–6.65 (m, 4 H), 3.89 (t, J = 7.2 Hz, 2 H), 3.28 (q, J = 6.6 Hz, 6 H), 1.94 (s, 3 H), 1.69–1.66 
(m, 2 H), 1.32 (t, J = 6.6 Hz, 9 H), 0.71–0.66 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 
δ 171.2, 149.4, 118.6, 110.7, 67.3, 46.1, 23.6, 21.0, 12.4, 8.4 ppm; IR:  = 3038, 1725, 1483, 1238, 
1197, 1030, 1016, 815, 735, 701, 664 cm-1; HRMS (ESI) m/z calc. for C17H17O6Si [M – HNEt3]– 
345.0794, found 345.0796. 
 
 
3-Ammoniumpropylbis(catecholato)silicate (14): obtained as a white powder using THF as 
solvent (1.97 g, 94%), crystallized with 0.75 equiv THF, mp >250 °C; 1H NMR (DMSO-d6, 500.4 
MHz): δ 7.43 (br s, 3 H), 6.55–6.51 (m, 4 H), 6.47–6.42 (m, 4 H), 2.59 (t, J = 7.6 Hz, 2 H), 1.48 
(td, J = 7.6, 7.6 Hz, 2 H), 0.53–0.48 (m, 2 H) ppm; 13C {1H} NMR (DMSO-d6, 125.8 MHz): δ 
150.8, 117.6, 110.0, 42.3, 23.3, 15.3 ppm; IR:  = 3048, 2930, 1601, 1483, 1355, 1242, 1101, 1048, 
1013, 889, 826, 733, 705 cm-1; HRMS (ESI) m/z calc. for C15H16NO4Si [M – H]– 302.0854, found 
302.0859. 
 
 
1-Benzyl-4-methoxybenzene (15): obtained as a colorless oil (76 mg, 77%); 1H NMR (CDCl3, 
500.4 MHz): δ 7.28 (t, J = 7.5 Hz, 2 H), 7.20–7.16 (m, 3 H), 7.10 (d, J = 9.0 Hz, 2 H), 6.83 (d, J = 
9.0 Hz, 2 H), 3.92 (s, 2 H), 3.78 (s, 3 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 158.1, 141.7, 
133.4, 130.0, 129.0, 128.6, 126.1, 114.0, 55.4, 41.2 ppm; HRMS (ESI) m/z calc. for C14H14O [M]+ 
198.1045, found 198.1048.28 
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1-Cyclohexyl-4-methoxybenzene (16): obtained as a colorless oil (89 mg, 94%); 1H NMR (CDCl3, 
500.4 MHz): δ 7.13 (d, J = 7.6 Hz, 2 H), 6.84 (d, J = 7.6 Hz, 2 H), 3.78 (s, 3 H), 2.47–2.41 (m, 1 
H), 1.86–1.71 (m, 4 H), 1.73 (dd, J = 13.0, 4.7 Hz, 1 H), 1.44–1.32 (m, 4 H), 1.29–1.19 (m, 1 H) 
ppm; 13C NMR (CDCl3, 125.8 MHz): 157.8, 140.5, 127.8, 113.8, 55.4, 43.9, 34.9, 27.1, 26.3 ppm; 
HRMS (ESI) m/z calc. for C13H18O [M]+ 190.1358, found 190.1359.29 
 
 
 
exo-2-(4-Methoxyphenyl)bicyclo[2.2.1]heptane (17): obtained as a colorless oil (92 mg, 91%); 
1H NMR (CDCl3, 500.4 MHz): δ 7.16 (d, J = 8.6 Hz, 2 H), 6.86 (d, J = 8.6 Hz, 2 H), 3.81 (s, 3 H), 
2.71 (dd, J = 6.3, 8.8 Hz, 1 H), 2.37 (d, J = 5.8 Hz, 2 H), 1.77 (ddd, J = 2.4, 9.9, 9.9 Hz, 1 H), 1.69–
1.52 (m, 4 H), 1.41–1.34 (m, 1 H), 1.31–1.26 (m, 1 H), 1.19 (d, J = 4.5 Hz, 1 H) ppm; 13C {1H} 
NMR (CDCl3, 125.8 MHz): 157.6, 139.9, 128.1, 113.7, 55.4, 46.7, 43.3, 39.3, 37.0, 36.1, 30.7, 29.1 
ppm; IR:  = 2948, 2848, 2833, 1611, 1510, 1463, 1454, 1441, 1294, 1277, 1245, 1208, 1178, 
1139, 1107, 1035, 822, 763, 600, 532 cm-1; HRMS (ESI) m/z calc. for C14H18O [M]+ 202.1358, 
found 202.1356. 
 
 
 
441 
1-Hexyl-4-methoxybenzene (19): obtained as a colorless oil (82 mg, 85%); 1H NMR (CDCl3, 
500.4 MHz): δ 7.09 (d, J = 8.7 Hz, 2 H), 6.82 (d, J = 8.7 Hz, 2 H), 3.78 (s, 3 H), 2.54 (t, J = 7.4 Hz, 
2 H), 1.57 (q, J = 7.2 Hz, 2 H), 1.35–1.26 (m, 6 H), 0.88 (t, J = 6.9 Hz, 3 H) ppm; 13C {1H} NMR 
(CDCl3, 125.8 MHz): 157.7, 146.1, 129.4, 113.8, 55.4, 35.2, 31.9, 29.1, 22.8, 14.7 ppm; HRMS 
(ESI) m/z calc. for C13H19O [M – H]+ 191.1436, found 191.1426.30 
 
 
 
1-(2-(Cyclohex-3-en-1-yl)ethyl)-4-methoxybenzene (21): obtained as a colorless oil (100 mg, 
93%); 1H NMR (CDCl3, 500.4 MHz): δ 7.12 (d, J = 8.0 Hz, 2 H), 6.84 (d, J = 8.0 Hz, 2 H), 5.67 
(br s, 2 H), 3.80 (s, 3 H), 2.61 (t, J = 7.3 Hz, 2 H), 2.16 (dd, J = 17.3, 4.0 Hz, 1 H), 2.09–2.02 (m, 
2 H), 1.83–1.77 (m, 1 H), 1.76–1.68 (m, 1 H), 1.63–1.55 (m, 3 H), 1.33–1.22 (m, 1 H) ppm; 13C 
{1H} NMR (CDCl3, 125.8 MHz): 157.5, 134.9, 129.1, 126.9, 126.4, 113.6, 55.2, 38.7, 32.9, 32.2, 
31.7, 28.8, 25.1 ppm; IR:  = 3021, 2910, 2834, 1612, 1511, 1489, 1454, 1440, 1300, 1242, 1176, 
1141, 1109, 1037, 820, 727, 653, 562, 521 cm-1; HRMS (ESI) m/z calc. for C15H20O [M]+ 216.1514, 
found 216.1511. 
 
 
 
N-[(3-(4-Methoxyphenyl)propyl)-2-aza-1-oxopentyl]caprolactam (23): obtained as a colorless 
oil (81 mg, 53%); 1H NMR (CDCl3, 500.4 MHz): δ 9.30 (br s, 1 H), 7.10 (d, J = 8.3 Hz, 2 H), 6.82 
(d, J = 8.3 Hz, 2 H), 3.98 (d, J = 2.1 Hz, 2 H), 3.77 (s, 3 H), 3.29 (q, J = 6.4 Hz, 2 H), 2.71–2.68 
(m, 2 H), 2.61 (t, J = 8.3 Hz, 2 H), 1.85 (q, J = 7.7 Hz, 2 H), 1.80–1.68 (m, 6 H) ppm; 13C {1H} 
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NMR (CDCl3, 125.8 MHz): 179.6, 157.9, 155.0, 133.7, 129.4, 113.9, 55.4, 43.9, 40.1, 39.9, 32.4, 
31.4, 29.3, 28.5, 23.7 ppm; IR:  = 2930, 1695, 1610, 1529, 1510, 1462, 1454, 1437, 1317, 1350, 
1332, 1300, 1242, 1213, 1175, 1164, 969, 809 cm-1; HRMS (ESI) m/z calc. for C17H25N2O3 [M + 
H]+ 305.1865, found 305.1861. 
 
 
 
N-(3-(4-Methoxyphenyl)propyl)aniline (24): obtained as a yellow crystalline solid (77 mg, 64%); 
mp, 66-67 °C, 1H NMR (CDCl3, 500.4 MHz): δ 7.18 (td, J = 7.4, 1.1 Hz, 2 Hz), 7.13 (d, J = 8.2 
Hz, 2 H), 6.86 (d, J = 8.9 Hz, 2 H), 6.71 (tt, J = 7.3, 1.1 Hz, 1 H), 6.60 (dd, J = 8.6, 1.1 Hz, 2 H), 
3.81 (s, 3 H), 3.38–3.92 (br s, 1 H), 3.16 (t, J = 7.5 Hz, 2 H), 2.70 (t, J = 7.5 Hz, 2 H), 1.94 (tt, J = 
7.5, 7.5 Hz, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 157.8, 148.3, 133.6, 129.8, 129.1, 
117.2, 113.8, 112.7, 55.2, 43.4, 32.4, 31.2 ppm; IR:  = 3388, 2911, 2851, 1603, 1507, 1472, 1320, 
1255, 1237, 1176, 1095, 1057, 991, 811, 768, 748, 557, 511 cm-1; HRMS (ESI) m/z calc. for 
C16H20NO [M + H]+ 242.1545, found 242.1550. 
 
 
 
2-(4-Methoxyphenethyl)pyridine (25): obtained as a colorless oil (53 mg, 50%); 1H NMR 
(CDCl3, 500.4 MHz): δ 8.55 (dd, J = 4.5, 2.3 Hz, 1 H), 7.55 (ddd, J = 7.5, 7.5, 2.1 Hz, 1 H), 7.12–
7.08 (m, 3 H), 7.06 (d, J = 7.7 Hz, 1 H), 6.81 (d, J = 8.6 Hz, 2 H), 3.77 (s, 3 H), 3.09–3.03 (m, 2 
H), 3.02–2.96 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 161.3, 157.8, 149.2, 136.2, 
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133.6, 129.3, 122.9, 121.0, 113.7, 55.15, 40.42, 35.1 ppm; IR:  = 3006, 2932, 1610, 1588, 1568, 
1510, 1473, 1454, 1434, 1300, 1242, 1177, 1149, 1034, 822, 749 cm-1; HRMS (ESI) m/z calc. for 
C14H16NO [M + H]+ 214.1232, found 214.1236. 
 
 
 
4-(3,3,4,4,5,5,6,6,6-Nonafluorohexyl)-1,1'-biphenyl (26): obtained as a colorless solid (177 mg, 
88%), mp 55 °C; 1H NMR (CDCl3, 500.4 MHz): δ 7.57 (d, J = 7.8 Hz, 2 H), 7.54 (d, J = 7.8 Hz, 2 
H), 7.43 (dd, J = 7.7, 7.4 Hz, 2 H), 7.33 (t, J = 7.4 Hz, 1 H), 7.27 (d, J = 7.7 Hz, 2 H), 2.98–2.84 
(m, 2 H), 2.47–2.34 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 140.7, 139.7, 138.1, 128.7, 
128.6, 127.4, 127.2, 126.9, 32.8 (t, J = 22.3 Hz), 26.0 ppm; 19F {1H} NMR (CDCl3, 470.8 MHz): 
–81.1, –114.2, –124.4, –125.9 ppm; IR:  = 1488, 1357, 1301, 1215, 1167, 1130, 1089, 1049, 1007, 
983, 881, 838, 760, 750, 734, 693 cm-1; HRMS (ESI) m/z calc. for C18H13F9 [M]+ 400.0874, found 
400.0875. 
 
 
 
3-(4-Methoxyphenyl)propyl acetate (27): obtained as a colorless oil (82 mg, 79%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.10 (d, J = 8.4 Hz, 2 H), 6.83 (d, J = 8.4 Hz, 2 H), 4.07 (t, J = 6.5 Hz, 2 
H), 3.79 (s, 3 H), 2.63 (t, J = 7.9 Hz, 2 H), 2.06 (s, 3 H), 1.92 (tt, J = 6.5, 7.9 Hz, 2 H) ppm; 13C 
{1H} NMR (CDCl3, 125.8 MHz): 171.3, 158.0, 133.4, 129.4, 114.0, 64.0, 55.4, 31.4, 30.6, 21.2 
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ppm; IR:  = 2953, 1735, 1612, 1511, 1464, 1386, 1365, 1300, 1235, 1177, 1113, 1033, 951, 810, 
700, 532 cm-1; HRMS (ESI) m/z calc. for C12H16O3 [M]+ 208.1299, found 208.1297. 
 
 
 
3-(4-Methoxyphenyl)propan-1-amine (28): obtained as a yellow oil (56 mg, 68%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.09 (d, J = 7.0 Hz, 2 H), 6.82 (d, J = 7.0 Hz, 2 H), 3.78 (s, 3 H), 2.71 (t, 
J = 6.8 Hz, 2 H), 2.59 (t, J = 7.8 Hz, 2 H), 1.78 (tt, J = 6.8, 7.8 Hz 2 H) 1.39 (br s, 2 H) ppm; 13C 
{1H} NMR (CDCl3, 125.8 MHz): 157.7, 134.1, 129.2, 113.7, 55.1, 41.6, 35.5, 32.2 ppm; IR:  = 
3320, 2925, 2854, 1663, 1611, 1584, 1512, 1464, 1300, 1245, 1177, 1093, 1035, 907, 648, 530 cm-
1; HRMS (ESI) m/z calc. for C10H16NO [M + H]+ 166.1231, found 166.1232. 
 
 
 
4-(3-Aminopropyl)benzonitrile (29): obtained as a light brown oil (69 mg, 86%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.57 (d, J = 8.0 Hz, 2 H), 7.29 (d, J = 8.0 Hz, 2 H), 2.88–2.80 (br s, 2 H), 
2.80–2.70 (m, 4 H), 1.81 (tt, J = 7.7, 7.5 Hz, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 147.5, 
132.1, 129.1, 119.0, 109.7, 41.0, 33.8, 33.2 ppm; IR:  = 3124, 3110, 2869, 2270, 1678, 1607, 
1554, 1452, 1403, 1179, 850, 698 cm-1; HRMS (ESI) m/z calc. for C10H13N2 [M + H]+ 161.1079, 
found 161.1082. 
 
 
 
445 
2-(3-Aminopropyl)benzonitrile (30): obtained as a dark yellow oil (67 mg, 84%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.58 (d, J = 8.0 Hz, 1 H), 7.49 (t, J = 7.5 Hz, 1 H), 7.31 (d, J = 7.5 Hz, 1 
H), 7.29–7.24 (m, 1 H), 2.87 (t, J = 6.6 Hz, 2 H), 2.76 (t, J = 5.7 Hz, 2 H), 2.24 (br s, 2 H), 1.87–
1.77 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 146.2, 133.0, 132.9, 129.7, 126.7, 118.2, 
112.4, 41.5, 34.4, 32.0 ppm; IR:  = 3364, 2933, 2867, 2223, 1710, 1661, 1599, 1573, 1448, 1364, 
1314, 1164, 1035, 844, 759, 665, 539, 508 cm-1; HRMS (ESI) m/z calc. for C10H12N2Na [M + Na]+ 
183.0898, found 183.0901. 
 
 
3-(4-(Trifluoromethyl)phenyl)propan-1-amine (31): obtained as a brown oil (82 mg, 81%); 1H 
NMR (CDCl3, 500.4 MHz): 7.54 (d, J = 7.5 Hz, 2 H), 7.31 (d, J = 7.5 Hz, 2 H), 2.78–2.71 (m, 4 
H), 1.80 (tt, J = 7.3, 7.2 Hz, 2 H), 1.36 (br s, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 146.9, 
128.6, 128.1, 125.2 (q, J = 3.4 Hz), 123.2, 41.5, 34.9, 33.02 ppm; 19F {1H} NMR (CDCl3, 470.8 
MHz): –62.3 ppm; IR:  = 2934, 2862, 1617, 1585, 1454, 1418, 1322, 1160, 1112, 1065, 1018, 
953, 840, 815, 730, 630 cm-1; HRMS (ESI) m/z calc. for C10H13NF3 [M + H]+ 204.1002, found 
204.1000. 
 
 
Methyl 4-(3-aminopropyl)benzoate (32): obtained as a colorless solid (91 mg, 94%), mp 104 °C; 
1H NMR (CDCl3, 500.4 MHz): 7.94 (d, J = 7.7 Hz, 2 H), 7.24 (d, J = 7.7 Hz, 2 H), 3.89 (s, 3 H), 
2.75–2.66 (m, 4 H), 2.43–2.00 (m, 2 H), 1.78 (tt, J = 7.2, 7.4 Hz, 2 H) ppm; 13C {1H} NMR (CDCl3, 
125.8 MHz): 166.9, 147.5, 129.6, 128.3, 127.7, 51.8, 41.5, 34.7, 33.2 ppm; IR:  = 2922, 2857, 
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1717, 1608, 1574, 1435, 1416, 1392, 1310, 1271, 1210, 1177, 110, 1020, 763, 701 cm-1; HRMS 
(ESI) m/z calc. for C11H16NO2 [M + H]+ 194.1181, found 194.1183. 
 
 
 
N-(4-(3-Aminopropyl)phenyl)acetamide (33): obtained as an off white powder (72 mg, 75%), 
mp 94 °C; 1H NMR (DMSO-d6, 500.4 MHz): δ 9.91 (s, 1 H), 7.49 (d, J = 8.9 Hz, 2 H), 7.10 (d, J 
= 8.9 Hz, 2 H), 4.21 (br s, 2 H), 2.61 (br s, 1 H), 2.55 (t, J = 6.6 Hz, 2 H), 2.52–2.49 (m, 1 H), 2.02 
(s, 3 H), 1.77–1.66 (m, 2 H) ppm; 13C {1H} NMR (DMSO-d6, 125.8 MHz): 168.4, 137.6, 136.6, 
128.7, 119.4, 33.1, 32.8, 32.1, 24.3 ppm; IR:  = 3244, 3180, 3112, 3030, 2930, 2858, 1662, 1601, 
1536, 1813, 1410, 1370, 1316, 1264, 828, 790, 745 cm-1; HRMS (ESI) m/z calc. for C11H16N2ONa 
[M + Na]+ 215.1166, found 215.1160. 
 
 
 
(4-(3-Aminopropyl)phenyl)methanol (34): obtained as a brown oil (69 mg, 85%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.30 (d, J = 8.2 Hz, 2 H), 7.19 (d, J = 8.9 Hz, 2 H), 4.67 (s, 2 H), 2.74 (t, J 
= 7.1 Hz, 2 H), 2.67 (t, J = 7.9 Hz, 2 H), 1.78 (tt, J = 7.1, 7.9 Hz, 2 H), 1.51 (br s, 3 H) ppm; 13C 
{1H} NMR (CDCl3, 125.8 MHz): 141.4, 138.5, 128.5, 127.1, 65.0, 41.6, 35.2, 32.9 ppm; IR:  = 
3338, 2970, 2933, 2883, 1466, 1407, 1378, 1341, 1306, 1160, 1128, 1108, 951, 817, 644, 487 cm-
1; HRMS (ESI) m/z calc. for C10H16NO [M + H]+ 166.1236, found 166.1232. 
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3-(3-(1H-Pyrazol-5-yl)phenyl)propan-1-amine (35): obtained as a dark yellow oil (71 mg, 71%); 
1H NMR (CDCl3, 500.4 MHz): δ 7.58-7.52 (m, 3 H), 7.26 (dd, J = 7.5, 7.5 Hz, 1 H), 7.08 (d, J = 
7.5 Hz, 1 H), 6.55 (s, 1 H), 5.15–4.81 (br s, 3 H), 2.70 (tt, J = 7.0, 7.0 Hz, 2 H), 2.61 (t, J = 7.0 Hz, 
2 H), 1.76 (t, J = 7.0 Hz, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 148.7, 142.6, 133.7, 
132.3, 128.9, 128.2, 125.8, 123.5, 102.6, 41.5, 34.8, 30.7 ppm; IR:  = 3158, 3049, 2924, 2855, 
1661, 1607, 1587, 1471, 1434, 1352, 1248, 1097, 1041, 923, 907, 794, 759, 699, 609 cm-1; HRMS 
(ESI) m/z calc. for C12H16N3 [M + H]+ 202.1343, found 202.1344. 
 
 
 
3-(1-Methyl-1H-indazol-5-yl)propan-1-amine (36): obtained as a light brown oil (91 mg, 96%); 
1H NMR (CDCl3, 500.4 MHz): δ 7.98 (s, 1 H), 7.27 (dd, J = 6.8, 7.4 Hz, 1 H), 7.20 (d, J = 7.4 Hz, 
1 H), 6.89 (d, J = 6.8 Hz, 1 H), 4.03 (s, 3 H), 2.91 (t, J = 6.9 H, 2 H), 2.85–2.59 (m, 2 H), 1.92 (t, 
J = 8.2 H, 2 H), 1.27 (br s, 1 H), 0.97 (br s, 1 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 140.1, 
135.2, 131.4, 126.6, 123.9, 119.7, 107.0, 41.4, 35.7, 32.6, 30.7 ppm; IR:  = 2928, 2848, 2727, 
1611, 1463, 1449, 1440, 1432, 1392, 1230, 1152, 987, 970, 954, 817, 783, 744, 730 cm-1; HRMS 
(ESI) m/z calc. for C11H16N3 [M + H]+ 190.1344, found 190.1346. 
 
 
 
3-(1H-Indol-5-yl)propan-1-amine (37): obtained as a light yellow oil (76 mg, 87%); 1H NMR 
(CDCl3, 500.4 MHz): δ 8.54 (br s, 1 H), 7.45 (s, 1 H), 7.29 (d, J = 5.1 Hz, 1 H), 7.15 (s, 1 H), 7.02 
(d, J = 5.1 Hz, 1 H), 6.49 (s, 1 H), 2.92–2.71 (m, 4 H), 1.87 (br s, 2 H), 1.34–1.21 (m, 2 H) ppm; 
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13C {1H} NMR (CDCl3, 125.8 MHz): δ 134.39, 133.0, 126.0, 124.4, 122.7, 119.0, 110.8, 101.9, 
33.4, 33.2, 29.6 ppm; IR:  = 3229, 2922, 1615, 1512, 1476, 1422, 1343, 1046, 1022, 999, 820, 
767 cm-1; HRMS (ESI) m/z calc. for C11H15N2 [M + H]+ 175.1235, found 175.1239. 
  
 
tert-Butyl 4-(5-(3-aminopropyl)pyrimidin-2-yl)piperazine-1-carboxylate (38): obtained as an 
off white powder (86 mg, 53%), mp 126 °C; 1H NMR (CDCl3, 500.4 MHz): δ 8.16 (s, 2 H), 4.60–
4.07 (m, 2 H), 3.74 (br s, 4 H), 3.47 (br s, 4 H), 2.90–2.70 (m, 2 H), 2.48 (br s, 2 H), 1.86–1.69 (m, 
2 H), 1.47 (s, 9 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 180.7, 157.4, 154.7, 122.3, 79.8, 
43.7, 44.4–42.8 (m, 2 C) 43.1, 28.35, 26.6 ppm; IR:  = 2922, 2858, 1683, 1603, 1537, 1487, 1450, 
1417, 1365, 1243, 1166, 1126, 1085, 997, 949 cm-1; HRMS (ESI) m/z calc. for C16H28N5O2 [M + 
H]+ 322.2243, found 322.2238. 
 
 
5-(exo-Bicyclo[2.2.1]heptan-2-yl)pyrimidine (39): reaction carried out starting from 0.368 mmol 
of ArBr, obtained as a colorless oil (63 mg, 98%); 1H NMR (CDCl3, 500.4 MHz): δ 9.02 (s, 1 H), 
8.58 (s, 2 H), 2.72 (dd, J = 5.6, 9.3 Hz, 1 H), 2.42 (t, J = 4.6 Hz, 1 H), 2.38 (d, J = 3.3 Hz, 1 H), 
1.83 (ddd, J = 2.4, 9.4, 11.2 Hz, 1 H), 1.71–1.57 (m, 3 H), 1.48 (dt, J = 2.0, 2.0, 10.0 Hz, 1 H), 
1.42–1.36 (m, 1 H), 1.32–1.23 (m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 156.1, 155.6, 
139.8, 42.9, 42.3, 38.4, 36.8, 36.0, 30.2, 28.5 ppm; IR:  = 3041, 2950, 2870, 1557, 1454, 1411, 
1330, 1312, 1298, 1273, 1236, 1208, 1190, 1166, 1138, 1036, 728 cm-1; HRMS (ESI) m/z calc. for 
C11H15N2 [M + H]+ 175.1235, found 175.1238. 
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2-(4-(exo-Bicyclo[2.2.1]heptan-2-yl)phenyl)-1,3,4-oxadiazole (40): obtained as a colorless solid 
(113 mg, 94%), mp 101 °C; 1H NMR (CDCl3, 500.4 MHz): δ 8.44 (s, 1 H), 7.99 (d, J = 7.7 Hz, 2 
H), 7.37 (d, J = 7.7 Hz, 2 H), 2.82 (dd, J = 5.7, 8.9 Hz, 1 H), 2.38–2.34 (m, 2 H), 1.78 (ddd, J = 
2.2, 9.5, 11.9 Hz, 1 H), 1.71–1.57 (m, 3 H), 1.53 (dd, J = 2.8, 9.4 Hz, 1 H), 1.39 (t, J = 9.2 Hz, 1 
H), 1.34–1.27 (m, 1 H), 1.24 (dd, J = 2.8, 9.3 Hz, 1 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 
164.8, 152.3, 152.1, 127.7, 126.9, 120.5, 47.4, 42.6, 39.0, 36.8, 36.1, 30.5, 28.7 ppm; IR:  = 3110, 
2955, 2867, 1611, 1578, 1504, 1493, 1453, 1413, 1097, 1066, 1015, 954, 895, 847, 831, 713 cm-1; 
HRMS (ESI) m/z calc. for C15H16N2ONa [M + Na]+ 263.1160, found 263.1163. 
 
 
 
3-(exo-Bicyclo[2.2.1]heptan-2-yl)-5-methoxypyridine (41): obtained as a light brown oil (77 mg, 
76%); 1H NMR (CDCl3, 500.4 MHz): δ 8.09 (br s, 2 H), 7.02 (s, 1 H), 3.83 (s, 3 H), 2.72 (dd, J = 
5.6, 9.0 Hz, 1 H), 2.38–2.34 (m, 2 H), 1.78 (ddd, J = 2.0, 10.0, 11.0 Hz, 1 H), 1.65–1.52 (m, 3 H), 
1.49 (dd, J = 2.5, 9.7 Hz, 1 H), 1.36 (t, J = 9.0 Hz, 1 H), 1.30–1.24 (m, 1 H), 1.21 (dd, J = 2.8, 9.3 
Hz, 1 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 155.5, 143.4, 141.6, 133.7, 119.5, 55.40, 44.7, 
42.6, 38.7, 36.7, 36.1, 30.4, 28.6 ppm; IR:  = 2949, 2869, 1585, 1456, 1242, 1283, 1264, 1178, 
1158, 1039, 866, 716 cm-1; HRMS (ESI) m/z calc. for C13H18NO [M + H]+ 204.1388, found 
204.1392. 
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5-(exo-Bicyclo[2.2.1]heptan-2-yl)thiophene-2-sulfonamide (42): obtained as a colorless oil (91 
mg, 71%); 1H NMR (CDCl3, 500.4 MHz): δ 7.48 (d, J = 4.1 Hz, 1 H), 6.74 (d, J = 4.1 Hz, 1 H), 
5.13 (br s, 2 H), 2.95 (dd, J = 5.5, 8.8 Hz, 1 H), 2.40–2.35 (m, 2 H), 1.87 (ddd, J = 3.4, 9.8, 10.9 
Hz, 1 H), 1.71–1.57 (m, 3 H), 1.53 (dt, J = 2.0, 2.0, 10.0 Hz, 1 H), 1.40–1.34 (m, 1 H), 1.29–1.24 
(m, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 160.4, 138.9, 131.8, 122.7, 44.8, 43.5, 40.5, 
36.5, 36.2, 29.7, 28.4 ppm; IR:  = 3264, 2950, 2870, 1593, 1545, 1440, 1330, 1154, 1083, 1013, 
892, 810, 804, 729, 671 cm-1; HRMS (ESI) m/z calc. for C11H14NO2S2 [M – H]– 256.0466, found 
256.0464. 
 
 
 
5-(exo-Bicyclo[2.2.1]heptan-2-yl)pyridin-2-amine (43): obtained as a light brown solid (60 mg, 
64%), mp 104 °C; 1H NMR (CDCl3, 500.4 MHz): δ 7.93 (d, J = 1.9 Hz, 1 H), 7.29 (dd, J = 1.9, 8.3 
Hz, 1 H), 6.44 (d, J = 8.3 Hz, 1 H), 4.31 (br s, 2 H), 2.60 (dd, J = 5.9, 8.9 Hz, 1 H), 2.34 (br s, 1 
H), 2.26 (br s, 1 H), 1.72 (ddd, J = 3.3, 9.1, 10.0 Hz, 1 H), 1.60–1.55 (m, 3 H), 1.47 (dt, J = 1.9, 
1.9, 10.1 Hz, 1 H), 1.36–1.20 (m, 2 H), 1.17 (d, J = 8.3 Hz, 1 H) ppm; 13C {1H} NMR (CDCl3, 
125.8 MHz): 156.2, 146.4, 136.7, 132.8, 108.2, 44.2, 42.9, 38.8, 36.7, 35.9, 30.4, 28.7 ppm; IR:  
= 3352, 3186, 2948, 2868, 1621, 1499, 1454, 1392, 1257, 1204, 1147, 823, 766, 742 cm-1; HRMS 
(ESI) m/z calc. for C12H17N2 [M + H]+ 189.1392, found 189.1394. 
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3-(Naphthalen-1-yl)propyl acetate (44): obtained as a colorless oil (108 mg, 95%); 1H NMR 
(CDCl3, 500.4 MHz): δ 8.06 (d, J = 8.4 Hz, 1 H), 7.89 (d, J = 7.9 Hz, 1 H), 7.76 (d, J = 7.9 Hz, 1 
H), 7.57–7.49 (m, 2 H), 7.43 (t, J = 7.8 Hz, 1 H), 7.36 (d, J = 6.7 Hz, 1 H), 4.20 (t, J = 6.7 Hz, 2 
H), 3.19 (t, J = 8.0 Hz, 2 H), 1.92 (tt, J = 6.7, 8.0 Hz, 2 H), 2.11 (s, 3 H) ppm; 13C NMR (CDCl3, 
125.8 MHz): 171.1, 137.2, 133.9, 131.7, 128.8, 126.8, 126.0, 125.8, 125.4, 125.3, 123.5, 64.0, 29.4, 
29.2, 20.9 ppm; IR:  = 2954, 1733, 1596, 1510, 1464, 1434, 1386, 1232, 1166, 1038, 976, 950, 
876, 791, 776, 734 cm-1; HRMS (ESI) m/z calc. for C15H16O2Na [M + Na]+ 251.1048, found 
251.1049.  
 
 
 
3-(3-(1H-Pyrazol-5-yl)phenyl)propyl acetate (45): obtained as a pale yellow oil (88 mg, 72%); 
1H NMR (CDCl3, 500.4 MHz): δ 12.8–10.2 (br s, 1 H), 7.61-7.59 (m, 3 H), 7.32 (dd, J = 8.0, 7.5 
Hz,  1 H), 7.15 (d, J = 7.5 Hz, 1 H), 6.61 (s, 1 H), 4.10 (t, J = 6.5 Hz, 2 H), 2.71 (t, J = 7.5 Hz, 2 
H), 2.05 (s, 3 H), 1.92 (tt, J = 6.5, 7.5 Hz, 2 H) ppm 13C NMR (CDCl3, 125.8 MHz): 171.5, 149.1, 
141.9, 133.5, 132.3, 129.1, 128.3, 125.9, 123.7, 102.8, 64.0, 32.3, 30.3, 21.2 ppm; IR:  = 3173, 
3055, 2954, 1733, 1610, 1470, 1450, 1366, 1095, 1037, 972, 933, 898, 764, 699, 605 cm-1; HRMS 
(ESI) m/z calc. for C14H16N2O2Na [M + Na]+ 267.1109, found 267.1121. 
 
 
3-(4-Hydroxyphenyl)propyl acetate (46): obtained as a light brown oil (66 mg, 68%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.04 (dd, J = 8.0, 2.0 Hz, 2 H), 6.79 (dd, J = 8.0, 2.0 Hz, 2 H), 5.29 (s br, 
452 
1 H), 4.08 (m, 2 H), 2.61 (t, J = 7.5 Hz, 2 H), 2.06 (s, 3 H), 1.93 (m, 2 H) ppm; 13C NMR (CDCl3, 
125.8 MHz): 171.8, 154.1, 133.3, 129.6, 115.4, 64.1, 31.3, 30.5, 21.2 ppm; IR:  = 3385, 3090, 
2905, 1734, 1707, 1614, 1596, 1390, 1229, 1172, 1035, 846, 822, 746, 555 cm-1; HRMS (ESI) m/z 
calc. for C11H13O3 [M - H]- 193.0865, found 193.0864. 
 
 
3-(Benzofuran-5-yl)propyl acetate (47): obtained as a colorless oil (95 mg, 87%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.60 (d, J = 2.0 Hz, 1 H), 7.43-7.40 (m, 2 H), 7.12 (d, J = 8.5, 1.5 Hz, 1 H), 
6.71 (dd, J = 1.5, 2.0 Hz, 1 H), 4.10 (t, J = 7.0 Hz, 2 H), 2.78 (t, J = 7.5 Hz, 2 H), 2.06 (s, 3 H), 
1.99 (tt, J = 7.0, 7.5 Hz, 2 H) ppm; 13C NMR (CDCl3, 125.8 MHz): 171.3, 153.8, 145.3, 135.8, 
127.7, 125.0, 120.6, 111.3, 106.5, 64.0, 32.3, 30.9, 21.1 ppm; IR:  = 2953, 1734, 1468, 1445, 
1387, 1365, 1197, 1126, 1110, 1031, 978, 884, 813, 792, 767, 631, 606 cm-1; HRMS (ESI) m/z 
calc. for C13H14O3Na [M + Na]+ 241.0841, found 251.0844. 
 
3-(1H-Indol-5-yl)propyl acetate (48): obtained as a white crystalline solid (81 mg, 75%); mp 121 
°C, 1H NMR (CDCl3, 500.4 MHz): δ 8.10 (s br, 1 H), 7.46 (s, 1 H), 7.31 (d, J = 8.0 Hz, 1 H), 7.18 
(s, 1 H), 7.04 (d, J = 8.0 Hz, 1 H), 6.51 (s, 1 H), 4.13 (t, J = 6.5 Hz, 2 H), 2.80 (t, J = 7.5 Hz, 2 H), 
2.09 (s, 3 H), 1.93 (tt, J = 6.5, 7.5 Hz, 2 H) ppm; 13C NMR (CDCl3, 125.8 MHz): 171.6, 134.6, 
132.6, 128.3, 124.6, 123.0, 120.1, 111.1, 102.3, 64.3, 32.4, 31.1, 21.2 ppm ; IR:  = 3281, 2852, 
1702, 1368, 1238, 1142, 1070, 896, 868, 809, 760, 731, 631, 607, 573 cm-1; HRMS (ESI) m/z calc. 
for C13H16NO2 [M + H]+ 218.1181, found 218.1186. 
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N-(3-(4-Fluorophenyl)propyl)aniline (49): obtained as a pale yellow oil (102 mg, 89%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.18–7.09 (m, 4 H), 6.79 (t, J = 8.5 Hz, 2 H), 6.68 (t, J = 7.3 Hz, 1 H), 6.56 
(t, J = 7.8 Hz, 2 H), 3.57 (br s, 1 H), 3.11 (t, J = 7.3 Hz, 2 H), 2.68 (t, J = 7.3 Hz, 2 H), 1.90 (q, J = 
7.3 Hz, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 161.5 (d, J = 240.9 Hz), 148.5, 137.5 (d, 
J = 3.9 Hz), 129.9 (d, J = 9.0 Hz), 129.4, 117.4, 115.2 (d, J = 21.1 Hz), 112.9, 43.4, 32.7, 31.4 ppm; 
19F {1H} NMR (CDCl3, 470.8 MHz): –117.5 ppm; IR:  = 2932, 2860, 1601, 1505, 1476, 1454, 
1430, 1318, 1256, 1218, 1179, 1156, 1095, 869, 848, 820, 747, 691, 542, 500 cm-1; HRMS (ESI) 
m/z calc. for C15H16NF [M]+ 229.1267, found 229.1260. 
 
 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(3-(phenylamino)propyl)phenyl)propan- 
oate (50): obtained as a colorless oil (158 mg, 76%); [α]20D = –89.5 (CHCl3, c = 1.0); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.18 (t, J = 7.4 Hz, 2 H), 7.14 (d, J = 8.2 Hz, 2 H), 7.07 (d, J = 7.4 Hz, 2 
H), 6.71 (t, J = 7.5 Hz, 1 H), 6.60 (d, J = 8.5 Hz, 2 H), 5.04 (d, J = 9.4 Hz, 1 H),4.60 (dd, J = 9.4, 
4.7 Hz, 1 H), 3.88–3.45 (br s, 1 H), 3.71 (s, 3 H), 3.15 (t, J = 6.9 Hz, 2 H), 3.13–3.01 (m, 2 H), 2.72 
(t, J = 7.8 Hz, 2 H), 1.92 (tt, J = 6.9, 7.8 Hz, 2 H), 1.44 (s, 9 H) ppm; 13C {1H} NMR (CDCl3, 125.8 
MHz): 172.3, 155.1, 148.3, 140.3, 133.5, 129.3, 129.2, 128.5, 117.2, 112.7, 79.8, 54.4, 52.1, 43.4, 
37.9, 32.9, 30.9, 28.3 ppm; IR:  = 3352, 2976, 1742, 1704, 1602, 15034, 1435, 1365, 1320, 1252, 
1214, 1161, 1115, 1058, 1020, 991, 910, 748, 732, 692 cm-1; HRMS (ESI) m/z calc. for 
C24H32N2O4Na [M + Na]+ 435.2260, found 435.2263.  
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N-(3-(2-Chlorophenyl)propyl)aniline (51): obtained as a yellow oil (108 mg, 88%); 1H NMR 
(CDCl3, 500.4 MHz): δ 7.33 (d, J = 7.4 Hz, 1 H), 7.22–7.09 (m, 5 H), 6.68 (t, J = 7.4 Hz, 1 H), 6.58 
(d, J = 8.1 Hz, 2 H), 3.62 (br s, 1 H), 3.15 (t, J = 6.8 Hz, 2 H), 2.83 (t, J = 7.6 Hz, 2 H), 1.92 (tt, J 
= 6.8, 7.6 Hz, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 148.5, 139.4, 134.1, 130.6, 129.7, 
129.4, 127.7, 127.1, 117.4, 112.9, 43.6, 31.3, 29.7 ppm; IR:  = 3310, 2930, 2862, 1601, 1504, 
1473, 1256, 1153, 1131, 1051, 992, 744, 691, 680, 508 cm-1; HRMS (ESI) m/z calc. for C15H17NCl 
[M + H]+ 246.1050, found 246.1048. 
 
 
 
1-(4-(3-(Phenylamino)propyl)phenyl)ethan-1-one (52): obtained as a colorless crystalline solid 
(120 mg, 95%); mp 104-105 °C, 1H NMR (CDCl3, 500.4 MHz): δ 7.90 (d, J = 7.6 Hz, 2 H), 7.30 
(d, J = 7.6 Hz, 2 H), 7.18 (t, J = 7.6 Hz, 2 H), 6.71 (t, J = 7.6 Hz, 1 H), 6.58 (d, J = 7.6 Hz, 2 H), 
3.64 (br s, 1 H), 3.11 (t, J = 7.5 Hz, 2 H), 2.68 (t, J = 7.5 Hz, 2 H), 2.59 (s, 3 H), 1.98 (q, J = 7.5 
Hz, 2 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 197.9, 148.3, 147.7, 135.4, 129.4, 128.8 [× 
2], 117.5, 112.9, 43.4, 33.6, 30.9, 26.8 ppm; IR:  = 3358, 2118, 1642, 1604, 1503, 1413, 1361, 
1258, 1236, 1118, 1082, 891, 870, 748, 693, 614, 539 cm-1; HRMS (ESI) m/z calc. for C17H20NO 
[M + H]+ 254.1545, found 254.1549. 
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tert-Butyl 5-(3-(phenylamino)propyl)-1H-indazole-1-carboxylate (53): obtained as a yellow oil 
(165 mg, 94%); 1H NMR (CDCl3, 500.4 MHz): δ 8.12 (s, 1 H), 8.08 (s, 1 H), 7.64 (d, J = 8.3 Hz, 
1 H), 7.20–7.14 (m, 3 H), 6.70 (t, J = 7.5 Hz, 1 H), 6.59 (d, J = 8.1 Hz, 2 H), 3.65 (br s, 1 H), 3.18 
(t, J = 6.8 Hz, 2 H), 2.91 (t, J = 8.0 Hz, 2 H), 2.03 (m, 2 H), 1.72 (s, 9 H) ppm; 13C {1H} NMR 
(CDCl3, 125.8 MHz): 149.6, 148.4, 143.6, 140.5, 139.6, 129.4, 125.0, 124.5, 121.1, 117.4, 114.1, 
112.9, 85.0, 43.5, 34.2, 31.4, 28.4 ppm; IR:  = 3342, 2980, 2854, 1735, 1712, 1602, 1480, 1345, 
1291, 1251, 1150, 1028, 938, 764, 748, 730, 692 cm-1; HRMS (ESI) m/z calc. for C21H26N3O2 [M 
+ H]+ 352.2025, found 352.2023. 
 
 
3-(2-(Tetrahydro-2H-pyran-4-yl)phenyl)propyl acetate (55): obtained as a crystalline powder 
(127 mg, 97%), mp 46 °C; 1H NMR (CDCl3, 500.4 MHz): δ 7.28–7.25 (m, 1 H), 7.24–7.20 (m, 1 
H), 7.18–7.14 (m, 2 H), 4.16–4.09 (m, 4 H), 3.56 (t, J = 11.2 Hz, 2 H), 2.99 (tt, J = 11.9, 3.0 Hz, 1 
H), 2.75 (t, J = 8.1 Hz, 2 H), 2.09 (s, 3 H), 1.96–1.94 (m, 4 H), 1.69–1.64 (m, 2 H) ppm; 13C {1H} 
NMR (CDCl3, 125.8 MHz): 171.0, 143.3, 138.8, 129.5, 126.6, 126.2, 126.1, 68.6, 63.9, 36.8, 34.0, 
30.5, 29.0, 20.9 ppm; IR:  = 2923, 2848, 1734, 1493, 1465, 1385, 1365, 1236, 1126, 1087, 1034, 
1019, 980, 901, 838, 764 cm-1; HRMS (ESI) m/z calc. for C16H23O3 [M + H]+ 263.1647, found 
263.1653. 
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2-Benzyl-6-(tetrahydro-2H-pyran-4-yl)pyridine (57): obtained as a light yellow oil (91 mg, 
72%); 1H NMR (CDCl3, 500.4 MHz): δ 7.52 (d, J = 7.9 Hz, 1 H), 7.4–7.27 (m, 4 H), 7.25-7.20 (m, 
1 H), 7.00 (d, J = 7.7 Hz, 1 H), 6.92 (d, J = 7.7 Hz, 1 H), 4.15 (s, 2 H), 4.11 (dt, J = 10.9, 2.7 Hz, 2 
H), 3.61–3.53 (m, 2 H), 2.98 (q, J = 7.8 Hz, 1 H), 1.95–1.87 (m, 4 H) ppm; 13C {1H} NMR (CDCl3, 
125.8 MHz): 163.8, 160.3, 139.6, 136.9, 129.0, 128.4, 126.2, 120.6, 117.8, 68.1, 44.7, 43.4, 32.5 
ppm; IR:  = 2949, 2917, 2841, 1588, 1575, 1494, 1451, 1386, 1237, 1128, 1086, 1029, 980, 866, 
823, 774 cm-1; HRMS (ESI) m/z calc. for C17H20NO [M + H]+ 254.1545, found 254.1548. 
 
 
 
2,6-Dibenzylpyridine (58): obtained as a light yellow oil (24 mg, 19%); 1H NMR (CDCl3, 500.4 
MHz): δ 7.46 (t, J = 7.9 Hz, 1 H), 7.34–7.26 (m, 8 H), 7.26–7.21 (m, 2 H), 6.90 (d, J = 7.2 Hz, 2 
H), 4.18 (s, 4 H) ppm; 13C {1H} NMR (CDCl3, 125.8 MHz): 160.4, 139.5, 136.9, 129.1, 128.4, 
126.2, 120.5, 44.5 ppm; IR:  = 3026, 2919, 1588, 1573, 1494, 1450, 1427, 1260, 1217, 1091, 
1074, 1029, 769, 737, 696 cm-1; HRMS (ESI) m/z calc. for C19H18N [M + H]+ 260.1439, found 
260.1445. 
 
 
Triethylammonium phenylbis(catecholato)silicate (59): obtained as a white powder using THF 
as solvent (3.28 g, 93%), mp = 203 °C; 1H NMR (DMSO-d6, 500.4 MHz): δ 8.79 (br. s, 1 H), 7.51 
N
O
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(d, J = 7.0 Hz, 2 H), 7.16–7.10 (m, 3 H), 6.63–6.58 (m, 4 H), 6.51–6.48 (m, 4 H), 3.06 (q, J = 7.5 
Hz, 6 H), 1.14 (t, J = 7.5 Hz, 9 H) ppm; 13C {1H} NMR (DMSO-d6, 125.8 MHz): δ 150.8, 142.3, 
135.1, 128.2, 127.1, 117.9, 110.2, 46.2, 9.0 ppm; IR:  = 1483, 1439, 1388, 1351, 1240, 1227, 
1157, 1113, 1101, 1012, 889, 819, 761, 737, 723, 700 cm-1; HRMS (ESI) m/z calc. for C18H13O4Si 
[M – HNEt3]– 321.0582, found 321.0588; Epa = + 0.76 V vs SCE. 
 
 
Triethylammonium benzylbis(methyl-2-hydroxyisobuyro)silicate (60): Alpha-
hydroxyisobutyric acid (477 mg, 4.89 mmol, 1.95 equiv) was introduced into a microwave vial 
with a stirring bar. The vial was sealed with a Teflon-coated septum cap then purged with N2 and 
evacuated four times. 1,4–Dioxane (5 mL) and triethylamine (0.39 mL, 287 mg, 2.88 mmol, 1.2 
equiv) were introduced, and the resulting slurry was stirred at rt for 15 min before addition of 
benzyltrimethoxysilane (500 mg, 2.35 mmol, 1 equiv). The reaction mixture was refluxed for 16 h, 
then the vial was cooled to rt and the reaction mixture concentrated to a glue before the Et2O (25 
mL) was introduced. The mixture was then sonicated 15 min to allow the corresponding product to 
precipitate as a white powder. The filter cake was finally washed with Et2O to afford 60 as a white 
powder (810 mg, 81%), mp = 96 °C; 1H NMR (DMSO-d6, 500.4 MHz): δ 8.89 (br. s, 1 H), 7.09 (t, 
J = 7.1 Hz, 2 H), 6.99 (t, J = 7.1 Hz, 2 H), 6.93 (d, J = 7.1 Hz, 1 H), 3.85 (q, J = 7.3 Hz, 6 H), 2.04–
1.93 (m, 2 H), 1.16 (t, J = 7.3 Hz, 9 H), 1.10 (s, 6 H), 0.84 (s, 6 H) ppm; 13C {1H} NMR (DMSO-
d6, 125.8 MHz): δ 179.2, 141.8, 129.1, 127.8, 123.5, 73.5, 46.2, 28.9, 28.3, 26.7, 9.1 ppm; IR:  = 
1707, 1668, 1470, 1378, 1357, 1325, 1204, 1187, 1164, 1012, 861, 810, 796, 778, 694 cm-1; HRMS 
(ESI) m/z calc. for C15H19O6Si [M – HNEt3]– 323.0950, found 323.0945; Epa > + 2.00 V vs SCE. 
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Appendix A8. 1H, 13C, and 19F NMR Spectra Relevant to Chapter 7 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium benzylbis(catecholato)silicate (1) 
 
13C {1H} NMR (CDCl3, 125.8 MHz) of triethylammonium benzylbis(catecholato)silicate (1) 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium benzylbis(catecholato)silicate (1) after 3 
months on benchtop. 
 
1H NMR (CDCl3, 500.4 MHz) of triethylammonium cyclohexylbis(catecholato)silicate (2) 
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13C {1H} NMR (CDCl3, 125.8 MHz) of triethylammonium cyclohexylbis(catecholato)silicate (2)
 
1H NMR (CDCl3, 500.4 MHz) of triethylammonium cyclohexylbis(catecholato)silicate (2) after 3 
months on benchtop. 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium exo-2-
bicyclo[2.2.1]heptylbis(catecholato)silicate (3) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of triethylammonium exo-2-
bicyclo[2.2.1]heptylbis(catecholato)silicate (3)  
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium exo-2-
bicyclo[2.2.1]heptylbis(catecholato)silicate (3) 
after 3 months on benchtop. 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium methylbis(catecholato)silicate (4) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of triethylammonium methylbis(catecholato)silicate (4) 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium hexylbis(catecholato)silicate (5) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of triethylammonium hexylbis(catecholato)silicate (5) 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium chloromethylbis(catecholato)silicate (6) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of triethylammonium chloromethylbis(catecholato)silicate 
(6) 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium 2-(3-
cyclohexenyl)ethylbis(catecholato)silicate (7) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of triethylammonium 2-(3-
cyclohexenyl)ethylbis(catecholato)silicate (7)  
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1H NMR (DMSO–d6, 500.4 MHz) of diisopropylammonium 2-(3,4-
epoxycyclohexyl)ethylbis(catecholato)silicate (8) 
 
13C NMR {1H} (DMSO–d6, 125.8 MHz) of diisopropylammonium 2-(3,4- 
epoxycyclohexyl)ethylbis(catecholato)silicate (8)  
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1H NMR (CD3CN, 500.4 MHz) of diisopropylammonium N-[5-(bis(catecholato)silicate)-2-aza-1-
oxopentyl]caprolactam (9) 
 
13C NMR {1H} (DMSO-d6, 125.8 MHz) of diisopropylammonium N-[5-(bis(catecholato)silicate)-
2-aza-1-oxopentyl]caprolactam (9)  
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1H NMR (DMSO-d6, 500.4 MHz) of diisopropylammonium 3-
(phenylamino)propylbis(catecholato)silicate (10) 
 
13C NMR {1H} (DMSO-d6, 125.8 MHz) of diisopropylammonium 3-
(phenylamino)propylbis(catecholato) 
silicate (10)  
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium 2-(pyridin-2-yl)ethylbis(catecholato)silicate 
(11) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of of triethylammonium 2-(pyridin-2-
yl)ethylbis(catecholato)silicate (11)  
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1H NMR (CDCl3, 500.4 MHz) of diisopropylammonium 3,3,4,4,5,5,6,6,6-
nonafluorohexylbis(catecholato)silicate (12) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of diisopropylammonium 3,3,4,4,5,5,6,6,6-
nonafluorohexylbis(catecholato)silicate (12)  
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19F NMR {1H} (CDCl3, 470.8 MHz) of diisopropylammonium 3,3,4,4,5,5,6,6,6-
nonafluorohexylbis(catecholato)silicate (12) 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium 3-acetoxypropylbis(catecholato)silicate (13) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of triethylammonium 3-
acetoxypropylbis(catecholato)silicate (13) 
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1H NMR (CDCl3, 500.4 MHz) of triethylammonium 3-acetoxypropylbis(catecholato)silicate (13) 
after 3 months on benchtop. 
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1H NMR (DMSO-d6, 500.4 MHz) of 3-ammoniumpropylbis(catecholato)silicate (14) 
 
13C NMR {1H} (DMSO-d6, 125.8 MHz) of 3-ammoniumpropylbis(catecholato)silicate (14) 
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1H NMR (DMSO-d6, 500.4 MHz) of 3-ammoniumpropylbis(catecholato)silicate (14) after 3 
months on benchtop. 
 
481 
 
1H NMR (CDCl3, 500.4 MHz) of 1-benzyl-4-methoxybenzene (15) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 1-benzyl-4-methoxybenzene (15) 
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1H NMR (CDCl3, 500.4 MHz) of 1-cyclohexyl-4-methoxybenzene (16) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 1-cyclohexyl-4-methoxybenzene (16) 
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1H NMR (CDCl3, 500.4 MHz) of exo-2-(4-methoxyphenyl)bicyclo[2.2.1]heptane (17) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of exo-2-(4-methoxyphenyl)bicyclo[2.2.1]heptane (17) 
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1H NMR (CDCl3, 500.4 MHz) of 1-hexyl-4-methoxybenzene (19) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 1-hexyl-4-methoxybenzene (19) 
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1H NMR (CDCl3, 500.4 MHz) of  1-(2-(cyclohex-3-en-1-yl)ethyl)-4-methoxybenzene (21) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 1-(2-(cyclohex-3-en-1-yl)ethyl)-4-methoxybenzene (21) 
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1H NMR (CDCl3, 500.4 MHz) of  N-[(3-(4-methoxyphenyl)propyl)-2-aza-1-
oxopentyl]caprolactam (23) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of N-[(3-(4-methoxyphenyl)propyl)-2-aza-1-
oxopentyl]caprolactam (23)  
487 
 
1H NMR (CDCl3, 500.4 MHz) of N-(3-(4-methoxyphenyl)propyl)aniline (24) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of N-(3-(4-methoxyphenyl)propyl)aniline (24) 
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1H NMR (CDCl3, 500.4 MHz) of 2-(4-methoxyphenethyl)pyridine (25) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 2-(4-methoxyphenethyl)pyridine (25) 
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1H NMR (CDCl3, 500.4 MHz) of 4-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)-1,1'-biphenyl (26) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 4-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)-1,1'-biphenyl (26) 
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19F NMR {1H} (CDCl3, 470.8 MHz) of 4-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)-1,1'-biphenyl (26) 
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1H NMR (CDCl3, 500.4 MHz) of  3-(4-methoxyphenyl)propyl acetate (27) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(4-methoxyphenyl)propyl acetate (27) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(4-methoxyphenyl)propan-1-amine (28) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(4-methoxyphenyl)propan-1-amine (28)
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1H NMR (CDCl3, 500.4 MHz) of 4-(3-aminopropyl)benzonitrile (29) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 4-(3-aminopropyl)benzonitrile (29) 
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1H NMR (CDCl3, 500.4 MHz) of 2-(3-aminopropyl)benzonitrile (30) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 2-(3-aminopropyl)benzonitrile (30) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(4-(trifluoromethyl)phenyl)propan-1-amine (31) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(4-(trifluoromethyl)phenyl)propan-1-amine (31) 
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19F NMR {1H} (CDCl3, 470.8 MHz) of 3-(4-(trifluoromethyl)phenyl)propan-1-amine (31) 
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1H NMR (CDCl3, 500.4 MHz) of methyl 4-(3-aminopropyl)benzoate (32) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of methyl 4-(3-aminopropyl)benzoate (32)
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1H NMR (DMSO-d6, 500.4 MHz) of N-(4-(3-aminopropyl)phenyl)acetamide (33) 
 
13C NMR {1H} (DMSO-d6, 125.8 MHz) of N-(4-(3-aminopropyl)phenyl)acetamide (33) 
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1H NMR (CDCl3, 500.4 MHz) of (4-(3-aminopropyl)phenyl)methanol (34) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of (4-(3-aminopropyl)phenyl)methanol (34) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(3-(1H-pyrazol-5-yl)phenyl)propan-1-amine (35) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(3-(1H-pyrazol-5-yl)phenyl)propan-1-amine (35) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(1-methyl-1H-indazol-5-yl)propan-1-amine (36) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(1-methyl-1H-indazol-5-yl)propan-1-amine (36) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(1H-indol-5-yl)propan-1-amine (37) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(1H-indol-5-yl)propan-1-amine (37) 
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1H NMR (CDCl3, 500.4 MHz) of tert-butyl 4-(5-(3-aminopropyl)pyrimidin-2-yl)piperazine-1-
carboxylate (38) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of tert-butyl 4-(5-(3-aminopropyl)pyrimidin-2-
yl)piperazine-1-carboxylate (38)
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1H NMR (CDCl3, 500.4 MHz) of 5-(exo-bicyclo[2.2.1]heptan-2-yl)pyrimidine (39) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 5-(exo-bicyclo[2.2.1]heptan-2-yl)pyrimidine (39) 
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1H NMR (CDCl3, 500.4 MHz) of 2-(4-(exo-bicyclo[2.2.1]heptan-2-yl)phenyl)-1,3,4-oxadiazole 
(40) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 2-(4-(exo-bicyclo[2.2.1]heptan-2-yl)phenyl)-1,3,4-
oxadiazole (40)
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1H NMR (CDCl3, 500.4 MHz) of 3-(exo-bicyclo[2.2.1]heptan-2-yl)-5-methoxypyridine (41) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(exo-bicyclo[2.2.1]heptan-2-yl)-5-methoxypyridine 
(41) 
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1H NMR (CDCl3, 500.4 MHz) of 5-(exo-bicyclo[2.2.1]heptan-2-yl)thiophene-2-sulfonamide (42) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 5-(exo-bicyclo[2.2.1]heptan-2-yl)thiophene-2-
sulfonamide (42)  
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1H NMR (CDCl3, 500.4 MHz) of 5-(exo-bicyclo[2.2.1]heptan-2-yl)pyridin-2-amine (43) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 5-(exo-bicyclo[2.2.1]heptan-2-yl)pyridin-2-amine (43) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(naphthalen-1-yl)propyl acetate (44) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(naphthalen-1-yl)propyl acetate (44) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(3-(1H-pyrazol-5-yl)phenyl)propyl acetate (45) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(3-(1H-pyrazol-5-yl)phenyl)propyl acetate (45) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(4-hydroxyphenyl)propyl acetate (46) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(4-hydroxyphenyl)propyl acetate (46) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(benzofuran-5-yl)propyl acetate (47) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(benzofuran-5-yl)propyl acetate (47) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(1H-indol-5-yl)propyl acetate (48) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(1H-indol-5-yl)propyl acetate (48)  
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1H NMR (CDCl3, 500.4 MHz) of N-(3-(4-fluorophenyl)propyl)aniline (49) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of N-(3-(4-fluorophenyl)propyl)aniline (49) 
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19F NMR {1H} (CDCl3, 470.8 MHz) of N-(3-(4-fluorophenyl)propyl)aniline (49) 
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1H NMR (CDCl3, 500.4 MHz) of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(3-
(phenylamino)propyl)phenyl)propanoate (50). 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(3-
(phenylamino)propyl)phenyl)propanoate (50).  
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1H NMR (CDCl3, 500.4 MHz) of N-(3-(2-chlorophenyl)propyl)aniline (51) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of N-(3-(2-chlorophenyl)propyl)aniline (51) 
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1H NMR (CDCl3, 500.4 MHz) of 1-(4-(3-(phenylamino)propyl)phenyl)ethan-1-one (52) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 1-(4-(3-(phenylamino)propyl)phenyl)ethan-1-one (52) 
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1H NMR (CDCl3, 500.4 MHz) of tert-butyl 5-(3-(phenylamino)propyl)-1H-indazole-1-
carboxylate (53) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of tert-butyl 5-(3-(phenylamino)propyl)-1H-indazole-1-
carboxylate (53) 
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1H NMR (CDCl3, 500.4 MHz) of 3-(2-(tetrahydro-2H-pyran-4-yl)phenyl)propyl acetate (55) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 3-(2-(tetrahydro-2H-pyran-4-yl)phenyl)propyl acetate 
(55) 
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1H NMR (CDCl3, 500.4 MHz) of 2-benzyl-6-(tetrahydro-2H-pyran-4-yl)pyridine (57) 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 2-benzyl-6-(tetrahydro-2H-pyran-4-yl)pyridine (57)  
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1H NMR (CDCl3, 500.4 MHz) of 2,6-dibenzylpyridine (58) 
 
 
13C NMR {1H} (CDCl3, 125.8 MHz) of 2,6-dibenzylpyridine (58)  
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1H NMR (DMSO-d6, 500.4 MHz) of triethylammonium phenylbis(catecholato)silicate (59) 
 
13C NMR {1H} (DMSO-d6, 125.8 MHz) of triethylammonium phenylbis(catecholato)silicate (59)  
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1H NMR (DMSO-d6, 500.4 MHz) of triethylammonium benzylbis(methyl-2-
hydroxyisobuyro)silicate (60) 
 
13C NMR {1H} (DMSO-d6, 125.8 MHz) of triethylammonium benzylbis(methyl-2-
hydroxyisobuyro)silicate (60)  
525 
Appendix A9. Cyclic Voltammetry Data Relevant to Chapter 7 
 
Voltammetric measurements were recorded on a CH Instruments: Model 600E Series 
Electrochemical Analyzer using a standard three electrodes setup in dry and degassed MeCN (10 
mL), with ferrocene as internal reference (E01/2 = + 0.40 V vs SCE) and tetrabutylammonium 
hexafluorophosphate as electrolyte (0.10 mmol). Cyclic voltammograms were recorded with a step 
potential of 0.002 V at a scan rate of 0.1 V/s. 
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Chapter 8. Computational and Experimental Investigations into Reaction Mechanism 
8.1 Introduction 
 
In the originally proposed reaction mechanism for these photoredox mediated cross-
couplings,1 we hypothesized that the Ni(0) catalyst 1 first engages the aryl bromide in oxidative 
addition to afford arylnickel(II) complex 3 (Figure 8.1, red). In parallel, oxidative fragmentation 
of an alkyltrifluoroborate 6 by the excited state of Ir photoredox catalyst 4 yields a carbon-centered 
radical that is rapidly captured by this Ni(II) complex. Reductive elimination from the resultant 
Ni(III) species 10 yields the cross-coupled product and Ni(I) complex 12. Finally, single-electron 
reduction of Ni(I) by anionic Ir complex 8 simultaneously regenerates the Ni(0) catalyst and the 
ground state photocatalyst. MacMillan, Doyle, and coworkers hypothesized a similar mechanistic 
scenario for the related cross-coupling of α-amino acids and N,N-dialkyl-N-arylamines with aryl 
halides.2 
 
Figure 8.1: Possible catalytic cycles (red: oxidative addition first; blue: radical addition first) 
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Although there are no clear faults with the original mechanism,i we also recognized the 
possibility of an alternative pathway in which radical addition precedes oxidative addition (Figure 
8.1, blue). Considering the success of this chemistry in achieving stereoconvergent transformations 
as highlighted in the cross-coupling of a secondary alkyltrifluoroborate in the presence of a chiral 
Ni complex (Figure 8.2), we deemed it necessary to parse out the differences between these two 
competing mechanisms. Greater understanding of this reaction coordinate would improve our 
development of these stereoconvergent cross-couplings by giving us clues about how to alter ligand 
structure and reaction conditions to achieve enhanced stereocontrol. As these reactions are difficult 
to monitor experimentally (variable induction period, visible light irradiation, and multiple 
catalysts), we hoped that a computational collaboration between the Molander group and the 
Kozlowski group. 
 
Figure 8.2. Stereoconvergent cross-coupling of a secondary benzylic trifluoroborate 
Here, to paint the differences between these two mechanistic scenarios, we undertook a 
computational analysis of the Ni catalytic cycle with the goal of addressing two key questions, (1) 
to which oxidation state of Ni does the radical add? and (2) which step in the catalytic cycle is 
enantio-determining? Importantly, although there have been numerous computational and 
experimental studies of traditional transition-metal catalyzed CCRs,3 there are limited 
                                                     
i Reproduced in part from J. Am. Chem. Soc., 2015, 137, 4896, 
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computational analyses of nickel-catalyzed CCRs in which carbon-centered radicals and 
paramagnetic Ni species are invoked.4–6 
To address this, we began a detailed DFT study of the catalytic cross-coupling of 
alkyltrifluoroborates and aryl bromides via single electron transmetalation. Results reveal that the 
final reductive elimination accounts for the origin of stereoinduction for this important 
transformation. A stereochemical model is proposed and supported by experiments with a series of 
substituted aryl bromides. These mechanistic findings are proposed to have far-reaching 
implications related to other stereoconvergent CCRs. 
8.2 Results and Discussion 
 
We initiated our studies by calculating the Gibbs free energy profile with 2,2’-bipyridine as 
a model ligand for the 4,4’-dtbbpy ligand used experimentally (Figure 2). Because of the presence 
of radicals and low-spin nickel intermediates, all optimizations were performed using a spin-
unrestricted broken-symmetry UB3LYP functional with both the LANL2DZ and 6-31G(d) basis 
sets (with the Guess=mix keyword as implemented in Gaussian09).7  Multiple spin states were 
considered for all intermediates and transition states.  This method has been used before to 
rationalize selectivities accurately,8 model radical nickel systems,6 and account for changes 
associated with ligands.9  Single point energy calculations of optimized structures were carried out 
in water (SMD solvation model) at the (U)M06/6-311+G(d,p) level of theory. For comparison, we 
computed the energetic profile by varying the basis set [6-311+G(d,p) for C, N, O, Br, H and SDD 
for Ni] and solvent (SMD in acetone), which showed similar energetics (see Experimental). 
Exhaustive conformational searches were performed for all intermediates to map out the lowest 
energy profile, and intrinsic reaction coordinate (IRC) calculations were undertaken to ensure 
transitions states connected the illustrated ground states. 
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Beginning from square planar Ni(bpy)(COD) A, dissociation of 1,5,-cyclooctadiene (COD) 
and complexation to bromobenzene is energetically disfavored by 6-8 kcal/mol (Figure 8.3). 
However, oxidative addition is energetically feasible (15-18 kcal/mol) leading to square planar 
Ni(II) intermediate A2, which is ~26 kcal/mol downhill in energy. The Ni(II) to Ni(III) process, 
occurring via addition of a benzyl radical (presumably generated in the concomitant photocatalytic 
cycle1,2,10 from Figure 1), is found to proceed via a low barrier (~4 kcal/mol) transition state A2-
TS and is reversible. Significantly, the reductive elimination transition state (C-TS) leading to the 
CCR product and Ni(bpy)Br intermediate is ~6 kcal/mol higher in energy than the radical 
addition/dissociation.  
In an alternative mechanistic pathway, the nickel catalytic cycle can proceed via an 
alkylnickel(I) intermediate preceding oxidative addition (Figure 8.1 red). Ligand dissociation and 
radical η2-complexation to nickel(0) leads to intermediate B1, which proceeds via a ~5 kcal/mol 
energy barrier to form benzyl nickel(I) intermediate B2, a process that is favorable by ~10-15 
kcal/mol. This Ni(I) intermediate can undergo facile and irreversible oxidative addition (via B2-
TS) to merge the two energetically feasible pathways via the pentacoordinated Ni(III) intermediate 
C. This implies that, irrespective of the specific pathway, e.g., radical capture of Ni(0) or Ni(II), 
the dual photoredox/cross-coupling cycle converges onto a Ni(III) intermediate that can dissociate 
the stabilized radical to form Ni(II) more rapidly than undergoing reductive elimination! 
Subsequent reduction by the photoredox cycle will generate the Ni(0) intermediate to restart the 
catalytic cycle. 
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Figure 8.3.  Reaction coordinate for the competing pathways using 2,2’-bipyridine. Relative 
Gibbs free energy values calculated with SMD-water-(U)M06/6-311+G(d,p)//UB3LYP/6-
31G(d,p) and SMD-water-(U)M06/6-311+G(d,p) //UB3LYP/LANL2DZ (in parentheses). 
 
In our recent report, we observed modest enantioselectivity (75:25 er) with the use of chiral 
4,4’-dibenzyl-2,2’-bis(2-oxazoline) ligand, L1 (Figure 8.2). We had previously suggested that the 
origin of enantioselectivity in the single-electron transmetalation of secondary alkyltrifluoroborates 
arises from facial selectivity in the addition of the prochiral radical to the ligated nickel(II) center, 
followed by stereoretentive reductive elimination. However, if homolytic equilibration of the 
Ni(III)/Ni(II) pair is faster than reductive elimination, as these calculations indicate, then the origin 
of stereoselectivity should be found in the reductive elimination step. Thus, we propose that 
enantioselectivity arises from a process best described as a dynamic kinetic resolution (DKR)11 of 
Ni(III) complex C’.  In other words, addition of the secondary radical to the Ni center operates 
under Curtin-Hammett conditions12 furnishing two equilibrating diastereomeric Ni(III) complexes, 
one of which reductively eliminates at a faster rate, leading to the major enantiomer. 
Stereoconvergence then results via stereochemical scrambling of the secondary alkyl subunit 
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through dissociation and recombination. Indeed, computations of the diastereomeric transition 
states C’ correlate well with experiment; specifically, a Boltzmann distribution from calculated free 
energies of the eight lowest energy diastereomeric transition states predicts a 68% ee vs the 
experimental 50% ee. Examination of the structures reveals that the α-methylbenzyl group rotates 
to avoid gauche-like interactions along the forming C-C bond (Figure 8.4).  In the lower energy 
diastereomeric transition state these interactions are minimized.  
 
Figure 8.4. Competing diastereomeric transition states in the reductive elimination. Relative free 
energies, (kcal/mol) are computed using SMD-water-(U)M06/6-311+G(d,p)//UB3LYP/6-
31G(d,p). 
Having established reductive elimination as the enantio-determining step in these systems, 
other potential substrates were probed with the aim of establishing a correlation between the 
calculated and experimental selectivities. Calculations of the diastereomeric transition states for 
several substrates suggested that substituents at the para-position of the aryl bromide could enhance 
the enantioselectivity. In particular, larger para-substituents encounter steric interactions with the 
ligand benzyl group in the transition state leading to the minor enantiomeric product (see bottom 
structure in Figure 8.4). Notably, the stereochemical influence of these substituents distal from the 
bond-forming site would not be evident in the absence of this computational model.  Gratifyingly, 
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these predictions correlated well with experiment and afforded improved enantioselectivity in 
generating 1,1-diarylethane 13-15 (Figure 8.5). 
 
Figure 8.5. Predicted and experimental reaction enantioselectivities. 
 
Moving forward, we became curious whether this DKR-controlled enantioselectivity 
operates in other asymmetric nickel-catalyzed cross-coupling processes.  Of particular interest are 
reports documenting nickel-catalyzed asymmetric cross-couplings (Suzuki, Negishi, Hiyama, and 
Kumada)13,14 and reductive cross-couplings.15,16  Importantly, it can be argued that the “black box” 
nature of these transformations have limited their widespread development and adaptation, as no 
general model for stereoinduction has yet been proposed despite the large number of processes 
reported to date. Although a number of these asymmetric cross-couplings employ alkyl groups that 
would be precursors to stabilized radicals (i.e., benzylic, allylic, α-carbonyl, etc.), several examples 
of asymmetric cross-couplings of electronically unactivated alkyl subunits have been reported.17,18  
Although the analogy of the former examples to that reported here is readily apparent, it was less 
clear whether the proposed Ni(III) DKR manifold would be viable for systems in which less stable 
(e.g., unstabilized secondary alkyl) radicals were generated via homolysis of the Ni(III) 
intermediate. In an effort to address this question, the stereoconvergent cross-coupling of 
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unactivated secondary alkyl bromides and primary alkylboranes reported by Fu and coworkers 
(Figure 8.6)19 was examined computationally. 
 
 
Figure 8.6. Stereoconvergent unactivated alkyl cross-coupling 
  
Beginning from the putative Ni(III) complex, the transition states for homolysis of the 
secondary alkyl substituent and C-C bond-forming reductive elimination were computed. As shown 
in Figure 8.7, these calculations convincingly support a scenario analogous to that described above; 
that is, Ni(III) complex 10a exists in homolytic equilibrium with Ni(II) complex 3a and the free 
alkyl radical in a process that is much faster than the subsequent reductive elimination leading to 
Ni(I) complex 12a and cross-coupled alkane product. As such, we propose that stereoconvergence 
in these processes occurs by the same Ni(III) DKR process that we have elucidated for 
photoredox/nickel dual catalytic organoboron cross-coupling. This newfound knowledge regarding 
the fundamental origin of enantioinduction in Ni-catalyzed stereoconvergent processes can be used 
to augment stereoselectivity in known transformations through rational design and may be helpful 
in identifying new substrate classes that can participate via this reactivity manifold. These results 
are in agreement with the lack of products with long-lived radical intermediates. Specifically, 
radicals that quickly and favorably complex to the nickel center as proposed in Figure 8.3 avoid 
radical pathways such as cyclization by a pendant alkene. We are currently investigating the full 
scope of this proposal for various Ni-catalyzed C-C bond-forming processes involving alkyl radical 
intermediates, including the factors that might change the enantiodetermining step.  
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Figure 8.7. Energy barriers for the competing stabilized alkyl radical dissociation and reductive 
elimination transition states with chiral diamine ligand L2. Relative free energies (kcal/mol) are 
computed at the UM06/6-311+g(d,p) in SMD (water) level of theory. 
 
 
8.3 Conclusion 
 
In summary, we have employed DFT calculations to investigate the reaction pathway of the 
nickel/photoredox dual catalytic cross-coupling of aryl bromides with carbon-centered radicals 
derived from alkyltrifluoroborates. These computations suggest a mechanistic scenario wherein the 
radical can enter the cross-coupling cycle by addition to either Ni(0) or Ni(II).20   The two pathways 
converge upon a common Ni(III) intermediate that is able to release the stabilized alkyl radical via 
Ni-C bond homolysis, thus establishing an unexpected equilibrium between this high valent Ni(III) 
and the Ni(II)/radical pair. The cross-coupled product is then generated via irreversible reductive 
elimination. The reductive elimination barrier was computed to be significantly higher in energy 
than the barrier associated with the reversible homolysis process. Calculations show that the 
stereoinduction occurs through DKR of the Ni(III) intermediate according to the Curtin-Hammett 
principle. Experimental results have offered support for the proposed stereochemical model. Most 
importantly, the Curtin-Hammett DKR stereoinduction model appears to be broadly operative in 
various related stereoconvergent Ni-catalyzed processes, offering a rationalization for the 
mechanism of stereoselectivity in these transformations for the first time. 
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8.4 Experimental 
 
General Considerations 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless otherwise 
noted. 2,6-Lutidine (>99%, purified by redistillation) was used without further purification. 
Ni(COD)2 and 2,2′-Bis[(4S)-4-benzyl-2-oxazoline] were purchased from commercial sources. 
Potassium trifluoro(1-phenylethyl)borate was prepared according to a published procedure.21 THF 
(99.9% for HPLC, unstabilized) was dried by passing through activated alumina under an argon 
atmosphere using a J. C. Meyer solvent system. All other reagents were purchased commercially 
and used as received. Photocatalyst 4 was prepared according to the previously reported procedure.1 
Photoredox reactions were irradiated with a standard 26 W compact fluorescent light bulb (CFL) 
or blue LED light strips (~425 nm). NMR spectra were recorded on a 500 MHz spectrometer. Data 
are presented as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, dd 
= doublet of doublets, q = quartet, m = multiplet, br = broad), coupling constant J (Hz) and 
integration. Optical rotation data was collected on a Jasco P-2000 polarimeter. 
General Procedure for Preparation of Enantioenriched 1,1-Diarylethanes 
To a two dram (8 mL) borosilicate glass vial equipped with a Teflon-coated magnetic stir bar was 
added aryl bromide (0.5 mmol, 1 equiv), potassium trifluoro(1-phenylethyl)borate (127 mg, 0.6 
mmol, 1.2 equiv), Ir[dFCF3ppy]2(bpy)PF6 2.1 (15 mg, 0.015 mmol), and L1 (8.0 mg, 0.025 mmol). 
The vial was taken into a glovebox and Ni(COD)2 (6.8 mg, 0.025 mmol) was added. The vial was 
sealed with a plastic screw cap containing a Teflon-lined silicone septum, removed from the 
glovebox, and evacuated and purged with inert gas three times. Under an inert atmosphere THF (5 
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mL) and 2,6-lutidine (202 μL, 1.75 mmol, 3.5 equiv) were introduced successively. The vial was 
sealed with parafilm and stirred for the specified time with irradiation from a 26 W CFL or blue 
LED light strips. The crude reaction mixture was filtered through a plug of Celite, washing with 
EtOAc (3 x 4 mL). The residue was purified using the method specified below to obtain the 
products in pure form. 
Computational Details 
Full Reference of Gaussian09:  
Gaussian 09, Revision B.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. 
Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. 
Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, 
M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. 
Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. 
Brothers, K. N. Kudin, V. N. Staroverov, T.Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. 
Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. 
Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, 
A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. 
Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. 
B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2010. 
 
All optimizations were performed using spin-unrestricted broken-symmetry DFT using 
UB3LYP22–24 with both the LANL2DZ25 and 6-31G(d) basis sets (with the guess=mix keyword as 
implemented in Gaussian09) in the gas phase. Vibrational frequencies were computed at the same 
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level to obtain thermal corrections (at 298 K; enthalpic and free energy) and to characterize the 
stationary points as transition states (one and only one imaginary frequency) or minima (zero 
imaginary frequencies). For comparison, free energies were corrected (+1.89 kcal/mol) on going 
from standard state to 1 M in solution. Single point energy calculations in solvent [both water (ε 
=78.3553) and acetone (ε=20.493)] were performed using the SMD26-solvation model using the 
UM0627 functional with the 6-311+G(d,p) basis set on both UB3LYP/LANL2DZ and UB3LYP/6-
31G(d) optimized geometries. For comparison, we also computed single point energy calculations 
using UM06 functional and split basis [6-311+G(d,p) basis for C, H, N, Br, O atoms and SDD basis 
set with effective core potential28 for Ni]. The choice of method had a minor effect on the relative 
energetics and did not change the overall conclusions. Exhaustive conformational searches were 
performed for all intermediates to map out the lowest energy profile, and intrinsic reaction 
coordinate (IRCs) calculations were undertaken to ensure transitions states connected the illustrated 
ground states.  
Compound Characterization Data 
 
Methyl (S)-3-(1-phenylethyl)benzoate (S1): Prepared as part of a prior publication.1 Absolute 
stereochemistry was assigned as (S) based on data reported in the literature.29 
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(S)-4-(1-Phenylethyl)benzonitrile (13): Reaction time was 24 h; purified by flash column 
chromatography on silica gel; obtained as a colorless oil; 1H NMR (CDCl3, 500 MHz): δ 7.56 (d, J 
= 8.2 Hz, 2 H), 7.30 (dd, J = 8.1, 8.1 Hz, 4 H), 7.22 (t, J = 7.4 Hz, 1 H), 7.20-7.15 (m, 2 H), 4.20 
(q, J = 7.2 Hz, 1 H), 1.65 (d, J = 7.2 Hz, 3 H) ppm; 13C NMR (CDC3, 125.8 MHz): δ 152.1, 144.8, 
132.4, 128.8, 128.6, 127.1, 126.8, 119.1, 110.1, 45.0, 21.6 ppm; Chiral SFC analysis indicated that 
the product was formed in 57% ee [ChiralPak OJ-H column: 5% i-PrOH in CO2, 2.0 mL/min, tr = 
8.48 (major peak) tr = 9.88 (minor peak)]; [𝛼]𝐷
22 = 3.1 (c = 0.10, CHCl3); Absolute stereochemistry 
was assigned as (S) based on analogy to S1; Characterization data matched that previously reported 
in the literature.30 
 
(S)-1-Methyl-4-(1-phenylethyl)benzene (14): Reaction time was 48 h; purified by preparatory 
high performance liquid chromatography (Waters AutoPure system, Sunfire C18 column, 49 x 100 
mm, 5 μm particle size, 50%  96% MeCN/H2O, 0.1% TFA); obtained as a colorless oil; 1H NMR 
(CDCl3, 500 MHz): δ 7.28 (m, 2 H), 7.22 (d, J = 7.0 Hz, 2 H), 7.17 (t, J = 7.2 Hz, 1 H), 7.14-7.06 
(m, 4 H), 4.12 (q, J = 7.2 Hz, 1 H), 2.31 (s, 3 H), 1.63 (d, J = 7.2 Hz, 3 H); 13C NMR (CDC3, 125.8 
MHz): δ 146.7, 143.5, 135.6, 129.2, 128.5, 127.7, 127.6, 126.1, 44.5, 22.1, 21.1; Chiral SFC 
analysis indicated that the product was formed in 62% ee [ChiralPak OJ-H column: 3% i-PrOH in 
CO2, 2.0 mL/min, tr = 10.63 (major peak) tr = 14.47 (minor peak)]; [𝛼]𝐷
22 = 0.5 (c = 0.10, CHCl3); 
Absolute stereochemistry was assigned as (S) based on analogy to S1; Characterization data 
matched that previously reported in the literature.31 
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(S)-1-(tert-Butyl)-4-(1-phenylethyl)benzene (15): Reaction time was 24 h; purified by 
preparatory high performance liquid chromatography (Waters AutoPure system, Sunfire C18 
column, 49 x 100 mm, 5 μm particle size, 50%  96% MeCN/H2O, 0.1% TFA); obtained as a 
colorless oil; 1H NMR (CDCl3, 500 MHz): δ 7.31-7.23 (m, 6 H), 7.19-7.15 (m, 3 H), 4.12 (q, J = 
7.2 Hz, 1 H), 1.64 (d, J = 7.2 Hz, 3 H), 1.30 (s, 9 H); 13C NMR (CDC3, 125.8 MHz): δ 148.8, 146.8, 
143.4, 128.5, 127.8, 127.3, 126.1, 125.4, 44.5, 34.5, 31.5, 22.0; Chiral SFC analysis indicated that 
the product was formed in 65% ee [ChiralPak OJ-H column: 3% i-PrOH in CO2, 2.0 mL/min, tr = 
5.67 (major peak) tr = 6.80 (minor peak)]; [𝛼]𝐷
22 = 2.5 (c = 0.10, CHCl3); Absolute stereochemistry 
was assigned as (S) based on analogy to S1; Characterization data matched that previously reported 
in the literature.32 
Experiments with Enantioenriched Starting Materials 
 To rule out the possibility of stereoselectivity arising from classical kinetic resolution of 
potassium (±)-1-phenylethyltrifluoroborate, potassium (R)-1-phenylethyltrifluoroborate was 
prepared according to literature procedures. All characterization data were consistent with those 
previously reported.33,34 This compound, prepared as an 85:15 mixture of R and S enantiomers as 
judged by oxidation to the corresponding alcohols and chromatographic analysis thereof, was 
subjected to asymmetric photoredox cross-coupling with 4-bromobenzonitrile according to the 
general procedure described for 13 above using L1 as a ligand. The enantioselectivity and absolute 
configuration of the major cross-coupled enantiomer of 13 observed in this reaction were the same 
as those observed using racemic potassium 1-phenylethyltrifluoroborate. Furthermore, reaction of 
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the enantioenriched trifluoroborate with 4-bromobenzonitrile under dual catalytic photoredox 
conditions using achiral 2,2’-bioxazoline as a ligand generated racemic product. These data are 
consistent with the proposed stereoconvergent pathway and provide strong evidence against a 
classical kinetic resolution as the source of stereoselectivity. 
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Appendix A10. 1H, 13C Spectra and Chiral SFC Chromatograms Relevant to Chapter 8  
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Figure A10.1. 1H NMR (CDCl3, 500 MHz) spectrum of (S)-4-(1-phenylethyl)benzonitrile (13) 
Figure A10.2. 13C NMR (CDCl3, 125.8 MHz) spectrum of (S)-4-(1-phenylethyl)benzonitrile (13) 
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Figure A10.3. Chiral SFC chromatogram (OJ-H column: 5% i-PrOH in CO2, 2.0 mL/min) of 
racemic (A) and enantioenriched (B) 4-(1-phenylethyl)benzonitrile (13) 
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Figure A10.4. 1H NMR (CDCl3, 500 MHz) spectrum of (S)-1-methyl-4-(1-phenylethyl)benzene 
(14) 
Figure A10.5. 13C NMR (CDCl3, 500 MHz) spectrum of (S)-1-methyl-4-(1-phenylethyl)benzene 
(14) 
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Figure A10.6. Chiral SFC chromatogram (OJ-H column: 3% i-PrOH in CO2, 2.0 mL/min) of 
racemic (A) and enantioenriched (B) 1-methyl-4-(1-phenylethyl)benzene (14) 
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Figure A10.7. 1H NMR (CDCl3, 500 MHz) spectrum of (S)-1-(tert-butyl)-4-(1-
phenylethyl)benzene (15) 
Figure A10.8. 13C NMR (CDCl3, 125.8 MHz) spectrum of (S)-1-(tert-butyl)-4-(1-
phenylethyl)benzene (15) 
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Figure A10.9. Chiral SFC chromatogram (OJ-H column: 3% i-PrOH in CO2, 2.0 mL/min)of 
racemic (A) and enantioenriched (B) 1-(tert-butyl)-4-(1- phenylethyl)benzene (15) 
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Chapter 9. Photoredox Generated Radicals in Minisci Chemistry 
9.1 Introduction 
 
Heteroaryl subunits are among the most commonly employed,i privileged structures in 
medicinal chemistry.1 Unfortunately, the synthesis of many of these structures is often predicated 
on cyclization reactions2 from simple starting materials (e.g., aldehydes, hydrazines, alkynes, etc.). 
Although these methods often prove advantageous when the precursors needed for a particular 
molecular target are inexpensive and commercially available, these sequences are untenable when 
attempting to access a diverse library of structurally rich heteroarenes with a common core (Figure 
9.1).  
 
Figure 9.1. Complex heteroarenes poised for diversification. 
 
To overcome this challenge, two predominant anionic strategies have emerged for 
diversifying common heteroaryl motifs: fluorination to enable facile SNAr-based chemistry3 and 
halogenation (bromination,4 chlorination5) to provide a site for cross-coupling.6 These methods are 
                                                     
i Reproduced in part from Chem. Sci., 2017, 8, 3512. 
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highly effective for many systems, but in numerous cases installation of the halide at the desired 
site is unselective or impossible, requiring re-evaluation of the synthetic strategy. Furthermore, 
when successful incorporation of halides has occurred, heteroarenes are often obstinate partners in 
cross-coupling chemistry,7 requiring careful screening to achieve fruitful union. Most importantly, 
from an efficiency standpoint, these strategies are sub-optimal as they first require a functional 
handle to be installed, only to be immediately replaced in a subsequent displacement reaction. 
Radical alkylations of heteroarenes (Minisci reactions)8 represent a more direct 
functionalization of specific C-H bonds. For this reason, radical alkylation strategies have recently 
risen to prominence for the late-stage functionalization of heteroaryl systems. Although Minisci 
and coworkers initially used silver oxidants at elevated temperatures to generate alkyl radicals from 
the corresponding carboxylic acids,9 advances in alkyl radical generation have enabled much milder 
methods to be developed (Figure 9.2). These have included methods using boronic acids,10 
peresters,11 and other precursors12 under much less forcing conditions. Most notably, the Baran 
laboratory has pioneered the use of sulfinate salts13 that have enabled the extremely facile 
introduction of functionalized alkyl radicals into an impressive array of heteroarenes. These 
methods allow the formal C-H alkylation of heterocycles in a mild, metal-free manner – drawing 
rapid adoption by medicinal chemists for the late stage diversification of pharmaceutically relevant 
compounds.14 
Unfortunately, even with these advances, current methods are not without their limitations, 
particularly with regard to the continued requirement for high loadings of both the radical partner  
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Figure 9.2. Approaches to Heteroarene Functionalization 
 
and oxidant. Even the milder methods employing sulfinate salts often require a significant excess 
of an expensive and synthetically demanding precursor (3–6 equiv) and oxidant (5–10 equiv) to 
achieve good yields.13 To date, methods grounded on stoichiometric radical generation have been 
continually limited by parasitic reactivity (e.g., homocoupling, H-atom abstraction, and chain 
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processes) that appear to outcompete the desired Minisci alkylation. As such, often the only 
solution has been to push reactions to completion with increased reagent loadings or successive 
dosing (Figure 9.2A). 
To combat the disproportionate stoichiometry and typically harsh conditions, other groups 
have turned to photoredox catalysis for the efficient generation of radicals.15 Contributions by the 
MacMillan,16 DiRocco,17 Chen,18 and Barriault19 groups have all highlighted the advantages 
afforded under this paradigm. Although a variety of alkyl radicals precursors were presented in 
these photoredox contributions, each method exhibits some inherent limitations. For example, the 
MacMillan group targets weak C-H bonds and were largely limited to α-heteroatom bonds. 
Barriault and coworkers demonstrated that alkyl bromides could be reduced to generate the 
corresponding alkyl radicals, but 3 equivalents of these precursors and a UVA LED light source 
were required. Additionally, MacMillan and Barriault used expensive iridium or gold 
photocatalysts, respectively. The recent report by Chen addressed many of these issues with the use 
of sustainable boronic acid partners and inexpensive Ru(bpy)3, but their method employs the use 
of a stoichiometric iodine oxidant that seems uniquely required for activation. 
In light of these advances, we recognized the potential to marry photoredox Minisci 
chemistry with our laboratory’s interest in alkyltrifluoroborate reagents, especially given reports 
by our laboratory and others20 on the favorable single electron oxidation potentials of these salts to 
form alkyl radicals (Ered = +1.10 V vs SCE for 1o benzylic20a and +1.50 V vs SCE for 2o 
alkyltrifluoroborates20b). Here, with appropriate organic photocatalyst selection (for 1: *Ered = 
+2.06 V vs SCE21), all representative radical classes could be activated under identical reaction 
conditions (Figure 9.2B). In this scenario, one can envision photocatalyst excitation serving as a 
chaperone for steady, synchronized, catalytic radical generation. Such a protocol insures that an 
excess of radicals are not generated, minimizing at least some of the byproducts formed through 
stoichiometric processes. The photoredox catalyst-coordinated generation of radicals in this 
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manner leads to improvement in reagent and oxidant loading, thus enhancing the efficiency and 
sustainability of these methods. Serendipitiously, these aforementioned concepts, in conjuction 
with the generation of Lewis acidic BF3 byproduct, also led to enhanced reactivity and selectivity 
in these transformations. 
 
9.2 Results and Discussion 
 
Mechanistically, we anticipated that visible light irradiation of organic photocatalyst 1 would 
generate the excited complex 1*, which is highly oxidizing and capable of oxidizing an 
alkyltrifluoroborate to release the desired alkyl radical 3 and BF3 (Figure 9.3). The generated 
radical 3 can then intercept the protonated heteroarene to form the radical cation 5. Reduction of 
persulfate (Ered =  > +0.35 V vs SCE22) by the reduced form of the photocatalyst 4 (Ered = +0.49 V 
vs SCE21) generates the sulfate dianion and sulfate radical anion, regenerating photocatalyst 1.21 
Finally, H-atom abstraction of 5 by the sulfate radical anion leads to rearomatization, affording the 
desired alkylated heteroarene 6.16 Quantum yield studies indicate this is not a radical chain process 
as evidenced by a  of 0.31 (see experimental). Furthermore, addition of excess allyl acetate (a 
known sulfate radical anion trap23) did not interfere with reaction efficiency or conversion. 
To begin this optimization, we keyed in on tertiary radical partners for our initial studies – in 
particular, tert-butyltrifluoroborate as the appropriate radical precursor and isoquinoline 
carboxylate as the heteroaryl partner. Before screening various photocatalysts, controls probing the 
need for oxidant (Table 9.1, entry 2), light (entry 3), and photocatalyst (entry 4) were completed. 
Additionally, the absence of acid (entry 5) afforded 30% conversion to product, although as alkyl 
radical 3 is generated, BF3 (an electron-deficient Lewis acid) is concomitantly being formed. 
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Performing the reaction in air provided a comparable yield (entry 6) to a reaction carried out under 
inert conditions (entry 1).  
The mesityl acridinium photocatalyst was then compared to other photocatalysts (entries 7–
10). Noting the need for a relatively high oxidizing potential of the photocatalyst, it was expected 
that ruthenium photocatalysts (with significantly lower oxidation potentials than the acridinium 
dyes) would experience diminished yields, which proved to be the case (entries 7, 8). During the 
period that photoredox catalysis has gained traction in the organic chemistry community, one major 
criticism has been the high cost of the key metal-based photocatalysts (i.e., those based on iridium 
and ruthenium). Nicewicz24 and Zhang25 have explored alternative organophotocatalysts that have 
been shown to exhibit similar reactivity to their metal-based counterparts. Surprisingly, 4CzIPN 
(entry 10) significantly outperformed MesAcr over a 12 h period. Neither excess 
alkyltrifluoroborate (entry 11) nor excess oxidant (entry 12) provided any perceived advantages.    
Of note, acridine afforded only trace amounts of alkylation product at the C9 position during our 
heteroarene scope investigation. For mesityl acridinium, the C9 position is occupied by the mesityl 
substituent and is therefore unable to participate in Minisci alkylation, thus making it a suitable 
photocatalyst for the reactions described herein. 
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Figure 9.3. Proposed Mechanism 
 
In view of their low cost and ease of access, going forward we focused on the two 
organophotocatalysts, MesAcr and 4CzIPN.  To determine the most suitable organic photocatalyst 
for our purposes, we scaled up the reactions described in entries 1 and 10, and discovered that 
running the reaction for 16 h afforded similar yields, consistent with the small scale reactions. It 
was important for this protocol to be general for primary, secondary, and tertiary 
alkyltrifluoroborates. Because primary alkyltrifluoroborates have a markedly higher oxidation 
potential (Ered = +1.80 V vs SCE20k) than secondary or tertiary alkyltrifluoroborates, MesAcr and 
4CzIPN were compared with a primary alkyltrifluoroborate (Figure 9.4). In this assay, MesAcr 
outperformed CzIPN with 76% versus <10% isolated yields, respectively. 
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Table 9.1. Optimization for Tertiary Alkyl Couplinga 
 
aOptimization reactions were run with heteroarene (1.0 equiv), tert-butyltrifluoroborate (1.0 equiv), 
photocatalyst (5 mol %), K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O 
(1:1) on 0.1 mmol scale. bYields were obtained by HPLC using a calibration curve. 
 
 
Figure 9.4. Comparing Organophotocatalysts 
 
Tricoordinate organoboron compounds are isoelectronic with carbocations, and thus would 
not be expected to be easily oxidized by single electron transfer (SET) processes. To confirm that 
this chemistry was unique to alkyltrifluoroborates, a variety of organoboron reagents were 
synthesized and analyzed by cyclic voltammetry to determine their relative oxidation potentials 
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% Yield
57
<5
<5
0
30
53
8
16
86
96
45
84
t-BuBF3K (1.0 equiv)
MesAcr (5 mol %)
K2S2O8 (2.0 equiv)
trifluoroacetic acid (1.0 equiv)
MeCN/H2O (0.1 M), 26 W CFL, rt, 12 h
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N
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(Table 9.2). As expected, the trivalent organoboron variants exhibit very high oxidation potentials 
as compared to their tetravalent, “ate” complex analogues. Consequently, under the reaction 
conditions, no radical formation from the boronic acids and/or esters was observed. For the 
tetravalent species, triolborates exhibit comparatively low reduction potentials. Unfortunately, the 
swift hydrolysis of triolborates under the acidic, aqueous reaction conditions forms the redox 
inactive boronic acid.26 By contrast, alkyltrifluoroborates are both stable to the reaction conditions 
and redox amenable, resulting in an excellent 72% yield with methyl isoquinoline carboxylate after 
16 h. 
Table 9.2. Exploring Various Alkylboron Compoundsa 
 
aReactions were run with heteroarene (1.0 equiv), alkylboron reagent (1.0 equiv), MesAcr (5 mol %),  
K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O (1:1) on 0.2 mmol scale. 
 
tert-Butyltrifluoroborate was selected to examine the amenability of various heteroarene 
partners (Figure 9.5). Regioselectivity was probed using quinoline itself, leaving both the C2 and 
C4 positions available for alkylation. Currently there are two methods for installing tertiary radicals 
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regioselectively into the quinoline core structure. Namgoong and coworkers reported the use of 
excess TMP-zincate to deprotonate selectively at the C2 position, followed by incorporation of the 
tert-butyl substituent.27 This was a singular transformation, with no demonstrated scope. 
Additionally, Minisci and coworkers have reported selective C2 C-H substitution on quinolines 
using a 3-fold excess of alkyl iodide radical precursors.8b Although efficient, drawbacks of this 
approach included using peroxide as the oxidant, thereby limiting functional group tolerance, and 
the limited number of commercially available, complex alkyl iodides. Therefore, we were pleased 
to observe regioselective addition to the C2 position of the heteroarene in 72% yield (1a). With 
substitution at the C4 position of quinoline, the reaction reached full conversion to product within 
16 h as determined by GC-MS analysis (1b). When isolated, a 95% yield of the desired product 
was achieved. Beyond alkyl substituents, halides and trifluoromethyl groups incorporated within 
the heteroaromatics allowed excellent conversion to product (1c, 1d).  
In addition to quinoline cores, indazole (1e), isoquinoline (1g), and quinoxaline (1h, 1i) 
moieties were successful partners under standard conditions. Indazole 1e is particularly notable 
because of the prevalence in medicinal chemistry1 and, to the best of our knowledge, the absence 
of Minisci examples in the literature. As expected, the use of the benzimidazole core resulted in no 
conversion (1f) because of the electron-rich nature of the C2 site. Additionally, N-methyl 
benzimidazole was similarly unreactive. Pyridines also exhibited selective mono-addition (1j–1l, 
1n). Only one reported of nicotinamide alkylation via Minisci chemistry has been previously, 
wherein three equiv of the corresponding carboxylic acid were necessary under silver catalyzed 
conditions.28 A medicinally relevant core, quinazolinone 1p, afforded product in 90% yield. Purine 
1q contains two sites of potential radical addition, but substitution was observed only on the 
pyrimidine subunit. Overall, this method is broadly tolerant of a wide range of functional groups 
as demonstrated with quinine 1r (possessing alkene, alcohol, tertiary amine groups). Notably, the 
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tertiary amine embedded within quinine did not interfere with the photocatalytic cycle despite its 
propensity for competitive oxidation. 
 
Figure 9.5. Heteroarene Scopea 
aReactions were run with heteroarene (1.0 equiv), tert-butyltrifluoroborate (1.0 equiv), MesAcr (5 mol %), 
 K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O (1:1) on 0.3 mmol scale. 
 bYield determined by fluorine NMR using fluorobenzene as internal standard. 
 
 
Currently, there are a limited number of tertiary alkylboranes commercially available and no 
alkyltrifluoroborates. Presumably, this is a result of narrow synthetic utility compared to their 
primary and secondary counterparts. Although we demonstrated that tert-butyltrifluoroborate was 
viable, more highly elaborated systems could also be incorporated. Cook and coworkers recently 
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reported a manganese-catalyzed borylation of alkyl bromides. Using Cook’s procedure,29 >1 g of 
pinacolborane intermediate 1t was synthesized from the corresponding alkyl bromide 1s. This 
borylation was followed by treatment with saturated KHF2 to afford the corresponding 
alkyltrifluoroborate 1u (Figure 9.6). 
With tertiary alkyltrifluoroborate 1u in hand, radical addition to caffeine 1v and 
benzothiophene 1w was carried out. The development of the Cook approach to 3° 
alkyltrifluoroborates thus allows access to an even greater array of coupling partners. 
 
Figure 9.6. Synthesis of Tertiary Alkyltrifluoroboratea 
aReactions were run with heteroarene (1.0 equiv), tertiary alkyltrifluoroborate (1.0 equiv), MesAcr (5 mol %), 
 K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O (1:1) on 0.3 mmol scale. 
 
 
In further studies, a wide range of alkyltrifluoroborates were found to be suitable partners in 
the developed photoredox Minisci conditions (Figure 9.7 -
alkoxyalkyltrifluoroborate afforded 2a in 58% yield. Additional examples of unactivated, 
secondary alkyl radical precursors could be appended as in 2b–2j.  For 2b, the successful addition 
of fluorinated isosteres is encouraging, given the well-documented propensity these subunits have 
for modulating solubility and binding affinity in medicinal chemistry.30 For 2c–2e, the 
tetrahydropyranyl and piperidinyl moieties are commonly introduced ring structures that serve as 
useful probes for H-bond donors/acceptors in SAR efforts.31 
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To the best of our knowledge, primary alcohols appended to the radical coupling partner have 
not been reported in Minisci-type reactions, perhaps owing to their propensity to undergo H-atom 
abstraction alpha to the hydroxyl group. Therefore, we were pleased to obtain 2f, albeit in low 
yield. Of note, this selecitivity is complementary to the MacMillan group’s work on alcohols as 
radical precursors in photoredox-Minisci couplings.16a A further exploration of 5- and 4-membered 
heterocycles (2g–2i) was conducted  with promising results, where tetrahydrofuran 2g was afforded 
in 34% yield, but access to pyrrolidine 2h was not successful. For azetidine 2i, standard solvent 
conditions provided only trace amounts of product, but switching to DCE/H2O (1:1) proved to be 
beneficial. Cyclopropyltrifluoroborate, although unproductive in previously reported 
photoredox/Ni dual cross-coupling methods,20b afforded 2j, albeit in 20% yield. 1-
Adamantyltrifluoroborate has never been used in Minisci-type alkylations. Using the standard 
conditions, 2k was isolated in 45% yield. Lastly, chemoselective radical addition to the 
isoquinoline was observed for 2l despite containing an alternate site for alkylation within the 
alkyltrifluoroborate partner. 
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Table 9.7. Secondary and Tertiary Alkyltrifluoroborate Scopea 
aReactions were run with methyl isoquinoline-3-carboxylate (1.0 equiv), alkyltrifluoroborate (1.0 equiv),  
MesAcr (5 mol %),  K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O (1:1)  
on 0.3 mmol scale. bReaction run in DCE/H2O (1:1). 
 
Moving forward, this Minisci process was anticipated to be broadly applicable even to primary 
alkyltrifluoroborates, which possess relatively high oxidation potentials (Table 9.8). As an initial 
foray, we first investigated whether stabilized primary α-alkoxymethyltrifluoroborates could be 
competent partners in this process (3a–3d). Non-stabilized alkyl radicals were also demonstrated 
in examples 3e–3l. Notably, 3j contains an ortho bromide functional handle for further elaboration. 
Unfortunantely, electron deficient 3,3,3-trifluoropropyltrifluoroborate afforded 3l in diminished 
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yield, likely because of its high oxidation potential and resultant destabilization of the generated 
radical. These trends track with other recent reports specifically targeting more electrophilic 
radicals.13e, 16b 
 
Figure 9.8. Primary Alkyltrifluoroborate Scopea 
aReactions were run with 1-methyl isoquinolinecarboxylate (1.0 equiv), primary alkyltrifluoroborate (1.0 equiv), 
 MesAcr (5 mol %), K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O (1:1) on 0.3 mmol scale. 
 
As would be anticipated for the radical-based mechanism of the transformation, 
cyclopropylcarbinyltrifluoroborate 3m formed the corresponding radical 3o after SET oxidation 
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and subequent rearrangement. Following radical addition to the activated heteroaromatic, 3p was 
isolated in 55% yield. 
The diversity of the process was expanded to underline the potential for widespread utility 
(Figure 9.9). Lepidine was coupled with a variety of stabilized α-alkoxy (4a–4c) and unstabilized 
(4d–4f) radicals. With quinoline, C2 regiospecificity was again observed (4d, 4e), albeit in 
diminished yields. This is particularly noteworthy given the challenges associated with avoiding 
complex mixtures of isomers in prior Minisci-type reaction reports.32 With heteroarene cores such 
as pyridine (4f), benzothiazole (4g), indazole (4h), and quinazolinone (4i, 4j), exceptional yields 
were observed. When exploring reactivity with caffeine, methylcyclopentyltrifluoroborate afforded 
4k in 37% yield. Additionally, a secondary alkyl radical was successfully appended to functionally 
rich quinine as demonstrated in 4l.  
Given the success of this method, the use of this technology for selective ligand modifications 
was envisioned (Figure 9.10). As a case study, difunctionalization of a bipyridine-based ligand 
was selected for further investigation. Commonly these ligands are synthesized through the SNAr 
reaction of strong nucleophiles (e.g., tert-butyllithium) to a fluorinated bipyridine precursor, which 
is unfortunate given the popularity of these ligands in Cu and Ni catalysis.33 In contrast to the use 
of such pyrophoric alkylating agents, bench-stable alkyltrifluoroborates represent an attractive 
alternative. Gratifyingly, unfunctionalized substructures 5a and 5c were converted to the desired 
products in 84% and 68% yields, respectively. Pyridine ligands are also valuable for the synthesis 
of iridium photocatalysts. Under the same reaction conditions, heteroarene 5e afforded mono-
alkylated product 5f in 82% yield. When tridentate ligand terpyridine 5g was subjected to the 
standard conditions with two equivalents of tert-butyltrifluoroborate, mono-alkylated 5h was 
formed exclusively.34  
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Figure 9.9. Demonstration of Diversitya 
aReactions were run with heteroarene (1.0 equiv), primary alkyltrifluoroborate (1.0 equiv), MesAcr (5 mol %), 
K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O (1:1) on 0.3 mmol scale. 
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Figure 9.10. Mild Alternative for Ligand Synthesisa 
aReactions were run with heteroarene (1.0 equiv), alkyltrifluoroborate (1.0 or 2.0 equiv), MesAcr (5 mol %), 
K2S2O8 (2.0 equiv), trifluoroacetic acid (1.0 equiv) in MeCN/H2O (1:1) on 0.3 mmol scale. 
 
 
Although medicinal chemists have principally capitalized on late-stage Minisci heteroarene 
alkylation,9 it can be advantageous to introduce alkyl substitution earlier in a synthetic sequence.35 
Using the present protocol, the installation of alkyl subunits on brominated heteroarenes provides 
an excellent opportunity to highlight divergency in molecular synthesis. Furthermore, the halides 
installed within a variety of heteroarenes can serve a dual purpose: they may serve as an electronic 
bias for regioselective alkylations ortho to the halide,13d and they provide a functional handle for 
cross-coupling reactions, etc.5c To initiate studies to explore these concepts, a number of 
brominated heteroarenes were selected (Table 7). First, pyrimidine 6a -
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alkoxyalkyltrifluoroborate to yield exclusively the C4-substituted product. When moving to 
pyridines, a mixture of C2 and C6 alkylation occurred with tosyl-protected 
piperidinyltrifluoroborate (6b). Conversely, with primary alkyltrifluoroborates, only the C2-
substituted products were observed in examples 6c and 6d. Chloride substitution was also well 
tolerated as demonstrated in 6d. When 4-bromoisoquinoline was utilized as a substrate, a mixture 
of regioisomers 6e and 6f was generated. Based on these studies, 6a and 6c contrast favorably with 
previous findings in the Baran laboratory wherein regiomeric isomers were observed for heteroaryl 
bromides and chlorides.13d 
 
Figure 9.11. Utilizing Heteroarenes with Functional Handles 
 
As a final highlight of the potential for late-stage functionalization, camptothecin (CPT) was 
selected as an appropriate, complex heteroarene. In medicinal chemistry, CPT was identified as an 
anti-cancer drug candidate because of its cytotoxic activity in a number of cancer cell lines. 
Unfortunately, poor solubility was a systemic issue and prevented moving it forward as a drug 
candidate.36 To tackle this challenge, various alkyl substitutions on the C7 position of the natural 
alkaloid were introduced, resulting in a more highly-active clinical candidate.37 Although SAR 
studies were conducted to confirm the promising properties of alkyl decoration, the alkyl 
substituents were primarily limited to simple alkyl groups (e.g., methyl, ethyl) using the 
corresponding alkyl bromides, peroxide, and acid under thermal conditions.38 To demonstrate the 
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advantages of using the currently developed, mild photoredox conditions, secondary and primary 
alkyltrifluoroborates were selected as reagents for generation of analogues. As displayed in Figure 
9.12, primary α-alkoxyalkyl subunits could be incorporated, along with secondary alkyl moieties 
(7a, 7b). 
 
Figure 9.12. Camptothecin Analogues: Examples of Late-Stage Functionalization 
 
Based on our previous reports on Minisci chemistry12 and the results provided herein, it 
became clear that the use of alkyltrifluoroborates provided clear advantages in terms of both 
reactivity (permitting a single equivalent of radical precursor to be employed) and regioselectivity 
in heteroarene alkylation. Given these observations, it seemed that there might be some inherent 
advantage to the generation of BF3 byproduct during the course of the reaction. Two distinct 
possibilities were considered: (1) the BF3 produced was intimately involved with the generated 
radical, providing a shepherding effect in delivering the radical with enhanced selectivity, or (2) 
the BF3 was coordinating to the heteroarene prior to the radical addition, activating the heteroaryl 
substrate and enhancing preference for one site beyond the activation provided by the added protic 
acid.  
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To assess the first hypothesis, DFT calculations were performed to determine the effective 
“bond order” for radical association with BF3 in solution. This potential interaction was of 
particular interest as this escorting effect has little precedent in the chemical literature; currently, 
there are only examples of nitrogen- and oxygen-centered radicals interacting with BF3 in 
solution.39 Indeed, preliminary calculations suggest that a strong preference exists for the free 
radical over a BF3-bound complex in solution (see experimental). Noting this lack of association, 
we were quick to investigate an alternative hypothesis.  
To probe each of the possible heteroarene complexes, we prepared stoichiometric solutions 
of one of our successful, selective    substrates, quinoline, with no additive, trifluoroacetic acid 
(TFA) alone, BF3 alone, and finally TFA with added BF3, hoping to probe the effect of coordination 
on the proton and carbon shifts of heteroarene and provide some rationale for the differences 
between our chemistry and previously established protocols. 
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Figure 9.13. 1H NMR of A with trifluoroacetic acid and/or BF3 additive in  
CD3CN/H2O (1:1). TMS was used as a reference. 
 
For trifluoroacetic acid, a clear downfield shift was observed in the H2 and H4 protons of 
quinoline (Figure 9.13). Likewise, for the addition of BF3, a slightly less pronounced, but clear, 
downfield shift was also observed for the same protons. However, the combination of both 
additives together produced a wholly different shift in resonances to a unique heteroarene species.  
Most importantly, the carbon shifts of C2 relative to C4 (the best indicator of relative 
radicophilicity) possess enhanced differentiation in relative downfield shift (~3 ppm) in comparison 
to the BF3 and trifluoroacetic acid complexes alone (~1 ppm) (Figure 9.14). Based on these 
chemical shifts, it is reasonable to suggest the C2 position is preferentially activated over the C4 
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position40 under the reaction conditions, resulting in the enhanced regioselective mono-alkylation 
observed for the quinoline system and, by analogy, many of the other systems in which 
alkyltrifluoroborates appear uniquely reactive and selective (vida infra).  
 
 
Figure 9.14. 13C NMR of A with trifluoroacetic acid and/or BF3 additive in  
CD3CN/H2O (1:1). CD3CN solvent peak was used as a reference. 
 
To probe these findings further, we hoped that the use of alternative radical precursors (e.g., 
sulfinate salts or carboxylic acids) could be used in the presence and/or absence of BF3 to achieve 
the same desired regioselectivity. Unfortunately, under our standard conditions, sulfinate salts were 
universally ineffective, and carboxylic acids gave the same regiomixture, even with added BF3. 
Given this current ambiguity, this enhanced reactivity and regioselectivity appears to remain unique 
to the trifluoroborate precursors (see experimental). 
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At this time, although it is impossible to propose a structure for this distinct, activated species, 
we speculate that BF3 activation of either the heteroarene π-cloud41 or polarization of the 
trifluoroacetic acid42 to increase its effective pKa may be responsible. Intriguingly, this type of dual 
activation could perhaps be more broadly operative in the selective alkylation of other heteroaryl 
cores. 
 
9.3 Conclusion 
 
In summary, a mild, room temperature method for the introduction of a diverse palette of 
alkyl groups has been developed. Under a set of unified reaction conditions, primary, secondary, 
and tertiary alkyltrifluoroborates can be employed in photoredox Minisci chemistry for the first 
time. This chemistry makes use of an inexpensive, mild oxidant, organic photocatalyst, and requires 
only one equivalent of alkyl radical partner, providing one of the most cost efficient and sustainable 
approaches to date. Additionally, enhanced regioselectivity was observed compared to current 
“state of the art” Minisci-type alkylations. Both of these phenomena may be related to the 
synchronized, catalytic generation of radicals in conjunction with the in situ generation of BF3 
during the course of the reaction. The resultant method has been demonstrated broadly with respect 
to the heteroarene and alkyltrifluoroborate partners. Furthermore, access to bipyridine-type ligands 
as well as the late stage diversification of medicinally relevant substructures has been showcased. 
Finally, NMR studies provided support for a unique, highly activated species caused by the 
formation of BF3 upon the single-electron oxidation of alkyltrifluoroborates. Currently, further 
mechanistic studies are underway to elucidate the nature of this complex. 
Given the wide array of commercially available alkyltrifluoroborates, in addition to those 
synthesized by our laboratory and emerging from other groups, this approach provides a valuable 
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contribution to the Minisci-type alkylation literature that is both highly competitive with, and 
complementary to, existing protocols. As alkyltrifluoroborates are well behaved, bench stable salts, 
these reagents will continue to serve as useful “radicals in a bottle” for synthetic chemists. 
 
9.4 Experimental 
 
NMR Spectra (1H, 13C, 19F) were performed at 298 K. 1H NMR spectra were referenced to residual 
non-deuterated chloroform (δ 7.26) in CDCl3, residual DMSO-d5 (δ 2.50) in DMSO-d6, acetone-d5 
(δ 2.09) in acetone-d6, and residual MeCN-d2 (δ 1.94) in MeCN-d3. 13C NMR spectra were 
referenced to CDCl3 (δ 77.2) and DMSO-d6 (δ 39.5). Reactions were monitored by HPLC, GC/MS, 
1H NMR, and/or by TLC on silica gel plates (60 Å porosity, 250 μm thickness). TLC analysis was 
performed using hexanes/EtOAc as the eluant and visualized using UV light. Silica plugs utilized 
flash silica gel (60 Å porosity, 32–63 µm). Flash chromatography was accomplished using an 
automated system (visualizing at 254 nm, monitoring at 280 nm) with silica cartridges (60 Å 
porosity, 20–40 µm). Solvents were purified by use of drying cartridges through a solvent delivery 
system. Melting points (°C) are uncorrected.  
Deuterated NMR solvents were either used as purchased (DMSO-d6) or were stored over 4Å 
molecular sieves and/or K2CO3 (CDCl3). Na2SO4, MgSO4, MeOH, CH2Cl2, MeCN, pentane, Et2O, 
trifluoroacetic acid, and K2S2O8 were used as purchased. Heteroarenes were purchased from 
commercial suppliers and used without further purification. MeCN/H2O was degassed thoroughly 
with N2 and stored under N2. The photocatalyst N-Me-9-mesityl acridinium tetrafluoroborate was 
donated by Pfizer and used without further purification. 
 
General Procedure 
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To a 4.0 mL vial, alkyltrifluoroborate (0.30 mmol, 1.0 equiv), heteroarene (0.30 mmol, 1.0 equiv), 
photocatalyst (6.2 mg, 0.015 mmol, 0.05 equiv), and K2S2O8 (162.2 mg, 0.60 mmol, 2.0 equiv) 
were added. Open to air, a mixture of 3.0 mL MeCN/H2O (1:1) was added, followed by 
trifluoroacetic acid (34.2 mg, 0.30 mmol, 1.0 equiv). The mixture was stirred under white LEDs 
for 5–48 h under a fan. The reaction mixture was quenched with saturated NaHCO3 and extracted 
with CH2Cl2 (3 x 20 mL). The organic extracts were combined and concentrated on Celite. The 
crude mixture was purified by silica gel column chromatography. 
HETEROARENE SCOPE WITH TERT-BUTYLTRIFLUOROBORATE 
 
 
2-(tert-Butyl)quinoline (1a). Physical state: 40 mg, 72% yield, clear oil. 1H NMR (500 MHz, 
CDCl3) δ 8.07 (d, J = 8.6 Hz, 2H), 7.77 – 7.75 (m, 1H), 7.68 – 7.64 (m, 1H), 7.54 – 7.52 (m, 1H), 
7.49 – 7.46 (m, 1H), 1.48 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 169.4, 147.6, 136.0, 129.6, 129.1, 
127.4, 126.6, 125.7, 118.3, 38.3, 30.3. HRMS (ES+) m/z calc. for C13H16N [M+H] 186.1283, found 
186.1280. FT-IR (cm-1, neat, ATR) 2961, 1619, 1601, 1565, 1504, 1364, 1138, 1103, 829, 756, 
478. 
 
2-(tert-Butyl)-4-methylquinoline (1b) Reference: Gabriele, B.; Mancuso, R; Salerno, G.; Ruffolo, 
G.; Plastina, P. J. Org. Chem. 2007, 72, 6873. Physical state: 57 mg, 95% yield, clear oil. 1H NMR 
(500 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 7.93-7.90 (m, 1H), 7.66-7.64 (m, 1H), 7.49-7.27 (m, 
N t-Bu
N t-Bu
Me
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1H), 7.34 (s, 1H), 2.67 (s, 3H), 1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 169.1, 147.5, 143.7, 
130.1, 128.8, 126.7, 125.5 123.5, 119.0, 38.1, 30.3, 19.1. 
 
4-Bromo-2-(tert-butyl)quinoline (1c) Physical state: 68 mg, 86% yield, clear oil. 1H NMR (500 
MHz, CDCl3) δ 8.10 (d, J = 8.4 Hz, 1H), 8.06-8.02 (m, 1H), 7.79 (s, 1H), 7.69 (dd J = 7.7, 7.6 Hz, 
1H), 7.54 (dd, J = 7.7, 7.6 Hz, 1H), 1.45 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 169.5, 148.3, 
134.0, 130.1, 130.0, 127.0, 126.5, 126.2, 122.5, 38.3, 30.2. HRMS (ES+) m/z calc. for C13H15BrN 
[M+H] 264.0388, found 264.0397. FT-IR (cm-1, neat, ATR) 2957, 1585, 1488, 820, 756. 
 
 
2-(tert-Butyl)-4-chloro-8-(trifluoromethyl)quinoline (1d). Physical state: 78 mg, 70% yield, clear 
oil. 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 8.4 Hz, 1H), 8.08 (d, J = 7.2 Hz, 1H), 7.68 (s, 1H), 
7.61-7.59 (m, 1H), 1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 170.5, 144.9, 142.6, 128.5 (q, J = 5.5 
Hz), 128.3 (q, J = 29.1 Hz), 128.2, 125.3, 125.2, 123.1, 119.3, 38.9, 29.9. HRMS (ES+) m/z calc. for 
C14H14ClF3N [M+H] 288.0767, found 288.0762. FT-IR (cm-1, neat, ATR) 2965, 1592, 1489, 1463, 
1293, 1145, 1118, 766. 
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3-(tert-Butyl)-1H-indazole (1e). Reference: Li, P.; Wu, C.; Zhao, J.; Rogness, D. C.; Shi, F. J. Org. 
Chem. 2012, 77, 3149. Physical state: 41 mg, 80% yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 
10.07 (bs, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 7.36-7.33 (m, 1H), 7.14-7.11 (m, 
1H), 1.55 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 154.8, 142.1, 126.3, 122.3, 120.7, 120.0, 110.1, 
34.0, 30.2. HRMS (ES+) m/z calc. for C11H15N2 [M+H] 175.1235, found 175.1229. FT-IR (cm-1, 
neat, ATR) 3146, 3112, 3073, 2963, 2928, 2900, 1342, 739. 
 
Methyl 1-(tert-Butyl)isoquinoline-3-carboxylate (1g). Physical state: 55 mg isolated, 77% yield, 
white solid (mp = 55 °C). 1H NMR (500 MHz, CDCl3) δ 11.64 (s, 1H), 8.50 – 8.45 (m, 2H), 7.72 
– 7.70 (m, 2H), 4.06 (s, 3H), 1.64 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.8, 158.0, 155.4, 
129.6, 129.3, 129.0, 128.8, 127.3, 124.3, 118.4, 52.9, 39.7, 31.2.  FT-IR (cm-1, neat, ATR) 2953, 
1661, 1450, 1337, 1242, 1164. 
 
2-(tert-Butyl)quinoxaline (1h). Physical state: 39 mg, 70% yield, clear oil. 1H NMR (500 MHz, 
CDCl3) δ 8.99 (s, 1H), 8.06 (dd, J = 8.0, 3.8 Hz, 2H), 7.71 (m, 2H), 1.52 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 163.8, 143.6, 141.8, 141.0, 129.8, 129.5, 129.1, 129.0, 37.4, 29.9. HRMS (ES+) 
m/z calc. for C12H15N2 [M+H] 186.1157, found 186.1158. FT-IR (cm-1, neat, ATR) 2963, 1558, 
1492, 1464, 1365, 1237, 1155, 1128, 1097, 1014, 968, 761, 607. 
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2-(tert-Butyl)-3-chloroquinoxaline (1i). Physical state: 28 mg isolated, 43% yield, clear oil. 1H 
NMR (500 MHz, CDCl3) δ 8.99 (s, 1H), 8.07 – 8.05 (m, 2H), 7.74 – 7.68 (m, 2H), 1.52 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 163.8, 143.6, 141.8, 141.0, 129.8, 129.5, 129.1, 129.0, 37.4, 29.9. 
HRMS (ES+) m/z calc. for C12H15ClN2 [M+H] 221.0846, found 221.0844. FT-IR (cm-1, neat, 
ATR) 2977, 1167, 1104, 1008, 761. 
 
6-(tert-Butyl)nicotinonitrile (1j). Physical state: 42 mg, 89% yield, yellow oil. 1H NMR (500 
MHz, CDCl3) δ 8.82 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 1.38 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 174.1, 151.7, 139.5, 119.3, 117.3, 106.9, 38.4, 30.0. HRMS (ES+) m/z 
calc. for C10H13N2 [M+H] 161.1079, found 161.1078. FT-IR (cm-1, neat, ATR) 2960, 2050, 1721, 
1596. 
 
 
2-(tert-Butyl)-4-(trifluoromethyl)pyridine (1k). Reference: Stowers, K. J.; Fortner, K. C.; Sanford, 
M. S. J. Am. Chem. Soc. 2011, 133, 6541. Physical state: 58 mg, 95% yield, light yellow oil. 1H NMR 
(500 MHz, CDCl3) δ 8.74 (d, J = 4.9 Hz, 1H), 7.53 (s, 1H), 7.31 (d, J = 5.0 Hz, 1H), 1.40 (d, J = 1.9 Hz, 9H). 
13C NMR (126 MHz, CDCl3) δ 171.2, 149.7, 138.7 (q, J = 34.0 Hz), 123.4 (q, J = 271.0), 116.4 (q, 
J = 4.0 Hz), 114.8, 114.81, 38.0, 30.2. 19F NMR (500 MHz) δ -64.70. 
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1,1'-(4-(tert-Butyl)pyridine-2,6-diyl)bis(ethan-1-one) (1l). Physical state: 48 mg, 73% yield, clear 
oil. 1H NMR (500 MHz, CDCl3) δ 8.22 (s, 2H), 2.78 (s, 6H), 1.36 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 200.1, 162.9, 153.0, 122.0, 35.6, 30.6, 25.9. HRMS (ES+) m/z calc. for C13H18NO2 
[M+H] 220.1338, found 220.1334. FT-IR (cm-1, neat, ATR) 2968, 2975, 1700, 1362, 1244, 1131, 
610. 
 
8-(tert-Butyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione (1m) Physical state: 52 mg, 70% 
yield, white solid (173 °C). 1H NMR (500 MHz, CDCl3) δ 4.11 (s, 3H), 3.56 (s, 3H), 3.39 (s, 3H), 
1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 160.1, 155.8, 151.9, 147.1, 108.4, 34.3, 34.2, 29.7, 
29.1, 28.0. HRMS (ES+) m/z calc. for C12H19N4O2 [M+H] 251.1508, found 251.1505. FT-IR (cm-
1, neat, ATR) 2974, 1699, 1656, 1543, 1492, 1428, 1364, 1240, 740. 
 
2-(tert-Butyl)nicotinamide (1n) Reference: Tada, M.; Yokoi, Y. J. Heterocyclic Chem. 1989, 26, 
45. Physical state: 36 mg, 67% yield, light yellow solid (mp = 94 °C). 1H NMR (500 MHz, 
DMSO-d6) δ 8.95 (d, J = 2.3 Hz, 1H), 8.17 – 7.99 (m, 2H), 7.51 (d, J = 8.2 Hz, 2H), 1.31 (s, 9H). 
13C NMR (126 MHz, DMSO) δ 171.2, 166.5, 147.6, 135.6, 127.0, 118.5, 20.8, 14.1. HRMS (ES+) 
m/z calc. for C10H15N2O [M+H] 179.1184, found 179.1190. FT-IR (cm-1, neat, ATR) 3433, 2253, 
2127, 1667, 1394, 1051, 1023, 820, 760. 
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 2-(tert-Butyl)benzo[d]thiazole (1o). Physical state: 38 mg, 66% yield, yellow oil. 1H NMR (500 
MHz, CDCl3) δ 8.00 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.46 – 7.43 (m, 1H), 7.35 – 7.32 
(m, 1H), 1.53 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 182.0, 153.4, 135.1, 125.9, 124.6, 122.8, 
121.6, 38.5, 30.9. HRMS (ES+) m/z calc. for C11H14NS [M+H] 192.0847, found 192.0847. FT-IR 
(cm-1, neat, ATR) 2965, 1513, 1438, 1044, 1008, 758. 
 
2-(tert-Butyl)quinazolin-4(3H)-one (1p). Reference: Li, Z.; Dong, J.; Chen, X.; Li, Q.; Zhou, Y.; 
Yin, S. -F. J. Org, Chem. 2015, 80, 9392. Physical state: 54 mg, 90% yield, white solid (mp = 
110–113 °C). 1H NMR (500 MHz, CDCl3) δ 11.40 (s, 1H), 8.29 (d, J = 7.6 Hz, 1H), 7.74 (d, J = 
9.8 Hz, 2H), 7.45 (t, J = 7.6 Hz, 1H), 1.50 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 164.1, 162.3, 
149.4, 134.6, 127.8, 126.4, 126.3, 120.7, 100.1, 37.6, 28.4. HRMS (ES+) m/z calc. for C12H15N2O 
[M+H] 203.1184, found 203.1183. FT-IR (cm-1, neat, ATR) 3189, 3079, 2968, 1667, 1611, 772. 
 
N-Benzyl-2-(tert-butyl)-7H-purin-6-amine (1q). Physical state: 67 mg, 79% yield, yellow solid 
(mp = 125–127 °C). 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 7.44 – 7.41 (m, 2H), (dd, J = 7.5, 
7.5 Hz, 2H), 7.29 (d, J = 7.5 Hz, 1H), 6.12 (bs, 1H), 4.89 (s, 2H), 1.53 (s, 9H) (highlighted proton 
not observed). 13C NMR (126 MHz, CDCl3) δ 160.7, 154.2, 151.6, 138.7, 128.8, 128.7, 128.2, 
S
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127.6, 100.1, 33.9, 29.6, 27.8. HRMS (ES+) m/z calc. for C16H20N5 [M+H] 282.1719, found 
282.1718. FT-IR (cm-1, neat, ATR) 2972, 1619, 1598, 1351, 1299. 
 
(1R)-(2-(tert-Butyl)-6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (1r). Reference: 
Yardley, J. P.; Bright, R. E.; Rane, L.; Rees, R. W.; Russell, P. B.; Smith, H. J. Med. Chem. 1971, 
14, 62. Physical state: 62 mg, 54% yield, light yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.98 (d, 
J = 9.2 Hz, 1H), 7.67 (s, 1H), 7.30 (d, J = 9.2 Hz, 1H), 7.20 (s, 1H), 5.73 (dt, J = 17.6, 9.0 Hz, 1H), 
5.58 (s, 1H), 4.97 – 4.90  (m, 2H), 3.89 (s, 3H), 3.50 – 3.45 (m, 1H), 3.20 – 3.08 (m, 2H), 2.71 – 
2.65 (m, 2H), 2.29 – 2.25 (m, 1H), 1.81 (s, 1H), 1.79 – 1.65 (m, 2H), 1.52 – 1.43 (m, 11H). 13C 
NMR (126 MHz, CDCl3) δ 166.6, 157.4, 146.9, 143.8, 142.0, 131.9, 124.7, 120.9, 115.5, 114.6, 
101.3, 72.6, 60.1, 57.3, 55.8, 43.5, 40.1, 38.1, 30.3, 28.1, 27.8, 21.6. HRMS (ES+) m/z calc. for 
C24H32N2O2 [M+H] 381.2536, found 381.2543. FT-IR (cm-1, neat, ATR)2954, 1621, 1601, 1561, 
1505, 1471, 1363, 1343, 1263, 1231, 1106, 1034, 911, 832, 734, 645. 
TERTIARY EXAMPLES 
 
1,3,9-Trimethyl-8-(2-methyl-1-phenylpropan-2-yl)-3,9-dihydro-1H-purine-2,6-dione 
(1v).Physical state: 52 mg, 53% yield, pale yellow solid (mp = 101–103 oC). 1H NMR (500 MHz, 
CDCl3) δ 7.23-7.21 (m, 3H), 6.88-6.85 (m, 2H), 3.80 (s, 3H), 3.56 (s, 3H), 3.41 (s, 3H), 3.03 (s, 
O
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NHO
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2H), 1.51 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 158.7, 155.5, 146.9(4), 146.9(1), 137.4, 129.8, 
128.1, 126.7, 107.7, 48.2, 39.4, 33.8, 29.5, 27.8, 27.2. HRMS (ES+) m/z calc. for C17H23N4O2 
[M+H] 327.1821, found 327.1820. FT-IR (cm-1, neat, ATR) 3055, 2987, 1758, 1699, 1656, 1422, 
1040, 896, 733, 703. 
 
2-(2-Methyl-1-phenylpropan-2-yl)benzo[d]thiazole (1w). Physical state: 52 mg, 53% yield, pale 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.2 Hz, 1H), 7.86 (dd, J = 8.0, 0.5 Hz, 1H), 
7.53 – 7.44 (m, 1H), 7.41 – 7.32 (m, 1H), 7.27 – 7.12 (m, 3H), 7.09 – 6.98 (m, 2H), 3.18 (s, 2H), 
1.52 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 180.7, 153.2, 137.6, 134.8, 130.4, 127.8, 126.3, 125.7, 
124.5, 122.7, 121.4, 49.5, 42.2, 28.0. HRMS (ES+) m/z calc. for C17H18NS [M+H] 268.1160, found 
268.1168. FT-IR (cm-1, neat, ATR) 3028, 2927, 1505, 1495, 1385, 1280, 1005, 743, 687. 
SECONDARY AND TERTIARY ALKYLTRIFLUOROBORATE SCOPE 
 
Methyl 1-(1-(Benzyloxy)-3-phenylpropyl)isoquinoline-3-carboxylate (2a). Physical state: 71 mg, 
58% yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 8.88 (d, J = 8.5 Hz, 1H), 8.52 (s, 1H), 7.98 (d, 
J = 8.0 Hz, 1H), 7.78 – 7.76 (m, 1H), 7.70 – 7.66 (m, 1H), 7.41 – 7.35 (m, 1H), 7.31 – 7.22 (m, 
7H), 7.19 – 7.12 (m, 2H), 5.26 – 5.22 (m, 1H), 4.52 – 4.43 (m, 2H), 4.08 (s, 3H), 3.12 – 2.96 (m, 
1H), 2.78 – 2.72 (m, 1H), 2.61 – 2.53 (m, 1H), 2.33 – 2.25 (m, 1H). 13C NMR (126 MHz, CDCl3) 
δ 166.4, 161.5, 141.7, 140.2, 138.1, 136.5, 130.6, 129.1, 128.8, 128.4, 128.2, 128.1(9), 127.8, 127.7, 
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127.5, 126.2, 125.7, 124.2, 85.1, 71.5, 52.8, 37.8, 32.5. HRMS (ES+) m/z calc. for C27H25NO3Na 
[M+Na] 434.1732, found 434.1734. FT-IR (cm-1, neat, ATR) 3052, 2950, 1736, 1717, 1373, 1147, 
1027, 908, 782, 490. 
 
Methyl 1-(4,4-Difluorocyclohexyl)isoquinoline-3-carboxylate (2b). Physical state: 32 mg, 35% 
yield, yellow oil. 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.98 – 7.95 
(m, 1H), 7.77 – 7.72 (m, 2H), 4.02 (s, 3H), 3.72 – 3.58 (m, 1H), 2.40 – 2.27 (m, 4H), 2.16 – 1.90 
(m, 4H). 13C NMR (126 MHz, CDCl3) δ 166.7, 163.5, 163.5, 140.6, 136.1, 130.4, 129.4, 129.4, 
129.3, 127.6, 125.2, 124.5, 123.3, 122.9, 121.4, 52.7, 39.7, 28.3, 28.2. 19F NMR (471 MHz, C6D6) 
δ 2.26 (d, J = 235.5 Hz), 6.03 (d, J = 235.5 Hz). HRMS (ES+) m/z calc. for C17H17F2NO3 [M+Na] 
328.1125, found 328.1124. FT-IR (cm-1, neat, ATR) 2951, 1736, 1450, 1374, 1236, 1205, 1101, 
956, 784. 
 
Methyl 1-(Tetrahydro-2H-pyran-4-yl)isoquinoline-3-carboxylate (2c). Physical state: 60 mg, 74% 
yield, white semi-solid. 1H NMR (300 MHz, CDCl3) δ 8.45 (s, 1H), 8.35 – 8.22 (m, 1H), 8.07 – 
7.90 (m, 1H), 7.76 (dt, J = 5.4, 3.2 Hz, 2H), 4.20 (dd, J = 11.4, 2.6 Hz, 2H), 4.05 (s, 3H), 3.93 – 
3.56 (m, 3H), 2.51 – 2.23 (m, 2H), 1.91 (dd, J = 13.4, 1.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
166.9, 163.9, 141.0, 140.9, 136.3, 130.4, 129.4, 127.7, 124.6, 122.9, 68.3, 52.8, 39.4, 32.0. HRMS 
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(ES+) m/z calc. for C16H17NO3Na [M+Na] 294.1106, found 294.1111. FT-IR (cm-1, neat, ATR) 
2962, 1589, 1489, 1387, 850. 
 
Methyl 1-(1-Tosylpiperidin-4-yl)isoquinoline-3-carboxylate (2d). Physical state: 84 mg, 66% 
yield, pale yellow solid (mp = dec ~195 ⁰C). 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.11 (d, 
J = 8.5 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.74-7.66 (m, 4H), 7.37 (d, J = 8.0 Hz, 2H), 4.03 (s, 3H), 
3.98 (d, J = 11.5 Hz, 2H), 3.53-3.48 (m, 1H), 2.62-2.52 (m, 2H), 2.48 (s, 3H), 2.45-2.32 (m, 2H), 
2.05-2.03 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 166.5, 162.9, 143.3, 140.6, 133.3, 130.2, 129.5, 
129.2, 129.1(9), 128.8, 127.8, 127.4, 124.1, 122.8, 52.6, 46.3, 39.1, 30.4, 21.5. HRMS (ES+) m/z 
calc. for C23H25N2O4S [M+H] 425.1535, found 425.1531. FT-IR (cm-1, neat, ATR) 2962, 1589, 
1489, 1387, 850. 
 
Methyl 1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)isoquinoline-3-carboxylate (2e). Physical state: 
41 mg, 51% yield, white semi-solid. 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.25 (d, J = 7.3 Hz, 
1H), 8.06 – 7.89 (m, 1H), 7.84 – 7.64 (m, 2H), 4.32 (m, 2H), 4.02 (s, 3H), 3.72 (t, J = 11.4 Hz, 1H), 
2.99 (m, 2H), 2.03 (m, 4H), 1.49 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 166.8, 164.1, 154.9, 140.8, 
136.3, 130.5, 129.4, 127.8, 124.6, 122.9, 79.6, 58.5, 52.8, 40.2, 31.2, 28.7. HRMS (ES+) m/z calc. for 
C21H27N2O4 [M+H] 371.1971, found 371.1984. FT-IR (cm-1, neat, ATR) 2962, 1589, 1489, 1387, 850. 
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Methyl 1-(1-Hydroxy-3-phenylpropan-2-yl)isoquinoline-3-carboxylate (2f). Physical state: 20 
mg, 20% yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 8.48 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.98 
(d, J = 8.1 Hz, 1H), 7.78 – 7.75 (m, 1H), 7.72 – 7.68 (m, 1H), 7.34 – 7.18 (m, 5H), 5.65 (d, J = 10.1 
Hz, 1H), 4.19 (d, J = 11.3 Hz, 1H), 4.05 (s, 3H), 3.98 – 3.93 (m, 1H), 3.88 – 3.84 (m, 1H), 3.39 – 
3.34 (m, 1H), 3.12 – 3.07 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 166.2, 165.4, 140.1, 139.6, 
136.3, 131.1, 129.9, 129.5, 129.4, 128.7, 128.0, 126.5, 125.0, 123.2, 63.1, 53.0, 44.4, 38.1. HRMS 
(ES+) m/z calc. for C20H20NO2 [M+H] 322.1443, found 322.1452. FT-IR (cm-1, neat, ATR) 1734, 
1451, 1244, 1207, 749, 702. 
 
Methyl 1-(Tetrahydrofuran-3-yl)isoquinoline-3-carboxylate (2g). Physical state: 43.7 mg, 34% 
yield, colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.27 (d, J = 7.2 Hz, 1H), 8.00 – 
7.93 (m, 1H), 7.80 – 7.70 (m, 2H), 4.42 – 4.32 (m, 2H), 4.25 – 4.15 (m, 2H), 4.08 – 3.96 (m, 4H), 
2.79 – 2.57 (m, 1H), 2.53 – 2.31 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 166.5, 161.2, 136.0, 
134.0, 130.4, 129.4, 129.0, 128.4, 124.8, 123.0, 112.7, 77.2, 68.8, 52.6, 43.4, 32.1. HRMS (ES+) 
m/z calc. for C15H16NO3 [M+H] 258.1130, found 258.1140. FT-IR (cm-1, neat, ATR) 2987, 2870, 
1208, 1063, 861, 837. 
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Methyl 1-(1-(tert-Butoxycarbonyl)azetidin-3-yl)isoquinoline-3-carboxylate (2i). 1H NMR (500 
MHz, CDCl3) δ 8.50 (s, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.82 – 7.71 (m, 
2H), 4.64 – 4.45 (m, 5H), 4.05 (s, 3H), 1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 166.3, 159.7, 
156.3, 140.3, 135.9, 130.7, 129.7, 129.2, 127.7, 124.3, 123.4, 79.4, 52.6, 33.0, 28.3. HRMS (ES+) 
m/z calc. for C19H23N2O4 [M+H] 343.1658, found 343.1666. FT-IR (cm-1, neat, ATR) 2987, 2870, 
1208, 1063, 861, 837. 
 
Methyl 1-Cyclopropylisoquinoline-3-carboxylate (2j). Physical state: 21 mg, 31% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.54 – 8.44 (m, 1H), 8.36 (s, 1H), 8.01 – 7.89 (m, 1H), 7.76 – 7.73 
(m, 2H), 4.01 (s, 3H), 2.75 (tt, J = 8.5, 4.9 Hz, 1H), 1.37 – 1.34 (m, 2H), 1.17 – 1.13 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 166.9, 162.5, 140.7, 135.8, 130.6, 129.5, 129.4, 129.0, 125.6, 122.3, 
52.9, 14.4, 9.3. HRMS (ES+) m/z calc. for C14H13NO2 [M+H] 228.1025, found 228.1019. FT-IR 
(cm-1, neat, ATR) 2951, 1737, 1321, 1269, 1244, 988. 
  
Methyl 1-((3r,5r,7r)-Adamantan-1-yl)isoquinoline-3-carboxylate (2k). Physical state: 43.4 mg, 
45% yield, off-white solid (mp = 210–212 oC). 1H NMR (500 MHz, CDCl3) δ 11.63 (s, 1H), 8.73 
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– 8.71 (m, 1H), 8.58 – 8.38 (m, 1H), 7.71 – 7.70 (m, 2H), 4.08 (s, 3H), 2.38 (s, 6H), 2.21 (s, 3H), 
1.89 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 171.6, 157.4, 155.1, 129.5, 129.1, 128.6, 128.4, 
126.8, 124.2, 118.5, 52.7, 42.2, 41.9, 37.0, 29.1. HRMS (ES+) m/z calc. for C21H24NO2 [M+H] 
322.1807, found 322.1797. FT-IR (cm-1, neat, ATR) 2951, 1737, 1321, 1269, 1244, 988. 
 
Methyl 1-(1-(Pyridin-2-yl)piperidin-4-yl)isoquinoline-3-carboxylate (2l). Physical state: 75 mg, 
72% yield, yellow solid (mp = 154–157 oC). 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.31 (s, 
1H), 8.20 (s, 1H) 7.98 (d, J = 3.5 Hz, 1H), 7.76 – 7.74 (m, 2H), 7.49 – 7.45 (m, 1H), 6.74 (d, J = 
8.5 Hz, 1H), 6.60-6.59 (m, 1H), 4.52 (d, J = 12.5 Hz, 2H), 4.00 (s, 3H), 3.82-3.80 (m, 1H), 3.12 (t, 
J = 12.5 Hz, 2H), 2.34-2.26 (m, 2H), 2.10-2.04 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 166.9, 
164.3, 159.6, 148.1, 140.9, 137.5, 136.3, 130.4, 129.4, 129.4, 127.8, 124.8, 122.9, 112.8, 107.4, 
52.8, 45.8, 40.7, 31.2. HRMS (ES+) m/z calc. for C21H22N3O2 [M+H] 348.1712, found 348.1714. 
FT-IR (cm-1, neat, ATR) 2962, 1589, 1489, 1387, 850, 1236. 
PRIMARY ALKYLTRIFLUOROBORATE COUPLING 
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Methyl 1-((Benzyloxy)methyl)isoquinoline-3-carboxylate (3a). Physical state: 52 mg, 56% yield, 
clear oil. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 7.4 Hz, 
2H), 7.96 (d, J = 8.1 Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.54 (t, J = 7.0 Hz, 
1H), 7.42 (t, J = 7.6 Hz, 2H), 4.41 (t, J = 6.4 Hz, 2H), 4.04 (s, 3H), 3.46 (t, J = 7.9 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 166.8, 166.8, 162.5, 140.8, 136.1, 133.0, 133.0, 130.7, 130.6, 129.7, 
129.7, 129.52, 129.1, 128.5, 125.6, 123.1, 100.1, 77.4, 77.2, 76.9, 64.9, 64.8, 62.6, 53.0, 35.3, 29.4, 
29.0, 26.4, 25.4. HRMS (ES+) m/z calc. for C19H17NO3 [M+Na] 308.1287, found 308.1283. FT-
IR (cm-1, neat, ATR) 2951, 1716, 1315, 1275, 1246, 712. 
 
Methyl 1-((2-(Trimethylsilyl)ethoxy)methyl)isoquinoline-3-carboxylate (3b). Physical state: 61 
mg, 86% yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H), 8.47 (d, J = 7.9 Hz, 1H), 7.96 
(d, J = 7.9 Hz, 1H), 7.78 – 7.71 (m, 2H), 5.13 (s, 2H), 4.04 (s, 3H), 3.76 – 3.55 (m, 2H), 1.11 – 0.90 
(m, 2H), -0.03 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 166.5, 158.4, 140.4, 136.3, 130.9, 129.6, 
129.0, 128.6, 126.6, 124.7, 73.5, 68.5, 52.9, 18.5, -1.3. HRMS (ES+) m/z calc. for C17H23NO3Si 
[M+Na] 340.1345, found 340.1347. FT-IR (cm-1, neat, ATR) 2951, 1740, 1719, 1247, 1208, 860. 
  
Methyl 1-(((3-Methylbut-3-en-1-yl)oxy)methyl)isoquinoline-3-carboxylate (3c). Physical state: 
55 mg, 64% yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 8.54 (s, 1H), 8.49 (d, J = 8.2 Hz, 1H), 
7.96 (d, J = 7.9 Hz, 1H), 7.78 – 7.70 (m, 2H), 5.16 (s, 2H), 4.74 (s, 1H), 4.70 (s, 1H), 4.04 (s, 3H), 
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3.68 (t, J = 6.9 Hz, 2H), 2.32 (t, J = 6.9 Hz, 2H), 1.68 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
166.4, 158.2, 142.8, 140.3, 136.3, 131.0, 129.6, 129.0, 128.6, 126.6, 124.8, 111.7, 74.2, 69.4, 53.0, 
37.9, 22.7. HRMS (ES+) m/z calc. for C17H19NO3Na [M+Na] 308.1263, found 308.1263. FT-IR 
(cm-1, neat, ATR) 2950, 1738, 1450, 1295, 1209, 1109. 
 
Methyl 1-((Cyclopentyloxy)methyl)isoquinoline-3-carboxylate (3d). Physical state: 72 mg, 84% 
yield, clear viscous oil. 1H NMR (500 MHz, CDCl3) δ 8.52 (s, 1H), 8.45 (d, J = 7.7 Hz, 1H), 7.94 
(d, J = 7.4 Hz, 1H), 7.74 (s, 2H), 5.10 (s, 2H), 4.13 (s, 1H), 4.04 (s, 3H), 1.52 (m, 8H). 13C NMR 
(126 MHz, CDCl3) δ 166.5, 158.6, 140.3, 136.3, 130.9, 129.6, 129.1, 128.6, 126.7, 124.7, 82.3, 
77.4, 77.2, 76.9, 72.5, 53.0, 32.4, 23.6. HRMS (ES+) m/z calc. for C17H20NO3 [M+H] 286.1443, 
found 286.1454. FT-IR (cm-1, neat, ATR) 2952, 1737, 1334, 1246, 1110, 1096, 791. 
 
Methyl 1-((((1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl)oxy)methyl)isoquinoline-3-carboxylate 
(3e). Physical state: 65 mg, 61% yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H), 8.46 
(d, J = 7.7 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.79 – 7.70 (m, 2H), 5.30 (d, J = 11.3 Hz, 1H), 5.04 
(d, J = 11.3 Hz, 1H), 4.04 (s, 3H), 3.28 (td, J = 10.5, 4.1 Hz, 1H), 2.07 – 2.03 (m, 1H), 1.67 – 1.54 
(m, 2H), 1.43 – 1.17 (m, 3H), 0.97 – 0.75 (m, 9H), 0.43 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 166.6, 158.9, 140.3, 136.3, 130.9, 129.4, 129.2, 128.6, 127.0, 124.8, 79.3, 71.3, 52.9, 
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48.5, 40.4, 34.6, 31.6, 25.3, 23.1, 22.5, 21.1, 15.7. HRMS (ES+) m/z calc. for C22H29NO3Na 
[M+Na] 378.2047, found 378.2045. FT-IR (cm-1, neat, ATR) 2954, 2869, 1722, 1244, 1108, 984, 
907, 688, 646. 
 
Methyl 1-Isobutylisoquinoline-3-carboxylate (3f). Physical state: 45 mg, 62% yield, clear oil. 1H 
NMR (500 MHz, CDCl3) δ 8.43 (s, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.71 
(m, 2H), 4.03 (s, 3H), 3.25 (d, J = 7.3 Hz, 2H), 2.32 (m, 1H), 0.98 (d, J = 6.7 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 166.9, 162.5, 140.8, 136.1, 130.5, 129.2, 129.0, 129.0, 125.9, 122.8, 52.9, 
44.1, 29.8, 22.9. HRMS (ES+) m/z calc. for C15H17NO2Na [M+Na] 266.1157, found 266.1161. 
FT-IR (cm-1, neat, ATR) 2955, 1737, 1718, 1294, 1242, 1205. 
 
Methyl 1-Benzylisoquinoline-3-carboxylate (3g). Physical state: 56 mg, 67% yield, clear oil. 1H 
NMR (500 MHz, CDCl3) δ 8.51 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.73 – 
7.68 (m, 1H), 7.64 – 7.60 (m, 1H), 7.27 – 7.20 (m, 4H), 7.19 – 7.13 (t, J = 7.0 Hz, 1H), 4.78 (s, 
2H), 4.07 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.7, 160.9, 140.8, 139.2, 136.4, 130.7, 129.6, 
129.0, 128.8, 128.7 128.7, 126.5, 126.4, 123.7, 53.0, 42.6. HRMS (ES+) m/z calc. for C18H16NO2 
[M+H] 278.1181, found 278.1171. FT-IR (cm-1, neat, ATR) 2949, 1736, 1568, 1438, 1242, 1208, 
1150, 1106, 742, 692. 
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Methyl 1-Phenethylisoquinoline-3-carboxylate (3h). Physical state: 28 mg, 32% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.47 (s, 1H), 8.19 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.78 
– 7.66 (m, 2H), 7.32 – 7.15 (m, 5H), 4.06 (s, 3H), 3.76 – 3.62 (m, 2H), 3.28 – 3.15 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 166.8, 166.8, 162.0, 141.8, 140.8, 136.1, 130.7, 129.5, 129.1, 128.6, 
128.6, 126.2, 125.5, 123.2, 53.0, 37.4, 35.6 (one aryl carbon peak overlaps). HRMS (ES+) m/z 
calc. for C19H18NO2 [M+H] 314.1157, found 314.1157. FT-IR (cm-1, neat, ATR) 2949, 1737, 1716, 
1240, 1208, 749. 
 
Methyl 1-(3-Phenylpropyl)isoquinoline-3-carboxylate (3i). Physical state: 76% yield, clear oil. 1H 
NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.06 (d, J = 8.3 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.76 – 7.68 (m, 
2H), 7.35 – 7.26 (m, 2H), 7.25 – 7.16 (m, 3H), 4.05 (s, 3H), 3.48 – 3.27 (m, 2H), 2.81 (t, J = 7.7 Hz, 2H), 
2.26 – 2.19 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 166.8, 162.8, 142.1, 140.8, 136.1, 130.6 129.4, 129.0, 
128.7, 128.5, 128.5, 126.0, 125.6, 123.1, 53.0, 36.1, 35.2, 31.6. HRMS (ES+) m/z calc. for C20H20NO2 
[M+H] 306.1494, found 306.1492. FT-IR (cm-1, neat, ATR) 2949, 1736, 1716, 1242, 1209, 747. 
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Methyl 1-(4-(2-Bromophenyl)butyl)isoquinoline-3-carboxylate (3j). Physical state: 67 mg, 56% 
yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 7.8 Hz, 
1H), 7.75 – 7.70 (m, 2H), 7.51 (d, J = 8.0 Hz, 1H), 7.24 – 7.19 (m, 2H), 7.03 (s, 1H), 4.04 (s, 3H), 3.42 (t, J 
= 8.1 Hz, 2H), 2.85 – 2.76 (m, 2H), 2.01 – 1.90 (m, 2H), 1.85 – 1.76 (m, 2H). 13C NMR (126 MHz, CDCl3) 
δ 166.8, 162.9, 141.7, 140.8, 136.1, 132.9, 130.6, 130.5, 129.4, 129.0, 128.5, 127.6, 125.7, 124.6, 123.0, 53.0, 
36.2, 35.7, 30.2, 29.8. HRMS (ES+) m/z calc. for C21H20BrNO2 [M+Na] 420.0575, found 420.0576. 
FT-IR (cm-1, neat, ATR) 2946, 1735, 1438, 1239, 1207, 1020, 748. 
 
Methyl 1-(3-(Phenylthio)propyl)isoquinoline-3-carboxylate (3k) Physical state: 50 mg, 49% 
yield, clear oil. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 
8.1 Hz, 1H), 7.76 – 7.70 (m, 1H), 7.70 – 7.64 (m, 1H), 7.36 (d, J = 7.7 Hz, 2H), 7.31 – 7.21 (m, 
2H), 7.19 – 7.14 (m, 1H), 4.04 (s, 3H), 3.58 – 3.46 (m, 2H), 3.11 (t, J = 7.0 Hz, 2H), 2.30 – 2.21 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 166.7, 161.9, 140.7, 136.5, 136.1, 130.7, 129.6, 129.4, 
129.0, 128.5, 126.1 125.6, 123.2, 53.0, 34.4, 33.6, 29.0 (one aryl peak overlaps). HRMS (ES+) 
m/z calc. for C20H20NO2S [M+H] 338.1215, found 338.1198. FT-IR (cm-1, neat, ATR) 2950, 1737, 
1716, 1449, 1325, 1294, 1243, 1210. 
 
Methyl 1-(3,3,3-Trifluoropropyl)isoquinoline-3-carboxylate (3l). Physical state: 15 mg, 18% 
yield, viscous oil. 1H NMR (500 MHz, CDCl3) δ 8.48 (s, 1H), 8.20 (d, J = 8.6 Hz, 1H), 8.06 – 7.93 
(m, 1H), 7.86 – 7.74 (m, 2H), 4.05 (s, 3H), 3.68 – 3.57 (m, 2H), 2.96 – 2.77 (m, 2H). 13C NMR 
(126 MHz, CDCl3) δ 166.5, 158.7, 140.6, 136.0, 131.1, 130.1, 129.3, 128.4, 124.8, 123.7, 53.1, 
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32.5 (q, J = 29.0 Hz), 29.0, 27.4. 19F NMR (471 MHz, CDCl3) δ -66.42. HRMS (ES+) m/z calc. 
for C14H12F3NO2Na [M+Na] 306.0718, found 306.0721. FT-IR (cm-1, neat, ATR) 3071, 1715, 
1240, 1126. 
TANDEM RING OPENING EXAMPLE 
 
 
Methyl 1-(But-3-en-1-yl)isoquinoline-3-carboxylate (3p). Physical state: 40 mg, 55% yield, 
crystalline powder (mp = 54–57 °C). 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.21 (d, J = 7.9 
Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.76 – 7.68 (m, 2H), 6.05 – 5.90 (m, 1H), 5.12 (d, J = 17.0 Hz, 
1H), 5.01 (d, J = 10.2 Hz, 1H), 4.04 (s, 3H), 3.47 (t, J = 8.2 Hz, 2H), 2.70 – 2.60 (m, 2H). 13C NMR 
(126 MHz, CDCl3) δ 166.7, 162.3, 140.8, 137.8, 136.1, 130.6, 129.5, 129.1, 128.5, 125.6, 123.1, 
115.3, 53.0, 35.0, 33.8. HRMS (ES+) m/z calc. for C15H15NO2 [M+Na] 264.1000, found 264.0998. 
FT-IR (cm-1, neat, ATR) 1748, 1656, 1596, 1157. 
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4-Methyl-2-((2-(Trimethylsilyl)ethoxy)methyl)quinoline (4a). Reference: Molander, G. A.; 
Colombel, V.; Braz, V. Org. Lett. 2011, 13, 1852. Physical state: 62 mg, 77% yield, clear oil. 1H 
NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.3 Hz, 1H), 7.71 – 7.66 (m, 1H), 
7.55 – 7.51 (m, 1H), 7.46 (s, 1H), 4.74 (s, 2H), 3.72 – 3.63 (m, 2H), 2.71 (s, 3H), 1.11 – 1.03 (m, 
2H), -0.03 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 159.3, 147.5, 145.0, 129.7, 129.3, 127.7, 126.1, 
123.8, 120.2, 74.1, 68.6, 19.0, 18.5, -1.2. FT-IR (cm-1, neat, ATR) 2953, 1603, 1249, 1101, 850, 
836, 757. 
 
1-(4-Methylquinolin-2-yl)-3-phenylpropyl benzoate (4b). Physical state: 48 mg, 42% yield, clear 
oil. 1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 7.7 Hz, 2H), 8.10 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 
8.3 Hz, 1H), 7.72 – 7.69 (m, 1H), 7.62 – 7.59 (m, 1H), 7.56 – 7.52 (m, 1H), 7.51 – 7.47 (m, 2H), 
7.34 (s, 1H), 7.30 – 7.12 (m, 5H), 6.20 (dd, J = 8.3, 5.1 Hz, 1H), 2.90 – 2.78 (m, 2H), 2.69 (s, 3H), 
2.60 – 2.45 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 166.1, 159.7, 147.6, 145.3, 141.5 133.3, 130.3, 
130.0, 129.4, 128.8, 128.6, 128.4, 127.8, 126.5, 126.4, 126.1, 123.8, 119.1, 36.9, 32.1, 19.1. HRMS 
(ES+) m/z calc. for C26H23NO2 [M+Na] 404.1626, found 404.1630. FT-IR (cm-1, neat, ATR) 1719, 
1602, 1451, 1270, 1111, 1070, 1027, 713. 
 
2-((But-3-en-1-yloxy)methyl)quinoline (4c). Physical state: 24 mg, 38% yield, clear oil. 1H NMR 
(500 MHz, CDCl3) δ 8.18 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 
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7.72 – 7.68 (m, 1H), 7.64 – 7.61 (m, 1H), 7.54 – 7.51 (m, 1H), 5.92 – 5.84 (m, 1H), 5.15 – 5.06 (m, 
2H), 4.82 (s, 2H), 3.65 (t, J = 6.6 Hz, 2H), 2.45 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 159.6, 
147.7, 136.9, 135.3, 129.7, 129.1, 127.8, 127.7, 126.4, 119.5, 116.7, 74.6, 70.5, 34.4. HRMS (ES+) 
m/z calc. for C14H16NO [M+H] 214.1232, found 214.1234. FT-IR (cm-1, neat, ATR) 2858, 1601, 
1506, 1428, 1359, 1106, 996, 916, 829, 784, 755, 618. 
 
2-Octylquinoline (4d). Physical state: 32 mg, 44% yield, yellow oil. 1H NMR (500 MHz, CDCl3) 
δ 8.80 (d, J = 4.4 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.71 – 7.68 (m, 1H), 
7.57 – 7.54 (m, 1H), 7.23 (d, J = 4.3 Hz, 1H), 3.09 – 3.04 (m, 2H), 1.80 – 1.73 (m, 2H), 1.47 – 1.41 
(m, 2H), 1.40 – 1.17 (m, 8H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 150.4, 148.9, 
148.5, 130.4, 129.1, 127.8, 126.3, 123.8, 120.9, 32.3, 32.0, 30.3, 29.9, 29.6, 29.4, 22.8, 14.2. 
HRMS (ES+) m/z calc. for C17H24N [M+H] 242.1909, found 242.1904. FT-IR (cm-1, neat, ATR) 
2924, 2855, 1592, 1508, 1463, 760. 
 
2-((2R)-2-Methylcyclopentyl)quinoline (4e). Physical state: 38 mg, 60% yield, clear oil. 1H NMR 
(500 MHz, CDCl3) δ 8.08 – 8.04 (m, 2H), 7.77 (d, J = 8.1 Hz, 1H), 7.69 – 7.65 (m, 1H), 7.49 – 
7.45 (m, 1H), 7.31 (d, J = 8.6 Hz, 1H), 2.90 – 2.84 (m, 1H), 2.33 – 2.17 (m, 2H), 2.09 – 1.93 (m, 
2H), 1.92 – 1.77 (m, 2H), 1.45 – 1.37 (m, 1H), 1.01 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 165.6, 148.1, 136.2, 129.3, 129.2, 127.6, 127.1, 125.7, 120.4, 57.3, 42.5, 35.2, 34.3, 24.5, 
19.0. HRMS (ES+) m/z calc. for C15H18N [M+H] 212.1439, found 212.1444. FT-IR (cm-1, neat, 
ATR) 3050, 2946, 1601, 1255. 
N
Me
N
Me
598 
 
 
 
1,1'-(3-Phenethylpyridine-2,6-diyl)bis(ethan-1-one) (4f). Physical state: 52 mg, 65% yield, clear 
oil. 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.30 – 7.25 
(m, 2H), 7.22 – 7.18 (m, 3H), 3.33 – 3.30 (m, 2H), 2.93 – 2.90 (m, 2H), 2.75 (s, 3H), 2.73 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 201.8, 199.4, 151.1, 150.6, 142.0, 141.0, 140.9, 128.8, 128.6, 126.4, 
123.7, 37.4, 35.4, 28.4, 25.7. HRMS (ES+) m/z calc. for C17H18NO2 [M+H] 268.1338, found 
268.1339. FT-IR (cm-1, neat, ATR) 1699, 1358, 1296, 700. 
 
2-(1-(Benzyloxy)-2-phenylethyl)benzo[d]thiazole (4g). Physical state: 52 mg, 53% yield, 
colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.07 – 8.00 (m, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.52 – 
7.47 (m, 1H), 7.43 – 7.36 (m, 5H), 7.35 – 7.31 (m, 1H), 7.28 – 7.24 (m, 2H), 7.17 (d, J = 7.8 Hz, 
3H), 4.85 (dd, J = 8.3, 4.8 Hz, 1H), 4.70 (d, J = 11.4 Hz, 1H), 4.52 (d, J = 11.4 Hz, 1H), 2.93 – 
2.82 (m, 1H), 2.82 – 2.71 (m, 1H), 2.41 – 2.29 (m, 1H), 2.29 – 2.19 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 175.4, 153.3, 141.3, 137.6, 135.1, 128.7, 128.6(5), 128.5(7), 128.3, 128.1, 126.1(5), 
126.1(3), 125.3, 123.2, 122.1, 79.0, 72.3, 38.9, 31.7. HRMS (ES+) m/z calc. for C23H23NOS 
[M+H] 360.1422, found 360.1420. FT-IR (cm-1, neat, ATR) 3027, 2922, 2861, 1516, 1495, 1093, 
1027, 1014, 758, 697. 
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3-Isopropyl-1H-indazole (4h). Physical state: 33 mg, 69% yield, clear oil. 1H NMR (500 MHz, 
CDCl3) δ 9.84 (bs, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.45 – 7.42 (m, 1H), 7.38 – 7.35 (m, 1H), 7.15 – 
7.12 (m, 1H), 3.44 (sept, J = 7.0 Hz, 1H), 1.48 (d, J = 7.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
152.8, 141.6, 126.7, 121.4, 120.8, 120.2, 109.9, 27.9, 22.3. HRMS (ES+) m/z calc. for C10H12N2 
[M+] 160.1000, found 160.1001. FT-IR (cm-1, neat, ATR) 3189, 2968, 1623, 1501, 1349, 742. 
 
2-Isopropylquinazolin-4(3H)-one (4i). Reference: Shen, G.; Zhou, H.; Sui, Y.; Liu, Q.; Zou, K. 
Tetrahedron Lett. 2016, 57, 587. Physical state: 45 mg, 79% yield, white solid (mp = 123 °C). 1H 
NMR (500 MHz, CDCl3) δ 11.64 (s, 1H), 8.30 (d, J = 7.9 Hz, 1H), 7.79 – 7.72 (m, 2H), 7.47 – 
7.45 (m, 1H), 3.06 (sept, J = 7.0 Hz, 1H), 1.45 (d, J = 7.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
164.4, 161.0, 149.6, 134.8, 127.5, 126.4, 126.4, 120.9, 35.1, 20.6. HRMS (ES+) m/z calc. for 
C11H12N2ONa [M+Na] 211.0847, found 211.0851. FT-IR (cm-1, neat, ATR) 2970, 2932, 1622, 
1609, 1472, 1384, 1252, 772. 
 
2-((1R,2R)-2-Methylcyclohexyl)quinazolin-4(3H)-one (4j). Physical state: 30 mg, 41% yield, 
white powder (mp = 89–93 °C). 1H NMR (500 MHz, CDCl3) δ 11.48 (s, 1H), 8.29 (d, J = 7.9 Hz, 
1H), 7.80 – 7.71 (m, 2H), 7.48 – 7.46 (m, 1H), 2.39 – 2.33 (m, 1H), 2.05 – 1.96 (m, 2H), 1.92 – 
1.73 (m, 4H), 1.57 – 1.49 (m, 1H), 1.43 – 1.35 (m, 1H), 1.26 – 1.12 (m, 1H), 0.88 (d, J = 6.5 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 164.1, 159.9, 149.6, 134.8, 127.5, 126.4, 120.9, 100.1, 52.9, 
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35.2, 35.2, 31.5, 26.2, 26.1, 20.6. HRMS (ES+) m/z calc. for C15H19N2O [M+H] 243.1497, found 
243.1500. FT-IR (cm-1, neat, ATR) 2926, 1668, 1471, 773. 
 
1,3,7-Trimethyl-8-((2S)-2-methylcyclopentyl)-3,7-dihydro-1H-purine-2,6-dione (4k). Physical 
state: 31 mg, 37%, light yellow oil. 1H NMR (500 MHz, CDCl3) δ 3.93 (s, 3H), 3.56 (s, 3H), 3.40 
(s, 3H), 2.67 – 2.63 (m, 1H), 2.50 -2.40 (m, 1H), 2.14 – 2.01 (m, 2H), 1.96 – 1.76 (m, 4H), 1.02 (d, 
J = 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 157.6, 155.5, 152.0, 148.4, 107.4, 44.8, 41.3, 34.6, 
32.4, 31.7, 29.9, 28.0, 24.2, 19.2. HRMS (ES+) m/z calc. for C14H21N4O2 [M+H] 277.1658, found 
277.1661. FT-IR (cm-1, neat, ATR) 2954, 1703, 1661, 1543, 1436, 1221, 1041, 981, 747. 
 
(1R)-(2-Isopropyl-6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (4l). Physical state: 82 mg, 
75% yield, light yellow solid (mp = 145 °C). 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 9.1 Hz, 1H), 7.52 
(s, 1H), 7.22 (d, J = 9.1 Hz, 1H), 7.07 (s, 1H), 5.80 (s, 1H), 5.73 – 5.60 (m, 1H), 5.00 – 4.92 (m, 2H), 3.81 – 
3.73 (m, 4H), 3.26 – 3.08 (m, 3H), 2.85 – 2.75 (m, 3H), 2.42 – 2.35 (m, 1H), 1.90 – 1.80 (m, 2H), 1.65 – 1.60 
(m, 1H), 1.49 – 1.39 (m, 1H), 1.34 (d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 164.7, 157.6, 146.3, 
143.8, 140.1, 131.3, 124.7, 121.5, 116.5, 115.8, 100.6, 60.2, 60.1, 56.2, 55.9, 43.7, 39.0, 37.2, 27.7, 26.4, 
22.7, 20.2. HRMS (ES+) m/z calc. for C23H30N2O2 [M+H] 367.2361, found 367.2394. FT-IR (cm-1, neat, 
ATR) 2962, 1674, 1620, 
 
O N
N
Me
N
N
Me
O
MeMe
MeO
N
NHO
i-Pr
601 
 
 
HETEROARENE WITH FUNCTION HANDLES 
 
4-((Benzyloxy)methyl)-5-bromopyrimidine (5a). Physical state: 42 mg, 50% yield, clear oil. 1H 
NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.77 (s, 1H), 7.43 – 7.30 (m, 5H), 4.73 (s, 2H), 4.71 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 164.1, 158.9, 157.1, 137.4, 128.7, 128.2, 128.2, 120.3, 73.7, 
71.1. HRMS (ES+) m/z calc. for C12H12BrN3O [M+H] 279.0133, found 279.0135. FT-IR (cm-1, 
neat, ATR) 2860, 1560, 1454, 1388, 1360, 1216, 1097, 1036, 738, 698. 
 
2-((Benzyloxy)methyl)-3-bromo-4-methylpyridine (5b). Physical state: 55 mg, 63% yield, clear 
oil. 1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 4.8 Hz, 1H), 7.30 (m, 4H), 7.22 (m, 1H), 7.03 (d, J 
= 4.8 Hz, 1H), 3.40 – 3.21 (m, 2H), 3.05 (dd, J = 10.2, 6.7 Hz, 2H), 2.43 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 159.9, 148.0, 147.2, 141.9, 128.7, 128.6, 126.2, 124.4, 124.0, 40.4, 34.8, 23.6. 
HRMS (ES+) m/z calc. for C14H15BrNO [M+H] 292.0701, found 292.0701. FT-IR (cm-1, neat, 
ATR) 1735, 1716, 1452, 1296, 1243, 1211, 794. 
 
3-Bromo-4-methyl-2-phenethylpyridine (5c). Physical state: 50 mg, 60% yield, clear oil. 1H NMR 
(500 MHz, CDCl3) δ 8.33 (d, J = 4.8 Hz, 1H), 7.30 (d, J = 4.4 Hz, 4H), 7.21 (p, J = 4.1 Hz, 1H), 
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7.03 (d, J = 4.8 Hz, 1H), 3.37 – 3.22 (m, 2H), 3.05 (dd, J = 10.2, 6.7 Hz, 2H), 2.43 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 159.9, 147.9, 147.2, 141.9, 128.6, 128.5, 126.1, 124.3, 123.9, 40.4, 
34.8, 23.6. HRMS (ES+) m/z calc. for C14H14BrN [M+H] 276.0388, found 276.0388. FT-IR (cm-
1, neat, ATR) 1727, 1591, 1435, 1281, 1258, 1084, 738, 698. 
  
4-Chloro-2-phenethylquinoline (5d). Physical state: 38 mg, 47% yield, clear oil. 1H NMR (500 
MHz, CDCl3) δ 8.20 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.76 (t, J = 7.7 Hz, 1H), 7.60 (t, 
J = 7.6 Hz, 1H), 7.35 (s, 1H), 7.30 (t, J = 7.5 Hz, 2H), 7.22 (dd, J = 15.9, 8.7 Hz, 2H), 3.29 – 3.23 
(m, 2H), 3.16 (dd, J = 9.7, 6.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 161.9, 149.0, 142.7, 141.3, 
130.5, 129.4, 128.6, 126.9, 126.3, 125.2, 124.1, 121.7, 40.9, 35.8. HRMS (ES+) m/z calc. for 
C17H15ClN [M+H] 268.0893, found 268.0896. FT-IR (cm-1, neat, ATR) 3062, 3027, 1589, 1493, 
1149, 866, 759, 698. 
 
4-Bromo-3-isopropylisoquinoline (5e). Physical state: 30 mg, 40% yield, clear oil. 1H NMR (500 
MHz, CDCl3) δ 8.67 (s, 1H), 8.24 – 8.18 (m, 2H), 7.79 – 7.76 (m, 1H), 7.67 – 7.64 (m, 1H), 3.91 
(sept, J = 6.8 Hz, 1H), 1.43 (d, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 166.1, 143.8, 135.0, 
130.9, 127.9, 127.7, 127.0, 125.2, 117.7, 31.2, 22.3. HRMS (ES+) m/z calc. for C12H13BrN [M+H] 
250.0231, found 250.0224. FT-IR (cm-1, neat, ATR) 2965, 2929, 1565, 1387, 1240, 1009, 928. 
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4-Bromo-1-isopropylisoquinoline (5f). Physical state: 22 mg, 29% yield, clear oil. 1H NMR (500 
MHz, CDCl3) δ 8.51 (s, 1H), 8.35 (d, J = 8.5 Hz, 1H), 7.62 – 7.59 (m, 1H), 7.52 – 7.49 (m, 1H), 
7.43 (d, J = 8.5 Hz, 1H), 4.08 (sept, J = 6.8 Hz, 1H), 1.55 (d, J = 6.8 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 166.8, 143.2, 136.3, 129.9, 127.1, 126.9, 126.3, 125.9, 125.1, 31.3, 22.4. HRMS (ES+) 
m/z calc. for C12H14BrN [M+H] 250.0231, found 250.0224. FT-IR (cm-1, neat, ATR) 2965, 1556, 
1502, 1388, 1246, 765. 
LIGAND FUCNTIONALIZATION 
 
2,9-Di-tert-butyl-1,10-phenanthroline (9). Reference: Xu, C.; Zhang, L.; Dong, C.; Xu, J.; Pan, Y.; 
Li, Y.; Zhang, H.; Li, H.; Yu, Z.; Xu, L. Adv. Synth. Catal. 2016, 358, 567. Physical state: 38 mg, 
42% yield, white semi-solid. 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 8.4 Hz, 2H), 7.84 – 7.48 
(m, 4H), 1.60 (s, 18H). 13C NMR (126 MHz, CDCl3) δ 169.4, 145.0, 136.0, 127.0, 125.5, 119.7, 
38.8, 30.4. HRMS (ES+) m/z calc. for C20H25N [M+H] 293.2018, found 293.2020. FT-IR (cm-1, 
neat, ATR) 2962, 1589, 1489, 1387, 850. 
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2,9-Di-tert-butyl-4,7-diphenyl-1,10-phenanthroline (11). Reference: Sugihara, S.; Okada, T.; 
Hiratani, K. Anal. Sci. 1993, 9, 593. Physical state: 152 mg, 68% yield, yellow oil. 1H NMR (500 
MHz, CDCl3) δ 7.72 (s, 2H), 7.63 (s, 2H), 7.56 – 7.43 (m, 10H), 1.64 (s, 18H). 13C NMR (126 MHz, CDCl3) 
δ 168.8, 148.4, 145.7, 139.2, 129.9, 128.6, 128.2, 124.9, 123.1, 120.1, 38.9, 30.5. 
 
2-(tert-Butyl)-6-(2,4-difluorophenyl)pyridine (13). Physical state: 61 mg, 82% yield, light yellow 
oil. 1H NMR (500 MHz, CDCl3) δ 8.61 (d, J = 5.1 Hz, 1H), 7.96 (m, 1H), 7.72 (s, 1H), 7.28 – 7.22 (m, 1H), 
6.99 (t, J = 8.4 Hz, 1H), 6.91 (m, 1H), 1.36 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 163.2 (dd, J = 250.5, 
12.1 Hz), 160.6 (dd, J = 252.0, 11.9 Hz), 160.6, 149.8, 132.4 (dd, J = 9.7, 4.6 Hz), 124.5 (dd, J = 12.0, 3.9 
Hz), 122.6, 121.5 (d, J = 8.9 Hz), 119.7, 111.9 (dd, J = 21.0, 3.8 Hz), 104.4 (m), 35.0, 30.7. HRMS (ES+) 
m/z calc. for C15H16F2N [M+H] 248.1251, found 248.1241. FT-IR (cm-1, neat, ATR) 2949, 1736, 1716, 
1242, 1209, 747, 700. 
 
CAMPTOTHECIN ANALOGUES 
 
(S)-4-Ethyl-4-hydroxy-11-isopropyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-
b]quinoline-3,14(4H)-dione (5a). Reference: Miao, Z. et al. J. Med. Chem. 2013, 56, 7902 Physical 
state: 67 mg, 57% yield, light yellow solid (mp = 192 °C). 1H NMR (500 MHz, CDCl3) δ 8.25 – 
8.20 (m, 2H), 7.79 – 7.76 (m, 1H), 7.70 – 7.61 (m, 2H), 5.74 (d, J = 16.1 Hz, 1H), 5.38 (s, 2H), 
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5.30 (d, J = 16.1 Hz, 1H), 4.05 – 3.92 (m, 1H), 3.90 (bs, 1H), 1.94 – 1.84 (m, 2H), 1.56 (d, J = 8.3 
Hz, 6H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.1, 157.7, 152.5, 150.4, 149.9, 
149.5, 146.6, 130.9, 130.1, 127.8, 126.9, 125.5, 123.9, 118.5, 98.0, 72.9, 66.5, 50.4, 31.8, 21.7, 
21.6, 8.0. HRMS (ES+) m/z calc. for C23H22N2O4 [M+Na] 413.1477, found 413.1460. FT-IR (cm-
1, neat, ATR) 3320, 2971, 1748, 1657, 1157, 727. 
 
(S)-11-((Benzyloxy)methyl)-4-ethyl-4-hydroxy-1,12-dihydro-14H-
pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (5b). Physical state: 23 mg, 33% 
yield, yellow oil. 1H NMR (500 MHz, CDCl3) δ 8.22 (d, J = 8.5 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 
7.80 -7.76 (m, 1H), 7.69 – 7.59 (m, 2H), 7.42 – 7.34 (m, 5H), 5.75 (d, J = 16.2 Hz, 1H), 5.42 (s, 
2H), 5.31 (d, J = 16.2 Hz, 1H), 5.18 (s, 2H), 4.78 (s, 2H), 3.78 (s, 1H), 1.95 – 1.86 (m, 2H), 1.04 
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.1, 157.8, 152.8, 150.1, 149.1, 146.5, 139.4, 
137.1, 130.7, 130.3, 128.9, 128.5, 128.1, 128.1, 127.2, 126.0, 123.5, 118.8, 97.9, 73.9, 72.9, 67.2, 
66.6, 51.0, 31.8, 8.0. HRMS (ES+) m/z calc. for C28H25N2O5 [M+H] 469.1763, found 469.1774. 
FT-IR (cm-1, neat, ATR) 2987, 2870, 1208, 1063, 861, 837. 
 
Cyclic Voltammetry of Organoboron Reagents: 
 
Electrochemical measurements were recorded on a CH Instruments: Model 600E Series 
Electrochemical Analyzer (observed in 0.002 M MeCN; [N(Bu)4](PF6) = 0.1 M; Ag/AgCl = 
electrode; reported in SCE based on a ferrocene internal standard). 
N
N
O
O
O
HO
Me
OBn
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Of the organoboron reagents examined, only the potassium cyclohexyltriolborate (~1.1 V vs SCE) 
and potassium cyclohexyltrifluoroborate (~1.5 V vs SCE) exhibited oxidations within the solvent 
window of MeCN. These potentials have been reported previously by Akita and coworkers. No 
features were observed for oxidation of the cyclohexyl boronic acid, MIDA, and pincaol boronates. 
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Appendix A11. 1H, 13C, 11B, 19F Spectra Relevant to Chapter 9  
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Figure A11.1. 1H NMR (CDCl3, 500 MHz) spectrum of  2-(tert-butyl)quinoline  (1a) 
Figure A11.2. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)quinoline (1a) 
613 
 
 
Figure A11.3. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-butyl)-4-methylquinoline (1b) 
Figure A11.4. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)-4-methylquinoline (1b) 
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Figure A11.5. 1H NMR (CDCl3, 500 MHz) spectrum of 4-bromo-2-(tert-butyl)quinoline (1c) 
Figure A11.6. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-bromo-2-(tert-butyl)quinoline (1c) 
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Figure A11.7. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-butyl)-4-chloro-8-
(trifluoromethyl)quinoline (1d) 
Figure A11.8. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)-4-chloro-8-
(trifluoromethyl)quinoline (1d) 
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Figure A11.9. 1H NMR (CDCl3, 500 MHz) spectrum of 3-(tert-butyl)-1H-indazole (1e) 
Figure A11.10. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-(tert-butyl)-1H-indazole (1e) 
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Figure A11.9. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(tert-butyl)isoquinoline-3-
carboxylate (1g) 
Figure A11.10. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(tert-butyl)isoquinoline-3-
carboxylate (1g) 
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Figure A11.11. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-butyl)quinoxaline (1h) 
Figure A11.12. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)quinoxaline (1h) 
619 
 
 
Figure A11.13. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-butyl)-3-chloroquinoxaline (1i) 
Figure A11.14. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)-3-chloroquinoxaline 
(1i) 
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Figure A11.15. 1H NMR (CDCl3, 500 MHz) spectrum of 6-(tert-butyl)nicotinonitrile (1j) 
Figure A11.16. 13C NMR (CDCl3, 125.8 MHz) spectrum of 6-(tert-butyl)nicotinonitrile (1j) 
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Figure A11.17. 19F NMR (CDCl3, 470.8 MHz) spectra of 2-(tert-Butyl)-4-
(trifluoromethyl)pyridine (1k) with fluorobenzene 
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Figure A11.18. 1H NMR (CDCl3, 500 MHz) spectrum of 1,1'-(4-(tert-butyl)pyridine-2,6-
diyl)bis(ethan-1-one) (1l) 
Figure A11.19. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1,1'-(4-(tert-butyl)pyridine-2,6-
diyl)bis(ethan-1-one) (1l) 
623 
 
 
Figure A11.20. 1H NMR (CDCl3, 500 MHz) spectrum of 8-(tert-butyl)-1,3,7-trimethyl-3,7-
dihydro-1H-purine-2,6-dione (1m) 
Figure A11.21. 13C NMR (CDCl3, 125.8 MHz) spectrum of  8-(tert-butyl)-1,3,7-trimethyl-3,7-
dihydro-1H-purine-2,6-dione (1m) 
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Figure A11.22. 1H NMR (CDCl3, 500 MHz) spectrum of 6-(tert-butyl)nicotinamide (1n) 
Figure A11.23. 13C NMR (CDCl3, 125.8 MHz) spectrum of 6-(tert-butyl)nicotinamide (1n) 
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Figure A11.24. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-butyl)benzo[d]thiazole (1o) 
Figure A11.25. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)benzo[d]thiazole (1o) 
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Figure A11.26. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-butyl)quinazolin-4(3H)-one (1p) 
Figure A11.27. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)quinazolin-4(3H)-one 
(1p) 
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Figure A11.28. 1H NMR (CDCl3, 500 MHz) spectrum of N-benzyl-2-(tert-butyl)-7H-purin-6-
amine (1q) 
Figure A11.29. 13C NMR (CDCl3, 125.8 MHz) spectrum of N-benzyl-2-(tert-butyl)-7H-purin-6-
amine (1q) 
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Figure A11.30. 1H NMR (CDCl3, 500 MHz) spectrum of (1R)-(2-(tert-butyl)-6-
methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (1r) 
Figure A11.31. 13C NMR (CDCl3, 125.8 MHz) spectrum of (1R)-(2-(tert-butyl)-6-
methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (1r) 
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Figure A11.32. 1H NMR (CDCl3, 500 MHz) spectrum of 1,3,9-trimethyl-8-(2-methyl-1-
phenylpropan-2-yl)-3,9-dihydro-1H-purine-2,6-dione (1v) 
Figure A11.33. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1,3,9-trimethyl-8-(2-methyl-1-
phenylpropan-2-yl)-3,9-dihydro-1H-purine-2,6-dione (1v) 
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Figure A11.34. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(2-methyl-1-phenylpropan-2-
yl)benzo[d]thiazole (1w) 
Figure A11.35. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(2-methyl-1-phenylpropan-2-
yl)benzo[d]thiazole (1w) 
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Figure A11.36. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(1-(benzyloxy)-3-
phenylpropyl)isoquinoline-3-carboxylate (2a) 
Figure A11.37. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-(benzyloxy)-3-
phenylpropyl)isoquinoline-3-carboxylate (2a) 
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Figure A11.38. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(4,4-
difluorocyclohexyl)isoquinoline-3-carboxylate (2b) 
Figure A11.39. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(4,4-
difluorocyclohexyl)isoquinoline-3-carboxylate (2b)  
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Figure A11.40. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(tetrahydro-2H-pyran-4-
yl)isoquinoline-3-carboxylate (2c)  
Figure A11.41. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(tetrahydro-2H-pyran-4-
yl)isoquinoline-3-carboxylate (2c)  
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Figure A11.42. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(1-tosylpiperidin-4-
yl)isoquinoline-3-carboxylate (2d) 
Figure A11.43. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-tosylpiperidin-4-
yl)isoquinoline-3-carboxylate (2d) 
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Figure A11.44. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(1-(tert-
butoxycarbonyl)piperidin-4-yl)isoquinoline-3-carboxylate (2e)  
Figure A11.45. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-(tert-
butoxycarbonyl)piperidin-4-yl)isoquinoline-3-carboxylate (2e) 
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Figure A11.46. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(1-hydroxy-3-phenylpropan-
2-yl)isoquinoline-3-carboxylate (2f) 
Figure A11.47. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-hydroxy-3-
phenylpropan-2-yl)isoquinoline-3-carboxylate (2f) 
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Figure A11.48. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(tetrahydrofuran-3-
yl)isoquinoline-3-carboxylate (2g) 
Figure A11.49. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(tetrahydrofuran-3-
yl)isoquinoline-3-carboxylate (2g)  
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Figure A11.50. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(1-(tert-
butoxycarbonyl)azetidin-3-yl)isoquinoline-3-carboxylate (2i) 
Figure A11.51. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-(tert-
butoxycarbonyl)azetidin-3-yl)isoquinoline-3-carboxylate (2i) 
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Figure A11.52. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-cyclopropylisoquinoline-3-
carboxylate (2j) 
Figure A11.53. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-cyclopropylisoquinoline-3-
carboxylate (2j) 
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Figure A11.54. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-((3r,5r,7r)-adamantan-1-
yl)isoquinoline-3-carboxylate (2k) 
Figure A11.55. 13C NMR (CDCl3, 125.8 MHz) spectrum of XX methyl 1-((3r,5r,7r)-adamantan-
1-yl)isoquinoline-3-carboxylate (2k)  
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Figure A11.56. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(1-(pyridin-2-yl)piperidin-4-
yl)isoquinoline-3-carboxylate (2l)  
Figure A11.57. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-(pyridin-2-yl)piperidin-
4-yl)isoquinoline-3-carboxylate (2l)  
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Figure A11.58. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-
((cyclopentyloxy)methyl)isoquinoline-3-carboxylate (3a) 
Figure A11.59. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-
((cyclopentyloxy)methyl)isoquinoline-3-carboxylate (3a) 
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Figure A11.60. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-((2-
(trimethylsilyl)ethoxy)methyl)isoquinoline-3-carboxylate (3b) 
Figure A11.61. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-((2-
(trimethylsilyl)ethoxy)methyl)isoquinoline-3-carboxylate (3b) 
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Figure A11.62. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(((3-methylbut-3-en-1-
yl)oxy)methyl)isoquinoline-3-carboxylate (3c) 
Figure A11.63. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(((3-methylbut-3-en-1-
yl)oxy)methyl)isoquinoline-3-carboxylate (3c) 
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Figure A11.64. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-((((1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl)oxy)methyl)isoquinoline-3-carboxylate (3d) 
Figure A11.65. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-((((1R,2S,5R)-2-isopropyl-
5-methylcyclohexyl)oxy)methyl)isoquinoline-3-carboxylate (3d) 
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Figure A11.66. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(3-
(benzyloxy)propyl)isoquinoline-3-carboxylate (3e) 
Figure A11.67. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(3-
(benzyloxy)propyl)isoquinoline-3-carboxylate (3e) 
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Figure A11.68. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-isobutylisoquinoline-3-
carboxylate (3f) 
Figure A11.69. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-isobutylisoquinoline-3-
carboxylate (3f) 
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Figure A11.70. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-benzylisoquinoline-3-
carboxylate (3g)  
Figure A11.71. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-benzylisoquinoline-3-
carboxylate (3g) 
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Figure A11.72. 1H NMR (CDCl3, 500 MHz) spectrum of ethyl 1-phenethylisoquinoline-3-
carboxylate (3h) 
Figure A11.73. 13C NMR (CDCl3, 125.8 MHz) spectrum of ethyl 1-phenethylisoquinoline-3-
carboxylate (3h) 
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Figure A11.74. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(3-phenylpropyl)isoquinoline-
3-carboxylate (3i) 
Figure A11.75. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(3-
phenylpropyl)isoquinoline-3-carboxylate (3i) 
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Figure A11.76. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(4-(2-
bromophenyl)butyl)isoquinoline-3-carboxylate (3j) 
Figure A11.77. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(4-(2-
bromophenyl)butyl)isoquinoline-3-carboxylate (3j) 
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Figure A11.78. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(3-
(phenylthio)propyl)isoquinoline-3-carboxylate (3k) 
Figure A11.79. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(3-
(phenylthio)propyl)isoquinoline-3-carboxylate (3k) 
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Figure A11.80. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(3,3,3-
trifluoropropyl)isoquinoline-3-carboxylate (3l) 
Figure A11.81. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(3,3,3-
trifluoropropyl)isoquinoline-3-carboxylate (3l) 
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Figure A11.82. 1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(but-3-en-1-yl)isoquinoline-3-
carboxylate (3p) 
Figure A11.83. 13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(but-3-en-1-
yl)isoquinoline-3-carboxylate (3p) 
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Figure A11.84. 1H NMR (CDCl3, 500 MHz) spectrum of 4-methyl-2-((2-
(trimethylsilyl)ethoxy)methyl)quinoline (4a) 
Figure A11.85. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-methyl-2-((2-
(trimethylsilyl)ethoxy)methyl)quinoline (4a) 
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Figure A11.86. 1H NMR (CDCl3, 500 MHz) spectrum of 1-(4-methylquinolin-2-yl)-3-
phenylpropyl benzoate (4b) 
Figure A11.87. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1-(4-methylquinolin-2-yl)-3-
phenylpropyl benzoate (4b) 
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Figure A11.88. 1H NMR (CDCl3, 500 MHz) spectrum of 2-((but-3-en-1-yloxy)methyl)quinoline 
(4c) 
Figure A11.89. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-((but-3-en-1-
yloxy)methyl)quinoline (4c) 
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Figure A11.90. 1H NMR (CDCl3, 500 MHz) spectrum of 2-octylquinoline (4d) 
Figure A11.91. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-octylquinoline (4d) 
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Figure A11.92. 1H NMR (CDCl3, 500 MHz) spectrum of 2-((trans)-2-
methylcyclopentyl)quinoline (4e) 
Figure A11.93. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-((trans)-2-
methylcyclopentyl)quinoline (4e) 
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Figure A11.94. 1H NMR (CDCl3, 500 MHz) spectrum of 1,1'-(3-phenethylpyridine-2,6-
diyl)bis(ethan-1-one) (4f) 
Figure A11.95. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1,1'-(3-phenethylpyridine-2,6-
diyl)bis(ethan-1-one) (4f) 
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Figure A11.96. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(1-(benzyloxy)-2-
phenylethyl)benzo[d]thiazole (4g) 
Figure A11.97. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(1-(benzyloxy)-2-
phenylethyl)benzo[d]thiazole (4g) 
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Figure A11.98. 1H NMR (CDCl3, 500 MHz) spectrum of 3-Isopropyl-1H-indazole (4h) 
Figure A11.99. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-Isopropyl-1H-indazole (4h) 
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Figure A11.100. 1H NMR (CDCl3, 500 MHz) spectrum of 2-isopropylquinazolin-4(3H)-one (4i) 
Figure A11.101. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-isopropylquinazolin-4(3H)-one 
(4i) 
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Figure A11.102. 1H NMR (CDCl3, 500 MHz) spectrum of 2-((trans)-2-
methylcyclohexyl)quinazolin-4(3H)-one (4j) 
Figure A11.103. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-((trans)-2-
methylcyclohexyl)quinazolin-4(3H)-one (4j) 
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Figure A11.104. 1H NMR (CDCl3, 500 MHz) spectrum of 1,3,7-trimethyl-8-((2S)-2-
methylcyclopentyl)-3,7-dihydro-1H-purine-2,6-dione (4k) 
Figure A11.105. 13C NMR (CDCl3, 125.8 MHz) spectrum of 1,3,7-trimethyl-8-((2S)-2-
methylcyclopentyl)-3,7-dihydro-1H-purine-2,6-dione (4k) 
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Figure A11.106. 1H NMR (CDCl3, 500 MHz) spectrum of (1R)-(2-isopropyl-6-methoxyquinolin-
4-yl)(5-vinylquinuclidin-2-yl)methanol (4l) 
Figure A11.107. 13C NMR (CDCl3, 125.8 MHz) spectrum of (1R)-(2-isopropyl-6-
methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (4l) 
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Figure A11.108. 1H NMR (CDCl3, 500 MHz) spectrum of 2,9-di-tert-butyl-1,10-phenanthroline 
(5b) 
Figure A11.109. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2,9-di-tert-butyl-1,10-
phenanthroline (5b) 
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Figure A11.110. 1H NMR (CDCl3, 500 MHz) spectrum of 2,9-di-tert-butyl-4,7-diphenyl-1,10-
phenanthroline (5d) 
Figure A11.111. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2,9-di-tert-butyl-4,7-diphenyl-1,10-
phenanthroline (5d) 
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Figure A11.112. 1H NMR (CDCl3, 500 MHz) spectrum of 2-(tert-butyl)-6-(2,4-
difluorophenyl)pyridine (5f) 
Figure A11.113. 13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)-6-(2,4-
difluorophenyl)pyridine (5f) 
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Figure A11.114. 1H NMR (CDCl3, 500 MHz) spectrum of 6-(tert-butyl)-2,2':6',2''-terpyridine 
(5h) 
Figure A11.115. 13C NMR (CDCl3, 125.8 MHz) spectrum of 6-(tert-butyl)-2,2':6',2''-terpyridine 
(5h) 
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Figure A11.116. 1H NMR (CDCl3, 500 MHz) spectrum of 4-((benzyloxy)methyl)-5-
bromopyrimidine (6a)  
Figure A11.117. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-((benzyloxy)methyl)-5-
bromopyrimidine (6a) 
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Figure A11.118. 1H NMR (CDCl3, 500 MHz) spectrum of 3-bromo-4-methyl-2-(1-
tosylpiperidin-4-yl)pyridine and 5-bromo-4-methyl-2-(1-tosylpiperidin-4-yl)pyridine (6b) 
Figure A11.119. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-bromo-4-methyl-2-(1-
tosylpiperidin-4-yl)pyridine and 5-bromo-4-methyl-2-(1-tosylpiperidin-4-yl)pyridine (6b) 
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Figure A11.120. 1H NMR (CDCl3, 500 MHz) spectrum of 3-bromo-4-methyl-2-
phenethylpyridine (6c) 
Figure A11.121. 13C NMR (CDCl3, 125.8 MHz) spectrum of 3-bromo-4-methyl-2-
phenethylpyridine (6c)  
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Figure A11.122. 1H NMR (CDCl3, 500 MHz) spectrum of 4-chloro-2-phenethylquinoline (6d) 
Figure A11.123. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-chloro-2-phenethylquinoline (6d) 
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Figure A11.124. 1H NMR (CDCl3, 500 MHz) spectrum of 4-bromo-3-isopropylisoquinoline (6e) 
Figure A11.125. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-bromo-3-isopropylisoquinoline 
(6e) 
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Figure A11.126. 1H NMR (CDCl3, 500 MHz) spectrum of 4-bromo-1-isopropylisoquinoline (6f) 
Figure A11.127. 13C NMR (CDCl3, 125.8 MHz) spectrum of 4-bromo-1-isopropylisoquinoline 
(6f) 
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Figure A11.128. 1H NMR (CDCl3, 500 MHz) spectrum of (S)-4-ethyl-4-hydroxy-11-isopropyl-
1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (7a) 
Figure A11.129. 13C NMR (CDCl3, 125.8 MHz) spectrum of (S)-4-ethyl-4-hydroxy-11-
isopropyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (7a) 
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Figure A11.130. 1H NMR (CDCl3, 500 MHz) spectrum of (S)-11-((benzyloxy)methyl)-4-ethyl-4-
hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (7b)  
Figure A11.131. 13C NMR (CDCl3, 125.8 MHz) spectrum of (S)-11-((benzyloxy)methyl)-4-
ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione 
(7b) 
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Figure A11.132. 1H NMR (acetone-d6, 125.8 MHz) spectrum of potassium trifluoro(2-methyl-1-
phenylpropan-2-yl)borate (1u) 
Figure A11.133. 13C NMR (acetone-d6, 125.8 MHz) spectrum of potassium trifluoro(2-methyl-1-
phenylpropan-2-yl)borate (1u) 
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Figure A11.134. 11B NMR (acetone-d6, 128.4 MHz) spectrum of potassium trifluoro(2-methyl-1-
phenylpropan-2-yl)borate (1u) 
Figure A11.135. 19F NMR (CDCl3, 470.8 MHz) spectrum of potassium trifluoro(2-methyl-1-
phenylpropan-2-yl)borate (1u) 
 
681 
 
 
About the Author 
David Neal Primer was born on December 20, 1989 in Baltimore, Maryland to Benjamin and 
Terry-Thomas Primer. He spent his early years with his older brother, Chris, in New Jersey where 
he attended Hopewell Valley Central High School. Here, his early interest in science and math 
developed. In particular, his science teachers pushed him to pursue a possible career in academic 
research and drug discovery and, after a summer interning at Jacobus Pharmaceutical Company, 
Dave was certain of what career and impact he hoped to have. 
In 2008, he began his undergraduate studies at Emory University in Atlanta, GA. After taking 
an outstanding introductory course in organic chemistry taught by Professor Jose Soria, Dave 
developed a deep interest in the art and creativity of organic synthesis. Inspired to begin research, 
Dave cut his teeth in the laboroatory of Professor Huw M. L Davies. Here, he learned to problem 
solve while investigating some chiral Au-catalyzed carbenoid chemistry; in particular, the 
mentorship of Fred Briones and Brendan Parr helped shape him into a solid, thoughtful scientist. 
In 2012, David graduated with a B.S. in chemistry and opted to continue to his studies before testing 
the job market. 
Encouraged by his Uncle John Caldwell, David applied to and was accepted to the University 
of Pennsylvania, where he began his graduate studies in the laboratory of Professor Gary A. 
Molander. Over his past four years, David has worked closely with a number of his colleagues (in 
particular, John Tellis and Jennifer Matsui) to collectively publish eight papers and two reviews on 
the use of photoredox catalysis to enable radical mediated C-C bond-forming reactions with 
alkylorganometallics. He plans to complete his thesis in July 2017 before joining the process team 
at Celgene Corporation in New Jersey. While in the New Jersey area, David will have a chance to 
be close to his family, friends and his amazing girlfriend of the last seven years, Nicole.  
